FINAL Program Guide PDF 10-9-12 - American College of Allergy ...

The American College of Allergy, Asthma & Immunology
2012 Annual Scientific Meeting
Program Guide
© Disney
November 8-13, 2012
Anaheim, California
acaai.org

Find out about a
component-specific IgE * blood
test to get the answers you need
Amelia’s risk for a systemic reaction to peanuts
is related to which protein she’s sensitized to.
*Immunoglobulin E.
Visit us during the 2012 ACAAI Annual Meeting!
Learn more about the uKnow ® Peanut Molecular Allergy Test.
Please join us.
Product Theater #2 - Hall C
Sunday, Nov. 11, 3:05 - 3:30pm
Monday, Nov. 12, 10:05 - 10:30am
Exhibiting at Booth # 2816
The Product Theater content and views expressed therein are those of the sponsor
and not of the American College of Allergy, Asthma & Immunology.

Welcome
American College of Allergy,
Asthma & Immunology
Over the Horizon:
Expanding Expertise
November 8-13, 2012
Anaheim Convention Center & Anaheim Marriott Hotel
Anaheim, California
2011 – 2012 Officers and Board of Regents
Stanley M. Fineman, MD, MBA, FACAAI
President . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2012
Richard W. Weber, MD, FACAAI
President-Elect . . . . . . . . . . . . . . . . . . . . . . . . . . 2012
Michael B. Foggs, MD, FACAAI
Vice-President. . . . . . . . . . . . . . . . . . . . . . . . . . . 2012
Bryan L. Martin, DO, FACAAI
Treasurer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2012
Dana V. Wallace, MD, FACAAI
Immediate Past President . . . . . . . . . . . . . . . . 2012
Sami L. Bahna, MD, DrPH, FACAAI
Past Immediate Past President . . . . . . . . . . . 2012
Kevin P. McGrath, MD, FACAAI. . . . . . . . . . . . . . . . 2012
Talal M. Nsouli, MD, FACAAI (Honorary). . . . . . . 2012
James M. Seltzer, MD, FACAAI . . . . . . . . . . . . . . . . 2012
Alnoor A. Malick, MD, FACAAI . . . . . . . . . . . . . . . . 2013
Janna M. Tuck, MD, FACAAI . . . . . . . . . . . . . . . . . . 2013
David R. Weldon, MD, FACAAI . . . . . . . . . . . . . . . . 2013
Leonard Bielory, MD, FACAAI. . . . . . . . . . . . . . . . . 2014
Warner W. Carr, MD, FACAAI. . . . . . . . . . . . . . . . . . 2014
Chitra Dinakar, MD, FACAAI . . . . . . . . . . . . . . . . . . 2014
FIT Representatives: Paul B. Keiser, MD (’12) and Meagan Shepherd, MD (’12)
Speaker of the House: Lawrence M. DuBuske, MD, FACAAI (‘12)
Executive Medical Director: Bobby Q. Lanier, MD, FACAAI
Alliance President: Rebecca A. Goldberg, RN

ACAAI Premier Partners
The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care
companies play in furthering the mission of the College. ACAAI would like to thank the following companies for their
generous support of this year’s Annual Meeting.
DIAMOND
$500,000 and above
Mylan Specialty L.P.
Sunovion Pharmaceuticals Inc.
Teva Respiratory, LLC
GOLD
$100,000 – $299,999
Baxter Healthcare Corporation
McNeil Consumer Healthcare
MEDA PHARMACEUTICALS®
Merck
Sanofi U.S.
ViroPharma Incorporated
SILVER
$50,000 – $99,999
Aerocrine
Allergan, Inc.
AstraZeneca
Genentech, Inc. and Novartis Pharmaceuticals Corporation
OTHER CONTRIBUTORS
ALK, Inc. • Boston Scientific Corporation • CSL Behring • GREER • HollisterStier Allergy
ISTA Pharmaceuticals • Lincoln Diagnostics, Inc. • Olympus Corporation of the Americas
Thermo Fisher Scientific

Table of Contents
Page
Greetings from the Officers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
Greetings from the Alliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Corporate Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9
Commercial Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10
Special Announcements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11
Fundraiser . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15
Education Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16
Maintenance of Certification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Daily Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18
Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25
Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26
Thursday Pre-Meeting Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
Thursday Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Friday Literature Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
Friday Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Saturday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43
Saturday ACAAI President’s Welcome Reception and Awards Ceremony . . . .48
Sunday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50
Sunday “Meet the Professor Breakfasts” . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51
Sunday Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55
Monday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59
Monday “Meet the Professor Breakfasts” . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60
Monday Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .63
Tuesday Annual Business Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
Tuesday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69
Advanced Practice Health Care Providers Course . . . . . . . . . . . . . . . . . . . . . . . . . . .70
Allied Health Professionals Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .72
Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75
Plenary and Symposia Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .100
Faculty Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .102
CME/CPD Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .103
Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .104
Special Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .110
Named Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111
Tribute to Our Past Presidents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .112
Distinguished Fellows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .113
ACAAI Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .114
Alliance Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .115
Fellows-in-Training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .116
Travel Grant Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .118
Product Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .123
Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .126
Index of Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .140
Index of Exhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .142
Exhibit Hall Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .144
Anaheim Convention Center Maps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145
Anaheim Hotel Maps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .146
General Information

Greetings From the Officers
Stanley M. Fineman, MD, MBA, FACAAI
President
The College is celebrating its 70th Anniversary!
Congratulations to all members on 70 years of shaping and
improving our specialty! It is humbling to
recall that our College was started by a
group of dedicated allergists who
established our organization to help
advance the science of allergy, meet the
educational needs of the practicing allergist
and ultimately improve the care of the
Dr. Fineman
allergy patients we serve. It is certainly
impressive to see how we’ve evolved.
At the start of my presidency this milestone year, the College
resolved to continue to help you, not only to promote your
allergy practice and learn more about our changing
marketplace, but also by advocating for the allergist.
Our 70th anniversary meeting, Over the Horizon: Expanding
Expertise, has been carefully orchestrated under the
leadership of President-Elect and Program Chair Richard W.
Weber, MD, FACAAI, and focuses on helping you adapt to our
changing health care environment through multiple tracks
including scientific sessions, Meet the Professor Breakfasts
and Workshops.
In addition to the annual meeting programs designed to
keep us at the forefront of change, we’ve initiated advocacy
activities for our members. A new section on our website
provides a resource for the “New Federal Health Regulations”
(see the “Advocacy and Inside Washington” menu on the
member website). This provides you easy access to
information that will help you understand the latest
developments in our changing health care marketplace
including several reports by our Joint Task Force on Health
Care Reform.
Our new D.C. Allergy Strike Force is an initiative to help
present the voice of allergists to our legislators on Capitol
Hill. It is made up of a group of members from the College,
Academy and Joint Council who interact with our legislators.
We met with Congressional leaders in D.C., October 2011 and
again in May, to discuss issues that are vital for the practicing
allergist, including Medicare reimbursement, GME,
importance of specialty care and the latest findings about
the benefit of allergy immunotherapy.
As you know, one of the major goals of the College is to help
promote the allergist, and we continue to make progress in
this area. More people than ever before have heard about our
unique qualifications through our Find an Allergist, Find Relief
campaign. This has been accomplished nationally through
increased ACAAI public microsite traffic, specifically to the
Find an Allergist Locator, improved search engine rankings
and ongoing coverage in national media. It has also been
implemented on a local level through our ACAAI member
use of professionally designed ACAAI Relief Team materials
which are free. The marketing campaign has:
• Raised awareness of allergies and asthma, and the benefits
of seeing an allergist for diagnosis and treatment
• Motivated allergy and asthma sufferers to take action
• Differentiated allergists from other clinicians
• Demonstrated improved patient outcomes with
allergist care
Our ACAAI Nationwide Asthma Screening Program is now in
its 16th year. More than a quarter of ACAAI members have
participated, reaching nearly 130,000 potential asthmatics.
Our publications are also very strong. The Annals of Allergy,
Asthma & Immunology, under the leadership of Editor-in-
Chief Gailen D. Marshall, MD, PhD, FACAAI, is in its 69th year
of publication and it continues to evolve to meet the needs
of College members. New features planned for this year will
be of great interest to the practicing allergist and we can
even get CME credit through the Annals. AllergyWatch, edited
by Anthony Montanaro, MD, FACAAI, continues to enjoy very
positive feedback from members and helps us remain
current through summaries of allergy articles from a variety
of journals.
I look forward to seeing you in Anaheim, as we explore Over
the Horizon: Expanding Expertise. We should all enjoy the
diverse educational programs, the planned social events and
the many fine local attractions in Anaheim.
If any of the original group of dedicated allergists who
founded the College 70 years ago were able to see us now, I
think they’d be very proud.

Greetings From the Officers
Richard W. Weber, MD, FACAAI
President-Elect and Program Chair
Welcome to the 2012 ACAAI Annual Scientific Meeting in
sunny Anaheim.
My concept of our meeting theme, Over the
Horizon: Expanding Expertise, is in the form of
an image looking out toward the horizon.
There has been encroachment of our allergyimmunology
territory by other specialists,
primary caregivers, and even non-medical
entities, squeezing and shrinking it.
Dr. Weber
Therefore, our practices are changing. Since
our training extends over the horizon of what we have
typically done and seen, we have expertise that allows us to
expand into areas of medical management that are just over
that horizon.
Working with ACAAI Vice President Michael B. Foggs, MD,
FACAAI, Symposium Committee Chair, it is our Annual
Program Committee’s goal for this meeting to present for
discussion areas we have knowledge about and in which we
can manage patients as effectively, or better, than other
practitioners.
The XIV International Food Allergy Conference on Thursday
will expand your diagnosis and management
armamentarium. The full day conference is co-chaired by
Amal H. Assa’ad, MD, FACAAI, Sami L. Bahna, MD, DrPH,
FACAAI, and Alessandro Fiocchi, MD, FACAAI (SC).
What to do about those medical journals you haven’t had
time to read Expert faculty will digest them for you at the
Friday Annual Literature Review, Everything You Should Have
Read Last Year, But Didn’t, organized by Mark T. O’Hollaren,
MD, FACAAI, and his committee.
Throughout the meeting, top experts will discuss issues
germane to your practice in a variety of formats including
workshops, led by Todd A. Mahr, MD, FACAAI, and Meet the
Professor Breakfasts, led by Bradley E. Chipps, MD, FACAAI.
The Abstract Review Committee, chaired by Jay M. Portnoy,
MD, FACAAI, selected preliminary research germane to the
specialty for concurrent oral and poster presentations.
I hope to see you Saturday evening at the President’s
Welcome Reception and Awards Ceremony, where we will
honor the accomplishments of our colleagues, and also on
Sunday evening at the Annual Fundraising Dinner featuring a
fun Beatles tribute performance by the talented Fab Four
band.
Special courses are tailored to the needs of your staff,
Advanced Practice Health Care Providers and Allied Health
Professionals, under the direction of David A. Khan, MD,
FACAAI, Mary Lou Hayden, MS, NP, AE-C, and Deidre H.
Sanders, MSN, FNP-BC.
The Alliance has special programs planned for your family,
and I am sure you will all enjoy the area’s many popular
attractions.
General Information
/TheACAAI @eACAAI /Allergists
Easy access at ACAAI.org

Greetings From the Alliance
Welcome to Anaheim!
Dear Alliance Members,
Anaheim – truly a wonderland for children of all ages! While
best known for the magic of Disneyland, California offers the
opportunity to spend a day at the beach, or
perhaps head south and visit LegoLand or
San Diego. Others might find a trip to
Pasadena and Cal Tech a treat.
To help give you the best experience
possible, the Alliance has planned
Rebecca Goldberg presentations in our Hospitality Suite, both
for adults and children, from 8:00 – 10:30 am, Friday through
Monday mornings in the Orange County Ballroom of the
Anaheim Marriott Hotel. We warmly welcome all registered
spouses and guests to attend.
Volunteers are always needed to work in the hospitality suite,
the ACAAI KIDS programs and for the photography contest.
This new exciting fundraiser will feature pictures taken by
ACAAI and Alliance members. By volunteering, you can meet
with Alliance members from around the world, chat with old
friends and discover new ones.
This year’s business meeting will be held on Sunday at the
Tiffany Terrace and Patio at the Sheraton Park Hotel. A short
two-block walk from the Marriott, the room with its Tiffany
style glass ceiling and outdoor patio is lovely. Enjoy great
company, excellent food and learn about the Alliance. The
luncheon ticket costs $15 and you must be registered to
attend, so please do so in advance.
We welcome you all to Anaheim!
Rebecca A. Goldberg, RN
Alliance President
2011-2012
Anaheim Information
http://microsite.anaheimoc.org/
american-college-allergy-asthma-immunology
Visit the ACAAI Anaheim Site for Anaheim information and
local attractions.

Please Join Us for a Corporate Forum Dinner at
The American College of Allergy, Asthma & Immunology
2012 Annual Scientific Meeting
The Evolving Science of Aerosol Therapy
in Asthma and Allergic Rhinitis
PM PM
Hilton Anaheim Hotel
California Pavilion AB, Anaheim, California
Talal M. Nsouli, MD
Clinical Professor of Pediatrics & Allergy-Immunology
Georgetown University School of Medicine
Medical Director, Watergate & Burke Allergy & Asthma Centers
Past President of the Greater Washington Asthma,
Allergy and Immunology Society
Distinguished Research Scientist, ICISI
Washington, DC
LeRoy M. Graham, MD, FCCP
Georgia Pediatric Pulmonology Associates, PC
Associate Clinical Professor of Pediatrics
Morehouse School of Medicine
Founder and Medical Director
Not One More Life, Inc.
Atlanta, Georgia
Nancy K. Ostrom, MD, CPI
Co-Director
Allergy & Asthma Medical Group & Research
Center, A P.C.
Associate Clinical Professor
Department of Pediatrics, Division of Allergy
and Immunology
University of California, San Diego
San Diego, California
Robert M. Naclerio, MD
Professor and Chief
Otolaryngology-Head and Neck Surgery
University of Chicago
Chicago, Illinois
A Complimentary Dinner Will Be Served
Sponsored by
TEVA 2012 November 2012 122405

Please Join Us for a Product Theater
Lunch Presentation at
The American College of Allergy, Asthma & Immunology
2012 Annual Scientific Meeting
Allergic Rhinitis:
Addressing the
Unmet Needs
PM PM
Anaheim Convention Center
Hall C, Product Theater #1
Anaheim, California
Ketan K. Sheth, MD, MBA
Medical Director
Lafayette Allergy and Asthma Clinic
Lafayette, Indiana
Sponsored by
A Complimentary Lunch Will Be Served
TEVA 2012 November 2012 120894

Corporate Supporters
ACAAI appreciates the following promotional contributions from its corporate supporters.
AstraZeneca
Supporter of two Product Theaters… and smartphone
charging stations.
Boston Scientific Corporation
Supporter of a Product Theater.
CSL Behring
Supporter of a Product Theater.
Genentech, Inc. and
Novartis Pharmaceuticals Corporation
Supporter of two tables at the fundraising dinner… a
Product Theater… and the ACAAI member e-newsletter.
GREER
Supporter of Friday’s Fellows-in-Training Welcome
Reception.
ISTA Pharmaceuticals
Supporter of the Board of Regents dinners.
Lincoln Diagnostics, Inc.
Supporter of two tables at the fundraising dinner.
McNeil Consumer Healthcare
Supporter of the Internet Café/Printer Stations.
MEDA PHARMACEUTICALS ®
Supporter of the President’s Private Dinner… Product
Theater… hotel room key… TV clings… convention center
window clings… badge lanyards… and belly wrap on
hotel newspaper.
Merck
Supporter of the ACAAI Awards Ceremony… and Allergy
Watch and its placement on the ACAAI website.
Mylan Specialty L.P.
Supporter of a Product Theater… banner in the convention
hotel… the Airport Shuttle Bus Transportation… Gobo
Lasers… Daily Schedule Board… exhibit aisle markers…
floor clings in the convention center… and the Anaphylaxis
Member Survey.
Sanofi U.S.
Supporter of the FIT Bowl… hotel video and tent card…
and a Non-CME Corporate Forum.
Sunovion Pharmaceuticals Inc.
Supporter of the President’s Private Dinner… Non-CME
Corporate Forum… Women in Medicine Program…
FIT Business Meeting… two tables and support of the
fundraising dinner… Preliminary Convention Program…
convention center column wraps… hotel plasma
monitors… hotel restaurant and lounge promotion…
Advanced Registrants brochure… Foundation Honor
Board… refreshment breaks… Nasal Allergy Web Journal
Tool… belly wrap on hotel newspaper… and the ACAAI
Member eNewsletter.
Teva Respiratory, LLC
Supporter of the Nationwide Asthma Screening Program…
two Non-CME Corporate Forums… three Product Theaters…
one table at the fundraising dinner… electronic signage…
escalator rails… hand sanitizer stations… banners in the
convention center… and the ACAAI printed Member
Newsletter.
Thermo Fisher Scientific
Supporter of two Product Theaters.
ViroPharma Incorporated
Supporter of the Hereditary Angioedema Campaign…
Hereditary Angioedema Roundtable… and the
Allergist Locator.
General Information

Commercial Supporters
This activity is supported by independent educational grants from the following commercial supporters:
Aerocrine
Supporter of the Monday symposium on FeNO: A Paradigm
Shift in Personalized Asthma Management… and in-kind
support consisting of loaned durable equipment and
disposable supplies for Workshop W-11 FeNO and other
Biomarkers.
ALK, Inc.
Supporter of 3 FIT Travel Grants.
Allergan, Inc.
Supporter of the Sunday Breakfast Symposium on Advances
in Ocular Allergy: Differential Diagnoses and Treatment.
Baxter Healthcare Corporation
Supporter of the Saturday symposium on Early Diagnosis
and Treatment of Primary Immunodeficiency (PID) in Adults:
Insights for the Practicing Allergist-Immunologist… and a
vodcast of the symposium.
Genentech, Inc. and
Novartis Pharmaceuticals Corporation
Supporter of 50 FIT Travel Grants.
GREER
In-kind support consisting of disposable supplies for
Workshop W-13 Allergy Testing – Optimal Choices and
Interpretation.
HollisterStier Allergy
Supporter of 3 FIT Travel Grants… and Workshop W-8 –
JCAAI Presents 2012 Coding Update.
Lincoln Diagnostics, Inc.
In-kind support consisting of disposable supplies for
Workshop W-13 Allergy Testing – Optimal Choices and
Interpretation.
McNeil Consumer Healthcare
Supporter of 20 FIT Travel Grants… and the Monday
breakfast symposium on Management of Allergy with
Non-Prescription Drugs.
MEDA PHARMACEUTICALS ®
Supporter of the Friday breakfast symposium on Allergic
Rhinitis: Optimal Therapeutic Strategies to Improve Patient
Outcomes.
Merck
Supporter of 25 FIT Travel Grants… and Meet the Professor
Breakfasts.
Mylan Specialty L.P.
Supporter of all Plenary Sessions… 35 FIT Travel Grants…
the Friday program on Recommendations for the
Management of Patients with Anaphylaxis: A Consensus
Update… and the Grand Rounds Program.
Olympus Corporation of the Americas
In-kind support consisting of loaned durable equipment for
Workshop W-16 – Hands-On Session in Rhinolaryngoscopy.
Sanofi U.S.
Supporter of the Convention Literature Review… the
Thursday dinner symposium on Debatable Issues Regarding
the Prescription and Administration of an Automatic
Epinephrine Injector for Patients with Anaphylaxis… and
10 FIT Travel Grants.
Sunovion Pharmaceuticals Inc.
Supporter of the Saturday breakfast symposium on Allergic
Rhinitis: Current and Future Therapeutic Options for the
Allergist.
ViroPharma Incorporated
Supporter of the Sunday symposium on Evolving Issues in the
Management of Hereditary Angioedema: Can We Reach a
Consensus

Special Announcements
Admission by Badge Only
Admission to all meeting rooms and the exhibit area is by
badge only. This rule will be strictly enforced by security
guards at all entrances. Note: Children under 12 are not
admitted to the Scientific Sessions or the exhibit area.
Alliance Hospitality Suite
The Alliance Hospitality Suite – located in the Orange County
Ballroom at the Anaheim Marriott Hotel – is open to
registered spouses and guests only from 8:00 – 10:30 am,
Friday through Monday.
Badge Designations
Blue Member Physicians
Purple Non–member Physicians
Green Nurses/Allied Health
Lime Fellows–in–Training/Residents
Orange Non Physicians
Red Technical Exhibitors
Teal Spouses/Guests
Lt Orange Press
Fuchsia Staff
Replacement badges – $. each
Child Care Services
Please contact the concierge at the hotel at which you are
staying for a list of bonded independent babysitters and
babysitting agencies. Note: Children under 12 are not
admitted to the Scientific Sessions or the exhibit area.
Coat & Luggage Check
A coat and luggage check is located in Hall C Lobby on the
1st floor of the Anaheim Convention Center. The cost is $2.00
per item.
Hours:
Corporate Forums
7:30 am – 6:00 pm, Sunday
7:30 am – 6:00 pm, Monday
8:00 am – 11:30 am, Tuesday
NOT FOR
CREDIT
Following the close of Friday’s scientific session, all registrants
are invited to attend the special Corporate Forums at the
Hilton Anaheim Hotel.
Corporate Forums are promotional dinner symposia
organized by industry and designed to enhance your
educational experience.
The Evolving Science of Aerosol Therapy
in Asthma and Allergic Rhinitis
6:00 – 7:30 pm California Pavilion Salons AB
Supported by Teva Respiratory, LLC
Anaphylaxis in Community Settings:
New Treatment Option
6:00 – 7:30 pm California Pavilion Salon C
Supported by Sanofi U.S.
ZETONNA® (ciclesonide) Nasal Aerosol: A Dry Alternative
For The Treatment of Allergic Rhinitis
8:30-10:00 pm California Pavilion Salon D
Supported by Sunovion Pharmaceuticals Inc.
Innovations in the Treatment of Allergic Rhinitis
9:00 – 11:00 pm California Pavilion Salons AB
Supported by Teva Respiratory, LLC
Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is
educational. Information, as well as technologies, products
and/or services discussed, are intended to inform participants
about the knowledge, techniques and experiences of specialists
who are willing to share such information with colleagues. A
diversity of professional opinions exists in the specialty and the
views of the ACAAI disclaim any and all liability for damages to
any individual attending this conference and for all claims which
may result from the use of information, technologies, products
and/or services discussed at the conference.
Doctors’ Job Fair
Looking for new opportunities, an associate for your group,
or a buyer for your practice The Doctors’ Job Fair brings
together all interested parties seeking or offering
professional opportunities.
This unique program is scheduled from Noon – 3:00 pm,
Sunday, in Hall C on the 1st floor of the Anaheim Convention
Center. Representatives of clinics, groups and physicians’
offices looking for associates, will be among those
conducting interviews, which will be held in private,
draped booths.
DVD-ROM
Selected sessions from the Plenaries, Symposia, Literature
Review and International Food Allergy Conference will be
placed on an interactive DVD. Visit the Conference Recordings
sales desk located on the 3rd floor outside Ballroom B-E of the
Anaheim Convention Center to learn more about this exciting
opportunity and order your copy at the special on-site
discounted rate. (Sorry, no personal audio or video recorders will
be allowed in the meeting rooms.)
Exhibit Hall
More than 80 technical and scientific exhibitors in 165
booths are displaying their latest products in Hall C on the
1st floor of the Anaheim Convention Center during the
convention. ACAAI appreciates the support of its exhibitors
and urges all registrants to visit the displays.
Exhibit hours are:
9:45 am – 4:00 pm, Saturday
9:45 am – 4:00 pm, Sunday
9:45 am – 1:30 pm, Monday
General Information

Special Announcements
First Aid Station
A First Aid Station is located in the Main Lobby between Halls
A & B of the Anaheim Convention Center during the
following hours:
7:00 am – 5:00 pm, Thursday
6:00 am – 6:00 pm, Friday
7:00 am – 5:30 pm, Saturday
7:00 am – 5:30 pm, Sunday
7:00 am – 11:00 pm, Monday
7:00 am – 11:00 am, Tuesday
Foundation Display
The Foundation of the ACAAI is proud to recognize those
individuals who have generously contributed to the
Foundation. A list of donors can be found on the Foundation
Honor Display located on the 3rd floor outside Ballroom B-E
of the Anaheim Convention Center.
Supported by Sunovion Pharmaceuticals Inc.
Internet Café
Visit the “Internet Café” to surf the internet and send and
retrieve email. The Internet Café is located on the 2nd level of
the Anaheim Convention Center and is complimentary to all
meeting registrants from Thursday to Tuesday.
Supported by McNeil Consumer Healthcare
Networking Goes Viral
with #ACAAI
Whether you’re sharing valuable insights from keynote
presentations or interacting with meeting attendees, don’t
miss the conversation taking place on Twitter! Use the
hashtag #ACAAI in your meeting-related tweets. This will
store a backlog of meeting news from ACAAI, members,
media and industry professionals. Be sure to follow @eACAAI
for professionals and @ACAAI for the public. The College will
also be posting meeting news on its Facebook page. Feel free
to “share” these posts with your followers.
Photography/Video Recordings
By registering for this meeting, attendees acknowledge and
agree that ACAAI or its agents may take photographs during
events and may freely use those photographs in any media
for ACAAI purposes, including but not limited to news and
promotional purposes.
The presentations, slides, and materials provided in this
program are the property of ACAAI or used by permission. You
may not photograph, videotape, audiotape or otherwise record
or reproduce any of the presentations without express written
permission from ACAAI. Any attendee believed to be violating
this restriction will be removed from the session and may be
prohibited from participating in further ACAAI meetings.
Poster Presentations
Scientific Posters #P1 – P352 will be on display in Hall C on
the 1st floor of the Anaheim Convention Center beginning
Saturday morning. Authors are requested to be at their
poster to discuss their work from 12:30 – 1:30 pm, Saturday
and noon – 1:00 pm, Sunday.
President’s Welcome Reception &
Awards Ceremony
The College invites all registrants to attend this event on
Saturday from 7:30 – 9:00 pm in the Marquis Ballroom at the
Anaheim Marriott Hotel. There will be drinks and light
appetizers, followed by a short program where we will honor
our new Fellows for their accomplishments and recognize
the recipients of the Distinguished Fellow, International
Distinguished Fellow, Distinguished Service, Woman in
Allergy, Young Faculty Support and the von Pirquet Awards.
Finally, we will introduce this year’s winner of the prestigious
Gold Headed Cane Award, Rufus E. Lee, Jr., MD, FACAAI,
and invite him on stage to accept the award and address
the audience.
Plan to join us for this fun-filled event.
Supported in part by Merck
This Conference is Paper-Lite
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai.conferencespot.com or snap the QR
code for a menu of online materials.
➧
ONLINE
MATERIALS

Special Announcements
Press Room
The Press Room, located in Room 304B at the Anaheim
Convention Center, is open from 8:30 am to 4:00 pm, Friday
through Monday for representatives of the general and
scientific media.
Registration Desk Hours
The Registration Desk is located in Hall C lobby on the 1st floor
of the Anaheim Convention Center and will be open:
7:00 am – 6:00 pm, Thursday
6:00 am – 6:00 pm, Friday
6:00 am – 4:00 pm, Saturday
6:30 am – 4:00 pm, Sunday
6:30 am – 4:00 pm, Monday
7:00 am – 11:00 am, Tuesday
Speaker Ready Room
The Speaker Ready Room is located in Room 304A at the
Anaheim Convention Center and will be open:
3:00 pm – 7:00 pm, Wednesday
7:00 am – 7:00 pm, Thursday
6:00 am – 7:00 pm, Friday
6:00 am – 6:00 pm, Saturday
6:00 am – 6:00 pm, Sunday
6:00 am – 6:00 pm, Monday
7:00 am – 11:00 am, Tuesday
Wireless Internet
The Anaheim Convention Center has complimentary
wireless internet.
General Information
Y Young Physicians – sessions that may be of
special interest to young physicians are
identified throughout the program.
Online Evaluation, Credit Claim and Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual Scientific
Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information, you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance.
Locations to access the evaluations, claim credit, and
obtain certificates:
• Kiosks (2nd level of the Anaheim Convention Center)
• Other available internet sources onsite
• Office or home computers (recommended)
Online access: http://www.pswebsurvey.com/ACAAI
You will be asked to enter your Last Name and ID Number
in order to complete the evaluations. Your ID Number is
located on your Registration Card and Badge.
We encourage you to complete the appropriate
evaluations, claim your credit, and obtain your certificates
as soon as possible either onsite or following the meeting.
A checklist will be provided to help you track the sessions
you attend. The Evaluation site will close on December ,
. Up until then, you will be able to complete the
evaluations, claim credit and obtain your certificates from
your home or office computers.
For sessions attended, nurses and other healthcare
professionals may receive a certificate of attendance via
the online system. However, nurses may also use the online
system this year to obtain a CBRN certificate for the Allied
Health and Advanced Practice sessions.
Attendees of a jointly sponsored activity will need to
complete the paper forms that will be available at that
session in order to obtain credit. These must be returned to
the coordinator onsite.
Visit www.acaai.org for additional information.

The American College of Allergy, Asthma & Immunology
2012 Annual Scientific Meeting
Please Join Us for Two
Product Theater Presentations
Saturday, November 10, 2012
10:35 AM – 11:00 AM
Advances in Exercise-
Induced Bronchospasm:
Therapeutic Considerations
Anaheim Convention Center
Hall C, Product Theater #1
Anaheim, California
William W. Storms, MD
USOC Sports Medicine Advisory Committee
USA Swimming Sports Medicine Committee
The William Storms Allergy Clinic
Colorado Springs, Colorado
Sunday, November 11, 2012
10:05 AM – 10:30 AM
The Value of Targeting the
Small Airways in Asthma
Anaheim Convention Center
Hall C, Product Theater #1
Anaheim, California
Phil Lieberman, MD
Clinical Professor of Medicine and Pediatrics
University of Tennessee College of Medicine
Memphis, Tennessee
Sponsored by
Complimentary Refreshments Will Be Served
TEVA 2012 November 2012 122404

Supported in part by Sunovion Pharmaceuticals Inc.

Education Information
This activity is supported by independent educational
grants from:
• Aerocrine
• ALK, Inc.
• Allergan, Inc.
• Baxter Healthcare Corporation
• Genentech, Inc. and Novartis Pharmaceuticals Corporation
• HollisterStier Allergy
• McNeil Consumer Healthcare
• MEDA PHARMACEUTICALS®
• Merck
• Mylan Specialty L.P.
• Sanofi U.S.
• Sunovion Pharmaceuticals Inc.
• ViroPharma Incorporated
This activity is also supported by Aerocrine, GREER, Lincoln
Diagnostics, Inc. and Olympus Corporation of the Americas
through independent educational grants consisting of loaned
durable equipment and disposable supplies.
Target Audience
• All practicing allergists/immunologists
• Fellows in allergy/immunology training programs
• Primary care physicians who care for allergy patients
• Allied health professionals in the field of allergy and
immunology
• Recognize emerging trends in the prevalence of allergic
and immunologic disorders and discuss their impact on
public health
• Evaluate the impact of new diagnostic and therapeutic
strategies on healthcare costs and outcomes
• Discuss processes, tools and technologies for the efficient
allergy and immunology practice
Accreditation
The American College of Allergy, Asthma &
Immunology (ACAAI) is accredited by the
Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education
for physicians.
The American College of Allergy, Asthma & Immunology
(ACAAI) designates this live activity for a maximum of
AMA PRA Category 1 Credits. Physicians should claim only
the credit commensurate with the extent of their
participation in the activity.
This continuing medical education activity has been
reviewed by the American Academy of Pediatrics and is
acceptable for a maximum of AAP credits. These credits
can be applied toward the AAP CME/CPD Award available to
Fellows and Candidate Members of the American Academy
of Pediatrics.
Overall Educational Objectives
At the conclusion of this activity, participants should be
able to:
• Identify major advances in key areas of cutting-edge
research in immunologic mechanisms and allergic
responses including anaphylaxis and pathophysiology of
the upper airways, lungs, eyes, skin, and gastrointestinal
tract
• Demonstrate knowledge of basic processes linking
molecular and cellular biology and genetics with allergic
pathophysiology and immunodeficiency
• Translate emerging clinical science principles to clinical
practice in patients with allergic and immunologic
disorders
• Evaluate and implement state-of-the-art diagnostic and
therapeutic strategies for treating patients with allergic
and immunologic diseases
• Explain the impact of environmental exposures and
external influences on patients with allergic disorders
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual
Scientific Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance for
most sessions.
See page 13 for details.

Maintenance of Certification
Through its responsibility to provide quality CME to its membership, the ACAAI continues its support of the ABAI, which
credentials and evaluates allergy and immunology specialists. Since 1977, ABAI has offered its Diplomates a recertification
process to demonstrate their efforts in continuing education. In 2009, ABAI transitioned to the more comprehensive
Maintenance of Certification (ABMS MOC © ) program.
Linking the education content of the ACAAI Annual Meetings to the MOC © program is one way ACAAI helps its members
provide ABAI with evidence of their commitment to lifelong learning. Ultimately, CME activities for which MOC © credit is
awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website: www.abai.org.
Members are encouraged to select areas of interest from the program, which will enhance their knowledge of state-of-the-art
allergy/immunology and improve the quality of patient care.
The ACAAI will assist Allergy/Immunology Training Programs with additional curricular resources and assessment measures
that may be used to help meet their requirements for assessing competency in the six core areas as designed by the ACGME.
The six core competencies include:
General Information
Patient Care – the ability to provide patient care that is
compassionate, appropriate, and effective for the treatment
of health problems and the promotion of health:
• data gathering
• history taking
• patient examination
• diagnosis
• interpretation/decision-making/assessment
• management/treatment plans
• preventive care
• procedures
Medical Knowledge – the knowledge about
established and evolving biomedical, clinical, and
cognate sciences and the application of this knowledge
to patient care:
• general principles/concepts/theories
• applied basic sciences
• applied biomedical sciences
• applied clinical knowledge
• epidemiology and psychosocial behavioral sciences
• population-based medicine
Practice-based Learning and Improvement – the
ability to investigate and evaluate patient care practices,
appraise and assimilate scientific evidence, and improve
their patient care practices:
• benchmarks/best practices
• practice related quality improvement
• evidence-based practice/medicine
• continuing professional development/continuing
medical education
• practice self-assessment
• information technology/medical informatics
• teaching and learning and life-long learning
Interpersonal and Communication Skills – the
ability to demonstrate interpersonal and communication
skills that result in effective information exchange and
collaboration with patients, their families, and other
health professionals:
• teaming and team leadership skills (inter-professional,
multi-disciplinary)
• effective communicator and listener
• caring, respectful behavior
• written and verbal communication skills
• educating/counseling patients and family members
• teaching skills
Professionalism – reflects a commitment to carrying
out professional responsibilities, adherence to ethical
principles, and sensitivity to a diverse patient population:
• physician accountability
• humanistic qualities (respect, compassion, integrity)
• professional ethics
• socio-cultural factors (sensitivity to culture, diversity,
gender, age, disabilities)
• advocacy for and responsive to patient needs
• commitment to excellence and quality care
• mentorship and role-modeling
System-based Practice – an awareness of and
responsiveness to the larger context and system of
healthcare, and the ability to call effectively on other
resources in the system to provide optimal health care:
• patient safety
• cost-effective care
• management of resources
• medical errors
• continuity of care
• healthcare delivery and systems of care models
• utilization issues
• risk management
• electronic record keeping
• management and leadership skills

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Thursday, November 8th
7:00 am – 6:00 pm Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
7:00 am – 7:00 pm Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
7:30 am – 5:00 pm Board of Regents Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1-3 (Marriott)
8:00 – 10:00 am International Food Allergy Conference: Navigating Eosinophilic
Gastrointestinal Disorders: The Allergist at the Helm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
10:00 – 10:15 am International Food Allergy Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A Foyer (3rd Flr)
10:15 am – 12:15 pm International Food Allergy Conference: Getting Comfortable With
Off-the-Beaten-Track Food Allergies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
Noon – 1:00 pm Board of Regents Luncheon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 7 (Marriott)
12:15 – 1:15 pm International Food Allergy Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
1:15 – 3:00 pm International Food Allergy Conference: Expanding Our Diagnosis and
Management Armamentarium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
3:00 – 3:15 pm International Food Allergy Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A Foyer (3rd Flr)
3:15 – 5:00 pm International Food Allergy Conference: The Allergist Among the Colleagues . . . . . . . .Ballroom A (3rd Flr)
6:15 – 8:15 pm Dinner Symposium: Debatable Issues Regarding the Prescription and
Administration of an Automatic Epinephrine Injector for Patients
With Anaphylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1-6 (Marriott)
Friday, November 9th
6:00 am – 6:00 pm Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
6:00 am – 7:00 pm Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
7:00 – 8:00 am Alliance Executive Committee Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 (Marriott)
7:45 – 11:30 am Literature Review – Part I Morning Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
8:00 – 10:30 am Alliance Hospitality Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:00 am – 12:30 pm Advanced Practice Health Care Providers Course . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
8:00 am – 3:00 pm W-1 A Practical Approach to Aeroallergen Identification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .212AB
8:30 – 9:30 am Alliance: The History of Anaheim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:30 – 10:30 am Breakfast Symposium: Allergic Rhinitis: Optimal Therapeutic Strategies
to Improve Patient Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1-6 (Marriott)
8:30 am – 4:00 pm Press Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304B
9:45 – 10:00 am Literature Review Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A Foyer (3rd Flr)
9:45 – 10:00 am Advanced Practice Health Care Providers Course Refreshment Break
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E Foyer (Marriott)
11:00 am – 1:00 pm FIT Bowl Planning Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208B
11:30 am – 1:00 pm Literature Review Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
11:30 am – 1:30 pm Luncheon Program: Recommendations for the Management of
Patients With Anaphylaxis: A Consensus Update . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1-6 (Marriott)
12:30 – 1:30 pm Advanced Practice Health Care Providers Course Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
1:00 – 3:45 pm Literature Review – Part II Afternoon Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
1:30 – 3:00 pm Advanced Practice Health Care Providers Workshops
AP1 Pulmonary Function Testing for Advanced Practice . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
AP2 Eosinophilic Esophagitis, GER, FPIES: Belly Pain . . . . . . . . . . . . . . . . . . .Grand Ballroom AB (Marriott)
AP3 Pharmacology for Advanced Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
1:45 – 2:45 pm AACA Board of Directors Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 (Marriott)

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Friday, November 9th (continued)
2:30 – 2:45 pm Literature Review Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A Foyer (3rd Flr)
3:00 – 3:15 pm Advanced Practice Health Care Providers Course Refreshment Break
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E Foyer (Marriott)
3:15 – 4:45 pm Advanced Practice Health Care Providers Workshops
AP4 Pulmonary Function Testing for Advanced Practice . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
AP5 Eosinophilic Esophagitis, GER, FPIES: Belly Pain . . . . . . . . . . . . . . . . . . .Grand Ballroom AB (Marriott)
AP6 Pharmacology for Advanced Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
3:30 – 5:30 pm Workshops
W-2 Drug Allergies / Eruptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .209AB
W-3 Chronic Cough: Pediatrics & Adult . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210AB
W-4 Insect Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213AB
W-5 Skin Biopsy for the Allergist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210C
3:30 – 5:30 pm FIT Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304CD
3:45 – 4:00 pm Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E Foyer (3rd Flr)
4:00 – 6:00 pm House of Delegates Meeting and Town Hall Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .303AB
4:00 – 6:00 pm Alliance Pre-Board Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 2 & 3 (Marriott)
5:30 – 6:30 pm FIT Business Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304CD
6:00 – 7:30 pm Non-CME Corporate Forum: Teva Respiratory . . . . . . . . . . . . . . . . . . . . . . . . . . .California Pavilion AB (Hilton)
6:00 – 7:30 pm Non-CME Corporate Forum: Sanofi U.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .California Pavilion C (Hilton)
6:00 – 9:00 pm American Association of Allergists & Immunologists of Indian Origin . . . . . .Grand Ballroom F (Marriott)
6:30 – 7:30 pm Fellows-in-Training Welcome Reception . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:30 – 10:00 pm Non-CME Corporate Forum: Sunovion Pharmaceuticals Inc. . . . . . . . . . . . . . .California Pavilion D (Hilton)
9:00 – 11:00 pm Non-CME Corporate Forum: Teva Respiratory . . . . . . . . . . . . . . . . . . . . . . . . . . .California Pavilion AB (Hilton)
Daily Events
Saturday, November 10th
6:00 – 7:30 am Breakfast Symposium: Allergic Rhinitis: Current and Future
Therapeutic Options for the Allergist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 5-6 (Marriott)
6:00 am – 4:00 pm Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
6:00 am – 6:00 pm Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
6:30 – 7:30 am Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
Adverse Reactions to Foods
Asthma & Respiratory Disease
Dermatological Allergy
Managed Care & Health Plans
Medical Informatics
Public Education & Outreach
6:30 – 7:30 am Immunotherapy & Diagnostics Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 4 (Marriott)
6:30 – 7:30 am Joint RADAR Task Force – Session 1 – Advocacy – Influencing Legislators
(By Invitation Only) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 3 (Marriott)
7:30 – 11:00 am Consortium on Children's Asthma Camps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 & 2 (Marriott)
7:45 – 8:10 am Opening Ceremony and Welcome Announcements . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
8:00 – 10:30 am Alliance Hospitality Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:00 am – noon Allied Health Professionals Course: Interactive Panels . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Saturday, November 10th (continued)
8:10 – 10:30 am Plenary Session: Managing Asthma Patients in the 21st Century . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
8:30 – 9:30 am Alliance: Artistic Anaheim . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:30 am – 4:00 pm Press Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304B
9:00 – 10:30 am Joint Task Force for Healthcare Reform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208A
9:30 – 10:30 am ACAAI KIDS: Learn to Draw . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
9:45 – 10:00 am Allied Health Professionals Course Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
9:45 am – 4:00 pm Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
9:45 am – 4:00 pm Poster Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:00 am – noon W-6 Creating a Website for Your Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
10:30 – 11:00 am Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:35 – 11:00 am Product Theater 1: Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:35 – 11:00 am Product Theater 2: CSL Behring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
11:00 am – 12:30 pm Plenary Session: When Shortness of Breath Is Not Asthma . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
Noon – 2:00 pm Allied Health Professionals Course Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
12:20 – 1:15 pm Allergy / Immunology Program Directors Luncheon Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
12:30 – 1:30 pm Lunch / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
12:30 – 1:30 pm Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
12:35 – 1:30 pm Product Theater 1: Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
12:35 – 1:30 pm Product Theater 2: MEDA PHARMACEUTICALS® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
1:00 – 3:00 pm W-7 Preparing Your Practice for an EHR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
1:30 – 2:30 pm ACAAI Foundation Board Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208A
1:30 – 3:00 pm Plenary Session: The Great Anaphylaxis Raft Debate: Which Is the Most
Important Mediator . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
2:00 – 3:15 pm Allied Health Professionals Workshops
SA1 Hands-on Basic Spirometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom AB (Marriott)
SA2 Advanced PFT: What to Order and How to Interpret . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
SA3 Obstructive Sleep Apnea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom GH (Marriott)
SA4 Competency and Procedural Skills . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom JK (Marriott)
SA5 Allergen Extracts: Evidence-based Vaccines . . . . . . . . . . .Orange County Ballroom 1 & 2 (Marriott)
SA6 Pharmacology in Allergy and Asthma: Update and
Patient / Family Education . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom 3 & 4 (Marriott)
3:00 – 3:30 pm Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
3:05 – 3:30 pm Product Theater 2: AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
3:15 – 3:30 pm Allied Health Professionals Course Refreshment Break . . . . . . . . . . . . . . . .Grand Ballroom Foyer (Marriott)
3:30 – 4:45 pm Allied Health Professionals Workshops
SA7 Hands-on Basic Spirometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom AB (Marriott)
SA8 Advanced PFT: What to Order and How to Interpret . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
SA9 Obstructive Sleep Apnea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom GH (Marriott)
SA10 Competency and Procedural Skills . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom JK (Marriott)
SA11 Allergen Extracts: Evidence-based Vaccines . . . . . . . . . . .Orange County Ballroom 1 & 2 (Marriott)
SA12 Pharmacology in Allergy and Asthma: Update and
Patient / Family Education . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom 3 & 4 (Marriott)

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Saturday, November 10th (continued)
3:30 – 5:00 pm Investments Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208A
3:30 – 5:30 pm Annals Editorial Board Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208B
3:30 – 5:30 pm Symposium: Early Diagnosis and Treatment of Primary Immunodeficiency (PID)
in Adults: Insights for the Practicing Allergist-Immunologist . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
3:30 – 5:30 pm Workshops
W-8 JCAAI Presents 2012 Coding Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .209AB
W-9 Patch Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210AB
W-10 Hot Topics in Pediatric Allergy (SOAI-AAP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210C
W-11 FeNO and Other Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210D
W-12 Dermatology Dilemmas: Fascinating Cases to Learn From . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
W-13 Allergy Testing – Optimal Choices and Interpretation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213AB
W-14 Introductory Course in Rhinolaryngoscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213CD
W-15 Anaphylaxis Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .303AB
5:00 – 7:00 pm 21st Annual FIT Bowl Competition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom EF (Marriott)
6:00 – 7:00 pm Alliance International Reception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1-2 (Marriott)
7:30 – 9:00 pm ACAAI President's Welcome Reception and Awards Ceremony . . . . . . . . . . . .Marquis Ballroom (Marriott)
Daily Events
Sunday, November 11th
6:00 am – 6:00 pm Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
6:15 – 8:15 am Breakfast Symposium: Advances in Ocular Allergy:
Differential Diagnoses and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 5-6 (Marriott)
6:30 – 8:15 am Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
Drugs & Anaphylaxis
Geriatrics
Integrative Medicine
Ocular Allergy
Pediatrics
Rhinitis / Sinusitis
Sports Medicine
Women's Health
6:30 – 8:30 am W-16 Hands-on Session in Rhinolaryngoscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .212AB
6:30 am – 4:00 pm Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
7:00 – 8:15 am Meet the Professor Breakfasts
S1 What Is the Current Status of SLIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom AB (Marriott)
S2 Management of Immunodeficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
S3 Assessment of Airway Reactivity: Mannitol vs. Methacholine . . . . .Grand Ballroom GH (Marriott)
S4 Cough in Children and Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom JK (Marriott)
S5 Chronic Rhinosinusitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1 (Marriott)
S6 Office Evaluation of Drug Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 2 (Marriott)
S7 Eosinophilic Gastrointestinal Disease . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 3 (Marriott)
S8 All That Wheezes Is Not Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 4 (Marriott)
S9 Implications of Local Allergic Responses: Entopy . . . . . . . . . . . . . . . .Platinum Ballroom 8 (Marriott)
S10 Food Allergy: Controversies in Therapy . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 9 (Marriott)

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Sunday, November 11th (continued)
7:30 am – noon JCAAI Board of Directors Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 & 2 (Marriott)
8:00 – 9:30 am Exhibitors Advisory Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208B
8:00 – 9:45 am W-17 Meaningful Use of EHRs and the Health Information Exchange . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
8:00 – 10:30 am Alliance Hospitality Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:00 am – noon Allied Health Professionals Course: Interactive Panels . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
8:30 – 9:30 am Alliance: Making a Difference, One Bowl of Pasta at a Time . . . . . . . .Orange County Ballroom (Marriott)
8:30 – 10:00 am Plenary Session: Developing Competence in Contact Dermatitis
Diagnosis and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
8:30 am – 4:00 pm Press Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304B
9:30 – 10:30 am ACAAI KIDS: Anaheim History for Kids . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
9:40 – 10:00 am Allied Health Professionals Course Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
9:45 am – 4:00 pm Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
9:45 am – 4:00 pm Poster Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:00 – 10:30 am Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:00 am – noon W-18 Marketing Your Practice Online: Beyond the Basics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
10:05 – 10:30 am Product Theater 1: Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:05 – 10:30 am Product Theater 2: AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:30 am – noon Plenary Session: Disturbed Sleep Syndromes: More Than Snoring . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
Noon – 1:00 pm Lunch / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
Noon – 1:00 pm Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
Noon – 1:30 pm 2013 Annual Meeting Program Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
Noon – 1:30 pm Meet the Professor Breakfasts Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
Noon – 1:30 pm Symposium Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
Noon – 1:30 pm Workshop Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
Noon – 2:00 pm Past Presidents' Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208B
Noon – 3:00 pm Doctors' Job Fair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
12:05 – 1:00 pm Product Theater 1: Mylan Specialty L.P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
12:05 – 1:00 pm Product Theater 2: Genentech, Inc. and Novartis Pharmaceuticals Corporation . . . . . . . . . .Hall C (1st Flr)
12:30 – 3:00 pm Alliance Annual Business Meeting and Luncheon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Off-Site
1:00 – 2:00 pm SETTaF-Specific IgE Testing Task Force . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208A
1:00 – 3:00 pm W-19 Implementing an EHR Successfully . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
1:00 – 3:00 pm W-20 RADAR Workshop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213AB
1:00 – 3:00 pm WAO Symposium: Current Insights on Eosinophilic Disorders . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
1:00 – 3:00 pm Concurrent Session A: Adverse Food and Drug Reactions, Insect Reactions,
Anaphylaxis and Food Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
Concurrent Session B: Asthma, Other Lower Airway Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .303AB
Concurrent Session C: Aerobiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .303CD
Concurrent Session D: Basic Science Allergy & Immunology and Rhinitis,
Other Upper Airway Disorders, and Ocular Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304CD
3:00 – 3:30 pm Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
3:05 – 3:30 pm Product Theater 1: Boston Scientific Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
3:05 – 3:30 pm Product Theater 2: Thermo Fisher Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Sunday, November 11th (continued)
3:30 – 5:30 pm Symposium: Evolving Issues in the Management of Hereditary Angioedema:
Can We Reach a Consensus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
3:30 – 5:30 pm Workshops
W-21 Food Allergy: What's New! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .209AB
W-22 Eosinophilic Gastrointestinal Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210AB
W-23 Anaphylaxis: Ready to Roll . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210C
W-24 JCAAI 2012 Reimbursement and Regulatory Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210D
W-25 Occupational Asthma and Dermatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
W-26 Statistics Simplified for Clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .212AB
W-27 Chronic Hypertrophic Sinusitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213AB
W-28 Molecular Biology of Allergens: Towards More Accurate Diagnosis and Treatment . . . . . . .213CD
W-29 Immunotherapy Beyond Traditional . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304CD
7:00 – 8:00 pm Fundraiser Reception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Marquis Ballroom Foyer (Marriott)
8:00 – 10:30 pm Fundraiser Dinner & Entertainment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Marquis Ballroom (Marriott)
Daily Events
Monday, November 12th
6:00 am – 6:00 pm Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
6:15 – 8:15 am Breakfast Symposium: Management of Allergy With
Non-Prescription Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 5-6 (Marriott)
6:30 am – 4:00 pm Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
6:30 – 8:15 am International Committee) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 & 2 (Marriott)
7:00 – 8:00 am Joint RADAR Task Force – Session II – Advocacy – Influencing Payers
(By Invitation Only) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 10 (Marriott)
7:00 – 8:15 am Meet the Professor Breakfasts
M1 How to Use Biomarkers in Diagnosis and Treatment of Asthma . . .Grand Ballroom AB (Marriott)
M2 Evaluation of Immunodeficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom CD (Marriott)
M3 Occupational Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom GH (Marriott)
M4 Indoor Allergens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom JK (Marriott)
M5 Dermatology for the Allergist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 1 (Marriott)
M6 HAE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 2 (Marriott)
M7 Severe Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 3 (Marriott)
M8 Dynamic Dosing in Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 4 (Marriott)
M9 Diagnostic Assessment of Airway Inflammatory Patterns . . . . . . . .Platinum Ballroom 8 (Marriott)
M10 Food Allergy: Controversies in Diagnosis . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 9 (Marriott)
8:00 – 9:45 am W-30 EHR Roundtable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213CD
8:00 – 10:30 am Alliance Hospitality Suite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Orange County Ballroom (Marriott)
8:30 – 10:00 am Plenary Session: Are There Differences in Urticaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
8:30 am – 4:00 pm Press Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304B
9:45 am – 1:30 pm Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:00 – 10:30 am Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:00 am – noon Continuing Medical Education / Continuing Professional Development Committee . . . . . . . . . . . . . .207C
10:00 am – noon W-31 Computerizing the Mixing Lab and Injection Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB

Daily Events
HOURS
All programs held at the Anaheim Convention Center unless otherwise noted
ROOM
Monday, November 12th (continued)
10:05 – 10:30 am Product Theater 2: Thermo Fisher Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
10:30 am – noon Plenary Session: Maintenance of Certification and the Allergist . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
10:30 am – noon Alliance Post-Board Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Elite Ballroom 1 & 2 (Marriott)
Noon – 1:00 pm Lunch / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C (1st Flr)
Noon – 1:00 pm Women in Medicine Luncheon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom E (Marriott)
1:00 – 3:00 pm Concurrent Session A: Clinical Immunology, Immunodeficiency . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
Concurrent Session B: Food Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom A (3rd Flr)
Concurrent Session C: Allergy Testing, Clinical Laboratory Immunology,
Immunotherapy/Immunizations and Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .303AB
Concurrent Session D: Pharmacology / Pharmacotherapeutics and Skin Disorders . . . . . . . . . . . . . . .303CD
1:30 – 2:30 pm Communications Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208A
1:30 – 2:30 pm Professional Education Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .208B
1:30 – 2:30 pm Scientific Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .207C
3:00 – 3:30 pm Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E Foyer (3rd Flr)
3:30 – 5:30 pm Symposium: FeNO: A Paradigm Shift in Personalized Asthma Management . . . . . .Ballroom B-E (3rd Flr)
3:30 – 5:30 pm Workshops
W-32 Severe Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .209AB
W-33 Everything You Thought Was Atopic Dermatitis That Wasn't . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210AB
W-34 Immunotherapy: How to Write the Prescription . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210C
W-35 Practical Ocular Examination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .210D
W-36 Basics of a Home Environment Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .211AB
W-37 Urticaria and Angioedema: Something Old, Something New . . . . . . . . . . . . . . . . . . . . . . . . . . . .212AB
W-38 Immunodeficiency and State Screens: Role of the Allergist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213AB
Tuesday, November 13th
7:00 – 7:30 am Past Presidents' Breakfast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 5-6 (Marriott)
7:00 – 11:00 am Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall C Lobby (1st Flr)
7:00 – 11:00 am Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .304A
7:30 – 8:45 am Annual Business Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Platinum Ballroom 5-6 (Marriott)
9:00 – 9:30 am Plenary Session: Bela Schick Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Ballroom B-E (3rd Flr)
9:30 – 11:00 am Plenary Session: Integrative Medicine for the Allergist-Immunologist . . . . . . . . . . . . .Ballroom B-E (3rd Flr)

Committee Meetings
Complimentary continental breakfasts will be served at the committee meetings listed below.
Saturday, November 10
Grand Ballroom E
Anaheim Marriott Hotel
6:30 – 7:30 am
Adverse Reactions to Foods Committee
Asthma & Respiratory Disease Committee
Dermatological Allergy Committee
Managed Care & Health Plans Committee
Medical Informatics Committee
Public Education & Outreach Committee
Sunday, November 11
Grand Ballroom E
Anaheim Marriott Hotel
6:30 – 8:15 am
Drugs and Anaphylaxis Committee
Geriatrics Committee
Integrative Medicine Committee
Ocular Allergy Committee
Pediatrics Committee
Rhinitis/Sinusitis Committee
Sports Medicine Committee
Women’s Health Committee
Friday, November 9
FIT Bowl Planning Committee
11:00 am – 1:00 pm Room 208B
Saturday, November 10
Immunotherapy &
Diagnostics Committee
6:30 – 7:30 am Platinum Ballroom 4
Anaheim Marriott Hotel
Consortium on Children’s
Asthma Camps
7:30 –11:00 am Elite Ballroom 1& 2
Anaheim Marriott Hotel
Joint Task Force for
Healthcare Reform
9:00 – 10:30 am Room 208A
Allergy/Immunology Program
Directors Luncheon Meeting
12:20 – 1:15 pm Room 207C
ACAAI Foundation Board
1:30 – 2:30 pm Room 208A
Investments Committee
3:30 – 5:00 pm Room 208A
Annals Editorial Board
3:30 – 5:30 pm Room 208B
Other Committee Meetings
All committee meetings will be held at the Anaheim Convention Center unless otherwise noted.
Sunday, November 11
Exhibitors Advisory Meeting
8:00 – 9:30 am Room 208B
Annual Meeting Program
Committee
Noon – 1:30 pm
Room 207C
Meet the Professor
Breakfasts Committee
Noon – 1:30 pm
Room 207C
Symposium Committee
Noon – 1:30 pm
Room 207C
Workshop Committee
Noon – 1:30 pm
Room 207C
Past Presidents’ Council
Noon – 2:00 pm
Room 208B
SETTaF – Specific IgE Testing
Task Force
1:00 – 2:00 pm Room 208A
Monday, November 12
International Committee
6:30 – 8:15 am Elite Ballroom 1 & 2
Anaheim Marriott Hotel
Continuing Medical Education/
Continuing Professional
Development Committee
10:00 am – noon Room 207C
Communications Council
1:30 – 2:30 pm Room 208A
Professional Education Council
1:30 – 2:30 pm Room 208B
Scientific Council
1:30 – 2:30 pm Room 207C
Committee Meetings

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Friday
W- A Practical Approach to
Aeroallergen Identification
Y
8:00 am – 3:00 pm Room 212AB
Fee: $100 (FITs $50) Lunch on your own.
Estelle Levetin, PhD and Richard W. Weber, MD, FACAAI
Upon completion of this session, participants should be able to:
1) set up a sampling station to collect airborne pollen and fungal
spores; 2) recognize the most common types of pollen and fungal
spores found in the atmosphere; 3) list pollen characteristics that help
identify specific pollen types; and 4) identify representative pollen
genera or groups.
W- Drug Allergies/Eruptions
3:30 – 5:30 pm Room 209AB
Fee: $60 (FITs $25)
Aleena Banerji, MD and Stephen A. Tilles, MD, FACAAI
Upon completion of this session, participants should be able to:
1) summarize the basic mechanisms of drug hypersensitivity;
2) recognize drug eruptions and differentiate from other causes; and
3) prepare a treatment plan to manage drug hypersensitivity and
eruptions more effectively.
The American Board of Allergy & Immunology (ABAI) will grant
MOC Part II credits to Diplomates who complete this workshop
and are currently enrolled in ABAI’s Maintenance of Certification
(MOC) program.
Special note re MOC/CME eligibility for this workshop:
To be eligible for MOC Part II credit, participants must participate in the
entire workshop and complete all necessary components, including:
brief Pre-/Post Surveys and Pre-/Post Tests onsite as well as the
Evaluation online. Additionally, a follow-up Outcomes Assessment
regarding application of this workshop to your practice will be sent
online approximately 6-8 weeks later and must also be promptly
completed and submitted to ACAAI online. ABAI will recognize the
2 AMA PRA Category 1 Credits earned as 4 MOC Part II credits after you
submit your ACAAI certificate of credit from the Anaheim meeting to
the ABAI portal and confirmation of eligibility for MOC credit is sent by
ACAAI to ABAI. ABAI will count this activity toward 4 of the 8 selfassessment
credits needed by physicians each year for Part II of MOC.
It is imperative that participants must participate in the entire
workshop and complete all necessary components, as partial
credits will not be permitted for MOC eligibility related to this
MOC/CME workshop.
W- Chronic Cough: Pediatrics & Adult
3:30 – 5:30 pm Room 210AB
Fee: $60 (FITs $25)
Alan B. Goldsobel, MD, FACAAI and Pramod S. Kelkar, MD
Upon completion of this session, participants should be able to:
1) describe current cough guidelines and pitfalls in cough management;
2) describe practical and cost-effective ways to manage chronic cough;
3) apply and interpret common tests used to evaluate patients with
chronic cough; 4) describe causes and management of cough; and
5) describe management strategies for habit, unexplained cough.
W- Insect Allergy
3:30 – 5:30 pm Room 213AB
Fee: $60 (FITs $25)
Theodore M. Freeman, MD, FACAAI and
David F. Graft, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss evaluation and management of stinging insect
hypersensitivity; and 2) discuss key changes from the 2004 to the 2011
practice parameter.
W- Skin Biopsy for the Allergist
3:30 – 5:30 pm Room 210C
Fee: $100 (FITs $50)
Marcella R. Aquino, FACAAI and
David R. Weldon, MD, FACAAI
Upon completion of this session, participants should be able to:
1) examine the use of punch biopsies to diagnose cutaneous disease;
2) demonstrate skills needed to perform a punch biopsy with optimal
results; 3) define common terms used in interpretation of biopsy
results; and 4) obtain correct biopsies to enhance diagnostic ability in
deciphering immune-mediated rashes.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Saturday
W- Creating a Website for
Your Practice
Y
10:00 am – noon Room 211AB
Fee: $60 (FITs $25)
G. David Hopper, MD and J. Allen Meadows, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss advantages of communicating online and explain how to
avoid potential medical-legal risks of online communication with
patients; 2) describe benefits to an allergy practice of having a dynamic
web site, including e-newsletters; 3) use effective strategies to reduce
non-revenue generating telephone traffic to the office; 4) describe the
basic components and design elements of Web design; and 5) discuss
the practical considerations and legal ramifications of using e-mail to
communicate with patients.
W- Preparing Your Practice for an EHR Y
1:00 – 3:00 pm Room 211AB
Fee: $60 (FITs $25)
David D. Tanner, MD, FACAAI and
Richard L. Wasserman, MD, FACAAI
Upon completion of this session, participants should be able to:
1) describe the options for electronic health records (EHR) in an allergy
practice, including fully integrated software, interfaced software and
application service provider model; 2) list five questions that should be
asked during a site visit of an EHR installation; 3) discuss requirements
to meet Meaningful Use criteria to qualify for federal incentives; and
4) evaluate an EHR for its ablility to record the measures needed to
attest and to report for Meaningful Use.
W- JCAAI Presents Coding
Update
Y
3:30 – 5:30 pm Room 209AB
Fee: $60 (FITs $25)
Donald W. Aaronson, MD, JD, MPH, FACAAI and
Gary N. Gross, MD, FACAAI
Upon completion of this session, participants should be able to:
1) implement new CPT coding for ingestion challenges and
venom/drug testing; and 2) discuss physician participation
requirements for vial preparation and skin test reading and
interpretation.
Supported by an independent educational grant from
HollisterStier Allergy
W- Patch Testing
3:30 – 5:30 pm Room 210AB
Fee: $60 (FITs $25)
Marcella R. Aquino, MD, FACAAI and
Luz S. Fonacier, MD, FACAAI
Upon completion of this session, participants should be able to:
1) identify the varied clinical manifestations of contact dermatitis; and
2) describe some practical pearls for diagnosis of contact dermatitis.
W- Hot Topics in Pediatric
Allergy (SOAI-AAP)
Y
3:30 – 5:30 pm Room 210C
Fee: $60 (FITs $25)
Chitra Dinakar, MD, FACAAI and Todd A. Mahr, MD, FACAAI
Upon completion of this session, participants should be able to:
1) review the current literature and discuss recent important
developments in pediatric allergy; 2) apply recent information on the
management of pediatric allergic disorders; 3) review new and current
recommendations for prevention and management of childhood
asthma; and 4) apply new and current diagnostic and therapeutic
options in respiratory allergies.
W- FeNO and Other Biomarkers
3:30 – 5:30 pm Room 210D
Fee: $60 (FITs $25)
Peter B. Boggs, MD, FACAAI; Neal Jain, MD, FACAAI and
Myron J. Zitt, MD, FACAAI
Upon completion of this session, participants should be able to:
1) identify biomarkers currently being utilized and studied in the
clinical management of asthma and other respiratory diseases;
2) identify the biologic origin of fractional exhaled nitric oxide (FeNO)
and how its biology helps to define its role in the clinical management
of asthma; 3) discuss monitoring of airway inflammation for improved
asthma control; 4) describe the role of fractional exhaled nitric oxide
(FeNO): a measurement of airway inflammation (“Inflammometry”) in
the diagnosis and management of asthma; 5) describe the ATS
Guidelines on the Interpretation of FeNO in Asthma Care; and 6) apply
the ATS Guideline recommendations to patient care.
This activity is supported by Aerocrine through an
independent educational grant consisting of loaned
durable equipment and disposable supplies.
Workshops
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Saturday (continued)
W- Dermatology Dilemmas:
Fascinating Cases to Learn From
Y
3:30 – 5:30 pm Room 211AB
Fee: $60 (FITs $25)
Kristin M. Leiferman, MD and Javed Sheikh, MD
Upon completion of this session, participants should be able to:
1) discuss challenging urticaria and dermatologic cases in the allergist’s
office; 2) discuss some distinguishing features of different causes of
eczema; 3) discuss the distinguishing features that are helpful in
diagnosis; and 4) identify different approaches to disease work-up as
well as the related controversies.
W- Allergy Testing: Optimal
Choices and Interpretation
Y
3:30 – 5:30 pm Room 213AB
Fee: $60 (FITs $25)
Bryan L. Martin, DO, FACAAI and
John J. Oppenheimer, MD, FACAAI
Upon completion of this session, participants should be able to:
1) describe the current burden of allergic disease and the diagnostic
value of allergy skin testing; 2) identify the factors affecting variability in
skin testing and describe the approval process for an allergy skin test;
3) discuss the most current practice parameters on allergy skin testing
and use currently available data to determine which skin test device is
best for their clinical practice; and 4) better perform, document and
interpret skin testing as well as utilize different forms of skin testing and
various devices that can be employed in prick skin testing.
This activity is supported by GREER and Lincoln
Diagnostics, Inc. through independent educational
grants consisting of disposable supplies.
W- Introductory Course in
Rhinolaryngoscopy
Y
3:30 – 5:30 pm Room 213CD
Fee: $60 (FITs $25)
Seong H. Cho, MD and Jerald W. Koepke, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss the surgical anatomy of the upper airway, including the nasal
cavity, pharynx, and larynx; 2) identify normal and abnormal anatomy,
as well as disease presentations and post-operative changes found with
endoscopic examination of the upper airway; and 3) identify the
indications for, and the use of, the fiberoptic rhinoscope in the
allergist’s office.
W- Anaphylaxis Review
3:30 – 5:30 pm Room 303AB
Fee: $60 (FITs $25)
John M. Kelso, MD, FACAAI and
Phillip L. Lieberman, MD, FACAAI
Upon completion of this session, participants should be able to:
1) describe the mechanisms and symptoms of anaphylaxis; 2) use
epinephrine appropriately to treat anaphylaxis; 3) prepare the office and
staff for the treatment of anaphylaxis; 4) recognize early anaphylaxis due
to immunotherapy; and 5) initiate appropriate treatment with
epinephrine and other office-based treatment modalities.
Sunday
W- Hands-on Session in
Y
Rhinolaryngoscopy
6:30 – 8:30 am Room 212AB
Fee: $100 (FITs $50) Includes Continental Breakfast.
Jerald W. Koepke, MD, FACAAI; Kevin R. Murphy, MD;
Grant C. Olson, MD, FACAAI; Donald W. Pulver, MD, FACAAI;
Nathan Segall, MD, FACAAI and C. Ross Westley, MD, FACAAI
SOLD OUT
Upon completion of this session, participants should be able to:
1) describe the major anatomical structures of the nasal, pharyngeal
and glottic areas as visualized during examination with the fiber-optic
rhinolaryngoscope; 2) describe variations of normal seen when
participants examine one another in this hands-on session; and
3) demonstrate the proper handling and initial skills needed to perform
a comprehensive upper airway examination with a fiberoptic
endoscope.
Prerequisite: Introductory Course in Rhinolaryngoscopy (W-14)
This activity is supported by Olympus Corporation of the
Americas through an independent educational grant
consisting of loaned durable equipment.
W- Meaningful Use in EHRs and the
Health Information Exchange
8:00 – 9:45 am Room 211AB
Fee: $60 (FITs $25)
G. David Hopper, MD, FACAAI and
A. Sean McKnight, MD, FACAAI
Upon completion of this session, participants should be able to:
1) define meaningful use; and 2) list the features of an EHR that are
required to meet meaningful use criteria.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Sunday (continued)
W- Marketing Your Practice Online:
Beyond the Basics
10:00 am – noon Room 211AB
Fee: $60 (FITs $25)
J. Allen Meadows, MD, FACAAI and Brooks Lape
Upon completion of this session, participants should be able to:
1) describe how patients are searching for allergy treatment and
practices online; 2) discuss tactics that are key to increasing online
visibility; 3) describe how to turn website visitors into patients;
4) discuss the impact of website design and content on lead
generation; and 5) implement reputation management through
monitoring and control of online information regarding a practice.
W- Implementing an EHR Successfully Y
1:00 – 3:00 pm Room 211AB
Fee: $60 (FITs $25)
David J. Shulan, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss whether they should have computers in their office or rent
space from a remote computer to run their electronic health record
system; 2) describe strategies and identify challenges in successful EHR
implementation; and 3) discuss EHR implementation as a continual
process.
W- RADAR Workshop
Y
1:00 – 3:00 pm Room 213AB
Fee: Complimentary
Lawrence M. DuBuske, MD, FACAAI;
Richard W. Honsinger, MD, MACP, FACAAI;
J. Allen Meadows, MD, FACAAI; and
James M. Tracy, DO, FACAAI
Upon completion of this session, participants should be able to:
1) describe techniques for building relationships with key leaders in the
local area; 2) effectively interact with insurers and governmental
officials; 3) make a decision to be willing to become a RADAR team
member; 4) be willing to enter the vetting process to join RADAR;
5) describe the genesis and purpose of the RADAR (regional, advocacy,
discussion and response) network; and 6) discuss the concept and
importance of vetting of regional representatives.
W- Food Allergy: What’s New!
3:30 – 5:30 pm Room 209AB
Fee: $60 (FITs $25)
Amal H. Assa’ad, MD, FACAAI and
A. Wesley Burks, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss the status of food allergen-specific immunotherapy and other
modalities in key clinical trials and studies in food allergy treatment;
2) utilize diagnostic tests for food allergy that are currently available,
and know about those under development; and 3) apply current
management strategies and therapies for IgE-mediated food allergy.
W- Eosinophilic Gastrointestinal
Diseases
3:30 – 5:30 pm Room 210AB
Fee: $60 (FITs $25)
Seema S. Aceves, MD, PhD and
Jonathan M. Spergel, MD, FACAAI
Upon completion of this session, participants should be able to:
1) explain the clinical presentation of eosinophilic gastrointestinal
diseases (EGIDs); 2) explain the management options in EGIDs;
3) discuss diagnosis of eosinophilic gastrointestinal diseases (EGIDs);
and 4) relationship of food allergies in EGIDs.
W- Anaphylaxis: Ready to Roll
3:30 – 5:30 pm Room 210C
Fee: $60 (FITs $25)
Nabil El Sanadi, MD and Dana V. Wallace, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss the most common life threatening presentations of
anaphylaxis; 2) describe how to best prepare their practice setting to
deal with emergencies; 3) ensure the entire office staff is comfortable
interacting with 911 responders; 4) define anaphylaxis and prepare for
anaphylaxis in the office; 5) help prevent anaphylaxis in the office; and
6) diagnose and treat anaphylaxis in the office.
Workshops
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Sunday (continued)
W- JCAAI Reimbursement and
Regulatory Issues
Y
3:30 – 5:30 pm Room 210D
Fee: $60 (FITs $25)
Donald W. Aaronson, MD, JD, MPH, FACAAI and
Gary N. Gross, MD, FACAAI
Upon completion of this session, participants should be able to:
1) implement new CPT Coding for oral food challenge and for venom
and drug testing; 2) discuss physician participation requirements for
vial preparation, skin test reading and skin test interpretation;
3) effectively manage claims denials from varying insurance carriers;
4) discuss the importance of compliance with allergy-adopted
standards of sterile compounding of allergy extracts; and 5) discuss
value-based purchasing.
W- Occupational Asthma and
Dermatitis
3:30 – 5:30 pm Room 211AB
Fee: $60 (FITs $25)
Jonathan A. Bernstein, MD, FACAAI and
Michael Zacharisen, MD, FACAAI
Upon completion of this session, participants should be able to:
1) explain the differences between high and low molecular weight
causes of occupational asthma (OA); 2) determine the different causes
of OA; 3) evaluate and manage a worker with OA; 4) recognize common
occupational asthma and dermatitis presentations; and 5) develop a
plan for evaluation and treatment of occupational asthma and
dermatitis.
W- Statistics Simplified for Clinicians
3:30 – 5:30 pm Room 212AB
Fee: $60 (FITs $25)
Sami L. Bahna, MD, DrPH, FACAAI and
Steve Conrad, MD, PhD
Upon completion of this session, participants should be able to:
1) plan study design and data collection appropriate for the research
objective; 2) use optimal tabular and graphic data presentation;
3) choose valid sampling methods and size; and 4) apply appropriate
simplified statistical methods for data analysis of clinical studies.
W- Chronic Hypertrophic Sinusitis
3:30 – 5:30 pm Room 213AB
Fee: $60 (FITs $25)
Larry Borish, MD, FACAAI and Eli O. Meltzer, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss chronic hyperplastic sinusitis as it comprises numerous
distinct diseases each with its own pathogenic mechanism;
2) incorporate disease-specific approaches into patient care and
treatment of these distinct diseases; and 3) review the distinct clinical
presentations and individualized disease-specific management of the
different presentations of chronic sinusitis, including non-eosinophilic,
eosinophilic and aspirin-intolerant sinusitis.
W- Molecular Biology of Allergens:
Towards More Accurate Diagnosis
and Treatment
3:30 – 5:30 pm Room 213CD
Fee: $60 (FITs $25)
Jay M. Portnoy, MD, FACAAI and
P. Brock Williams, PhD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss various allergens and the properties that they have in
common; 2) select relevant allergens from a variety of different sources
and review their prognostic values; 3) determine when and which
components to measure to help in diagnosis; and 4) interpret the
results of component tests.
W- Immunotherapy Beyond
Traditional
Y
3:30 – 5:30 pm Room 304CD
Fee: $60 (FITs $25)
Peter S. Creticos, MD and Charles J. Siegel, MD, FACAAI
Upon completion of this session, participants should be able to:
1) describe the mechanistic differences in newer immunotherapy (IT)
approaches including SLIT, T-cell tolerizing Peptide IT, and modified
constructs including adjuvants; 2) evaluate the clinical outcomes of
these therapeutic approaches based on the data from evidence-based
clinical trials; 3) discuss clinical findings from the recent North American
clinical trials of SLIT-tablet and SLIT-aqueous formulations in seasonal
pollen-induced allergic rhinitis; 4) recognize the role of cluster
immunotherapy in the treatment of airborne allergies; 5) judge the role
of rush immunotherapy in the treatment of airborne allergies; and
6) classify the reactions to immunotherapy according to the World
Allergy Organization guidelines.
.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Monday
W- EHR Roundtable
Y
8:00 – 9:45 am Room 213CD
Fee: $60 (FITS $25)
Tao T. Le, MD, MHS, FACAAI; David J. Shulan, MD, FACAAI;
Richard L. Wasserman, MD, PhD, FACAAI;
Ira Finegold, MD, FACAAI; A. Sean McKnight, MD, FACAAI;
Dana V. Wallace, MD, FACAAI; and Hugh H. Windom, MD
Upon completion of this session, participants should be able to:
1) list factors affecting EHR adoption and selection by allergists;
2) discuss best practices for EHR selection and implementation;
3) describe how allergists currently maximize their EHRs in practice;
4) identify resources for evaluating and selecting an EHR; 5) identify
resources for implementing an EHR; 6) list the benefits and challenges
of EHR adoption; 7) name two EHRs with allergy modules; and 8) list an
advantage of the application service provider model of EHR.
W- Computerizing the Mixing Lab
and Injection Room
10:00 am – noon Room 211AB
Fee: $60 (FITs $25)
Dan A. Dalan, MD, FACAAI and
Michael R. Nelson, MD, PhD, FACAAI
Upon completion of this session, participants should be able to:
1) identify advantages and complexities associated with conversion
from a paper based to an electronic mixing lab and shot room; and
2) improve adherence to current immunotherapy practice parameter
guidance by incorporating an electronic solution for a mixing lab and
shot room.
W- Severe Asthma
3:30 – 5:30 pm Room 209AB
Fee: $60 (FITs $25)
Bradley E. Chipps, MD, FACAAI and
Lanny J. Rosenwasser, MD, FACAAI
Upon completion of this session, participants should be able to:
1) describe the systematic approach to the evaluation of patients with
difficult to treat asthma; 2) review data from severe asthma registry
cohorts including ENFUMOSA, SARP, TENOR, and BTS; 3) discuss the
application of phenotype, endotype, and cluster for the clinical,
immunologic and pathophysiologic presentations of difficult to treat
asthma; and 4) investigate the adjunctive therapies that may be used in
patients with asthma not responding to Step 6 EPR-3 care.
W- Everything You Thought Was
Atopic Dermatitis That Wasn’t
3:30 – 5:30 pm Room 210AB
Fee: $60 (FITs $25)
Marcella R. Aquino, MD, FACAAI and
Mark Boguniewicz, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss differential of eczematous inflammatory skin lesions,
including contact dermatitis vs.drug eruption, hand dermatitis, facial
dermatitis, and diaper dermatitis; 2) recognize diseases that may be
misdiagnosed as atopic dermatitis; 3) discuss insights into
pathophysiology of primary immunodeficiencies with eczema and
aberrant IgE synthesis; and 4) utilize appropriate testing in patients
where the diagnosis of atopic dermatitis is in question.
W- Immunotherapy: How to
Write the Prescription
Y
3:30 – 5:30 pm Room 210C
Fee: $60 (FITs $25)
Bryan L. Martin, DO, FACAAI and
John J. Oppenheimer, MD, FACAAI
Upon completion of this session, participants should be able to:
1) explain the differences between standardized and non-standardized
extracts; 2) compose a therapeutic mix for immunotherapy through
review of the literature; 3) write a prescription for immunotherapy that
contains effective doses of each component; and 4) use current
guidelines to improve the safety and effectiveness of immunotherapy
in the office.
W- Practical Ocular Examination
3:30 – 5:30 pm Room 210D
Fee: $60 (FITs $25)
Anand Bhatt, MD and Milton Hom, OD
Upon completion of this session, participants should be able to:
1) describe the common ocular surface conditions that may present to
the allergist; 2) utilize questionnaires to diagnose ocular surface
conditions; and 3) identify common ocular allergic processes and
awareness of options to treat ocular allergic processes.
Workshops
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Workshops
Admission by ticket only • All Workshops will be held at the Anaheim Convention Center
Monday (continued)
W- Basics of a Home Environment
Assessment
3:30 – 5:30 pm Room 211AB
Fee: $60 (FITs $25)
Kevin Kennedy, CIEC and Jay M. Portnoy, MD, FACAAI
Upon completion of this session, participants should be able to:
1) ask appropriate questions to identify indoor environmental quality
(IEQ) issues; 2) use visual evidence observed in homes to identify
environmental quality issues; 3) explain and demonstrate the five
quantitative measurements recommended for home assessments; and
4) teach patients how to identify IEQ issues and help them develop an
action plan.
W- Immunodeficiency and State
Screens: Role of the Allergist
3:30 – 5:30 pm Room 213AB
Fee: $60 (FITs $25)
Stuart L. Abramson, MD and Mark Ballow, MD, FACAAI
Upon completion of this session, participants should be able to:
1) specify the components of the innate immune system; 2) evaluate
patients for deficiencies in innate immunity; 3) identify patients with
deficiencies of the cellular (T-cell) and humoral (B-cell) immune
systems; 4) initiate laboratory evaluation and treatment of patients with
innate, T-cell and antibody deficiencies; 5) describe the components
and the interpretation of state screens for immunodeficiency disorders;
and 6) discuss appropriate additional testing and treatment plans
based on immune screening results.
W- Urticaria and Angioedema:
Something Old, Something New
3:30 – 5:30 pm Room 212AB
Fee: $60 (FITs $25)
Richard G. Gower, MD, FACAAI and
William R. Lumry, MD, FACAAI
Upon completion of this session, participants should be able to:
1) discuss the differential diagnosis for urticaria and angioedema and
properly assess patients with these conditions; 2) identify patients with
physical urticaria/angioedema; 3) summarize current and emerging
therapies for urticaria and angioedema; and 4) describe an evidencebased
and cost-effective approach to diagnosis and management of
patients with chronic urticaria/angioedema.
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai.conferencespot.com or snap the QR
code for a menu of online materials.
➧
ONLINE
MATERIALS
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Thursday Pre-Meeting Course
Ballroom A (3rd Floor) • Anaheim Convention Center
International Food Allergy Conference
Separate Registration Fee • Ticket Required
7:00 am Registration (Hall C Lobby)
Navigating Eosinophilic Gastrointestinal
Disorders: The Allergist at the Helm
Moderators: Amal H. Assa’ad, MD, FACAAI and
Karen A. DeMuth, MD, FACAAI
8:00 am Welcome and Introductions
8:15 am Eosinophilic Esophagitis and
Food Allergy: Where Do They Meet
Marc Rothenberg, MD, PhD, FACAAI
8:45 am Optimal Pharmacotherapy:
Types and Duration
Seema Aceves, MD, PhD
9:15 am Clinical Relevance of the
Food-Pollen Syndrome
M. Antonella Muraro, MD
9:45 am Questions and Panel Discussion
10:00 am Refreshment Break (Ballroom A Foyer)
Getting Comfortable With
Off-the-Beaten-Track Food Allergies
Moderators: Helen H. Chan, MD, FACAAI and
Brian G. Wilson, MD, FACAAI
10:15 am Food Protein Induced
Enterocolitis: Raising Awareness
Among the Primary Care Physicians
Jonathan M. Spergel, MD, PhD, FACAAI
10:45 am Spice Allergy
Sami L. Bahna, MD, DrPH, FACAAI
11:15 am Allergy to Tree Nuts:
A Rising Concern
Alessandro Fiocchi, MD, FACAAI (SC)
Y
Y
Y
Y
Y
Y
11:45 am Abstract Presentation
F – Investigation of Eosinophilic Esophagitis in
Adults using Skin Testing, ImmunoCAP and
ImmunoCAP ISAC IgE Quantitation
A. Tripathi* 1 , L.J. Workman1, C.B. Cho 2 , A.S. Clark 1 ,
R.G. Hamilton 3 , T.A. Platts-Mills 1 , E.A. Erwin 2 ,
1. Charlottesville, VA; 2. Columbus, OH;
3. Baltimore, MD.
Noon Questions and Panel Discussion
12:15 pm Lunch Break (on own) and Poster Viewing
(see page 35 for poster listing)
1:15 pm
Expanding Our Diagnosis and
Management Armamentarium
Moderators: Sami L. Bahna, MD, DrPH, FACAAI and
Vivian Hernandez-Trujillo, MD, FACAAI
1:45 pm Food Immunotherapy
Procedures: Are We There Yet
A. Wesley Burks, MD, FACAAI
Luisa Businco Memorial Lecture
Predicting the
Natural History of
Food Allergy
Y
Amal H. Assa’ad, MD, FACAAI
Y
Continued next page
Thursday Symposia
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Thursday Pre-Meeting Course
Ballroom A (3rd Floor) • Anaheim Convention Center
International Food Allergy Conference
(continued from previous page)
2:15 pm Abstract Presentations
F – Age-Dependent Trends in Peanut Allergy
Versus Cross-Reactive Pollen Sensitization
J. Thompson* 1 , B. Williams 2 , M. Morris 1 ,
1. Onalaska, WI; 2. Kansas City, MO.
F – The High Economic Burden of Childhood
Food Allergy in the United States
R. Gupta*, L. Bilaver, D. Holdford, A. Dyer, C.H. Lau,
J. Pongracic, J.L. Holl, D. Meltzer, Chicago, IL.
2:45 pm Questions and Panel Discussion
3:00 pm Refreshment Break (Ballroom A Foyer)
The Allergist Among the Colleagues
Moderators: Marcella R. Aquino, MD, FACAAI and
Alessandro Fiocchi, MD, FACAAI (SC)
3:45 pm Immunodeficiency Disguised
as Food Allergy
Jordan S. Orange, MD, PhD, FACAAI
4:15 pm Abstract Presentations
F – Heiner Syndrome Masquerading as an
Immune Deficiency
J.A. Sigua* 1 , M. Zacharisen 2 , 1. Milwaukee, WI;
2. Bozeman, MT.
F – Performance of Skin Prick Testing and
Serum Specific IgE Testing in Pediatric
Oral Food Challenges to Cow’s Milk, Egg and
Peanut Allergy
M. Nanda*, P. Windom, J. Khoury, M. Lierl,
A. Assa'ad, Cincinnati, OH.
4:45 pm Questions and Panel Discussion
5:00 pm Adjourn
Y
3:15 pm Food Allergy and Atopic Dermatitis:
Generating a Common Approach
With the Dermatologist
Luz S. Fonacier, MD, FACAAI
Y
Conference Learning Objectives
Upon completion of this session, participants should be able to: Upon completion of this session, participants should be able to: 1) identify the
basic etiology and mechanism of eosinophil-associated gastrointestinal disorders (EGID); 2) explain the relationship of EGID to food allergy;
3) discuss current and future treatment strategies for EGID, especially, eosinophilic esophagitis; 4) list different therapeutic options for eosinophilic
esophagitis (EoE); 5) list the efficacy rates that are currently known for therapies; 6) recognize the clinical presentation of food-pollen syndrome and
utilize testing modalities for the diagnosis; 7) identify the best management strategy for each patient; 8) describe how to identify food proteininduced
enterocolitis (FPIES); 9) discuss outreach and educational efforts for FPIES; 10) review various types of spices; 11) recognize the important
spice proteins and the effect of processing on their allergenicity; 12) identify spice allergy manifestations; and 4) discuss the diagnosis and
management of spice allergy; 13) describe the prevalence of tree nut allergy; 14) discuss diagnostic itinerary for tree nut allergy and treating tree
nut allergy with avoidance; 15) summarize new options in desensitization; 16) recognize the difference in natural history among various food
allergens as well as among various food allergy syndromes; 17) apply the knowledge to the clinical management of patients; 18) apply current
management strategies and therapies for IgE-mediated food allergy; 19) discuss the status of food allergen-specific immunotherapy and other
modalities in key clinical trials and studies in food allergy treatment; 20) compare the approach of the dermatologist and the allergist to atopic
dermatitis; 21) generate consensus protocols for the co-management of atopic dermatitis; 22) discuss the primary immunodeficiencies that have
an increased prevalence of what can present as food allergy; and 23) identify primary immunodeficiencies within food allergy cohorts.
IFAC Oral Abstract Learning Objectives
Upon completion of this session, participants should be able to: F1) discuss food and aeroallergen sensitivity patterns in adult patients with
eosinophilic esophagitis (EoE) through skin and serum IgE testing with component analysis, as related to dietary therapy and disease management;
F2) distinguish peanut allergy from cross-sensitization and discuss how the prevalence of these conditions changes with the age of the patient;
F3) summarize the direct and indirect costs of childhood food allergy and discuss major components of both the direct and indirect costs;
F4) identify common manifestations of Heiner Syndrome and discuss a differential diagnosis of chronic pulmonary infiltrates and summarize an
appropriate diagnostic evaluation of Heiner Syndrome; and F5) identify the shortcomings of current skin prick testing and serum specifiic IgE
testing for clinically relevant food allergy.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Thursday Pre-Meeting Course
Room 303AB • Anaheim Convention Center
International Food Allergy Conference – Posters
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
Engineered Osmotin Variant Demonstrates
Reduced Allergenic Potency With Hypersensitive
Patients’ Sera and Mice
P. Sharma*, S.N. Gaur, N. Arora, Delhi, India.
Buckwheat Allergy- New Allergen to Watch in
the US
C. Radojicic, D. Mlinarik*, Independence, OH.
Pectin Anaphylaxis Associated With Cashew and
Pistachio Allergy
M. Rafeeq*, Oregon, OH.
Management of Anaphylaxis: Are We Compliant
With the National Guidelines
A. Chouksey*, D. Super, P. Puri, K. Swamy,
Cleveland, OH.
Epinephrine Auto-Injector and Medical Alert
Bracelet Preparedness in Pediatric Food Allergy
J. Shih*, K. Demuth, Atlanta, GA.
Food Allergy and Anaphylaxis Educational
Curriculum in Urban Child Care Centers
B.J. Lanser*, J.A. Bird, A.T. Tang, Dallas, TX.
Current Food Allergy Diagnosis and Management
Practices of Pediatricians
R. Gupta* 1 , A. Dyer 1 , C.H. Lau 1 , M.W. Sohn 1 ,
B. Altshuler 2 , J.A. Brown 3 , J. Necheles 1 , 1. Chicago, IL;
2. Crystal Lake, IL; 3. Barrington, IL.
Poor Predictability of Specific IgE and Skin Prick
Testing to Sesame as Demonstrated by Oral
Food Challenge
J. Kattan*, J.A. Lieberman, M. Vitale, H.A. Sampson,
A.L. Cox, New York, NY.
Identifying Characteristics in Egg-Allergic
Subjects to Predict Heated Egg Tolerance:
A Retrospective Review
N.U. Swamy*, M. Crain, J.A. Bird, Dallas, TX.
Baked Egg Oral Food Challenges: A Single-Center
Pediatric Hospital Experience
R.W. Saltzman*, M. Kelleher, J.M. Spergel,
Philadelphia, PA.
Potential Unreliability of RAST Testing for
Diagnosis of Food Allergy
D.E. Riester*, Burlington, MA.
A Significant Proportion of Patients With
Symptoms During an Oral Food Challenge Can
Successfully Complete the Challenge
I. Mikhail* 1 , L. Arnold 2 , S. Mancia 2 , H. Robinson 2 ,
A. Sprunger 2 , A. Troger 2 , D. Mansoor 2 , C. Nguyen 2 ,
H. Sharma 2 , 1. Arlington, VA; 2. Washington, DC.
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
FP
Serum Specific Immunoglobulin E (IgE) Levels of
Common Food Allergens in Children Presenting
With Food Allergy
M. Amin*, J.C. Khoury, A.H. Assa'ad, Cincinnati, OH.
Prevalence of Sensitivity to Food/Drug Additives in
Patients With Chronic Idiopathic Urticaria (CIUA)
J. Rajan* 1 , R. Simon 1 , J. Bosso 2 , 1. San Diego, CA;
2. West Nyack, NY.
Eosinophilic Esophagitis in South Dakota
M.E. Bubak, L.R. Peterson*, Sioux Falls, SD.
Eosinophilic Esophagitis (EoE) to Unsuspected
Food Allergens
S.K. Mane*, P. Jordan, S.L. Bahna, Shreveport, LA.
Outgrowing IgE Food Allergy to Milk and
Developing Eosinophilic Esophagitis
S.M. Maggadottir*, J.M. Spergel, T.F. Brown-
Whitehorn, Philadelphia, PA.
Childhood Food Allergy Tolerance and Associated
Factors
R. Gupta*, C.H. Lau, E.E. Springston, B. Smith,
J. Pongracic, S.M. Boudreau-Romano, J.L. Holl,
Chicago, IL.
Prevalence of Peanut Allergy in Children of
Peanut Farmers
A. Jagdis* 1 , G. Liss 1 , S. Maleki 2 , P. Vadas 1 , 1. Toronto,
ON, Canada; 2. New Orleans, LA.
Food Protein-Induced Enterocolitis Syndrome
Triggered by Orange Juice
T. Federly*, P. Ryan, C. Dinakar, Kansas City, MO.
Late onset of Food Protein-Induced Enterocolitis
Syndrome After Food Challenge in a Boy With
Gastroschisis
C.T. Quezada-Chalita* 1 , R.T. Quezada Medrano 2 ,
1. Mexico City, DF, Mexico; 2. Tepic, NA, Mexico.
Food Protein-Induced Enterocolitis Triggered by
Pork: a Case Report
G. Ram*, J. Heimall, S.P. DaVeiga, Philadelphia, PA.
Food Hypersensitivity Presenting as Protein-
Losing Enteropathy Without Gastrointestinal
Symptoms
N. Farooqui*, R. Scherzer, D.W. Hauswirth,
Columbus, OH.
Food Protein Induced Enterocolitis Syndrome
(FPIES) to Trivial Oral Mucosal Contact
S.K. Mane*, M. Hollister, S.L. Bahna, Shreveport, LA.
Peanut Induced Food Protein Enterocolitis
Syndrome: A Case Report
B. Prince*, C. Szychlinski, M. Makhija, Chicago, IL.
Thursday Symposia

Thursday Pre-Meeting Course
Room 303AB • Anaheim Convention Center
International Food Allergy Conference – Posters
(continued from previous page)
IFAC Poster Learning Objectives
Upon completion of this session, participants should be able to: FP1) discuss the reduction of allergenic potency with
hypersensitive patients’ sera and mice as demonstrated by an engineered osmotin variant; FP2) differentiate wheat allergy from
buckwheat wheat allergy and recognize potential allergens in 'gluten-free food'; FP3) review presentation of pectin allergy and
anaphylaxis and discuss association of pectin allergy with cashew and pistachio allergy; FP4) discuss compliance with the national
guidelines regarding anaphylaxis and the need for prompt diagnosis and treatment to prevent fatal outcomes and summarize the
need to educate patients about home epinephrine use and advise follow up for a definitive workup; FP5) discuss the reality of
allergy preparedness in food allergic pediatric patients; FP6) recognize the need for an educational curriculum regarding food
allergy and anaphylaxis among child care center workers and discuss the results of a pilot program and goals of future research;
FP7) summarize current trends in management of food allergy among pediatricians and compare current practices to the NIAID
food allergy management guidelines; FP8) discuss the limitations of current diagnostic testing for sesame allergy; FP9) identify
characteristics that predict heated egg tolerance in egg-allergic subjects; FP10) discuss the emerging phenotypes of food allergy
(heated egg, native egg) and implications for development of tolerance; FP11) discuss the potential limits of serological testing for
food allergy; FP12) discuss possible outcomes of oral food challenges following signs or symptoms during the challenge;
FP13) interpret serum food specific IgE levels in children for the common food allergens and recognize that the rise of serum food
specific IgE over time is an expected finding; FP14) identify the prevalence of reactions to food/drug additives in patients with
chronic idiopathic urticaria; FP15) discuss the current methods used for the diagnosis and treatment of eosinophilic esophagitis
by allergists and gastroenterologists in the state of South Dakota; FP16) obtain esophageal biopsy even if the mucosa appears
grossly normal and conduct a detailed food allergy evaluation in spite of lack of food suspicion by history; FP17) discuss cases
where apparent true IgE mediated food allergy evolves or changes into eosinophilic esophagitis and describe the plasticity of
food allergies; FP18) discuss the frequency of tolerance to food allergy among children in the US and identify food allergies that
children are likely to outgrow and discuss symptoms and other factors associated with the development of tolerance;
FP19) discuss the prevalence of peanut allergy in children of peanut farmers in comparison to the general population;
FP20) consider FPIES induced by unusual agents such as oranges or other citrus fruits; FP21) identify the possibility of a late onset
of food protein induced enterocolitis syndrome after a food challenge; FP22) identify patients with FPIES-mediated food allergy
and recognize mammalian meats as a possible trigger for FPIES; FP23) recognize uncommon symptoms presenting as food
hypersensitivity; FP24) recognize that FPIES can be caused by indirect exposure to trivial quantities of food allergen; and
FP25) discuss the clinical presentation and diagnosis of Food Protein Enterocolitis Syndrome (FPIES) and identify foods known
to cause this syndrome.

Thursday Symposia
Dinner Symposium • Platinum Ballroom 1-6 • Anaheim Marriott Hotel
Debatable Issues Regarding the Prescription and
Administration of an Automatic Epinephrine Injector for
Patients With Anaphylaxis
Supported by an independent educational grant from Sanofi U.S.
Moderator: Phillip L. Lieberman, MD, FACAAI
6:15 pm Panelists for Case Presentations
and Debates
8:15 pm Adjourn
Todd A. Mahr, MD, FACAAI
F. Estelle Simons, MD, FACAAI
Dana V. Wallace, MD, FACAAI
Upon completion of this session, participants should be able to: 1) correctly recognize the bulk of patients presenting signs and
symptoms of anaphylaxis requiring immediate treatment; 2) correctly apply guidelines and practice parameters in managing of
patients with anaphylaxis; and 3) develop educational plans to address compliance by patients for the proper administration and
maintenance of prescribed epinephrine auto injectors.
Thursday Symposia
Photo courtesy of AOCVCB
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Friday Literature Review
Ballroom A (3rd Floor) • Anaheim Convention Center
Everything You Should Have Read Last Year, But Didn’t!
Supported in part by an independent educational grant from Sanofi U.S.
Separate Registration Fee • Admission by Ticket Only
Part I – Morning Session
Moderator: James T. Li, MD, FACAAI
Chair: Mark T. O’Hollaren, MD, FACAAI
Part II – Afternoon Session
Moderator: Mark T. O’Hollaren, MD, FACAAI
7:45 am Basic Immunology and Genetics
for the Allergist
David A. Khan, MD, FACAAI
8:15 am Anaphylaxis, Drug Allergy and
Stinging Insect Hypersensitivity
Anthony Montanaro, MD, FACAAI
8:45 am Occupational and Environmental
Allergy
Mark S. Dykewicz, MD, FACAAI
9:15 am Asthma and Lower Respiratory
Diseases
James T. Li, MD, FACAAI
9:45 am Refreshment Break (Ballroom A Foyer)
10:00 am Urticaria, Angioedema and Other
Skin Disorders
Gerald W. Volcheck, MD, FACAAI
Y
Y
Y
Y
Y
1:00 pm Immunotherapy
David I. Bernstein, MD, FACAAI
1:30 pm Food and Additives Allergy
Vivian Hernandez-Trujillo, MD, FACAAI
2:00 pm Population Management
of Asthma
William W. Crawford, MD
2:30 pm Refreshment Break (Ballroom A Foyer)
2:45 pm Rhinitis and Sinusitis
Richard A. Nicklas, MD, FACAAI
3:15 pm The Ten Best Articles in the Specialty
of Allergy
Mark T. O’Hollaren MD, FACAAI
3:40 pm Questions and Discussion
3:45 pm Adjourn
Y
Y
Y
Y
Y
10:30 am Update in Pediatric Allergy
John M. Kelso, MD, FACAAI
Y
11:00 am Update on Infectious Diseases,
Antimicrobials, and Vaccines
Michael S. Blaiss, MD, FACAAI
Y
11:30 am Lunch (on your own)
Upon completion of this session, participants should be able to: 1) discuss recent updates in basic immunology and genetics as pertains to allergy and
immunology; 2) identify new concepts in anaphylaxis, drug allergy and stinging insect hypersensitivity; 3) utilize clinically relevant information in practice;
4) discuss recent advances in understanding environmental influences on respiratory and atopic disease; 5) discuss recent advances in the diagnosis and
management of latex allergy and occupational respiratory diseases; 6) apply the results reported in recently published articles on asthma and COPD to
clinical practice; 7) expand treatment options for patients with hereditary angioedema; 8) counsel patients on treatment options for chronic urticaria and
angioedema; 9) discuss recent literature in pediatric allergy, asthma and immunology regarding important developments with practical applications;
10) discuss asthma as related to the risk of pertussis infection; 11) discuss evidence of antibiotic use and intranasal corticosteroids in treatment of acute
rhinosinusitis as well as the efficacy of Dead Sea salt irrigation; 12) discuss new insights into mechanisms of immunotherapy and define long term efficacy
of sublingual immunotherapy; 13) compare effectiveness of immunotherapy with single vs. multiple allergens and identify new approaches to allergen
immunotherapy; 14) describe recent literature on food allergy and food additives; 15) apply new information and treatment strategies to the practice of
allergy; 16) list the 3 specific interventions that are most commonly used in asthma population management interventional studies; 17) name the precise
definition of an asthma exacerbation that is recommended for use in clinical trials; 18) use histologic information to determine the effectiveness of
corticosteroids in the treatment of nasal polyps; 19) decrease use of antibiotics in treatment of sinus infections; 20) review cutting edge research results
that will impact the practice of allergy; 21) discuss innovative clinical pearls and utilize the information to improve clinical practice; and 22) summarize
significant advances over the last year in the field of allergy and immunology.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Friday Symposia
Breakfast Symposium • Platinum Ballroom 1-6 • Anaheim Marriott Hotel
Allergic Rhinitis: Optimal Therapeutic Strategies to
Improve Patient Outcomes
Supported by an independent educational grant from MEDA PHARMACEUTICALS®
Moderator: William E. Berger, MD, MBA, FACAAI
8:30 am Welcome and Introductions
William E. Berger, MD, MBA, FACAAI
8:40 am Epidemiology and Characterization
of Rhinitis
William E. Berger, MD, MBA, FACAAI
9:10 am Topical Therapy for Allergic
Patients: Advantages and Underlying
Mechanisms
Phillip L. Lieberman, MD, FACAAI
9:40 am Emerging Therapies for
Allergic and Non-Allergic Rhinitis
Warner W. Carr, MD, FACAAI
10:10 am Questions and Discussion
10:30 am Adjourn
Upon completion of this session, participants should be able to: 1) describe the epidemiology and characterization of rhinitis;
2) delineate strategies to consider in the treatment of rhinitis; 3) explain the advantages of topical therapy for allergic rhinitis
(AR); 4) discuss the pharmacologic mechanisms underlying these advantages; and 5) describe emerging therapies for allergic and
non-allergic rhinitis.
Things to Do in Anaheim
http://microsite.anaheimoc.org/
attendees/what-to-do
Photo courtesy of AOCVCB/SeaWorld® Adventure Park
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.
Friday Symposia

Friday Luncheon Program
Platinum Ballroom 1-6 • Anaheim Marriott Hotel
Recommendations for the Management of
Patients With Anaphylaxis: A Consensus Update
Jointly Sponsored by the American College of Allergy, Asthma & Immunology (ACAAI)
and the American Association of Certified Allergists (AACA)
Supported by an independent educational grant from Mylan Specialty L.P.
Target Audience: This activity has been designed for board-certified allergists/immunologists and other health care
providers involved in the management of patients with anaphylaxis.
Learning Objectives: Upon completion of this activity, participants should be able to: 1) implement evidence-based
criteria to promptly recognize and diagnose anaphylaxis; 2) utilize intramuscular epinephrine for the treatment of an
anaphylactic episode; 3) provide patients and caregivers with education on avoidance of anaphylactic triggers and
self-management of anaphylaxis; and 4) create emergency action plans with patients and caregivers that incorporate
instructions for self-management.
Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and policies of the
Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American College
of Allergy, Asthma & Immunology (ACAAI) and the American Association of Certified Allergists (AACA). The American
College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for physicians.
Designation: American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of
2.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Moderator: Sheldon L. Spector, MD, FACAAI, President, American Association of Certified Allergists
11:30 am – 1:30 pm
With recent estimates suggesting that there has been a rise in allergic reactions, it has become critically
important that health care providers are armed with the most up-to-date information on the diagnosis,
treatment, and prevention of anaphylaxis. With 3 sets of clinical guidelines having been released
between 2010 and 2011, the ideal source of information on anaphylaxis management remains elusive.
In an educational setting, experts can better provide what must be known (diagnostic criteria, trigger
avoidance, treatment strategies, emergency action plans, etc.) to ensure that optimal care is given to
patients who are at risk for anaphylaxis, regardless of a patient’s past history or sensitivity to a given
allergic trigger.
Anaphylaxis
Phillip L. Lieberman, MD, FACAAI
Critical Issues in the Treatment of
Patients With Anaphylaxis
Lawrence M. DuBuske, MD, FACAAI
Difficult to Treat Anaphylaxis:
Case Study Review
Marianne Frieri, MD, PhD, FACAAI
Questions and Discussion

House of Delegates & Friday Program
4:00 – 6:00 pm • Room 303AB • Anaheim Convention Center
House of Delegates Meeting
and Town Hall Forum
Y
NOT FOR
CREDIT
Plan to attend the expanded House of Delegates Town Hall Forum. Pressing issues in allergy health care will be
discussed and everyone’s participation is welcome.
4:00 pm Welcome and Call to Order
Lawrence M. DuBuske, MD, FACAAI
Speaker, HOD
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
Richard W. Weber, MD, FACAAI
ACAAI President-Elect
4:10 pm Approve HOD Minutes
4:15 pm Update on the JCAAI
Richard W. Honsinger, MD, MACP, FACAAI
JCAAI President
4:30 pm Accountable Care Organizations
and the Allergy Specialist:
Navigating the System
Daniel Ein, MD, FACAAI
4:50 pm Update of Allergen Extracts and
the FDA: Where We Stand on Saving
Our Extracts
Ira Finegold, MD, FACAAI
5:10 pm New Role Proposed for Pharmacists
in Health Care Delivery: Impact on
Allergists
Bobby Q. Lanier, MD, FACAAI
5:30 pm Quorum Call
5:35 pm Election of Officers
5:40 pm Resolutions
5:50 pm New Business
6:00 pm Adjourn
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual
Scientific Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance for
most sessions.
See page 13 for details.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.
Friday Program

Friday Program
Annual Session and Business Meeting • Grand Ballroom F • Anaheim Marriott Hotel
American Association of Allergists and
Immunologists of Indian Origin
NOT FOR
CREDIT
Moderator: Mansi Kanuga, MD
Learning Objectives: Upon completion of this program, participants should be able to: 1) recognize the clinical signs and
symptoms of ocular allergies; 2) develop the differential diagnosis of ocular allergies; 3) identify use of new treatment
options in the management of allergic rhinitis; and 4) select and apply the various treatment options for ocular allergies
and allergic rhinitis.
6:00 pm Registration, Hors d’oeuvres/Cocktails
6:30 pm Update, Diagnosis and Management of
Allergic Conjunctivitis
Leonard Bielory, MD, FACAAI
7:00 pm New Treatment Options in the Management
of Seasonal and Perennial Allergic Rhinitis
William E. Berger, MD, MBA, FACAAI
7:30 pm TBD
8:00 pm Dinner
9:00 pm Adjourn
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai.conferencespot.com or snap the QR
code for a menu of online materials.
➧
ONLINE
MATERIALS

Saturday General Sessions
Breakfast Symposium • Platinum Ballroom 5-6 • Anaheim Marriott Hotel
Allergic Rhinitis: Current and Future Therapeutic
Options for the Allergist
Saturday Gen Sessions
Supported by an independent educational grant from Sunovion Pharmaceuticals Inc.
Moderator: Mark S. Dykewicz, MD, FACAAI
6:00 am Welcome and Introductions
Mark S. Dykewicz, MD, FACAAI
6:05 am The Pharmacological Basis of
Allergic Rhinitis Management: Past and Present
Therapies: What Have We Learned
Marianne Frieri, MD, PhD, FACAAI
6:55 am Individualizing Therapy for Allergic
Rhinitis: An Evidence-Based Approach
Todd A. Mahr, MD, FACAAI
7:20 am Questions and Discussion
7:30 am Adjourn
6:30 am The Pharmacological Basis of Allergic Rhinitis
Management: Emerging Therapies
Lawrence M. DuBuske, MD, FACAAI
Upon completion of this session, participants should be able to: 1) discuss past, present and recent advances in allergic rhinitis and
recent advances in allergen immunotherapy (SCIT vs SLIT); 2) review the comparison of SCIT vs SLIT, mechanisms and applications;
3) develop an individualized treatment plan for the patient with allergic rhinitis (AR); 4) discuss allergic trigger avoidance in the
management of AR; and 5) recognize where immunotherapy fits in the treatment algorithm of the patient with AR.
Theme Park Activities for
Convention Attendees
http://microsite.anaheimoc.org/attendees/
theme-parks-and-attractions/theme-parks
Photo courtesy of Knott’s Berry Farm/AOCVCB
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Saturday General Sessions
Opening Ceremony and Welcome Announcements
7:45 – 8:10 am • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Stanley M. Fineman, MD, MBA, FACAAI
President
Richard W. Weber, MD, FACAAI
Program Chair and President-Elect
Rebecca A. Goldberg, RN
Alliance President
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Managing Asthma Patients in the 21st Century
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: Bryan L. Martin, DO, FACAAI and John R. Seyerle, MD
8:10 am Welcome & Introductions
8:15 am
Daniel Goodman Lecture
Asthma
Heterogeneity:
Phenotypes and Endotypes
Sally E. Wenzel, MD, FACAAI
9:15 am Exhaled Nitric Oxide: Does It Have
a Role in Asthma Management
Rohit K. Katial, MD, FACAAI
9:45 am Practical Issues in Asthma
Management: Dealing With Confidence,
Compliance, and Satisfaction
Stanley M. Fineman, MD, MBA, FACAAI
8:45 am The Role of Vitamin D in Asthma:
Pathophysiology and Therapeutic Potentials
Michael B. Foggs, MD, FACAAI
10:15 am Questions and Discussion
10:30 am Adjourn
Upon completion of this session, participants should be able to: 1) identify ways to address asthma heterogeneity and define
phenotypes and potentially endotypes; 2) use these phenotypes and endotypes to begin to personalize the management of
asthma; 3) describe the pathophysiology of vitamin D metabolism; 4) define some of the major immunomodulatory functions of
vitamin D in association with asthma; 5) explain some of the epidemiology and seasonal variations associated with UVB band
radiation and its impact on vitamin D physiology; 6) discuss some of the controversies associated with vitamin D’s therapeutic
potentials as it relates to asthma; 7) discuss the role of the biomarker FeNO in airway inflammation; 8) identify key points of the
2011 practice guideline on the clinical applications of FeNO; 9) interpret FeNO values to aid in clinical decision making; 10) explain
why patients stop their asthma medications; and 11) discuss the concept of patient satisfaction with asthma treatment options.
10:30 – 11:00 am Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Saturday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
When Shortness of Breath Is Not Asthma
Saturday Gen Sessions
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: Bradley E. Chipps, MD, FACAAI and Travis A. Miller, MD, FACAAI
11:00 am Welcome and Introductions
11:05 am Hypersensitivity Pneumonitis/
Sarcoidosis: Clinical Presentations & Evaluation
Joshua Solomon, MD
11:55 am Swallowing Disorders & Aspiration:
Evaluation & Management
Richard W. Weber, MD, FACAAI
12:20 pm Questions and Discussion
11:30 am Autoimmune Lung Diseases: SLE, RA,
and Sjogren’s Syndrome Management
Kevin Brown, MD
12:30 pm Adjourn
Upon completion of this session, participants should be able to: 1) state the similarities and differences between granulomatous
lung diseases and asthma; 2) describe the workup of patients with suspected granulomatous lung diseases; 3) generate a list of
potential diagnoses associated with diffuse lung disease that may present with wheezing and dyspnea; 4) describe a number of
ways in which the lung is affected in the autoimmune diseases; 5) list the risk factors for chronic aspiration; 6) discuss the
diagnostic modalities available; and 7) discuss the treatment options available to minimize further aspiration.
12:30 – 1:30 pm
Visit Exhibits
Lunch On Own
(Concession Stand Open in Exhibit Hall C)
12:30 – 1:30 pm
Poster Session
Hall C
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual
Scientific Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance for
most sessions.
See page 13 for details.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Saturday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
The Great Anaphylaxis Raft Debate:
Which Is the Most Important Mediator
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: William K. Dolen, MD, FACAAI and David R. Weldon, MD, FACAAI
1:30 pm Histamine
Phillip L. Lieberman, MD, FACAAI
Nitric Oxide
Stephen F. Kemp, MD, FACAAI
Leukotrienes
Larry Borish, MD, FACAAI
3:00 pm Adjourn
Platelet Activating Factor
Mitchell H. Grayson, MD, FACAAI
Upon completion of this session, participants should be able to: 1) discuss the role of histamine in the pathophysiology of
anaphylaxis; 2) describe how histamine interacts with other mediators of anaphylaxis; 3) discuss cysteinyl leukotrienes as the most
important mediators of anaphylaxis; 4) discuss histamine, FeNO and PAF as having little if any role in causing anaphylaxis;
5) discuss the diverse roles of nitric oxide in anaphylaxis pathogenesis; 6) discuss the potential clinical relevance of nitric oxide in
refractory anaphylaxis; 7) discuss the studies that support the hypothesis that PAF is the most important mediator in anaphylaxis;
and 8) describe the beneficial effects of PAF antagonism in mouse models of anaphylaxis.
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Saturday General Sessions
Symposium • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Early Diagnosis and Treatment of
Primary Immunodeficiency (PID) in Adults:
Insights for the Practicing Allergist-Immunologist
Saturday Gen Sessions
Supported by an independent educational grant from Baxter Healthcare Corporation
Moderator: Mark Ballow, MD, FACAAI
3:30 pm Challenges in Early Diagnosis of PID in Adults
Mark Ballow, MD, FACAAI
3:40 pm PID Presenting in Later Life: Opportunities for
Earlier Diagnosis
Vincent R. Bonagura, MD, FACAAI
4:10 pm Confirming a Diagnosis of PID in Adults:
Current and Future Technologies
James Verbsky, MD, PhD
4:40 pm Management of Antibody
Deficiencies in Older Adults
Mark Ballow, MD, FACAAI
5:10 pm Questions and Panel Discussion
5:30 pm Adjourn
Upon completion of this session, participants should be able to: 1) recognize patterns of infections that correlate with specific
primary immune deficiencies; 2) discuss current testing that can help define suspected primary immune deficiencies; 3) describe
novel technologies used to define primary immune deficiencies; 4) calculate the appropriate dose of replacement
immunoglobulin (Ig) therapy for patients with antibody deficiency; and 5) determine the need for prophylactic antibiotic use in
patients with immune deficiency.
The above symposium will be featured on the ACAAI website.
21st Annual
FIT Bowl Competition
5:00 – 7:00 pm, Saturday
Grand Ballroom EF
Anaheim Marriott Hotel
Complimentary
Supported by Sanofi U.S.
NOT FOR
CREDIT
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Saturday President’s Welcome Reception
and Awards Ceremony
ACAAI President’s Welcome Reception and
Awards Ceremony
Marquis Ballroom • Anaheim Marriott Hotel • 7:30 – 9:00 pm
Supported in part by Merck
The College invites all registrants to this prestigious event where we will recognize our 2012 award recipients and
formally welcome our newly-approved Fellows.
This event begins at 7:30 pm with drinks and light appetizers, and will be followed by a short program where we
will honor our new Fellows and recognize the recipients of the Distinguished Fellow, International Distinguished
Fellow, Distinguished Service, Woman in Allergy, Young Faculty Support and the Clemens von Pirquet Awards.
Finally, we will introduce this year’s winner of the prestigious Gold Headed Cane Award, Dr. Rufus Lee, and invite
him on stage to accept the award and address the audience.
Plan to join us for this fun-filled event.
I. Welcome
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
II. Recognition of Newly-Elected Fellows
Richard W. Weber, MD, FACAAI, ACAAI President-Elect
III. Distinguished Fellow Award
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
IV. International Distinguished Fellow Award
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
V. Distinguished Service Award
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
VI. Woman in Allergy Award
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President
VII Young Faculty Support Awards
Nathan Segall, MD, FACAAI
ACAAI Foundation President
VIII. Clemens von Pirquet Awards
Rebecca A. Goldberg, RN, ACAAI Alliance President
IX. Gold Headed Cane Award
Stanley M. Fineman, MD, MBA, FACAAI
ACAAI President, and
Bobby Q. Lanier, MD, FACAAI
ACAAI Executive Medical Director
Photo courtesy of John Mairs/AOCVCB

Dr. Rufus E. Lee to Receive Gold Headed Cane Award
The College is proud to honor Rufus E. Lee,
Jr., MD, FACAAI, as this year’s recipient of
the ACAAI Gold Headed Cane Award. The
Award will be presented during the ACAAI
President’s Welcome Reception & Awards
Ceremony scheduled at 7:30 pm, Saturday,
in the Marquis Ballroom, at the Anaheim
Dr. Lee Marriott Hotel.
The ACAAI Gold Headed Cane Award is presented annually
to an allergist who has demonstrated the highest
standards of scientific excellence and integrity while
serving as a Fellow of the College for at least 20 years. It is
designed to serve as an inspiration to younger doctors and
encourage them in their family, social, civil, religious and
professional lives. Past winners include Harold S. Nelson,
MD, FACAAI; Joseph A. Bellanti, MD, FACAAI; Edward J.
O’Connell, MD, FACAAI; Elliot F. Ellis, MD, FACAAI; John C.
Selner, MD, FACAAI; Phillip L. Lieberman, MD, FACAAI; Betty
B. Wray, MD, FACAAI; Donald W. Aaronson, MD, JD, MPH,
FACAAI; Emil J. Bardana, Jr., MD, FACAAI; Raymond G.
Slavin, MD, MS, FACAAI; and Ira Finegold, MD, FACAAI.
Dr. Lee was ACAAI president, 1983-84. He orchestrated and
participated in several actions during his leadership that
helped build the College’s future foundation, including
hiring James Slawny with Executive Administration Inc.,
our current management group. Joseph Bellanti, MD,
FACAAI, also was hired as editor-in-chief of Annals of
Allergy, Asthma & Immunology, and the Annals was made
the sole property of ACAAI.
Gold Headed Cane
An extensive ACAAI membership drive recruited 200 new
members and Allergy-Immunology board-certification was
enacted as a requirement for College membership. Yearly
financial audits, the Site Selection Committee, Visiting
Professor grants and Fellows-in-Training grants were
established. The first all academic Annual Meeting was
held when Dr. Lee was program chairman. He continued
his involvement as a member of the Annals Editorial Board,
1983-90, and is current chair of the Financial Oversight
Committee.
Dr. Lee was president of the American Association of
Certified Allergists, 1985-1986, and a member of the first
Joint Council of Allergy and Immunology, 1979-1985.
Former co-chair of the Joint Task Force of Practice
Parameters, Dr. Lee worked for over 10 years as editor,
sharing responsibility for development of 20 practice
parameters and updates for all major diseases and
problems treated by allergists-immunologists.
He was founder and served as president of the Alabama
Society of Asthma, Allergy and Immunology 1975-76,
1990-91, and held many other state and county
appointments.
Dr. Lee received numerous honors including ACAAI’s
Distinguished Service Award in 1999, Distinguished Fellow
Award in 1985, and Awards of Appreciation from ACAAI
and JCAAI. He also received the Ira L. Meyers Service Award
from the Medical Association of Alabama in 2004.
Saturday Program

Sunday General Sessions
Breakfast Symposium • Platinum Ballroom 5-6 • Anaheim Marriott Hotel
Advances in Ocular Allergy:
Differential Diagnoses and Treatment
Supported by an independent educational grant from Allergan, Inc.
Moderator: Leonard Bielory, MD, FACAAI
6:15 am Welcome and Introductions
Leonard Bielory, MD, FACAAI
7:20 am Epithelial Barrier Defect and Ocular Allergy
Leonard Bielory, MD, FACAAI
6:20 am Differential Diagnosis of Ocular
Allergy/Dry Eye Syndromes: Signs
and Symptoms
Milton Hom, OD
7:50 am Panel: Presentation of Case Discussions
8:15 am Adjourn
6:50 am Treatment Update
William E. Berger, MD, MBA, FACAAI
Upon completion of this session, participants should be able to: 1) discuss questionnaires used to diagnose allergic conjunctivitis
and dry eyes; 2) describe the most common treatments for both conditions; 3) discuss the potential of the epithelial barrier defect
in allergy for lung, skin and eye; and 4) describe the potential impact of ophthalmic treatment on the ocular surface.
Photo courtesy of AOCVCB

Meet the Professor Breakfasts
Anaheim Marriott Hotel
: – : am • Admission by ticket only • Fee $ (FITs $) • Limit:
Supported by an independent educational grant from Merck
S
SOLD OUT
S
SOLD OUT
S
S
S
What Is the Current Status of SLIT
Grand Ballroom AB
Michael S. Blaiss, MD, FACAAI and
Peter S. Creticos, MD
Management of Immunodeficiency
Grand Ballroom CD
I. Celine Hanson, MD, FACAAI and
James Verbsky, MD, PhD
Assessment of Airway Reactivity:
Mannitol vs. Methacholine
Grand Ballroom GH
Aidan A. Long, MD, and
Sheldon L. Spector, MD, FACAAI
Cough in Children and Adults
Grand Ballroom JK
Alan Goldsobel, MD, FACAAI and
Pramod S. Kelkar, MD
Chronic Rhinosinusitis
Platinum Ballroom 1
Larry Borish, MD, FACAAI and
Talal M. Nsouli, MD, FACAAI (Honorary)
Sunday
S
SOLD OUT
S
S
S
S
Office Evaluation of Drug Allergy
Platinum Ballroom 2
Roland Solensky, MD and
Timothy J. Sullivan, MD, FACAAI
Eosinophilic Gastrointestinal
Disease
Platinum Ballroom 3
Amal H. Assa’ad, MD, FACAAI and
Jonathan M. Spergel, MD, PhD, FACAAI
All That Wheezes Is Not Asthma
Platinum Ballroom 4
Rohit K. Katial, MD, FACAAI
Implications of Local Allergic Responses:
Entopy
Platinum Ballroom 8
Mitchell H. Grayson, MD, FACAAI
Food Allergy: Controversies in
Therapy
Platinum Ballroom 9
A. Wesley Burks, MD, FACAAI
Sunday MTP Breakfasts
Upon completion of this session, participants should be able to: 1) discuss the requirements for SLIT approval in the US;
2) describe studies done in the US for approval of SLIT; 3) describe the mechanistic differences in newer IT approaches including
SLIT, T-cell tolerizing Peptide IT, and modified constructs including adjuvants; 4) evaluate the clinical outcomes of these
therapeutic approaches based on the data from evidence-based clinical trials; 5) discuss the clinical findings from the recent N.
American clinical trials of SLIT-tablet and SLIT-aqueous formulations in seasonal pollen-induced allergic rhinitis; 6) discuss the
diagnosis and management of primary immunodeficiencies; 7) state the purpose of bronchoconstriction challenges; 8) contrast
methacholine challenges with mannitol challenges; 9) discuss whether or not mannitol inhalation challenges will replace
methacholine challenges; 10) discuss differential diagnosis and treatment options for chronic cough; 11) describe management
strategies for habit, unexplained, idiopathic cough; 12) discuss differences in causes of chronic cough in children and adults;
13) describe approaches to treatment of chronic, idiopathic cough in adults; 14) discuss chronic hyperplastic sinusitis as it
comprises numerous distinct diseases each with its own pathogenic mechanism; 15) incorporate disease-specific approaches into
patient care and treatment of these distinct diseases; 16) discuss the pathophysiology of sinus disease and state of the art
treatment of chronic rhinosinusitis; 17) evaluate patients presenting with drug allergies with detailed drug allergy history and
available diagnostic testing; 18) manage patients with drug allergy using graded challenge or desensitization procedures;
19) identify from among their practice patients those who are likely to have an eosinophilic gastrointestinal disorder, perform the
diagnostic modalities and prescribe the most suitable therapy; 20) summarize the diagnosis criteria for eosinophilic
gastrointestinal disease (EGID); 21) describe management options for EGID; 22) describe what is meant by the term entopy and
how it relates to allergic disease; 23) describe the studies that support or refute the idea of entopy in allergic disease; 24) apply
current management strategies and therapies for IgE-mediated food allergy; 25) discuss the status of food allergen-specific
immunotherapy and other modalities in key clinical trials and studies in food allergy treatment; 26) discuss the differential
diagnosis for the wheezing patient who presents with a diagnosis of asthma; and 27) discuss appropriate evaluation for the
wheezing patient and current as well as new therapeutic options for the severe asthmatic.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Sunday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Developing Competence in Contact Dermatitis
Diagnosis and Treatment
Supported by an independent educational grant from Mylan Specialty L.P.
Moderator: David I. Bernstein, MD, FACAAI
8:30 am Welcome and Introductions
8:35 am
John P. McGovern Lecture
Defining Contact
Dermatitis: More Than Just a Rash
Luz S. Fonacier, MD, FACAAI
9:25 am Dealing Effectively With Contact
Dermatitis: Avoidance and More
Donald Belsito, MD
9:50 am Questions and Discussion
10:00 am Adjourn
9:00 am Diagnosis of Contact Dermatitis:
Beyond the Standard Test Panel
Kristin M. Leiferman, MD
Upon completion of this session, participants should be able to: 1) describe causative agents of dermatologic disorders;
2) recognize the range of allergens that may cause allergic contact dermatitis; 3) integrate the clinical presentation of allergic
contact dermatitis with exposures and immunological responses; 4) effectively counsel patients with allergic contact dermatitis in
allergen avoidance; and 5) manage and treat patients with allergic contact dermatitis in whom avoidance is not possible.
10:00 – 10:30 am Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual
Scientific Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance for
most sessions.
See page 13 for details.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Sunday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Disturbed Sleep Syndromes: More Than Snoring
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: Kevin P. McGrath, MD, FACAAI and Maeve E. O’Connor, MD, FACAAI
10:30 am Welcome and Introductions
10:35 am What Does Disturbed Sleep Mean for the
Provider and the Patient
Teofilo Lee-Chiong, MD
11:25 am The Upper Airway and Sleep
Disturbance
Richard D. deShazo, MD, FACAAI
11:50 am Questions and Discussion
11:00 am The Connection Between
Disturbed Sleep and Pulmonary Hypertension
Michael Littner, MD
Noon
Adjourn
Upon completion of this session, participants should be able to: 1) identify sleep disorders that contribute to pulmonary
hypertension; 2) identify the effects of normal sleep on respiratory conditions that contribute to pulmonary hypertension;
3) identify the important interactions between obesity, inflammation and sleep apnea; 4) enumerate the effects of sleep apnea on
various organ systems and neurocognition; 5) appropriately diagnose, treat and refer patients who have sleep disordered
breathing; 6) describe the complexity of the pathophysiology of obstructive sleep apnea and the contributions of the upper
airway to it; 7) identify sleep disorders that contribute to pulmonary hypertension; and 8) identify the effects of normal sleep on
respiratory conditions that contribute to pulmonary hypertension.
Sunday Gen Sessions
Noon – 1:00 pm
Visit Exhibits
Lunch On Own
(Concession Stand Open in Exhibit Hall C)
Noon – 1:00 pm
Poster Session
Hall C
Noon – 3:00 pm
Doctors’ Job Fair
Hall C
1:00 – 3:00 pm
Concurrent Sessions
(See pages 55-58)
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Sunday General Sessions
WAO Symposium • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Current Insights on Eosinophilic Disorders
Moderators: Ruby U. Pawankar, MD, PhD, President, WAO and Stanley M. Fineman, MD, MBA, FACAAI, President, ACAAI
1:00 pm Welcome and Introductions
1:05 pm Overview of Eosinophil Biology
Hirohito Kita, MD
1:35 pm Eosinophilic Esophagitis:
Current Insights
Amal H. Assa’ad, MD, FACAAI
2:05 pm Targeting Eosinophils in Asthma
and Allied Conditions
Lanny J. Rosenwasser, MD, FACAAI
2:35 pm Questions and Discussion
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 1) discuss the basic biology of eosinophils and the mechanisms of
eosinophilic disorders; 2) summarize new developments regarding eosinophil biology and Th2-type inflammation; 3) identify from
among their patients the ones who may have an eosinophilic gastrointesitnal disorder; 4) perform appropriate and timely
diagnostic procedures and treat the patients with the most effective treatment; 5) explain the function of eosinophils and
describe the classification of eosinophilic disorders in allergic disease; and 6) outline the treatment of eosinophilic disorders.
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.
Symposium • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Evolving Issues in the Management of Hereditary
Angioedema: Can We Reach a Consensus
Supported by an independent educational grant from ViroPharma Incorporated
3:30 pm Panelists:
Aleena Banerji, MD
Richard G. Gower, MD, FACAAI
David M. Lang, MD, FACAAI
William R. Lumry, MD, FACAAI
5:30 pm Adjourn
Upon completion of this session, participants should be able to: 1) review molecular pathways involved in the pathophysiology
of HAE; 2) use established clinical criteria to achieve early and accurate diagnosis of HAE; 3) review evidence-based strategies
for acute and prophylactic management of HAE; and 4) describe management strategies that minimize attack risk in patients
with HAE.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Sunday Concurrent Sessions
Ballroom A (3rd Floor) • Anaheim Convention Center
Session A – Adverse Food and Drug Reactions,
Insect Reactions, Anaphylaxis and Food Allergy
Moderators: Helen H. Chan, MD, FACAAI and Todd A. Mahr, MD, FACAAI
1:00 pm – Paramedic Detection of Signs and Symptoms
of Patients Calling for Possible Allergic
Reaction and Anaphylaxis
N. El Sanadi* 1 , P. Rowe-King 1 , D. Erdman 1 ,
K. Raczek 2 , K. Kutzarov 2 , 1. Fort Lauderdale, FL;
2. Miami, FL.
1:15 pm – Allergic Triggers and Profiles of Patients
Calling in a Large Urban Setting
N. El Sanadi* 1 , P. Rowe-King 1 , D. Erdman 1 ,
K. Raczek 2 , K. Kutzarov 2 , 1. Fort Lauderdale, FL;
2. Miami, FL.
1:30 pm – Penicillin Blood and Skin Prick Testing Are
Not Useful for the Clinical Diagnosis of Serious
Systemic Reactions in the United States
J.L. Mutnick*, Morris, MN.
1:45 pm – A Randomized Double Blind Placebo
Controlled Crossover Study of the Effect of
Swallowed Beclomethasone Dipropionate on
Inflammatory Markers in Adult Patients With
Eosinophilic Esophagitis: A Pilot Study
G. Ghaffari*, Hershey, PA.
2:00 pm – Anaphylaxis in America: Results From a
National Physician Survey
R. Wood* 1 , C.A. Camargo 2 , P. Lieberman 3 ,
H.A. Sampson 4 , L. Schwartz 5 , F.E. Simons 6 , M. Zitt 7 ,
M. Wilkinson 8 , C. Collins 9 , M. Tringale 9 , J. Boyle 8 ,
1. Baltimore, MD; 2. Boston, MA; 3. Germantown, TN;
4. New York, NY; 5. Richmond, VA; 6. Winnipeg, MB,
Canada; 7. Stony Brook, NY; 8. Silver Spring, MD;
9. Landover, MD.
2:15 pm – Management of Anaphylaxis: Are We
Compliant With the National Guidelines
A. Chouksey*, D. Super, P. Puri, K. Swamy,
Cleveland, OH.
2:30 pm – Age-Dependent Trends in Peanut Allergy
versus Cross-Reactive Pollen Sensitization
J. Thompson* 1 , B. Williams 2 , M. Morris 1 , 1. Onalaska,
WI; 2. Kansas City, MO.
2:45 pm – Surveillance of Alpha-Gal IgE Sensitization in
the United States
J. Hester*, L. Flebbe-Rehwaldt, A. Vatz, M. Altrich,
Lee’s Summit, MO.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 1) recognize the deficiencies and limitations of paramedic
prehospital assessment of patients with allergic reactions and anaphylaxis; 2) discuss strengths and weaknesses of paramedic
assessment and treatment of patients with allergic reactions and anaphylaxis in a prehospital setting; 3) discuss the limitations of
skin prick and blood testing for penicillin and penicillin-derivative reactions and discuss the danger of anaphylaxis with drug
provocation testing, the gold standard; 4) describe the effects of topical steroid treatment on variouse cytokines in patients with
EoE; 5) recognize potential limitations in the diagnosis and management of anaphylaxis by physicians in the U.S.; 6) discuss
compliance with the national guidelines regarding anaphylaxis and the need for prompt diagnosis and treatment to prevent fatal
outcomes and summarize the need to educate patients about home epinephrine use and advise follow up for a definitive workup;
7) distinguish peanut allergy from cross-sensitization and discuss how the prevalence of these conditions changes with the age of
the patient; and 8) identify regions of the United States that have a high prevalence of alpha-gal sensitization.
Concurrent Sessions
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.

Sunday Concurrent Sessions
Room 303AB • Anaheim Convention Center
Session B – Asthma and Other Lower Airway Disorders
Moderators: Chitra Dinakar, MD, FACAAI and John J. Oppenheimer, MD, FACAAI
1:00 pm – Diagnosis of Asthma at a Resident-Run
Primary Care Clinic
E. Karlin* 1 , M. Tang 2 , P. Korenblat 2 , 1. Nashville, TN;
2. St. Louis, MO.
1:15 pm – Relationship Between Asthma and
Depression: The Cooper Longitudinal Study
T.D. Trojan*, D.A. Khan, L.F. DeFina, E.S. Brown,
Dallas, TX.
1:30 pm – Ambulatory Fractional Exhaled Nitric Oxide
(Feno) Measurement in Children - Years of Age
J. Hanson*, S. DeLurgio, D. Williams, C. Dinakar,
Kansas City, MO.
1:45 pm – Identification of Ashtha Phenotypes at
MUSC
J.L. Kuhlen*, A.E. Wahlquist, P.J. Nietert, S.N. Bains,
Charleston, SC.
2:00 pm – Environmental Tobacco Smoke Exposure in
Children From Low-Income Families in Kansas
City and Its Influence on Asthma and IgE
Sensitization
C.E. Ciaccio*, A. DiDonna, C. Barnes,
L. Rosenwasser, J. Portnoy, Kansas City, MO.
2:15 pm – Severe Alpha - Antitrypsin (AAT) Deficiency
in a Patient With Persistent Cough
P. Bajaj*, S. Abbasi, G. Ghaffari, Hershey, PA.
2:30 pm – Assessing Usefulness and Accuracy of
Childhood Asthma Control Test (ACT) at a
University Medical Center in Mississippi
B.Q. Khan*, A. Yates, Jackson, MS.
2:45 pm – Alpha One Antitrypsin Genotypes in an
Asthma Referral Clinic
D.K. Hogarth*, Chicago, IL.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 9) recognize the disparities in medical education regarding
asthma diagnosis; 10) recognize that mild asthmatics may have current depressive symptoms beyond other comorbid conditions
and overall health status; 11) describe the relationship between FENO and multiple clinical variables and recognize office based
FENO measurement as a clinically useful tool in the management of asthma; 12) discuss a new asthmatic classification system and
describe how asthmatic patients are phenotypically classified using the SARP algorithm; 13) summarize the rates of environmental
tobacco smoke exposure in children from low-income families in the Kansas City area and summarize the influence of tobacco
smoke exposure on asthma development and IgE sensitization; 14) recognize that a diagnosis of AAT deficiency should be
considered in a patient with persistent cough or refractory asthma and describe how early diagnosis of AAT deficiency can prevent
pulmonary complications and improve patient outcomes; 15) discuss the accuracy of childhood asthma control test in assessing
asthma control in children in different population groups and educate caregivers about the importance of allowing the child to
answer questions intended for the child; and 16) describe the need for testing for alpha one antitrypsin deficiency (AATD) in
asthma patients.
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.

Sunday Concurrent Sessions
Room 303CD • Anaheim Convention Center
Session C – Aerobiology
Moderators: Joseph A. Bellanti, MD, FACAAI and Michael R. Nelson, MD, PhD, FACAAI
1:00 pm – Climate Change (CC) and Future Pollen
Production Using Intergovernmental Panel on
Climate Change Scenarios (IPCC): The Year
and
L. Bielory* 1 , Y. Zhang 2 , S. Isukapalli 2 ,
P. Georgopoulos 2 , 1. Springfield, NJ;
2. Piscataway, NJ.
1:15 pm – Ocular and Nasal Allergy in the U.S.,
- (NHANES II Vs III)
P. Panagiotis 1 , L. Bielory* 2 , 1. Piscataway, NJ;
2. Springfield, NJ.
1:30 pm – In Vitro Cross-Allergenicity Between
American Elm, Cedar Elm and Hackberry
D. Rose*, R. Gomez, K. White, San Antonio, TX.
1:45 pm – Sensitization to Pan-Allergen Predicts
Increased Skin Reactivity to Pollen Allergens
in Children
M.B. Hogan* 1 , N.W. Wilson 1 , G. Fenwick 1 , N. Mehta 1 ,
G. Plunkett 2 , E. Richardson 1 , 1. Reno, NV;
2. Redrock, TX.
2:00 pm – U.S. Internet Search Volume for Allergy-
Related Terms Compared With Pollen Counts
(-)
O. Zuckerman 1 , L. Bielory* 2 , 1. New Brunswick, NJ;
2. Springfield, NJ.
2:15 pm – Controlled Birch Pollen Distribution in the
Environmental Exposure Unit (EEU):
Confirmation of the Dispersal System
T. Walker, J. Thiele, C. Hartman, B. Hobsbawn,
A.K. Ellis*, Kingston, ON, Canada.
2:30 pm – Quantification of the Impact of Cleaning on
Surface and Airborne Allergen Associated With
Carpets
A. Southey 1 , V. Mahon 2 , M. Fox 2 , B. Mitchell* 2 ,
1. Dublin, Ireland; 2. Grand Canal Quay, Ireland.
2:45 pm – Identifying Aeroallergen Sensitization
Patterns in New Orleans for Improved
Aeroallegen Extract Selection
K. Anthony*, J.C. Carlson, L.G. Wild, New Orleans, LA.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 17) describe the potential impact of climate change on
aerobiology; 18) discuss the change in allergy skin testing and ocular and nasal symptoms in the United States based on a
national health survey; 19) identify the possible cross allergenicity patterns between American elm, cedar elm, and hackberry;
20) describe the role of pan-allergens in establishing IgE cross-sensitization and discuss how pan-allergen sensitization may alter
immunotherapy prescriptions; 21) discuss the use of internet searching for allergy terms corresponding to pollen counts;
22) explain that the Environmental Exposure Unit can be used as a model for the study of birch pollen allergic individuals;
23) quantify the effect that an intensive carpet cleaning procedure has on airborne particle counts and allergen levels at the
carpet surface; and 24) describe the techniques used for identifying pan allergen sensitizations within a population.
Concurrent Sessions
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.

Sunday Concurrent Sessions
Room 304CD • Anaheim Convention Center
Session D – Basic Science Allergy & Immunology and
Rhinitis, Other Upper Airway Disorders, Ocular Disorders
Moderators: Marianne Frieri, MD, PhD, FACAAI and Travis A. Miller, MD, FACAAI
1:00 pm – Microrna Expression in Eosinophilic
Esophagitis: A Pilot Study
N. Bhardwaj*, F.T. Ishmael, G. Ghaffari, Hershey, PA.
1:15 pm – Lung Function Impairment in Children With
Allergic Rhinitis
K. Chiong-Manaysay*, A. Andaya, Manila,
Philippines.
1:30 pm – Sino-Nasal Outcome Test (SNOT-):
A Predictor of Post-Surgical Improvement in
Patients With Chronic Sinusitis
J. Kennedy*, M. Hubbard, P. Huyett, J. Patrie,
L. Borish, S. Payne, Charlottesville, VA.
1:45 pm – Nasal Lavage Cytokine Levels After
Rhinoscopy Directed Allergen Challenge
B. Geng*, H. Wedner, St. Louis, MO
2:00 pm – Pollen and Allergies in a Changing Climate
S. Saha*, Atlanta, GA.
2:15 pm – Allergic Conjunctivitis Symptoms
Correlation With Ocular Surface Disease
Index (OSDI)
M.M. Hom* 1 , A.L. Nguyen 2 , L. Bielory 3 , 1. Azusa, CA;
2. Fullerton, CA; 3. Springfield, NJ.
2:30 pm – Clinical Predictors for the Diagnosis of Vocal
Cord Dysfunction
H.P. Windom*, U. Singh, S. Gorman, J. Bernstein,
Cincinnati, OH.
2:45 pm – High Correlation Between Responses to
Mountain Cedar Pollen in a Pollen Challenge
Chamber Versus Seasonal Exposure
D.A. Ramirez, R.L. Jacobs, N. Harper, W. He, C.
Rather, C.P. Andrews*, S.K. Ahuja, San Antonio, TX.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 25) identify diffential microRNA expression in serum of patients
with eosinophilic esophagitis compared to controls; 26) evaluate children with allergic rhinitis, investigate subtle signs of
obstruction and conduct spirometric measurements even without signs of obstructions as appropriate and discuss the
relationship between allergic rhinitis and asthma in children with allergic rhinitis and concurrent episodes of persistent coughing;
27) discuss the components of the Sino-nasal Outcome Test-22 (SNOT-22) that predict patient improvement after sinus surgery
and recognize which demographic and laboratory data may predict improvement after sinus surgery; 28) discuss techniques for
direct allergen stimulation of the nose and describe the changes in nasal cytokine level that occur rapidly following allergen
stimulation; 29) assess the association between elevated pollen levels and allergic rhinitis outpatient visits and allergy medication
refills; 30) describe the correlation between allergic conjunctivitis symptoms and dryness; 31) discuss the prevalence of vocal cord
dysfunction (VCD) in the US and identify clinical characteristics that predict a diagnosis of VCD; and 32) summarize the advantages
and limitations of potential use of pollen challenge chamber in clinical trials of therapeutic agents for allergic rhinoconjunctivitis.
3:00 – 3:30 pm Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.

Monday General Sessions
Breakfast Symposium • Platinum Ballroom 5-6 • Anaheim Marriott Hotel
Management of Allergy With Non-Prescription Drugs
Supported in part by an independent educational grant from McNeil Consumer Healthcare
Moderator: Michael B. Foggs, MD, FACAAI
6:15 am What Does History Tell Us:
The Background on OTCs
Michael B. Foggs, MD, FACAAI
7:20 am The Strategies by Allergists for
Adapting to a New Reality
William K. Dolen, MD, FACAAI
6:20 am The “System” Proposed by FDA
Using a New Paradigm
Bobby Q. Lanier, MD, FACAAI
7:50 am Questions and Discussion
8:15 am Adjourn
6:50 am The Economic Impact of a New
System for the United States Using Other
Countries’ Experiences
Michael S. Blaiss, MD, FACAAI
Upon completion of this session, participants should be able to: 1) describe options for change as outlined by FDA and
pharmacists; 2) discuss options for change as manifested by pharma: patient-pharmacist-specialist coalition; 3) discuss changes
occurring in the healthcare environment and its effect on switch of prescription to OTC status of allergy medicines; 4) describe
risks and benefits that patients face with the new OTC availability of previously prescribed allergy and asthma medications;
5) discuss how the allergist can educate the patients in order to mitigate the risks associated with inappropriate use of
medications for asthma and the other allergic diseases; 6) discuss what advice can be provided to practicing allergists to cope
with the new and evolving paradigm for drug availability for treatment of asthma and the other allergic diseases; and 7) discuss
the prospects for non-prescription management of asthma and the other allergic diseases.
Monday Gen Sessions
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Meet the Professor Breakfasts
Anaheim Marriott Hotel
: – : am • Admission by ticket only • Fee $ (FITs $) • Limit:
Supported by an independent educational grant from Merck
Monday
M
M
M
M
M
SOLD OUT
How to Use Biomarkers in Diagnosis
and Treatment of Asthma
Grand Ballroom AB
Don A. Bukstein, MD, FACAAI and
Sheldon L. Spector, MD, FACAAI
Evaluation of Immunodeficiency
Grand Ballroom CD
Mark Ballow, MD, FACAAI and
Vincent R. Bonagura, MD
Occupational Asthma
Grand Ballroom GH
David I. Bernstein, MD, FACAAI
Indoor Allergens
Grand Ballroom JK
Wanda Phipatanakul, MD, MS, FACAAI and
Jay M. Portnoy, MD, FACAAI
Dermatology for the Allergist
Platinum Ballroom 1
Gerald Gleich, MD and Kristen Leiferman, MD
M
M
M
M
M
HAE
Platinum Ballroom 2
William R. Lumry, MD, FACAAI and
Stephen A. Tilles, MD, FACAAI
Severe Asthma
Platinum Ballroom 3
Dennis K. Ledford, MD, FACAAI
Dynamic Dosing in Asthma
Platinum Ballroom 4
Bradley E. Chipps, MD, FACAAI and
John J. Oppenheimer, MD, FACAAI
Diagnostic Assessment of Airway
Inflammatory Patterns
Platinum Ballroom 8
Neal Jain, MD, FACAAI
Food Allergy: Controversies in
Diagnosis
Platinum Ballroom 9
Karen A. DeMuth, MD, FACAAI and
Chitra Dinakar, MD, FACAAI
Upon completion of this session, participants should be able to: 1) discuss broncho-challenge test as marker of inflammation and blocking the
challenge as an indicator of useful treatment; 2) discuss the advantage, disadvantage and limitation of NOe as a marker of inflammation;
3) delineate a role priostin, exhaled breath condensation and eosinophils in the blood and sputum have as markers of inflammation; 4) outline the
role of the biomarker FeNO and others in your daily care of asthma patients; 5) identify key points of the 2011 ATS practice guideline on the clinical
applications of biomarkers; 6) interpret FeNO/Biomarker values to aid in clinical decision making; 7) specify the components of the innate immune
system; 8) evaluate patients for deficiencies in innate immunity; 9) identify patients with deficiencies of the cellular (T-cell) and humoral (B-cell)
immune systems; 10) initiate laboratory evaluation and treatment of patients with T-cell and antibody deficiencies; 11) recognize adult primary
immunodeficiency and how to assess it; 12) identify some primary immunodeficiencies that commonly present in adulthood; 13) describe
approach to evaluation of occupational asthma; 14) identify effective interventions for patients diagnosed with occupational asthma; 15) define
the four components that lead to exposure, including facilitative factors, sources, reservoirs and pathways; 16) prescribe an integrated pest
management program for patients; 17) diagnose and treat problems arising from the indoor environment; 18) identify and work with qualified
home assessors and remediators; 19) discuss indoor allergens; 20) describe the role of environment in allergic disease development and morbidity;
21) utilize intervention strategies in practice; 22) interact in and expand discussions about dermatology problems faced by allergists in practice;
23) become collaborative in common patient care problems that allergists and dermatologists are presented with; 24) discuss the clinical and
laboratory features of hereditary angioedema with abnormal and normal C1-INH level; 25) summarize the current therapeutic options for
treatment of hereditary angioedema; 26) describe an evidence-based and cost-effective approach to diagnosis and management of patients with
hereditary angioedema; 27) list the available prophylactic and abortive treatment options for HAE patients; 28) compare relative costs of various
treatment approaches; 29) complete a more detailed differential diagnosis of severe asthma; 30) develop more effective treatment plans for severe
asthma; 31) discuss the literature regarding indicators of asthma exacerbation and potential interventions that may ameliorate further decay in
control; 32) identify the biologic factors that influence different measures of airway inflammation; 33) distinguish the utility of fractional exhaled
nitric oxide (FeNO), sputum eosinophils (EOS), and measures of airway hyperresponsiveness (AHR) in the diagnostic process of asthma; and
34) identify the role of FeNO, AHR, sputum EOS, periostin and other measures in determining the responsiveness to therapies for asthma; 35) utilize
dynamic dosing in asthma; 36) differentiate between proven and emerging diagnostic tests for food allergy; 37) identify clinical scenarios where
use of component resolved diagnostics might be appropriate in the evaluation of food allergy; 38) discuss the different mechanisms of food allergy
(IgE mediated, non-IgE mediated, etc.) and how that relates to testing; and 39) describe the different types of food allergy testing (Food-specific
IgE, Component resolved food specific IgE, skin prick testing, etc.)
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Monday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Are There Differences in Urticaria
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: Meagan W. Shepherd, MD and Janna M. Tuck, MD, FACAAI
8:30 am Welcome and Introductions
8:35 am Physical & Contact Urticaria:
Are They Different & What Is the Role of Further
Evaluation
Sandra M. Gawchik, DO, FACAAI
9:00 am
Bernard Berman Memorial Lecture
9:25 am Presented in memory of I. Leonard Bernstein, MD
Chronic Urticaria Management:
More Than Antihistamines
David A. Khan, MD, FACAAI
9:50 am Questions and Discussion
10:00 am Adjourn
Evaluation and
Management of
Pruritus Without Rash
Bobby Q. Lanier, MD, FACAAI
Upon completion of this session, participants should be able to: 1) identify characteristic features of the various forms of physical
urticaria and contact urticaria; 2) identify appropriate current diagnostic procedures; 3) discuss current concept, or lack thereof,
regarding the pathology of the physical and contact urticarias; 4) describe an approach to treatment based on current guidelines;
5) discuss a differential of the issue of pruritis; 6) describe treatment formats from several disciplines in medicine; 7) discuss
limitations and recommendations on testing in chronic urticaria; and 8) utilize alternative agents in refractory chronic urticaria.
10:00 – 10:30 am Refreshment Break in Exhibit Hall
Supported by Sunovion Pharmaceuticals Inc.
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2012 Annual
Scientific Meeting. This system will allow you to complete
evaluations of the certified CME sessions that you attend
which are directly sponsored by ACAAI. Upon completion
of the Overall Evaluation, Session Evaluations and credit
claiming information you will be able to immediately
access, save and/or print your certificate. Physicians will
receive a certificate of credit and other healthcare
professionals will receive a certificate of attendance for
most sessions.
See page 13 for details.
Monday Gen Sessions
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Monday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Maintenance of Certification and the Allergist
Supported by an independent educational grant from Mylan Specialty L.P.
Moderators: Chitra Dinakar, MD, FACAAI and Lyndon E. Mansfield, MD, FACAAI
10:30 am Welcome and Introductions
10:35 am The ABAI MOC Perspective and
Navigating the Process
Mary Beth Fasano, MD, FACAAI
11:00 am The MOC Non-enrolled Allergist
Charles J. Siegel, MD, FACAAI
Y
Y
11:25 am The MOC Compliant Allergist
Mark L. Corbett, MD, FACAAI
11:50 am Questions and Discussion
Noon Adjourn
Y
Upon completion of this session, participants should be able to: 1) list the four components of the ABAI Maintenance of
Certification (MOC) program; 2) describe how to access, navigate and utilize the ABAI Web Portal for MOC; 3) question the
necessity of a board certified allergist to have ongoing Maintenance of Certification (MOC) by the American Board of Allergy and
Immunology (ABAI); 4) critique the current ABAI MOC format; 5) decide the relevance of enrolling in the ABAI MOC program by
individuals who are diplomates of the ABAI and hold a time unlimited certificate; 6) describe reasons Maintenance of Certification
(MOC) is necessary for allergists; and 7) discuss potential benefits of participating in MOC.
Noon – 1:00 pm
Visit Exhibits
Lunch On Own
(Concession Stand Open in Exhibit Hall C)
1:00 – 3:00 pm
Concurrent Sessions
(See pages 63-66)
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Monday Concurrent Sessions
Ballroom B-E (3rd Floor) • Anaheim Convention Center
Session A – Clinical Immunology, Immunodeficiency
Moderators: Stuart L. Abramson, MD and Leonard Bielory, MD, FACAAI
1:00 pm – Underutilization of Self/Home On-Demand
Treatment for Attacks of Hereditary Angioedema:
Results of International Physician Survey
P. Bajaj*, M. Dispenza, T. Craig, Hershey, PA.
1:15 pm – Safety and Efficacy of Escalating Doses of
C Esterase Inhibitor [Human] as Prophylaxis in
Patients With Hereditary Angioedema (HAE)
J. Bernstein* 1 , M. Manning 2 , H. Li 3 , M.V. White 4 ,
J. Baker 5 , W.R. Lumry 6 , M. Davis-Lorton 7 ,
K. Jacobson 8 , R.G. Gower 9 , C. Broom 10 , D. Fitts 10 ,
J. Schranz 10 , 1. Cincinnati, OH; 2. Scottsdale, AZ;
3. Chevy Chase, MD; 4. Wheaton, MD; 5. Lake
Oswego, OR; 6. Dallas, TX; 7. Mineola, NY; 8. Eugene,
OR; 9. Spokane, WA; 10. Exton, PA.
1:30 pm – The Role of the Immune System in Cystic
Fibrosis: Benefits of IVIG
I. Melamed*, A. Testori, A. McDonald, Centennial, CO.
1:45 pm – B Cell Depletion in An Infant Exposed to
R-CHOP in Utero: Report of a Case
R. Mittel*, J.J. Kulik, Chicago, IL.
2:00 pm – Residual NADPH Oxidase Activity and
Isolated Lung Involvement in X-Linked Chronic
Granulomatous Disease
M.J. Gutierrez*, G.D. McSherry, F.T. Ishmael,
A.A. Horwitz, G.R. Nino, Hershey, PA.
2:15 pm – The Effect of Demographics on IgG, IgA and
IgM in a Large Pediatric Population With
Recurrent Infections
A. Mehta* 1 , G. Ye 2 , S.J. McGeady 1 , C. Chang 1 ,
1. Philadelphia, PA; 2. Orlando, FL.
2:30 pm – All in the Family: Siblings Diagnosed With
C Deficiency After Nongroupable
Meningococcal Meningitis
B.A. Locke* 1 , M.K. Hintermeyer 2 , J.M. Routes 2 ,
J.W. Verbsky 2 , 1. Marshall, WI; 2. Milwaukee, WI.
2:45 pm – Variable Clinical Phenotype in a Kindred
With STAT Deficiency/Hyper-IgE Syndrome
A.W. Boyd* 1 , T. Atkinson 2 , H. Schroeder 2 ,
A. Cajacob 2 , 1. Gainesville, AL; 2. Birmingham, AL.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 33) discuss that HAE attacks may be effectively treated by ondemand
self/home treatment and recognize that recommended self/home treatment is minimally utilized by physicians treating
HAE at international level; 34) summarize the results of an open-label study of a C1 esterase inhibitor [human] dose escalation in
patients with hereditary angioedema; 35) recognize the various forms of cystic fibrosis mutations and the benefit of IVIg therapy;
36) discuss the potential complications in the newborn of in utero exposure to B cell-depleting chemotherapy agents, such as
CHOP alone or combined with rituximab (R-CHOP) and summarize the associated immunologic defects, notably absence of
peripheral blood B cells and hypogammaglobulinemia in the newborn, and the appropriate management of these defects;
37) identify chronic granulomatous disease as a disorder with variable phenotype that correlates closely with residual NADPH
oxidase activity independenly of the gene affected; 38) identify and discuss how demographics can affect immunoglobulin levels;
39) discuss terminal complement deficiencies, despite no previous infections and describe the familial nature of some
immunodeficiencies; and 40) identify clinical features of autosomal dominant Hyper-IgE syndrome and unique features of
this kindred.
3:00 – 3:30 pm Refreshment Break in Ballroom B-E Foyer
Supported by Sunovion Pharmaceuticals Inc.
Concurrent Sessions

Monday Concurrent Sessions
Ballroom A (3rd Floor) • Anaheim Convention Center
Session B – Food Allergy
Moderators: Karen A. DeMuth, MD, FACAAI and Santiago E. Martinez, MD, FACAAI
1:00 pm – Microarray Component Testing in
Association With IgE Mediated Food Allergy: A
Retrospective Analysis Assessing Performance of
Multiple Versus Individual Components
I. Fung* 1 , J.S. Kim 2 , J.M. Spergel 1 , 1. Philadelphia, PA;
2. New York, NY.
1:15 pm – The High Economic Burden of Childhood
Food Allergy in the United States
R. Gupta*, L. Bilaver, D. Holdford, A. Dyer, C.H. Lau,
J. Pongracic, J.L. Holl, D. Meltzer, Chicago, IL.
1:30 pm – Childhood Food Allergy Tolerance and
Associated Factors
R. Gupta*, C.H. Lau, E.E. Springston, B. Smith,
J. Pongracic, S.M. Boudreau-Romano, J.L. Holl,
Chicago, IL.
1:45 pm – Poor Predictability of Specific IgE and Skin
Prick Testing to Sesame as Demonstrated by Oral
Food Challenge
J. Kattan*, J.A. Lieberman, M. Vitale, H.A. Sampson,
A.L. Cox, New York, NY.
2:00 pm – Identifying Characteristics in Egg-Allergic
Subjects to Predict Heated Egg Tolerance:
A Retrospective Review
N.U. Swamy*, M. Crain, J.A. Bird, Dallas, TX.
2:15 pm – Investigation of Eosinophilic Esophagitis in
Adults Using Skin Testing, ImmunoCAP, and
ImmunoCAP ISAC IgE Quantitation
A. Tripathi* 1 , L.J. Workman 1 , C.B. Cho 2 , A.S. Clark 1 ,
R.G. Hamilton 3 , T.A. Platts-Mills 1 , E.A. Erwin 2 ,
1. Charlottesville, VA; 2. Columbus, OH;
3. Baltimore, MD.
2:30 pm – Baked Egg Oral Food Challenges:
A Single-Center Pediatric Hospital Experience
R.W. Saltzman*, M. Kelleher, J.M. Spergel,
Philadelphia, PA.
2:45 pm – A Significant Proportion of Patients With
Symptoms During an Oral Food Challenge Can
Successfully Complete the Challenge
I. Mikhail* 1 , L. Arnold 2 , S. Mancia 2 , H. Robinson 2 ,
A. Sprunger 2 , A. Troger 2 , D. Mansoor 2 , C. Nguyen 2 ,
H. Sharma 2 , 1. Arlington, VA; 2. Washington, DC.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 41) discuss the use of microarray in the diagnosis of food allergy
and summarize the advantages, disadvantages and limitations of this technique in clinical practice; 42) summarize the direct and
indirect costs of childhood food allergy and discuss major components of both the direct and indirect costs; 43) discuss the
frequency of tolerance to food allergy among children in the US and identify food allergies that children are likely to outgrow and
discuss symptoms and other factors associated with the development of tolerance; 44) discuss the limitations of current
diagnostic testing for sesame allergy; 45) identify characteristics that predict heated egg tolerance in egg-allergic subjects;
46) discuss food and aeroallergen sensitivity patterns in adult patients with eosinophilic esophagitis (EoE) through skin and serum
IgE testing with component analysis, as related to dietary therapy and disease management; 47) discuss the emerging phenotypes
of food allergy (heated egg, native egg) and implications for development of tolerance; and 48) discuss possible outcomes of oral
food challenges following signs or symtoms during the challenge.
3:00 – 3:30 pm Refreshment Break in Ballroom B-E Foyer
Supported by Sunovion Pharmaceuticals Inc.

Monday Concurrent Sessions
Room 303AB • Anaheim Convention Center
Session C – Allergy Testing, Clinical Laboratory Immunology,
Immunotherapy/Immunizations and Other
Moderators: Ira Finegold, MD, FACAAI and J. Andrew Grant, MD, FACAAI
1:00 pm – Are Primary Care Offices Equipped to
Handle AIT Related Adverse Events
R.E. Parker* 1 , M. Lunn 2 , 1. South Portland, ME;
2. Portland, ME.
1:15 pm – A Comparative Study of the SPT and
Specific IgE in Patients of Bronchial Asthma
and Rhinitis
R. Kumar*, G. Mahakud, M. Kumar, I. Bisht,
S. Mathew, Delhi, India.
1:30 pm – Safety of Subcutaneous Allergy
Immunotherapy in Children < Years of Age With
Recurrent Wheeze
R.J. Epstein* 1 , Y. Pichardo 2 , R. Nazari 2 , M. Chin 2 ,
A. Wiznia 2 , D. Rosenstreich 2 , G. de Vos 2 , 1. New York,
NY; 2. Bronx, NY.
1:45 pm – Influence of Allergen Specific
Immunotherapy on Mitogen-Activated Protein
Kinase in Blood Serum of House Dust Mite
Allergic Patients
R. Gawlik* 1 , B. Jawor 1 , L.M. DuBuske 2 , 1. Katowice,
Poland; 2. Gardner, MA.
2:00 pm – Systemic Reactions to Inhalant
Immunotherapy in an Academic Practice Using
: Target Dosing
A. DeZure*, C.L. Holland, K.M. Samuels, E. Reed,
J. Postma, J.L. Baldwin, M.J. Greenhawt, Ann
Arbor, MI.
2:15 pm – Safe and Effective Rush Immunotherapy:
A Cumulative Experience of Patients
W. Smits 1 , J.T. Inglefield* 2 , 1. Fort Wayne, IN;
2. Hickory, NC.
2:30 pm – Improving the Quality of Care for
Hereditary Angioedema Patients
G. Sabharwal*, T.J. Craig, Hershey, PA.
2:45 pm – Is Localized Seminal Plasma
Hypersensitivity Associated With Infertility
J. Bernstein, J.S. Tan*, Cincinnati, OH.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 49) discuss adverse events related to allergen immunotherapy
(AIT) as well as the primary care physician’s role in administering AIT and summarize the practice parameters and up to date
protocols used in the event of an adverse reaction; 50) discuss the standard tools used to measure different allergens;
51) summarize the safety and severity of local and systemic reactions of immunotherapy in children less than 4 years of age;
52) discuss the influence of allergen specific immunotherapy on mitogen-activated protein kinase in serum of house dust mite
allergic patients; 53) identify risk factors for systemic reactions to subcutaneous immunotherapy, as well as the risks that may
result from dosing of subcutaneous immunotherapy at 1:1 maintenance target, in a large, academic population and describe
which aspects of use of 1:1 maintenance target dosing show equivocal safety to use of lesser concentration maintenance dosing;
54) discuss rapid desensitization and that premedication reduces systemic reaction rates and recognize that lower targeted end
point dosages for rapid desensitization minimizes anaphylaxis; 55) care for hereditary angioedema patients in accordance with
evidence based guidelines; and 56) identify the relationship between localized SPH and infertil and discuss the lack of correlation
between treatment response to localized SPH and infertility.
3:00 – 3:30 pm Refreshment Break in Ballroom B-E Foyer
Supported by Sunovion Pharmaceuticals Inc.
Concurrent Sessions

Monday Concurrent Sessions
Room 303CD • Anaheim Convention Center
Session D – Pharmacology/Pharmacotherapeutics
and Skin Disorders
Moderators: Luz S. Fonacier, MD, FACAAI and Jay M. Portnoy, MD, FACAAI
1:00 pm – Omalizumab in the Treatment of Severe
Refractory Chronic Idiopathic Urticaria
C. Song*, S. Stern, S. Maclachlan, N. Leader,
G.L. Sussman, Toronto, ON, Canada.
1:15 pm – Paramedic Assessment and Treatment of
Patients With Allergic Reactions and Anaphylaxis
in a Large Urban Pre-Hospital System
N. El Sanadi* 1 , P. Rowe-King 1 , D. Erdman 1 ,
K. Raczek 2 , K. Kutzarov 2 , 1. Fort Lauderdale, FL;
2. Miami, FL.
1:30 pm – Efficacy and Retention of Epinepherine
Auto-Injector Training
R.Q. Chaudhry* 1 , A. Wolff 2 , 1. Jersey City, NJ;
2. Newark, NJ.
1:45 pm – Comparison of Treatments for Chronic
Idiopathic Urticaria
J. Stitt*, R. Katial, Denver, CO.
2:00 pm – Nickel and Cobalt Content in Cell Phones in
the United States
T. Mucci*, A. Shaikh, M. Davis-Lorton, M.R. Aquino,
L.S. Fonacier, Mineola, NY.
2:15 pm – High-Dose Bilastine Is Effective in Reducing
Temperature Thresholds in Cold Contact
Urticaria
K. Krause*, A. Spohr, M.K. Church, T. Zuberbier,
M. Maurer, Berlin, Germany.
2:30 pm – A Case of Cutaneous T-Cell Lymphoma
Presenting as Steroid-Dependent Eczema
D.S. Gupta* 1 , J. Boggavarapu 2 , C.H. Kirkpatrick 3 ,
S.C. Dreskin 3 , 1. Denver, CO; 2. Lakewood, CO;
3. Aurora, CO.
2:45 pm – Asthma Symptoms: Potential Guide to the
Persistence of Atopic Dermatitis
J.P. Garrett*, D.J. Margolis, Philadelphia, PA.
3:00 pm Adjourn
Upon completion of this session, participants should be able to: 57) discuss omalizumab as an effective treatment for severe
chronic refractory idiopathic urticaria, and that it may induce complete remission in some patients and describe the effects of
omalizumab in the management of severe chronic refractory idiopathic urticaria that may be evident at a low dose (150 mg
subcutaneously); 58) discuss strengths and weaknesses of paramedic (prehospital) treatment for allergic reactions and
anaphylaxis; 59) describe deficiencies in current training of auto-injector usage and discuss practical methods of auto-injector
training for patient's who require epinephrine; 60) identify the rate of response of chronic urticaria patients to antihistamines and
name several immunomodulatory therapies for antihistamine resistant chronic urticaria; 61) identify nickel and cobalt content in
cellular phones and educate patients with a history of allergic contact dermatitis to these metals as to which phones are nickel
and cobalt free; 62) diagnose and treat cold contact urticaria more effectively; 63) identify patients with dermatitis who should be
screened for cutaneous T cell lymphoma and describe the diagnostic utility of an assay for T cell receptor clonality; and 64) list
specific symptoms that are consistent with asthma and summarize the symptoms of asthma that may influence control of atopic
dermatitis symptoms.
3:00 – 3:30 pm Refreshment Break in Ballroom B-E Foyer
Supported by Sunovion Pharmaceuticals Inc.

Monday General Sessions
Symposium • Ballroom B-E (3rd Floor) • Anaheim Convention Center
FeNO: A Paradigm Shift in Personalized Asthma Management
Monday Gen Sessions
Supported by an independent educational grant from Aerocrine
Moderator: James M. Seltzer, MD, FACAAI
3:30 pm Welcome and Introductions
James M. Seltzer, MD, FACAAI
3:35 pm Overview of FeNO in the Pathophysiology of
Inflammatory Airway Disease
Warner W. Carr, MD, FACAAI
4:05 pm Role of FeNO in the Diagnosis of
Asthma and Non-Specific Respiratory
Symptoms
Neal Jain, MD, FACAAI
4:35 pm Health Economic Impact of Using
FeNO in Asthma Diagnosis and Management
Myron J. Zitt, MD, FACAAI
5:05 pm Questions and Discussion
5:30 pm Adjourn
Upon completion of this session, participants should be able to: 1) identify the key biologic process that results in the
upregulation of iNOS and the production of FeNO; 2) demonstrate the utility of FeNO as a marker of likelihood to respond to ICS
in asthma and other respiratory conditions; 3) compare the utility of FeNO to other modalities in the diagnosis of the complex
clinical syndrome that is asthma; 4) recognize the economic impact of asthma; and 5) discuss the role of fractional exhaled nitric
oxide (FeNO), a measurement of airway inflammation (“Inflammometry”), to improve outcomes, in an effort to decrease costs.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Annual Business Meeting
Platinum Ballroom 5-6 • Anaheim Marriott Hotel
Tribute to Our Past Presidents
NOT FOR
CREDIT
The College will pay tribute to its leaders at the Past Presidents’ Breakfast, 7:00 am, Tuesday, in the Platinum Ballroom 5-6
at the Anaheim Marriott Hotel. All registrants and their registered spouses/guests are invited to join in the tribute at the
complimentary breakfast. The ACAAI Annual Business Meeting will follow the breakfast.
7:00 am
Past Presidents’ Breakfast
All registrants invited
7:30 am Annual Business Meeting
Stanley M. Fineman, MD, MBA, FACAAI
President, American College of Allergy,
Asthma & Immunology
Annual Business Meeting
7:30 – 8:45 am, Tuesday
Agenda
I. Call to Order – Stanley M. Fineman, MD, MBA, FACAAI
II. Approval of 2011 Minutes and Standing Rules – Stanley M. Fineman, MD, MBA, FACAAI
III. Historian’s Report – Joseph A. Bellanti, MD, FACAAI
IV. Alliance President’s Address –Rebecca A. Goldberg, RN
V. Recognition of Retiring Regents – Stanley M. Fineman, MD, MBA, FACAAI
VI. Nominating Committee Report and Election of Officers – Sami L. Bahna, MD, DrPH, FACAAI
VII. Presentation of New Officers and Regents – Stanley M. Fineman, MD, MBA, FACAAI
VIII. Installation of New President – Stanley M. Fineman, MD, MBA, FACAAI
IX. President’s Acceptance – Richard W. Weber, MD, FACAAI
X. Presentation to Retiring President – Richard W. Weber, MD, FACAAI
XI. New Business – Richard W. Weber, MD, FACAAI
XII. Adjournment – Richard W. Weber, MD, FACAAI

Tuesday General Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Supported by an independent educational grant from Mylan Specialty L.P.
Moderator: Leonard Bielory, MD, FACAAI
9:00 am
Bela Schick Lecture
The Future of
Allergy: What Would Bela Do
James L. Sublett, MD, FACAAI
Upon completion of this session, the participants should be able to: 1) improve patient care by applying the concept of patientfocused
care; 2) improve patient care by embracing practice parameters; and 3) improve community awareness of allergists
through public relations.
Tuesday Gen Sessions
Plenary Session • Ballroom B-E (3rd Floor) • Anaheim Convention Center
Integrative Medicine for the Allergist-Immunologist
Supported by an independent educational grant from Mylan Specialty L.P.
Moderator: Leonard Bielory, MD, FACAAI
9:30 am Welcome and Introductions
10:25 am
Anjuli S. Nayak Lecture
9:35 am Integrative Medicine and
Allergy-Immunology: Why Should We Care
Use of Traditional Chinese
Medicine in Food Allergy
Gailen D. Marshall, MD, PhD, FACAAI
Julie Wang, MD
10:00 am Use of Herbals in Our Allergy
Practices: Whether You Like it or Not
William S. Silvers, MD, FACAAI 10:50 am Questions and Discussion
Upon completion of this session, participants should be able to: 1) describe the components of care that define integrative
medicine; 2) define how an integrative approach, including conventional, complementary and spiritual aspects, can be used to
provide optimal care for allergy, asthma and immunology patients; 3) identify potential uses and adverse effects of herbs and
vitamin supplements in allergic and immunologic disorders for application in their practices; 4) demonstrate an increased
understanding of the impact and importance of complementary and alternative medicine (CAM) use in the United States moving
forward, resulting in improved communication of alternative options to the patient; 5) discuss the effects of Traditional Chinese
Medicine (FAHF-2) in a murine model of food allergy; and 6) describe recent clinical trials using FAHF-2 for food allergic patients.
11:00 am Meeting Adjourns
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Advanced Practice Health Care Providers Course
Grand Ballroom E • Anaheim Marriott Hotel
Separate Registration Fee • Admission by ticket only
Friday
Target Audience: Nurse practitioners, physician assistants, allergy/immunology nurses, other health care providers with extensive
experience, and physicians.
Overview: This course is designed for those in advanced practice, including allied health professionals and physicians who want to
network with other professionals, interactively learn state-of-the-art treatment of asthma, allergy-related dermatologic conditions,
hereditary angioedema, recurrent infections, eosinophilic esophagitis, pulmonary function testing, updated pharmacotherapy in
allergic and respiratory disease, and the use of technology in patient education.
Learning Objectives: Upon completion of this session, participants should be able to: 1) discuss signs and symptoms, testing and
treatment of recurrent infections; 2) discuss presentation, diagnostic testing and treatment options for hereditary angioedema;
3) describe and discuss most common skin rashes seen in an A/A/I office; 4) discuss presentation, testing and treatment of severe
and difficult-to-treat asthma; 5) discuss and apply current technology to teach patients in A/A/I practice; 6) discuss and interpret
pharmacotherapy for asthma; and 7) identify various presentations for eosinophilic esophagitis; and 8) discuss up-to-date
pharmacotherapy for asthma, COPD, allergic rhinoconjunctivitis and sinusitis.
Nursing Accreditation: Provider approved by the California Board of Registered Nursing, Provider Number 14486 for
8.7 contact hours.
Moderator: Deidra H. Sanders MSN, FNP-BC
Moderator: Charlotte M. Jacobsen, RN, MSN
8:00 am Introduction
Deidra H. Sanders MSN, FNP-BC
8:05 am Recurrent Infections
Paul V. Williams, MD, FACAAI
8:55 am Angioedema/HAE
Aleena Banerji, MD
9:45 am Refreshment Break (Foyer)
10:00 am Rashes and Itches in an
Allergy Practice
David R. Weldon, MD, FACAAI
10:50 am Severe and Difficult to Control
Asthma (Problem Based Learning format)
Gwen Carlton, DNP, AE-C and
Ray S. Davis, MD, FACAAI
11:40 am Allergy and Asthma Education in an
Ever-Changing World of Technology
Kathy Chojnacki, RN, MSN, CPNP-AC and
Jodi Shroba, RN, MSN, CPNP
12:30 pm Lunch (on your own)
Upon completion of this session, participants should be able to: 1) list criteria for when patients should be evaluated for an
immunodeficiency; 2) order preliminary tests appropriate for the type of infections presented; 3) discuss the pathophysiology of
hereditary angioedema; 4) discuss the clinical presentation and evaluation of hereditary angioedema; 5) develop a management
approach for both acute and prophylactic therapies for hereditary angioedema; 6) define the differential diagnoses for the most
common rashes seen in an allergist's practice; 7) recognize common dermatoses found in an allergist's practice; 8) interactively
discuss the differential diagnosis of a patient with exercise-induced dyspnea; 9) evaluate and treat a patient with exercise-induced
dyspnea in an interactive PBL group discussion; 10) recognize the expanding role of technology in health care education and the
benefits of using mobile devices and smart applications in patient education and treatment; and 11) describe current applications
that are available for allergy and asthma patients.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Advanced Practice Health Care Providers Course
1:30 – 3:00 pm
Anaheim Marriott Hotel
Separate Registration Fee • Admission by ticket only
Friday
Interactive Concurrent Workshops
3:15 – 4:45 pm
AP Pulmonary Function Testing for
Advanced Practice
Grand Ballroom E
Mary Kay Bossard BS, RRT, AE-C and
Concettina Tolomeo, DNP, AE-C
AP Eosinophilic Esophagitis, GER,
FPIES: Belly Pain
Grand Ballroom AB
Seema S. Aceves, MD, PhD
AP Pharmacology for
Advanced Practice
Grand Ballroom CD
Maureen George PhD, RN, AE-C and
Mary Lou Hayden MS, FNP-BC, AE-C
3:00 pm Refreshment Break (Grand Ballroom Foyer)
AP Pulmonary Function Testing for
Advanced Practice
Grand Ballroom E
Mary Kay Bossard BS, RRT, AE-C and
Concettina Tolomeo, DNP, AE-C
AP Eosinophilic Esophagitis, GER,
FPIES: Belly Pain
Grand Ballroom AB
Seema Aceves, MD, PhD
AP Pharmacology for
Advanced Practice
Grand Ballroom CD
Maureen George PhD, RN, AE-C and
Mary Lou Hayden MS, FNP-BC, AE-C
4:45 pm Adjourn
Health Care Providers
Upon completion of this session, participants should be able to: 1) identify indications and measurements related to spirometry;
2) identify indications and measurements related to spirometry; 3) list possible results of spirometry and steps for interpretation of
spirometry; 4) explain the clinical presentations and differences between GERD, EoE and FPIES; 5) compare and contrast the
mechanisms of action of the different bronchodilators used in patients who have both asthma and COPD; 6) explore alternative
explanations for "steroid resistance"; 7) discuss recently approved and some investigational medications for allergic rhinitis and
allergic conjunctivitis; 8) discuss 2012 recommendations from IDSA for treatment of acute sinusitis; and 9) discuss patient and
family education regarding newer medications.
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai.conferencespot.com or snap the QR
code for a menu of online materials.
➧
ONLINE
MATERIALS
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Allied Health Professionals Course
Ballroom A (3rd Floor) • Anaheim Convention Center
Saturday Interactive Panels
Separate Registration Fee • Admission by ticket only
Target Audience: Health professionals including, but not limited to, RNs, LPNs/LVNs, NPs, PAs, RTs, and medical assistants.
Learning Objectives: Upon completion of this activity, participants should be able to: 1) discuss the risk factors and diagnosis
of acute and chronic sinusitis and the pros and cons of pharmacologic and non-pharmacologic treatment; 2) identify various
presentations and state-of-the-art diagnostic testing and treatment options for eosinophilic esophagitis, vocal cord
dysfunction, anaphylaxis, common rashes and ocular allergy; 3) discuss the impact of culture and health literacy and develop
culturally and literacy appropriate educational materials; 4) perform accurate basic spirometry; 5) discuss performance and
interpretation of pulmonary function testing and apply to patient case presentations; 6) discuss risk factors, presentation, and
treatment of pharmacotherapy in A/A/I practice and appropriate patient/family education; and 7) describe ordering,
interpretation and patient/family education associated with most commonly ordered laboratory tests in A/A/I practice.
Accreditation: Provider approved by the California Board of Registered Nursing, Provider #CEP 14486, for 12.0 contact hours.
Moderator: Maureen George PhD, RN, AE-C
Moderator: Mary Lou Hayden, RN, MS, FNP-BC, AE-C
8:00 am Welcome
David A. Khan, MD, FACAAI and
Mary Lou Hayden, RN, MS, FNP-BC, AE-C
10:00 am Dermatology in the Allergy
Office
Jeannette Arnold, NP
8:05 am Sinusitis
Sheldon L. Spector, MD, FACAAI
8:55 am Eosinophilic Esophagitis, GER,
FPIES: Belly Pain
Seema S. Aceves, MD, PhD
9:45 am Refreshment Break (back of room)
10:50 am Cultural Diversity and Health
Literacy
Maureen George PhD, RN, AE-C
11:40 am Questions and Answers/Panel Discussion
Noon Lunch (on your own)
Upon completion of this session, participants should be able to: 1) discuss the pathogenesis, the etiology, predisposing factors
and diagnosis of acute sinusitis; 2) contrast the microbiology and treatment of acute and chronic sinusitis; 3) explain the clinical
presentation of EoE and explain the differences between EoE and GERD; 4) explain the clinical presentation of FPIES; 5) discuss key
clinical indicators toward identifying some of the most common skin dermatoses found in the allergy office; 6) identify
pathologies associated with chronic urticaria; 7) describe reasons why knowledge alone is not sufficient to explain, predict and
modify patient self-management behaviors; 8) implement an approach for obtaining culturally relevant perspectives of health and
health literacy levels; and 9) modify teaching plan based on one of these.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Allied Health Professionals Course
Anaheim Marriott Hotel
Saturday Interactive Concurrent Workshops
2:00 – 3:15 pm
3:30 – 4:45 pm
SA Hands-on Basic
Spirometry
Grand Ballroom AB
Mary Kay Bossard BS, RRT, AE-C and
Karen Gregory, DNP, AE-C
SA Advanced PFT: What to Order
and How to Interpret
Grand Ballroom CD
Concettina Tolomeo, DNP
SA Obstructive Sleep
Apnea
Grand Ballroom GH
Gwen Carlton, DNP and Kimberly Clay, NP
SA Competency and
Procedural Skills
Grand Ballroom JK
Cheryl A. Blackwell, RN and Deidra Sanders, NP
SA Allergen Extracts:
Evidence-based Vaccines Orange County 1 & 2
Cheryl Bernstein, BSN
SA Pharmacology in Allergy
and Asthma: Update and Orange County 3 & 4
Patient/Family Education
Maureen George PhD, RN, AE-C and
Mary Lou Hayden, RN, MS, FNP-BC, AE-C
3:15 pm Refreshment Break (Grand Ballroom Foyer)
SA Hands-on Basic
Spirometry
Grand Ballroom AB
Mary Kay Bossard BS, RRT, AE-C and
Karen Gregory, DNP, AE-C
SA Advanced PFT: What to Order
and How to Interpret
Grand Ballroom CD
Concettina Tolomeo, DNP
SA Obstructive Sleep
Apnea
Grand Ballroom GH
Gwen Carlton, DNP and Kimberly Clay, NP
SA Competency and
Procedural Skills
Grand Ballroom JK
Cheryl A. Blackwell, RN and Deidra Sanders, NP
SA Allergen Extracts:
Evidence-based Vaccines Orange County 1 & 2
Cheryl Bernstein, BSN
SA Pharmacology in Allergy
and Asthma: Update and Orange County 3 & 4
Patient/Family Education
Maureen George PhD, RN, AE-C and
Mary Lou Hayden, RN, MS, FNP-BC, AE-C
4:45 pm Adjourn
Health Care Providers
Upon completion of this session, participants should be able to: 1) identify ATS criteria for performance of spirometry;
2) demonstrate proper procedure for obtaining a valid, reproducible test and recognize two problems that may result in
inaccurate or invalid tests; 3) list indications for at least three different types of pulmonary function tests; 4) describe how to
interpret at least 2 different pulmonary function tests; 5) assess patients for the presence of signs and symptoms related to sleep
apnea and select which patients would benefit from referrals for sleep studies; 6) offer patients advice with regard to treatments
for sleep apnea and discuss the relationship between asthma & OSAS; 7) develop a comprehensive approach to assess the
cognitive and psychomotor skills of clinical staff to promote optimal patient care delivery; 8) describe how the identification of
staff strengths and weaknesses associated with procedure performance can be fostered, remediated and incorporated into the
annual review process; 9) describe the methods used to decrease the risk of bacterial contamination during extract preparation
and mixing; 10) discuss compliance with USP chapter 797; 11) describe the qualifications and certification process of the
compounding personnel; 12) compare and contrast priming, care and administration requirements for asthma MDIs and DPIs;
13) implement discussion of black box warnings to address a variety of patient concerns; 14) discuss recently approved
medication for allergic rhinitis and allergic conjunctivitis; 15) discuss pertinent patient and family education regarding
pharmacotherapy for allergic rhinoconjunctivitis; and 16) discuss 2012 recommendations from IDSA for the treatment of sinusitis.
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Allied Health Professionals Course
Ballroom A (3rd Floor) • Anaheim Convention Center
Sunday Interactive Panels
Moderator: Kimberly Clay, NP
Moderator: Gwen Carlton DNP, AE-C
8:00 am Ocular Allergy
Leonard Bielory, MD, FACAAI
8:50 am Anaphylaxis
David A. Khan, MD, FACAAI
9:40 am Refreshment Break (back of room)
10:00 am Vocal Cord Dysfunction: Diagnosis
and Treatment
Stephen A. Tilles, MD, FACAAI and
Karen Drake, MA, SLP
10:50 am Common Labs in Allergy
Christine Wagner, MSN, CPNP, FNP-BC, AE-C
11:40 am Question and Answer/Panel Discussion
Noon
Adjourn
Upon completion of this session, participants should be able to: 1) recognize the various clinical presentations of anaphylaxis;
2) describe the various etiologies of anaphylaxis; and 3) discuss the appropriate management of anaphylaxis; 3) describe the
major phenotypes of vocal cord dysfunction and how they are diagnosed; 4) feel confident with how speech pathologists
employ relaxed breathing exercises as a treatment for vocal cord dysfunction; 5) identify commonly ordered tests used in
allergy/immunology practice; 6) discuss what are normal vs abnormal results; and 7) describe appropriate patient education for
abnormal test results.
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai.conferencespot.com or snap the QR
code for a menu of online materials.
➧
ONLINE
MATERIALS
See page 17 for ACGME Competencies. • Y Sessions that may be of interest to young physicians.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
All Scientific Posters will be on display in Hall C beginning Saturday morning. Authors of these posters are requested to be
at their poster to discuss their work from 12:30 – 1:30 pm, Saturday and from Noon – 1:00 pm, Sunday.
Adverse Food and Drug Reactions, Insect
Reactions, Anaphylaxis
P
Utility of a Web Site Based Database of Drug
Allergy: Perceptions of Staff Allergists in Canada
T. Pun* 1 , Z. Abdurrahman 2 , A. Noyek 3 , R. Warrington 1 ,
1. Winnipeg, MB, Canada; 2. Hamilton, ON, Canada;
3. Toronto, ON, Canada.
P Successful Desensitization Protocol to L-
Asparaginase in a Boy With Acute Lymphoblastic
Leukemia
C.T. Quezada-Chalita* 1 , M. Castells 2 , G. Castellanos 3 ,
1. Mexico City, DF, Mexico; 2. Boston, MA; 3. Tepic, NA,
Mexico.
P High Dose Fluconazole Desensitization
M. Demirjian* 1 , J.S. Yusin 2 , 1. Granada Hills, CA; 2. Los
Angeles, CA.
P Rates of Honey Bee Sting Anaphylaxis in San
Antonio During “Honey Bee Colony Collapse”
B. Coons*, J. Quinn, San Antonio, TX.
P A Case of Post-Procedure Anaphylaxis
A. Trikha*, R.S. Bonds, Galveston, TX.
P Rapid Oral Desensitization to Trimethoprim-
Sulfamethoxazole in a Child of Years Old
With AIDS
G.A. Ricartti Humarán*, B.E. Del Rio Navarro, J. Del
Rio C, M.A. Rosas Vargas, Mexico City, DF, Mexico.
P A Case of IgE Mediated Anaphylaxis to Peppermint
R. Bayat, R. Borici-Mazi*, Kingston, ON, Canada.
P A Retrospective Database Study of US Patients
Treated in the Emergency Department (ED) or
Hospital With Anaphylaxis: Factors Associated
With Severe Anaphylaxis
S. Clark 1 , S. Rudders 2 , W. Wei* 3 , C. Camargo 4 , 1. New
York, NY; 2. Providence, RI; 3. Bridgewater, NJ;
4. Boston, MA.
P Infliximab-Graded Challenge in a Patient With
Crohn’s Disease and Adalimumab Hypersensitivity
C. Song* 1 , J. Quirt 2 , J.K. Lee 1 , 1. Toronto, ON, Canada;
2. Hamilton, ON, Canada.
P A Retrospective Database Study of US Patients
With an Emergency Department (ED) Visit or
Hospitalization for Stinging Insect Anaphylaxis
S. Rudders 1 , S. Clark 2 , W. Wei* 3 , C. Camargo 4 ,
1. Providence, RI; 2. New York, NY; 3. Bridgewater, NJ;
4. Boston, MA.
P
P
P
P
P
P
P
P
P
P
P
P
Ethosuximide Associated Drug-Induced
Hypersensitivity Syndrome
M.L. Tierce*, E. McGrath, J. Montejo, M. Pansare,
Detroit, MI.
An Unusual Case of Aspirin Desensitization
K. Farnam* 1 , S.S. Teuber 2 , 1. Sacramento, CA;
2. Davis, CA.
Successful Desensitization to Antithymocyte
Globulin in a Child With Severe Aplastic Anemia
M.A. Liévano*, R. Muriel, B. Del Rio, M. Rosas, Mexico
City, DF, Mexico.
Exanthematous Drug Eruption to Prasugrel:
A Case Report
M.H. Bashir*, P. Buddiga, M.N. Baz, Fresno, CA.
Gadolinium Adverse Reaction
A. Ravi*, M. Park, Rochester, MN.
Prevalence of Sensitivity to Food/Drug Additives
in Patients With Chronic Idiopathic Urticaria (CIUA)
J. Rajan* 1 , R. Simon 1 , J. Bosso 2 , 1. San Diego, CA;
2. West Nyack, NY.
Topical Triple Antibiotic Ointment Anaphylaxis:
A Case Report
J. Greiwe*, B. Schroer, Cleveland, OH.
Omalizumab as a Desensitizing Agent in a Patient
With Cutaneous Mastocytosis
K.C. Sokol*, N.K. Amar, R.D. Divekar, A. Ghazi,
A.P. Reddy, A. Trikha, S.S. Raimer, J.A. Grant,
Galveston, TX.
Food Protein Induced Enterocolitis Syndrome
(FPIES) to Trivial Oral Mucosal Contact
S.K. Mane* 1 , M. Hollister 1 , S.L. Bahna 2 , 1. Shreveport,
LA; 2. Shreeveport, LA.
Peanut Induced Food Protein Enterocolitis
Syndrome: A Case Report
B. Prince*, C. Szychlinski, M. Makhija, Chicago, IL.
Bullous Reactions to Bed Bug Bites Reflect
Cutaneous Vasculitis
P. Stewart* 1 , R.D. deShazo 1 , M.F. Feldlaufer 2 ,
M.C. Mihm 3 , J. Goddard 4 , 1. Jackson, MS; 2. Beltsville,
MD; 3. Boston, MA; 4. Mississippi State, MS.
Risk Factors for Increasing Severity of Adverse
Drug Reactions in a Tertiary Care Center
J.M. Sher*, K.J. Hahn, L.S. Fonacier, M.R. Aquino,
S. Wang, B. Malone, Mineola, NY.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
Corticosteroid Hypersensitivity: Case Report of
Urticaria Induced by Glucocorticosteroids and
Aspirin
Y. Zgherea* 1 , S. Gierer 2 , J.D. Martinez 2 , 1. Merriam, KS;
2. Kansas City, KS.
Compliance With Self-Injectable Epinephrine in
Patients With Imported Fire Ant Hypersensitivity
K.E. Adams* 1 , J.M. Quinn 1 , S.C. Stokes 2 , J.J. Sacha 3 ,
K.M. White 1 , 1. San Antonio, TX; 2. Glendale, AZ;
3. Fairfield, CA.
Upon completion of this session, participants should
be able to: P1) list 5 medications commonly seen on
the drug allergy consult service and 2) discuss the
utility of a web-site based database of drug allergy
case reports and desensitization protocols; P2) discuss
the safety and success of the twelve-step
desensitization protocol for L-asparaginase in children
with drug allergy, as well as, the reduction in the risk
of anaphylaxis in continued therapy; P3) use a safe
protocol for fluconazole desensitization with a 3-5 day
duration for non-HIV infected patients; P4) discuss the
origin of the Honey Bee Colony Collapse and describe
the method of Honey Bee venom skin testing and the
prevalence of Honey Bee anaphylaxis from 2006 until
present; P5) discuss evaluation of a patient with
procedure related anaphylaxis; P6) discuss a rapid and
safe desensitisation scheme to trimethoprimsulfamethoxazole
that can be used in clinical practice;
P7) recognize uncommon causes of anaphylaxis and
the role of airborne sensitization in prelude of
anaphylaxis and educate the patient to avoid
uncommon triggers; P8) identify demographic and
clinical characteristics associated with severe
anaphylaxis; P9) describe an approach to managing
patients with a history of hypersensitivity to an anti-
TNF therapy; P10) describe patients’ characteristics,
costs and post-discharge care associated with an ED
visit/hospitalization for stinging insect anaphylaxis;
P11) identify the causes of drug-induced
hypersensitivity (DIHS) and associated clinical
presentations and lab findings to better recognize the
presentation of DIHS; P12) discuss the clinical
presentation of aspirin exacerbated respiratory disease
and the optimal doses reported in the literature for
aspirin desensitization; P13) discuss available
techniques of drug desensitization for antithymocyte
globulin and summarize the advantages,
disadvantages, and limitations of these techniques in
clinical practice; P14) identify signs and symptoms of a
drug eruption and discuss the action steps once a
drug eruption is recognized; P15) discuss the clinical
manifestations of a gadolinium adverse reaction and
summarize the management options for a patient with
a history of a prior gadolinium or radioactive contrast
adverse reaction; P16) identify the prevalence of
reactions to food/drug additives in patients with
chronic idiopathic urticaria; P17) discuss the standard
approach to managing a case of anaphylaxis and
recognize the potential that triple antibiotic topical
ointments have to induce an anaphylactic response;
P18) discuss the benefit of administering omalizumab
concurrently with venom immunotherapy (VIT) to
reduce the risk of anaphylaxis and discuss whether
omalizumab has a role in improving symptoms,
including skin lesions of cutaneous mastocytosis;
P19) recognize that food protein induced enterocolitis
syndrome (FPIES) can be caused by indirect exposure
to trivial quantities of food allergen; P20) discuss the
clinical presentation and diagnosis of food protein
induced enterocolitis syndrome (FPIES) and identify
foods known to cause this syndrome; P21) identify the
time course and histopathologic findings of complex
(bullous) cutaneous reactions to bedbugs in order to
determine the optimal treatment for them;
P22) identify risk factors for more severe adverse drug
reactions that are allergic/immunologic in etiology;
P23) identify the possibility of side effects to
corticosteroids; and P24) identify factors that affect
compliance rates with self-injectible epinephrine in a
population with fire ant hypersensitivity.
Aerobiology, Allergens, Allergen Extracts
P
P
P
P
P
P
P
Allergen Stabilities and Compatibilities in Mixtures
of High Protease Fungal and Insect Extracts
T.J. Grier*, D.M. LeFevre, E.A. Duncan, R.E. Esch,
T.C. Coyne, Lenoir, NC.
Factorial Analysis of Allergenic Extract
Compatibilities Using a Fractional -Factor, -Level
Experimental Design Matrix
T.J. Grier*, D.M. LeFevre, E.A. Duncan, R.E. Esch,
T.C. Coyne, Lenoir, NC.
The Pollen Seasons of San Antonio
H.C. Crisp* 1 , R.A. Gomez 2 , J.M. Quinn 2 , K.M. White 2 ,
1. Lackland AFB, TX; 2. San Antonio, TX.
Skin Testing
K. McGrath*, A. Simoes, M. Guida, Wethersfield, CT.
Grass Pollen in Kansas City
S.C. Argo*, C.S. Barnes, M.G. Dhar, J.M. Portnoy,
P. Dowling, Kansas City, MO.
Shifting Trends of Ragweed (Ambrosia)
Measurements ( Factors): During a Year Period
in the New York /Northern New Jersey
Metropolitan Area (NY/NJ)
J. Maik* 1 , Y. Zhang 1 , P. Georgopoulos 1 , L. Bielory 2 ,
1. Piscataway, NJ; 2. Springfield, NJ.
The Association of Meteorological Conditions and
the Average Spore Counts in Kansas City
R.N. Donegan*, N. Raje, M. Dhar, H. Dai, C. Ciaccio,
C.S. Barnes, Kansas City, MO.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
Allergen Sensitivity by Region of the United
States, - (NHANES II to NHANES III)
P. Koutsoupias 1 , L. Bielory* 2 , 1. Piscataway, NJ;
2. Springfield, NJ.
Prevalence of Ambrosia (Ragweed) Pollen in
Ukraine
V. Rodinkova* 1 , O. Palamarchuk 1 , L. Kremenska 1 ,
O. Bilous 1 , I. Motruk 1 , O. Mazjur 1 , L. Slobodyanuk 2 ,
L.M. DuBuske 3 , 1. Vinnitsa, Ukraine; 2. Lviv, Ukraine;
3. Gardner, MA.
Allergy Shots
K. McGrath*, A. Simoes, M. Guida, Wethersfield, CT.
Sensitization to Indoor Aeroallergens in Pediatric
Patients
V. Yáñez-Pérez*, A. Arias-Cruz, S. González-Díaz,
C. Gallego-Corella, H. Hernández-Sánchez, K. Mejía-
Salas, M. Calva-Mariño, L. Domínguez-Sansores,
L. Rangel-Garza, Monterrey, NL, Mexico.
The Effects of Rainfall on Ragweed and Chenopod
Counts
S. Anvari*, C.S. Barnes, M.G. Dhar, J.M. Portnoy,
Kansas City, MO.
Upon completion of this session, participants should
be able to: P25) recognize the potential for proteases
from fungal or insect extracts to degrade allergens in
other high-protease products and describe the effects
of glycerin and mixing with other high -protease
extracts on fungal and insect extract activities;
P26) discuss the clinical importance and practical
limitations of studies examining allergen
compatibilities in complex, multi-extract mixtures
formulated for immunotherapy and recognize the
utility of factorial design matrices as tools for assessing
extract recoveries in diverse product mixtures using a
convenient subset of all possible combinations;
P27) identify the pollen seasons for trees, weeds, and
grasses in San Antonio; P28) describe the pertinent
allergens in the Connecticut region of the United
States; P29) discuss the features of grass pollen
dispersal in Kansas City over the last decades; P30)
describe the change in ragweed pollen release over
the past 25 years in the New York/New Jersey
metropolitan area; P31) discuss the association
between average mold spore counts and various
meteorological variables in Kansas City, such as
average yearly outdoor temperature, wind direction,
wind speed, humidity, barometric pressure and inches
of rainfall; P32) discuss the difference in skin test
reactivities in the various regions of the United States
and describe the changes in skin test reactivity in the
US regions over time; P33) discuss the prevalence of
ambrosia pollen in Ukraine; P34) identify the pertinent
immunotherapy components in the Connecticut
region of the United States; P35) identify the most
common indoor aeroallergens in pediatric patients;
P
P
P
P
P
P
P
and P36) identify the correlation between rainfall and
airborne ragweed and chenopod.
Allergy Testing, Clinical
Laboratory Immunology
A Cost Effective Algorithm for Determination of
Sensitization to Aeroallergens
N. Raje*, J.M. Portnoy, C.S. Barnes, C.E. Ciaccio,
Kansas City, MO.
Skin Test Reactivity to Blomia Tropicalis in Patients
With Allergic Rhinitis in an Urban Area
M. Javier* 1 , F. Padua 2 , 1. Quezon City, Philippines;
2. Manila, Philippines.
Upon completion of this session, participants should
be able to: P37) discuss the concept of algorithmic
approach to aeroallergen sensitization determination;
and P38) recognize Blomia tropicalis as an important
trigger of allergic rhinitis in urban areas that must be
included in the panel of tests for allergic rhinitis in
all ages.
Asthma and Other Lower
Airway Disorders
A Potential Relationship Between Genetic
Ancestry and Asthma Exacerbations Among
African American Individuals
J.A. Rumpel* 1 , B.K. Ahmedani 2 , E.L. Peterson 2 ,
K.E. Wells 2 , M. Yang 2 , A.M. Levin 2 , J.J. Yang 2 , R. Kumar 3 ,
E.G. Burchard 4 , L.K. Willliams 2 , 1. Bloomfield Hills, MI;
2. Detroit, MI; 3. Chicago, IL; 4. San Francisco, CA.
The Risk of Asthma Exacerbation After Stopping
Inhaled Corticosteroids: A Systematic Review and
Meta-Analysis
M.A. Rank*, J.B. Hagan, M.A. Park, J.C. Podjasek,
S.A. Samant, G.W. Volcheck, P.J. Erwin, C.P. West,
Rochester, MN.
Individualized Dynamic Phenotyping Using
Fractional Exhaled Nitric Oxide Levels in Children
With Asthma
D.A. Bukstein*, Madison, WI.
Meta Analysis of Asthma Exacerbation Rates
During Asthma Managed Using Fractional Exhaled
Nitric Oxide Versus Standard Clinical Parameters
Alone
N. Jain* 1 , J.F. Donohue 2 , P.M. Dorinsky 3 , 1. Gilbert, AZ;
2. Chapel Hill, NC; 3. Durham, NC.
Relation Between Serum Vitamin D Level and
Asthma
J.R. Zaragoza* 1 , L. Perez 2 , R. Bredy 2 , 1. Arecibo, Puerto
Rico; 2. Ponce, Puerto Rico.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
Correlation Between the Number of Outdoor Visits
and Climate Variables for Asthmatics in a
Developing Country: A Retrospective Study
S.H. Alam*, Z. Yousaf, Z. Butt, S. Afzal, Lahore,
Pakistan.
Sodium Sulfite Enhances Rhinovirus-Induced
Chemokine Production in Airway Epithelial Cells
J. Yoon*, W. Chung, Y. Chun, S. Won, H. Kim, J. Kim,
J. Lee, Seoul, Korea, Republic of.
Patient Characteristics Predictive of Omalizumab
Response in Extra
A. Dorenbaum* 1 , B. Trzaskoma 2 , T. Haselkorn 2 ,
D. Mink 2 , H. Chen 1 , P. Solari 1 , 1. South San Francisco,
CA; 2. San Francisco, CA.
Increased Epidermal Growth Factor in Nasal
Secretion of Young Children With Recurrent
Wheeze
H. Chung*, M. Chu, H.L. Chung, Taegu, Korea,
Republic of.
Efficacy of Fish Oil Oral Supplementation for the
Treatment of Exercise Induced Asthma
S.M. Nsouli*, Danville, CA.
Eucapnic Voluntary Hyperventilation (EVH)
Challenge but Not Methacholine Challenge
Identifies Exercise Induced Bronchospasm:
A Case Report
L. Shora 1 , R.R. Rosenthal* 2 , H. Howe 3 , P. Knause 3 ,
1. Vienna, VA; 2. Great Falls, VA; 3. Fairfax, VA.
Evaluation of Diary Data on Asthma Control
Factors Managed With Combined Mometasone
Furoate and Formoterol Fumarate in Patients With
Severe Asthma
H. Nolte 1 , M. White 2 , S.F. Weinstein 3 , R.A. Nathan 4 ,
D. Gates 1 , E.O. Meltzer* 5 , 1. Whitehouse Station, NJ;
2. Wheaton, MD; 3. Huntington Beach, CA; 4. Colorado
Springs, CO; 5. San Diego, CA.
Effects of Mometasone Furoate and Formoterol
Fumarate Combination Therapy on Quality of
Life Domains in Patients With Moderate Asthma
K.R. Murphy* 1 , E.O. Meltzer 2 , S.F. Weinstein 3 ,
R.A. Nathan 4 , M. White 5 , D. Gates 6 , H. Nolte 6 , 1. Boys
Town, NE; 2. San Diego, CA; 3. Huntington Beach, CA;
4. Colorado Springs, CO; 5. Wheaton, MD;
6. Whitehouse Station, NJ.
Asthma Champions: Defining the System and
Implementing a “Change Project” Proposal
N. Kolluru, T. Jimenez, M. Reddy*, D. Strom,
L. Krinsky, J. Jacobs, L. Brown, R. Kairam, Y. Persaud,
R. Neugebauer, Bronx, NY.
P
P
P
P
P
P
P
P
Making the Business Case: Importance of
Educating Physicians About Future Healthcare
Models
N. Kolluru, Y. Persaud*, M. Reddy, R. Kairam,
S. Hanumanthu, D. Strom, L. Krinsky, T. Jimenez,
J. Jacobs, R. Neugebauer, Bronx, NY.
Asthma Champions: Empowering Future Physician
Leaders to Improve Their Accuracy in Classifying
Asthma Severity
N. Kolluru, T. Jimenez, M. Reddy*, L. Krinsky,
L. Brown, D. Strom, J. Jacobs, R. Kairam, Y. Persaud,
R. Neugebauer, Bronx, NY.
The Safety and Preliminary Efficacy of Repeated
Administration Intravenous MN-: A Highly
Selective Beta Adrenergic Receptor Agonist, in
Stable Moderate to Severe Chronic Obstructive
Pulmonary Disease (COPD) Patients
P. Ratner* 1 , K. Johnson 2 , K. Matsuda 2 , H. Ishibashi 2 ,
F. Hampel 3 , 1. San Antonio, TX; 2. San Diego, CA;
3. New Braunfels, TX.
Effect of Fixed Airflow Obstruction (FAO) on
Response to Budesonide/Formoterol Pressurized
Metered-Dose Inhaler (BUD/FM pMDI) or BUD in
African-American Adolescents and Adults With
Moderate to Severe Asthma
D.P. Tashkin* 1 , B.E. Chipps 2 , T. Uryniak 3 , F. Trudo 3 ,
J.G. Zangrilli 3 , 1. Los Angeles, CA; 2. Sacramento, CA;
3. Wilmington, DE.
Asthma Symptoms and Immunotherapy Tablet
(AIT) Treatment: An Analysis of Data From Two
Ragweed AIT Clinical Trials
H. Nolte* 1 , P. Creticos 2 , S. Gawchik 3 , G. Berman 4 ,
D. Bernstein 5 , J. Maloney 1 , A. Kaur 6 , N. Liu 1 ,
K. Murphy 7 , 1. Whitehouse Station, NJ; 2. Baltimore,
MD; 3. Upton, PA; 4. Minneapolis, MN; 5. Cincinnati,
OH; 6. Whitehouse Station, NY; 7. Boys Town, NE.
Adherence to the EPR- Guidelines in Emergency
Department Management of Childhood Asthma
Exacerbations in a Private Community Hospital
C.Y. Lee*, S. Patel, Los Angeles, CA.
Effect of Obesity on Serum HDL-Cholesterol Levels,
Paroxonase Activity and Tiffeneau Index in
Mexican Adolescents With and Without Asthma
L.O. Hernandez-Mondragon*, B.E. DelRio-Navarro,
R.D. Pietropaolo-Cienfuegos, M.A. Rosas-Vargas,
Mexico City, DF, Mexico.
Clinical Features of Churg Strauss Syndrome in
Eastern Ukraine
K. Lishchuk-Yakymovych* 1 , R. Pukalyak 1 ,
L.M. DuBuske 2 , 1. Lviv, Ukraine; 2. Gardner, MA.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
Methacholine Challenge by Spirometry and
Impulse Oscillometry Versus Auscultation Method
in Preschool Asthmatic Children
J. Yoon*, Y. Shin, H. Kim, M. Han, Seongnam-si, Korea,
Republic of.
Increase of Exhaled Breath Temperature After
Mobilizing Secretions From the Lower Airways of
Asthmatics Using Acoustic Wave Technology
T.Z. Kralimarkova 1 , Z. Dimitrov 1 , M. Koleva 1 ,
V. Filipova 1 , M. Rasheva 1 , M. Gugutkova 1 ,
M. Mincheva 1 , V.D. Dimitrov 1 , L.M. DuBuske 2 ,
T.A. Popov* 1 , 1. Sofia, Bulgaria; 2. Gardner, MA.
Bronchial Thermoplasty Success and Failure:
Pathologic Correlates to Clinical Cases
D. Doeing 1 , A. Mahajan 1 , I. Gordon 2 , A. Husain 1 ,
D.K. Hogarth* 1 , 1. Chicago, IL; 2. Cleveland, OH.
Allergen Sensitization and Bronchial Reactivity in
Young Patients With Atopic Asthma
V. Tsybulkina* 1 , N. Kurmaeva 1 , N. Tsybulkin 1 ,
L.M. DuBuske 2 , 1. Kazan, Russian Federation;
2. Gardner, MA.
Expression and Targeting of Leukocyte Function
Antigen- (LFA-) on White Blood Cells From
Allergic Asthma Patients
A. Gupta 1 , L.E. Galusha 1 , V. Rahimian 2 , K.L. Miro* 1 ,
E. Capitle 1 , S.C. Kachlany 1 , 1. Newark, NJ; 2. Little
Neck, NY.
Upon completion of this session, participants should
be able to: P39) recognize the substantial disparities in
severe asthma exacerbations by race-ethnicity in the
United States and some of the factors that may
contribute to these disparities and discuss methods by
which genetic ancestry is estimated and how these
methods can be used to discern genetic and nongenetic
contributors to disease in admixed
populations; P40) estimate the risk of asthma
exacerbation in individuals who stop low-dose inhaled
corticosteroids compared to those who continue
inhaled corticosteroids; P41) describe how to establish
the most cost efficient way of monitoring childhood
asthma utilizing FeNO in individualized dynamic
phenotype of these patients; P42) discuss and
summarize the relative merits of asthma managed
with a FeNO based algorithm versus a standard clinical
algorithm on asthma exacerbation rates; P43) identify
serum vitamin D levels and the impact it has in
asthmatic patients; P44) identify the relationship
between climate variables and asthma exacerbations
that would help in educating patients regarding the
increased need for compliance in certain months and
identify the months in which a possible adjustment of
medication doses is needed due to the increasing
frequency of asthma, thus reducing the symptoms and
patient morbidity; P45) describe the combined action
of sodium sulfite and rhinovirus on human airway
epithelial cells; P46) identify patient characteristics
which differentiate the response to omalizumab and
improve asthma management in patients with
moderate-to-severe uncontrolled asthma;
P47) recognize the link between early recurrent
wheeze and development of later asthma; P48)
recognize the beneficial role and efficacy of fish oil as
oral supplementation in patients with documented
exercise induced bronchoconstriction; P49) describe
the differences in sensitivity between methacholine
and eucapnic voluntary hyperventilation (EVH)
challenge test and discuss the clinical utility of EVH
challenge; P50) identify the effects of mometasone
furoate/formoterol combination on patients' diaryrecorded
symptoms, SABA use, and peak flow;
P51) identify AQLQ(S) domains in which mometasone
furoate/formoterol combinations achieved significant
improvements compared with placebo and
formoterol; P52) discuss the six components of the
Chronic Care Model and summarize the relationship
between scores on the Assessment of Chronic Illness
Care (ACIC) Survey and an organization's level of
support for chronic illness care; P53) discuss the
importance of understanding various evolving health
care models, and summarize strategies for “making the
business case” in support of engaging in activities
related to systems improvement; P54) discuss three
key clinical concepts outlined by the National Asthma
Education and Prevention Program (NAEPP), and
summarize gaps in care demonstrated by early career
physicians in accurately classifying asthma severity;
P55) discuss the results of a clinical trial: “Safety and
Efficacy of Repeated Administration Intravenous MN-
221, a Highly Selective Beta2 Adrenergic Receptor
Agonist, in Stable Moderate to Severe Chronic
Obstructive Pulmonary Disease (COPD) Patients”;
P56) discuss the effect of fixed airflow obstruction on
asthma treatment response in African-American
patients with moderate to severe asthma; P57) discuss
the safety of ragweed allergy immunotherapy tablet in
patients with allergic rhinoconjunctivitis and
comorbid asthma; P58) recognize the need for: greater
adherence to national guidelines for acute asthma
exacerbation in the emergency department setting,
greater follow up and referral to appropriate
allergist/asthma specialists, personalized asthma
action plans, and the development and utilization of
education/instruction from medical staff on inhaler
technique upon discharge from an emergency
department; P59) identify obesity effects on
antioxidant parameters and lung function in
adolecents with and withot asthma; P60) recognize
clinical features of Churg-Strauss syndrome (CSS) in
Eastern Ukraine; P61) discuss techniques and
physiology of bronchial responsiveness; P62) discuss
the increase of exhaled breath temperature after
mobilizing secretions from the lower airways of
asthmatics using acoustic wave technology:
P63) evaluate the histologic changes seen with
bronchial thermoplastic and correlate these with
clinical responses; P64) discuss allergen sensitization
and bronchial reactivity in young patients with atopic
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
asthma: and P65) identify the importance of leukocyte
function antigen-1 (LFA-1) as a marker on cell types
involved in the pathogenesis of allergic asthma.
Basic Science Allergy and Immunology
P
P
P
P
P
P
P
Weight Reduction Modulates Ventilatory
Functions, Inflammatory and Adipocytokines in
Obese Asthmatic Children
O. Jiffri*, F. Al-Sahrif, S. Abd El-Kader, E. Ashmawy,
Jeddah, Saudi Arabia.
Caspase Has a Role in CD Induced Eosinophil
Apoptosis
J. Kim*, H.J. Lee, Uijeongbu, Korea, Republic of.
Carbamylcholine Increased the Mitogen-Activated
Protein Kinase (MAPK) Phosphorylation in Airway
Smooth Muscle Cells From a Murine Model of
Asthma
F.A. Placeres*, R. Gonzalez de Alfonzo, I. Lippo de
Becemberg, M. Alfonzo, Caracas, Distrito Capital,
Venezuela.
Effect of Histamine Strength and Devices on Skin
Prick Test (SPT) Response Following Antihistamine
Inhibition
G. Plunkett*, J. Young, R. Erskine, Round Rock, TX.
Purification of a Phosphodiesterase-A Coupled to
Muscarinic Receptors Located At Plasma
Membranes From Bovine Tracheal Smooth Muscle
P. Mastromatteo*, F.A. Placeres, R. Gonzalez de
Alfonzo, I. Lippo de Becemberg, M. Alfonzo, Caracas,
Distrito Capital, Venezuela.
Th- Cells in Bronchoalveolar Lavage Samples of
Asthmatic Patients
A. González-Carsolio*, A.A. Velasco-Medina,
A.L. Burbano-Cerón, G.A. Velázquez-Sámano, Mexico
City, DF, Mexico.
CDd+ Neutrophils are Found in the Nasal
Lavage of Atopic But Not Non-Atopic Individuals
B. Buelow*, M. Klancnik, D. Hunter, E. Buell,
M. Vasudev, D. Cheung, M. Grayson, Milwaukee, WI.
P
P
P
P
P
P
P
P
P
P
P
Upon completion of this session, participants should
be able to: P66) identify the effects of weight
reduction on cytokines and ventilatory functions in
obese children with bronchial asthma; P67) discuss
how to induce the eosinophil apoptosis in allergic
diseases; P68) evaluate the activation of the mitogenactivated
protein kinase (MAPK) in response to a
muscarinic agonist as carbamylcholine (Cch) in ASMC,
which were isolated from trachea of Sprague-Dawley
rats sensitized to ovalbumin (OVA) and the Control
group; P69) recognize the differences between
histamine strength and devices following
antihistamine on skin prick testing; P70) discuss a
study that purified and identified vinpocetinesensitive
and calmodulin-dependent cyclic nucleotide
PDE located at plasma membranes fractions from
BTSM; P71) discuss the demonstrated presence of
Th-17 cells in asthmatic patients; and P72) discuss the
significance of the presence of CD49d+ neutrophils in
nasal lavage and determine differences in CD49d+
neutrophils in atopic and non-atopic subjects.
Clinical Case Reports
Cutaneous Polyarteritis Nodosa in a Baby After
Hepatitis B Vaccination
C.T. Quezada Chalita*, Mexico City, DF, Mexico.
A Clinical Case of Wells Syndrome After An
Arthropod Bite
P. Wang*, A. Sarwari, Y. Demirdag, Morgantown, WV.
Acute Idiopathic Eosinophilic Pneumonia in a
Year Old Male With a Month History of Dyspnea,
Cough and Significant Dust Exposure
A. Pinion* 1 , S. Mathur 2 , 1. Fairway, KS; 2. Kansas City,
MO.
Successful Use of CINHRP as Procedural
Prophylaxis in a Patient With Isolated Abdominal
Attacks of Hereditary Angioedema and Normal
CINH
D.R. Scott*, K.M. Woessner, Del Mar, CA.
Systemic Lupus Erythematosus, Protein Losing
Enteropathy and Autoimmune Hemolytic Anemia
S. Akkina*, K. Bupathi, M. Frieri, East Meadow, NY.
Successful Intravenous Acyclovir Desensitization
in HIV Pediatric Patient With Cutaneous Herpes
Zoster Reactivation
E. Sandoval-Ramirez*, M. Rosas-Vargas, B. Del Rio-
Navarro, Mexico City, DF, Mexico.
Chronic Urticaria and Angioedema in a Pediatric
Patient With Elevated Total Tryptase Level Who
Responded to Cyproheptadine
C. Nguyen*, Washington, DC.
Prolonged Erythrodermic Reaction to Single Dose
Amoxil
C.C. Randolph*, Waterbury, CT.
A Protracted Course of Diarrhea Caused By
Cryptosporidium in a Nonimmunocompromised
Patient
H.K. Lin*, J. Yusin, Los Angeles, CA.
Congenital Nephrotic Syndrome and
Agammaglobulinemia: A Therapeutic Dilemma
K. Payne* 1 , M. Nelson 2 , M. Petersen 2 , 1. Silver Spring,
MD; 2. Bethesda, MD.
Unusual Presentation of DRESS Treated With IVIG
and Pulse Steroids
J. Hajjar*, S. Kumar, Richmond, VA.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
Cutaneous Polyarteritis Nodosa in a Baby After
Hepatitis B Vaccination: Case Report
C.T. Quezada-Chalita* 1 , B. Mercado 2 , R.T. Quezada
Medrano 2 , 1. Mexico City, DF, Mexico; 2. Tepic, NA,
Mexico.
Intravenous Hydration: A Novel Therapeutic
Option for Symptomatic Treatment in Systemic
Mastocytosis
S.R. Hariri* 1 , I.S. Randhawa 2 , T.W. Chin 2 , 1. Los Angeles,
CA; 2. Long Beach, CA.
Food Protein-Induced Enterocolitis Syndrome
Uncovers Heterozygosity of Trimethylaminuria
N.B. Miller*, M. Shinawi, A. Beigelman, St. Louis, MO.
Recurrent Anaphylaxis After Cystoscopy in a
Gentleman With Bladder and Prostate Cancer
C.L. Hedberg* 1 , L.N. Demers 2 , F.J. Pilgrim 2 ,
M.R. Wilson 2 , 1. Rogers, AR; 2. Fayetteville, AR.
The Need for Individualized Hereditary
Angioedema Acute Action Plans: Two Case Studies
of Misdiagnosed Attacks and Unnecessary
Surgeries
M. Dispenza* 1 , M. Gutierrez 2 , P. Bajaj 2 , T. Craig 2 , 1. York,
PA; 2. Hershey, PA.
Rare Case of Acquired Angioedema (Type ) Due
to T-Cell Lymphoproliferative Disorder
S. Benouni*, L. Do, A. Rafi, L. Sheinkopf, M. Bush,
S. Fisher, A. Spokojny, R. Katz, Los Angeles, CA.
Acute Hemolysis Secondary to High-Dose
Intravenous Immunoglobulin (IVIG)
A. Shakouri*, S.L. Bahna, Shreveport, LA.
A Young Woman With Chronic Urticarial Rash Since
Birth
P. Wang*, M. Alleman, Y. Demirdag, Morgantown, WV.
A Rare Case of Anaplastic Large T-Cell Lymphoma
Presenting With Peripheral Eosinophilia
S. Choi*, J. Yusin, Los Angeles, CA.
Brentuximab Vedotin Desensitization in a Female
With Relapsed, Refractory, Anaplastic Large-Cell
Lymphoma (ALCL)
N. Qamar*, S. Cho, Chicago, IL.
Intraoperative Anaphylaxis Caused by Indigo
Carmine: A Case Report
L.P. Newton*, R. Gutta, D. Lang, R. Siles,
Cleveland, OH.
Anaphylaxis to a Rat Bite in an Animal Handler
T. Kampitak*, S. Betschel, Toronto, ON, Canada.
Exercise-Induced Anaphylaxis to Grapes
T. Kampitak*, S. Betschel, Toronto, ON, Canada.
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Splenic Marginal Zone Lymphoma As a Rare Cause
of Acquired Angioedema
T. Burnett* 1 , F. Hoyte 2 , 1. Aurora, CO; 2. Denver, CO.
Successful Intravenous Heparin Infusion in a
Patient With Delayed-Type Hypersensitivity to
Heparin
B. Everist*, M. Hartz, M. Park, Rochester, MN.
Netherton’s Syndrome: Flexural Lichenification,
Not to be Confused With Atopic Dermatitis
A. Salami*, A. Suresh, S.R. Patel, Los Angeles, CA.
Type Hereditary Angioedema: A Case Report
N. Zhu*, A. Bewtra, Omaha, NE.
Chronic and Isolated Idiopathic Angioedema of
the Tongue
J.B. West* 1 , N.K. Amar 2 , J.A. Grant 2 , 1. Phoenix, AZ;
2. Galveston, TX.
Horse Allergy in a Patient Requiring Equine Anti-
Thymocyte Globulin (Eatg)
S. Anandan*, Y. Luo, D.W. Rosenthal, Manhasset, NY.
Allergic Bronchopulmonary Aspergillosis in a
Cystic Fibrosis Patient
C.T. Quezada-Chalita* 1 , R.T. Quezada Medrano 2 ,
1. Mexico City, DF, Mexico; 2. Tepic, NA, Mexico.
A Case of IgG Associated Cholangitis and Rapid
Response to Steroids
K.J. Garg* 1 , S. Reznick 2 , D. Anthony 2 , 1. Cleveland
Heights, OH; 2. Cleveland, OH.
Mast Cell Activation Syndrome Improved on
Multimodality Therapy: A Case Report
A.M. Jongco*, V.R. Bonagura, Great Neck, NY.
A Case of Pruritic Dermatitis for Years That
Failed to Resolve With Standard Therapy
S. Jain*, J.G. Black, L.G. Wild, E.E. Boh, New
Orleans, LA.
Tongue Microabscess Presenting As Angioedema
J. Hsu*, N. Qamar, K. McGrath, Chicago, IL.
Kikuchi-Fujimoto Disease and Angioedema:
Unusual Manifestation in an Uncommon Disease
R.D. Divekar*, A. Ghazi, R. Bonds, Galveston, TX.
A Case of Drug Induced Angioedema and
Dyshidrosis, or Is There Something More to It
M.G. Gates*, J. Anderson, Birmingham, AL.
A Case Report of Solid Food FPIES Presenting As
Gluten Sensitivity
N.S. Agarwal*, J. Yu, New York, NY.
A Patient With Hypereosinophilic Syndrome
Presented With Skin Rash and Angioedema and
Responded to Steroid Treatment
Y. Hui*, B. Corn, New York, NY.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
Incomplete Digeorge Syndrome With
Lymphadenopathy, Rash, and Thrombosis
Masquerading as Autoimmune
Lymphoproliferative Syndrome
M.W. Shepherd*, A. Patterson, Columbus, OH.
Mechanical Valve Versus Tissue Valve: Ask the
Allergist
S.S. Griffin*, J.T. Anderson, Birmingham, AL.
A Case of Benign Cutaneous Polyarteritis Nodosa
Associated With Inflammatory Bowel Disease
S. Bandi*, B. Yu, Chicago, IL.
Fixed Angioedema as a Presenting Sign of
Dermatomyositis
J.R. Duncan*, M.S. Tankersley, San Antonio, TX.
A Case of Acute Hepatotoxicity Caused by
Cetirizine
A. Subramanian*, D. Lang, Cleveland, OH.
Porcine Valve Replacement in a Patient With
Positive Titers to Alpha-GAL
S. Mozzicato*, J. Posthumus, T. Platts-Mills,
S. Commins, Charlottesville, VA.
Evaluation and Management of Suspected Steroid
and Heparin Allergies Before Organ
Transplantation
E. Wang*, A. Nickels, V. Dimov, Chicago, IL.
Allergy to Tonic Water
S. Ting*, El Paso, TX.
Onion Anaphylaxis: Case Report
A.L. Burbano-Cerón*, A.A. Velasco-Medina,
A. González-Carsolio, G. Velázquez-Sámano, Mexico
City, DF, Mexico.
Conversion to IgE-Mediated Dairy Allergy One
Week After Introduction of Dairy Into the Diet of a
Patient With a History of Food Protein-Induced
Enterocolitis Syndrome (FPIES) and Prior Negative
Allergy Testing and Food Challenge to Dairy
M.W. Shepherd*, R. Raveendran, R. Scherzer,
Columbus, OH.
Methylprednisolone Allergy in a Newly-Diagnosed
Demyelination Patient
J.K. Shorten*, Sutton Coldfield, United Kingdom.
Malakoplakia of the Colon in a Child With Common
Variable Immunodeficiency
C. Kuo*, S. Yusung, M. Garcia-Lloret, Los Angeles, CA.
Idiopathic Anaphylaxis in a Year Old Female
K. Tse*, D. Boide, B. Zuraw, La Jolla, CA.
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Recurrent Lip Angioedema With Unknown
Etiology
L. Helfner* 1 , Y. Luo 2 , S. Farzan 2 , 1. Manhasset, NY;
2. Great Neck, NY.
Autoimmune Progesterone Dermatitis Diagnosed
by a Delayed Hypersensitivity Reaction to
Progesterone
M. Saeedian*, M. Riedl, A. Akopians, Los Angeles, CA.
A Case Report of Bradykinin Receptor Antagonist
Use in Idiopathic Non-Histaminergic Angioedema
V. Sridhara*, C.R. Weiler, Rochester, MN.
Familial Cr Functional Deficiency
R. Honeine*, S. Ramesh, Buffalo, NY.
Hypersensitivity to Honey Demonstrated by
Elevated Honey Specific Serum IgE
K. Achar*, P. Parikh, D. Ferastraoaru, D. Rosenstreich,
New York, NY.
A Case of Anaphylaxis in a Fungi-Sensitized Tuba
Player
M.R. Henson*, D. Sedlak, Durham, NC.
Successful Treatment of Antihistamine-Resistant
Physical Urticarial/Angioedema Syndrome With
Omalizumab
A. Gonzalez-Estrada* 1 , R. Siles 2 , D. Lang 2 , 1. Cleveland
Heightts, OH; 2. Cleveland, OH.
Mounier-Kuhn Syndrome Presenting as Severe
Asthma in a Year Old Native-American Female
C. Cleveland*, D.M. Fleischer, Denver, CO.
A Case of Kimura’s Disease in an African American
Male
Y. Kopyltsova*, V. Bonagura, Great Neck, NY.
A Case of Acquired Angioedema Masquerading as
an Allergy to Shrimp
Y. Samarasena*, A.M. Staveren, M.S. Kaplan,
B.J. Goldberg, Los Angeles, CA.
Formaldehyde-Induced Systemic Reaction
A. Low*, M.T. Nguyen, Oakland, CA.
A Novel BTK Mutation With Normal Sequencing of
Genomic DNA
M. Mohiuddin* 1 , N. Hubbard 2 , J. Abbott 1 ,
T. Torgerson 2 , H. Ochs 2 , E. Gelfand 1 , 1. Denver, CO;
2. Seattle, WA.
A Case of Chronic Eosinophilia Associated With
Toxocariasis and Severe Asthma
N. Jinjolava*, G. Hudes, S. Jariwala, Bronx, NY.
Acquired Hemophilia: Case Report
F.R. Ruiz Hernandez*, Mexico City, DF, Mexico.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Idiopathic Nonhistaminergic Angioedema Treated
With Ecallantide and Icatibant
C.K. Harris* 1 , M. Stahl 2 , 1. Beavercreek, OH; 2. Dayton,
OH.
Successful Desensitization to Agalsidase Beta After
Anaphylaxis
A. Butt*, N. Talreja, R. Lopez, R. Fox, R.F. Lockey,
Tampa, FL.
Il- Receptor Defect Predisposes to
Histoplasmosis
T.A. Hwangpo* 1 , W.T. Harris 2 , P. Atkinson 2 , K. Cassady 2 ,
S. Kankirawatana 2 , 1. Helena, AL; 2. Birmingham, AL.
A Case of DRESS Syndrome Associated With
Strongyloidiasis
L. Rampur*, P. Patel, S. Jariwala, R. Viau, G. Hudes,
D.L. Rosenstreich, Bronx, NY.
Cq-Deficient Urticarial Vasculitis Sensitive to
Hydroxychloroquine
J.E. Fergeson*, D. Fitzhugh, M. Glaum, Tampa, FL.
Food Allergy Unmasked After a Lifetime of
Unexplained Food Aversion
J.L. Geslani*, R.S. Bonds, Galveston, TX.
Adult Hemophagocytic Lymphohistiocytosis and
q. Deletion
S. Sawlani*, A. Kulczycki, St. Louis, MO.
Uvular Edema: A Clinical Case Report
K.E. Holmberg*, Mölndal, Sweden.
TACI Mutation Associated Granulomatous CVID
Treated With Infliximab
T.J. Franxman*, J.R. Baker, Ann Arbor, MI.
Allergic Reactions to Vaccines
H. Mehta*, H.A. Sampson, A. Nowak-Wegrzy, New
York, NY.
Recurrent Fungal Infections and Lymphopenia in a
Girl With Turner’s Syndrome
J. Diaz*, B. Kaplan, Great Neck, NY.
Latex Exposure and Allergy
A. González-Carsolio*, A.A. Velasco-Medina,
A.L. Burbano-Cerón, G. Velázquez-Sámano, Mexico
City, DF, Mexico.
Septic Pneumonia With Transient Lymphopenia in
a Patient With IgA and IgG/IgG Deficiencies
R.M. Young* 1 , V. Chand 2 , C. Tiozzo 1 , 1. East Meadow,
NY; 2. New York, NY.
Refractory Thrombocytopenia in a -Year Old
Man With Digeorge Syndrome
A. Patel*, T. Hogan, Y. Demirdag, Morgantown, WV.
P
P
P
P
P
P
P
P
P
P
P
P
P
Autoimmune Progesterone Dermatitis: A Case
Report
P. Chopra*, G. Gibbon, J. Yusin, Los Angeles, CA.
Two Unusual Presentations of Chronic
Granulomatous Disease
A. Reddy*, F.C. Schmalstieg, Galveston, TX.
Patient Experience With Ecallantide Nurse Home
Administration
A.B. Vegh*, N. Boyden*, Tacoma, WA.
Successful Treatment of a Prolonged
Hypersensitivity Reaction to Intravesical Bacillus
Calmette-Guerin (BCG) Given for Bladder
Carcinoma With Cyclosporine
K. Hannouch*, B.A. McGoey, G. Rosenberg,
M. Michelis, Hackensack, NJ.
Hemodialysis-Induced Anaphylaxis With Elevated
Tryptase Level Using the AN- Membrane
J. Moreau*, Y. Kopyltsova, B. Kaplan, Great Neck, NY.
The Treatment of Inhibitors and Anaphylaxis in
Patients With Hemophilia A
B. Dyer*, J. El-Dahr, New Orleans, LA.
Mast Cell Leukemia on an Inner City African
American Female
M. Vastardi*, R. Joks, Brooklyn, NY.
An Interesting Case of Good Syndrome
A. Hamad, S.Z. Faghih*, A. Bulkhi, Detroit, MI.
Development of Interstitial Lung Disease in a Child
With Crohn’s Disease Receiving Treatment With
Infliximab
L. Wall*, C. Otu-Nyarko, K. Paris, New Orleans, LA.
Type Autoimmune Pancreatitis in a Pediatric
Patient
C.M. Pimentel* 1 , R. Marquez 2 , J.R. Alvarez 1 , F. Nieves 2 ,
C. Micames 3 , S. Nazario 1 , R. Diaz 1 , 1. San Juan, Puerto
Rico; 2. Bayamon, Puerto Rico; 3. Mayaguez, Puerto
Rico.
Childhood Maculopapular Mastocytosis With
Gastrointestinal Symptoms and Diffuse Cutaneous
Mastocytosis
S.K. Chan*, M.G. Buheis, I.C. Hanson, Houston, TX.
Agammaglobulinemia With Negative Genetic
Markers: A Nonspecific Immunodeficiency
S. Elenburg* 1 , R. Casper 2 , 1. Tolleson, AZ;
2. Phoenix, AZ.
Airway Fungal Isolation in Severe Asthma: A Short
Case Series
N. Seth*, M.B. Narra, G. Mak, P. Porter, D.B. Corry,
Houston, TX.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
A Year Old Woman With Eosinophilia and
Systemic Symptoms
S. Peterson*, A.M. Ditto, Chicago, IL.
Novel Intronic Mutation of STAT Resulting in
Features of Autosomal Dominant Hyper IgE
Syndrome
J. Brown*, M. Dorsey, N. Tang, St. Petersburg, FL.
An Unusual Case of Aspirin Hypersensitivity
M.D. Ikeda*, A.A. Petrov, Pittsburgh, PA.
Successful Treatment of Macrophage Activation
Syndrome in a Patient With Systemic onset
Juvenile Idiopathic Arthritis
M.E. Hollister* 1 , S. Umer 2 , A. Casillas 2 , 1. Bossier City,
LA; 2. Shreveport, LA.
Hypersomnia and Recurrent Sinusitis
A.B. Teodoro*, C. Akman, R. Herzog, New York, NY.
Mast Cell Activation Syndrome: Likely Diagnosis in
an Adolescent and Her Family With Elevated
Tryptase and Postural Tachycardia Syndrome
[POTS]
A.C. Sprunger* 1 , C.T. Nguyen 2 , 1. Annandale, VA;
2. Washington, DC.
Ketotifen in the Management of Angioedema
N.K. Amar*, R.S. Bonds, J.A. Grant, Galveston, TX.
A Case of Delayed-Pressure Urticaria as a
Dermatophytid “Id” Reaction to Tinea Infection
P. Parikh* 1 , D. Ferastraoaru 2 , S. Jariwala 2 ,
D. Rosenstreich 2 , 1. New York, NY; 2. Bronx, NY.
Heart Failure With Eosinophilia
M. Smith*, Indianapolis, IN.
Case Report: Overlapping of Henoch Schonlein
Purpura and Microscopic Polyangiitis
S. Cerda*, A. Gutiérrez- Hernandez, V. Hernández-
Bautista, M. Saez-de Ocariz, R. Rodríguez-Jurado,
A. Huante-Anaya, D. Carrasco-Daza, M. Yamazaki-
Nakashimada, D. Carrasco-Daza, Mexico City, DF,
Mexico.
A Patient With Neisseria Meningitidis Meningitis
After Receiving Appropriate Vaccination: Why We
Shouldn’t Always Blame the Immune System
S. Albin*, C. Cunningham-Rundles, New York, NY.
Successful Treatment of Exercise-Induced
Anaphylaxis With Omalizumab
M.L. Bandino*, M. Packer, M. Tankersley, San
Antonio, TX.
P
P
P
P
P
P
P
P
P
P
P
P
P
A Case of Monomac; Monocytopenia, B Cell and
NK Cell Lymphocytopenia in a Child With
Recurrent Infections
C.N. Spalding* 1 , A. Hersh 1 , M. Nassef 1 , A.P. Hsu 2 ,
C. Spalding 2 , S. Holland 2 , T. Mainardi 1 , 1. New York, NY;
2. Bethesda, MD.
Myocardial Infarction Following Intramuscular
Epinephrine for Anaphylaxis in a Year Old Male
E. Sarid*, A. Schneider, R. Joks, Brooklyn, NY.
A Case of Cystic Fibrosis With Immune
Dysregulation Characterized by Common Variable
Immunodeficiency, Transplant Tolerance, and
Autoimmunity
J.T. Abbott* 1 , J.D. Martinez 2 , S. Gierer 2 , 1. Olathe, KS;
2. Kansas City, KS.
A Case of Ethanol Induced Anaphylaxis
N. Lakhani* 1 , R. Borici-Mazi 2 , 1. Mississauga, ON,
Canada; 2. Kingston, ON, Canada.
Acute Attacks of Acquired Angioedema
Responding to Kallikrein Inhibitor (Ecallantide)
N. Vernon*, G. Ghaffari, Hershey, PA.
Angioedema Following Usage of a
Paraphynylenediamine-Free Hair Dye
P. Olson 1 , A. Kochin* 1 , J. Shliozberg 2 , 1. Bronx, NY;
2. Brooklyn, NY.
Autologous Seminal Fluid Allergy
S. Ho*, R.D. Divekar, R.S. Bonds, Galveston, TX.
Year Old Boy With X-HIGM Syndrome Due to a
Missense Mutation Manifested by Aplastic
Anemia, Crohn’s Disease and Recurrent Infections
A. Katta*, J. Hong, K. Convers, A. Knutsen,
St. Louis, MO.
A Case of IPEX Syndrome With Foxp Missense
Mutation
N.D. Schroeder*, A. Stallings, F. Saulsbury,
P. Heymann, Charlottesville, VA.
Progression of Kimura Disease Despite Treatment
With Cetirizine
K.A. von Elten*, P.B. Keiser, Bethesda, MD.
Cryopyrin-Associated Periodic Syndromes
Mutation in a Father and Daughter
S. Bantz*, R. Herzog, New York, NY.
Immunoglobulin E Multiple Myeloma
Masquerading as Systemic Mastocytosis: A Case
Report
W.C. Anderson*, E. Choo, Denver, CO.
A Case of Relapsing Polychondritis and
Hypogammaglobulinemia
N. Okeke, T. Gavrilova*, E. Capitle, Newark, NJ.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
Painless Proptosis in a Patient With Aspirin
Exacerbated Respiratory Disease
W. Stevens*, G. Lissner, L. Grammer, Chicago, IL.
Pre-Operative Patch Testing Successfully Predicted
Tolerance of a Titanium Metallic Implant in a Child
Who Had Previously Failed Insertion of Stainless
Steel Implants
A. Kochin*, M. Rasheed, J. Shliozberg, Bronx, NY.
Directly Observed Anaphylactic Reaction to
Acetaminophen
L. Li*, G.M. Sanders, Ann Arbor, MI.
Delayed Hypersensitivity to Nitrile and Synthetic
Polyisoprene Gloves in Health Care Workers
E. Kleiman* 1 , J.H. Moallem 1 , D.P. Erstein 1 , S. Kumar 2 ,
R. Joks 1 , 1. Brooklyn, NY; 2. Richmond, VA.
Delayed Diagnosis of Allergic Bronchopulmonary
Aspergillosis in an Asthmatic Patient on Xolair:
A Case Report
D. Hirsch*, J. Fagin, Great Neck, NY.
Premedication Protocol for the Prevention of Life-
Threatening Anaphylaxis From Protamine
N. Li*, P.A. Greenberger, Chicago, IL.
Tracheobronchomalacia Masquerading As
Asthma: Diagnosis by -D CT Scan
B. Hronek*, H.J. Wedner, St. Louis, MO.
Disseminated Blastomycosis in a Patient With
Idiopathic CD Lymphocytopenia
L. Zhou*, A. Hall, A. Morris, G.D. Marshall,
Jackson, MS.
Contact Hypersensitivity to Shea Butter
K.K. Brar*, R. Joks, H. Moallem, Brooklyn, NY.
Bare Lymphocyte Syndrome Severe Combined
Immunodeficiency Missed by T Cell Receptor
Excision Circles Newborn Screening
J. Chase* 1 , L.M. Randolph 1 , M.J. Matas-Aguilera 2 ,
J. Lopez-Siles 2 , J.A. Church 1 , 1. Los Angeles, CA;
2. Malaga, Spain.
Secretory Immunoglobulin a Deficiency in a
Pediatric Patient
J. Hochfelder*, Y. Lu, P. Ponda, New Hyde Park, NY.
Repeated Late-Onset Allergy-Like Reaction: A
Bullous Rash After IV Contrast Media
Administration in Spite of Pretreatment With
Steroids
D.A. Andreae*, M. Ramesh, C. Cunningham-Rundles,
New York, NY.
Ongoing Treatment of Chronic Idiopathic Urticaria
With Omalizumab: A Follow-Up Case Series
G. Bhargave*, A. Keswani, A.M. Ditto, C. Saltoun,
Chicago, IL.
P
P
P
Eosinophilic Fasciitis Associated With Medication
Use
R.J. Sporter*, Y. Kopyltsova, B. Kaplan, Great Neck, NY.
A Report of Follicular Dendritic Cell Sarcoma in a
Patient With CVID
M.A. Slack*, N. Farooqui, P. Ogbogu, Columbus, OH.
Treatment of BOOP in CVID Patient
M. Abdalgani*, W. Zhao, Richmond, VA.
Upon completion of this session, participants should
be able to: P73) recognize a pediatric case of
cutaneous polyarteritis nodosa following hepatitis B
vaccination; P74) identify Wells syndrome (eosinophilic
cellulitis) as a potential diagnosis in patients who
present with polymorphic skin lesions/cellulitis;
P75) discuss eosinophilic pneumonia in a smoker with
diffuse infiltrates and history of dust/soil exposure;
P76) discuss the different types of hereditary
angioedema (HAE), and summarize the pros and cons
of the available procedural prophylaxis options for
HAE; P77) discuss the role of PLE in SLE and summarize
the identification of AIHA and lupus nephritis in SLE as
well as treatment options; P78) describe a
desensitization protocol to drugs; P79) recognize that
in addition to anaphylaxis, mastocytosis and mast cell
activation syndromes, chronic urticaria and
angioedema may also present with elevated tryptase
levels; and discuss cyproheptadine as an additional
oral antihistamine used for management of chronic
urticaria and angioedema; P80) identify and properly
diagnose drug hypersensitivity to betalactam
antibiotic; P81) identify important differences in
clinical presentations of cryptosporidium infections in
nonimmunocompromised and immunocompromised
individuals and describe an atypical presentation of
cryptosporidium in an immunocompetent patient;
P82) discuss the pros and cons for treating secondary
immunodeficiency with immunoglobulin replacement;
P83) recognize the common and unusual
presentations of DRESS and discuss the available
treatment for DRESS; P84) recognize the possibility of
autoimmune complications, such as vasculitis, after
common vaccinations, including hepatitis B; P85)
identify the clincal symptoms of mastocytosis, and
their effect on the patients' quality of life and
recognize that IV fluid therapy might be a novel
therapeutic regimen in controlling symptoms of
mastocytosis; P86) recognize the clinical presentation
of trimethylaminuria and discuss the complex
pathophysiology of food-protein induced enterocolitis
syndrome and its possible interplay with metabolic
disorders; P87) identifiy the possible agents involved
in anaphylaxis following endoscopic procedures and
discuss a strategy for investigation of similar situations;
P88) recognize the need for all diagnosed HAE
patients to have acute action plans and rescue
medication at-hand and include HAE attack in the
differential diagnosis for an acute abdomen;
P89) interpret blood test results for hereditary versus
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
acquired angioedema and discusss differential
diagnosis for underlying disorders presenting with
angioedema; P90) identify and discuss the features of
the rarely reported adverse reaction of hemolysis
secondary to high-dose intravenous immunoglobulin
use and identify patients who are at increased risk for
developing hemolysis secondary to intravenous
immunoglobulin use; P91) identify symptoms of
NOMID and discuss the use of IL-1 receptor antagonist
as a treatment option for clinical improvement;
P92) discuss the differential diagnosis of eosinophilia
and describe the relationship between eosinophilia
and anaplastic large cell lymphoma; P93) recognize
that anaphylaxis may occur with administration of
brentuximab vedotin and discuss desensitization to
brentuximab vedotin using a protocol developed for
rituximab desensitization; P94) discuss the
presentation and evaluation of the potentially novel
cause of intraoperative anaphylaxis related to indigo
carmine; P95) recognize potential adverse reactions,
including anaphylaxis, in occupational workers in
contact with rodents and describe appropriate
treatment for anaphylaxis; P96) recognize that grapes
are a food that may be responsible for fooddependent
exercise induced anaphylaxis;
P97) recognize and diagnose acquired angioedema
secondary to lymphoproliferative disorders with
expanded consideration for splenic marginal zone
lymphoma as a possible cause; P98) discuss the
common presentation for delayed-type
hypersensitivity (DTH) to subcutaneously administered
heparin and its relative safety when administered
intravenously; P99) summarize the characteristics of
NS, its pathophysiology, as well as, the use of eyebrow
hair for diagnosis of NS and distinguish between
Netherton's syndrome and atopic dermatitis;
P100) make a clinical diagnosis of type 3 HAE and
select an appropriate treatment plan for patients with
type 3 HAE; P101) identify the paucity of data
regarding chronic isolated idiopathic angioedema of
the tongue and discuss the challenges associated with
its management; P102) discuss skin testing prior to
eATG administration and identify horse allergic
patients due to receive eATG, possibly with the use of
more in-depth pre-testing and describe the benefit of
further investigation to establish a robust preadministration
testing protocol for eATG; P103) discuss
allergic bronchopulmonary aspergillosis in patients
with cystic fibrosis and make an early diagnosis and
utilize proper treatment to avoid pulmonary
complications; P104) identify early steroid
administration in IgG4-associated cholangitis and
evaluate this treatment for other IgG4 plasma cellmediated
disorders; P105) discuss current diagnostic
criteria for mast cell activation syndrome and other
mast cell disorders and discuss possible treatment
modalities for mast cell disorders; P106) recognize that
pruritic dermatitis that does not improve with
standard therapy should be evaluated for underlying
systemic conditions, including hypothyroidism;
P107) utilize tongue microabscess in the differential
diagnosis of tongue angioedema; P108) describe rare
clinical situations that may present with angioedema;
P109) expand their differential diagnosis lists for
eczema, urticaria, and angioedema by the context of
precipitating factors from a patient history;
P110) review ingredient content in determining the
specific triggering food allergen in order to
differentiate solid food FPIES from celiac disease,
allergic proctocolitis, food protein-induced
enteropathy, and allergic eosinophilic
gastroenteropathies that can be triggered by the same
allergens and describe the characteristic clinical
pattern of presentation of FPIES, including delayed
reactions 1-5 hours after food ingestion and symptom
remission after removal of specific food allergens;
P111) identify hypereosinophilic syndrome (HES) and
discuss the underlying disorders in HES that may take
an indolent course and evolve over a long period of
time; P112) recognize that lymphadenopathy, rash,
and thrombophilia may occur with incomplete
DiGeorge syndrome patients and incomplete
DiGeorge syndrome with chromosome 22q11.2
deletion may initially present with symptoms similar to
autoimmune lymphoproliferative syndrome (ALPS);
P113) recognize that type I, IgE, mediated allergic
reactions to warfarin are rare and that warfarin
remains the drug of choice for prophylaxis against
thromboembolic events in patients requiring
mechanical heart valve replacement and present a
step wise approach to skin testing for warfarin allergy
using both prick and intradermal skin testing along
with graded dose challenge; P114) discuss the clinical
symptoms of benign cutaneous polyarteritis nodosa
and describe the possible association between
inflammatory bowel disease and vasculitis, including
benign cutaneous PAN; P115) recognize the clinical
manifestations of dermatomyositis and discuss
dermatomyositis in the differential diagnosis of
angioedema; P116) recognize hepatoxicity as a rare
potential complication of treatment with cetirizine;
P117) discuss the possible role of oligosaccharides on
transplanted tissue in patients with pre-existing IgE
antibodies to oligosaccharides; P118) discuss
appropriate preoperative evaluation of suspected
drug allergies; P119) identify quinine in tonic water as
a possible agent in causing urticaria; P120) identify
onion as a rare but possible food allergen with the
potential to cause anaphylaxis; P121) recognize that
FPIES patients may convert to an IgE-mediated food
allergy, even after negative skin testing and food
challenge; P122) summarize the indications for steroid
skin testing, test dosing and desensitisation in the
context of the urgent indication for steroid
administration, i.e., a pulsed course of steroid required
for a demyelination flare-up; P123) define
malakoplakia and summarize possible treatment
modalities for malakoplakia; P124) discuss the workup
of idiopathic anaphylaxis; P125) recognize appropriate
work up and treatment of acute and chronic
angioedema; P126) describe the manifestation of
autoimmune progesterone dermatitis and the

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
diagnosis of this condition; P127) discuss therapeutic
options for idiopathic non-histaminergic angioedema;
P128) discuss a novel cause of recurrent upper
respiratory infections; P129) recognize and diagnose
honey allergy using serum specific IgE; P130) list the
potentially pathogenic fungi found in wind
instruments and discuss novel immunologicallyinduced
diseases caused by fungi; P131) recognize
antihistamine resistant DPUA and discuss use of
omalizumab for resistant DPUA; P132) recognize that
high resolution chest CT should be considered in
children with asthma refractory to conventional
treatment, as uncommon pulmonary disorders may
present with similar symptoms; P133) describe most
common clinical and histopathological features of
Kimura's disease; P134) differentiate acquired
angioedema from food and medication induced
angioedema based on laboratory findings;
P135) identify systemic reactions to formaldehyde;
P136) discuss the importance of sequencing cDNA
when gDNA sequencing fails to reveal a mutation and
summarize the value of flow cytometry in the
detection of XLA; P137) describe the association
between helminthic infections and atopy and atopic
diseases; P138) identify patients with autoimmunity
and hemophilia as having a common disease as well
as establish diagnosis of autoimmune hemophilia by a
diagnostic path and summarize new treatment
strategies for autoimmune haemophilia; P139) discuss
the treatment patients with bradykinin-mediated
medication, such as ecallantide and icatibant, who
have attacks of laryngeal angioedema that do not
respond to antihistamines, steroids or epinephrine;
P140) recognize that premedication and
desensitization to A-B may result in the successful
reintroduction and continuation of therapy to A-β,
after a life-threatening anaphylactic event;
P141) discuss the IL-12/INF-γ axis as well as the
differential for immunodeficencies associated with
fungal diseases and recognize histoplasmosis as a
presentation for IL-12 receptor pathway defect;
P142) identify possible association of DRESS syndrome
with strongyloides infection, as several viral and other
infectious agents predispose patients to DRESS
syndrome through complex immune mechanisms;
P143) identify clinical and laboratory findings
consistent with various forms of urticarial vasculitis
and concomitant C1q deficiency and identify first line,
second line and adjunctive treatment available for
urticarial vasculitis; P144) discuss the natural history of
food allergies and recognize that a food aversion can
be the initial clinical presentation for a patient with an
unmasked food allergy; P145) identify the diagnosis of
HLH and consider testing in adult HLH patient for
chromosomal abnormalities to look for
immunodeficiencies; P146) identify the most common
cause of uvular edema; P147) identify signs and
symptoms of granulomatous CVID and recognize the
implications of a TACI mutation in the production of
the CVID phenotype and consider anti-TNF alpha
agents for treatment of granulomatous CVID;
P148) discuss immediate and delayed vaccine
reactions and recognize potential allergenic
components present in vaccines and discuss
management approaches to patients with a prior
vaccine reaction history; P149) recognize the
importance of immune evaluation in Turner's
syndrome patients; P150) discuss latex allergy as a
possible complication after multiple surgeries;
P151) discuss subclass deficiencies that may cause
lymphopenia in the presence of sepsis and recognize
that subclass deficiencies could be missed until later in
life; P152) identify the complexities of management of
refractory thrombocytopenia in patients with
DiGeorge syndrome; P153) recognize the different
presentations of autoimmune progesterone dermatitis
and discuss the differential diagnosis of dermatitis and
how to properly test for autoimmune progesterone
dermatitis; P154) recognize unusual presentations of
chronic granulomatous disease (CGD) and maintain a
high degree of suspicion regarding CGD; P155) discuss
nurse-administered home treatment of HAE patients
with ecallantide as a potentially convenient and costeffective
method; P156) discuss the different
treatment options available for common adverse
reactions of BCG treatment for bladder carcinoma;
P157) discuss the various types of dialyzer reactions
and recognize the limitations of reaction
classifications; P158) describe a treatment method for
hemophiliacs who have developed anaphylaxis to
factors; P159) discuss a rare case of mast cell leukemia;
P160) discuss the various presentations of Good
syndrome and how the definitive diagnosis is made
and discuss the management and long-term
complications of this disease; P161) recognize that
interstitial lung disease may be associated with
Crohn's disease and discuss the medications used in
the treatment of Crohn's, such as TNF inhibitors, that
may be associated with interstitial lung disease;
P162) recognize an autoimmune pancreatitis and
summarize its differential diagnosis, work-up and
treatment; P163) identifiy diffuse cutaneous
mastocytosis vs macularpapular mastocytosis and
escalate approprate medical therapy when needed;
P164) discuss common causes of
agammaglobulinemia and the use of clinical and
genetic markers to determine etiology; P165) discuss
active fungal airway infection and its possible
contribution to the expression of asthma;
P166) describe the differential diagnosis and
evaluation of a patient with episodic peripheral
eosinophilia; P167) discuss STAT3, the only gene
known to cause AD-HIES to date; P168) characterize
different types of aspirin hypersensitivity and
recognize differing indications for aspirin
desensitization protocols; P169) identify the clinical
symptoms and diagnostic criteria of macrophage
activation syndrome; P170) recognize that
hypersomnia disorders, such as Kleine-Levin
syndrome, may be triggered by recurrent sinusitis;
P171) identify the features of mast cell activation
disorder; P172) identify the potential benefit of
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
managing angioedema symptoms with ketotifen, in
conjunction with other agents; P173) recognize the
association between chronic urticaria and fungal
infections and treat dermatophytid reactions that
present as chronic urticaria; P174) discuss the
diagnosis of Churg Strauss syndrome and recognize
the common presentations as well as the atypical and
multisystem manifestations that are not often
described; P175) discuss small vessel vasculitis and
immunosuppressive therapy at an early stage;
P176) identify the serotypes of Neisseria meningitidis
that are covered by commercially available vaccines
and summarize the scenarios in which a person with
invasive meningococcal disease should be evaluated
for an immunodeficiency; P177) discuss possible
alternative treatment of exercise induced anaphylaxis
with omalizumab and discuss application of this
treatment for refractive EIA patients; P178) identify the
clinical presentation of a patient with MonoMAC
syndrome and discuss the diagnosis and treatment of
MonoMAC; P179) discuss possible adverse cardiac
outcomes of standard therapy in anaphylaxis;
P180) discuss the possible benefit to initiating an
immunodeficiency work-up early on in cystic fibrosis;
P181) recognize the presentation of an IgE-mediated
reaction to ethanol; P182) discuss safe and effective
treatment options for acute attacks of acquired
angioedema; P183) discuss the presentation and
possible cause of angioedema and discuss the PATCH
test and the utility of testing for the causative agents;
P184) identify signs and symptoms of possible allergy
to autologous seminal fluid; P185) diagnose and treat
patients of XHIGM syndrome; P186) identify patients in
whom IPEX syndrome should be considered in the
differential diagnosis to promote earlier diagnosis and
treatment and summarize key diagnostic methods in
IPEX syndrome patients; P187) identify Kimura disease
and describe modalities available for its treatment;
P188) describe the clinical features of Muckle-Wells
syndrome and the mutations that contribute to
different phenotypes and discuss the diagnosis and
treatment Muckle-Wells syndrome; P189) evaluate a
case of IgE multiple myeloma presenting atypically
with symptoms highly suggestive of, but lacking
sufficient diagnostic criteria for, systemic mastocytosis;
P190) discuss a new association between
hypogammaglobulinemia and systemic autoimmune
phenomenon, specifically relapsing polychondritis;
P191) generate a differential diagnosis of painless
proptosis and/or orbital mass in a patient with sinus
disease; P192) describe the utility of PATCH testing in
the setting of determining a possible allergy to a metal
and recognize identifying symptoms and
manifestations of a possible metal allergy;
P193) include allergic reaction to acetaminophen as
part of the differentials in similar clinical scenarios;
P194) recognize the possibility of type IV sensitivity in
patients who present with cutaneous findings when
exposed to nitrile or polyisoprene gloves;
P195) identify diagnostic criteria for allergic
bronchopulmonary aspergillosis (ABPA), make an early
diagnosis for ABPA and recognize the potential
consequences of undiagnosed ABPA and skin test
patients with difficult to control asthma for ABPA, as
appropriate; P196) identify a premedication protocol
for the prevention of life-threatening anaphylaxis from
protamine; P197) discuss 3-D CT scans in the diagnosis
of tracheobronchomalacia; P198) identify the
disseminated blastomycosis in idiopathic CD4
lymphocytopenia and monitor lymophocyte counts in
idiopathic CD4 lymphocytopenia and use antibiotic
prophylaxis when indicated; P199) identify shea butter
as a commonly used emollient in topical products and
recognize that shea butter can cause allergic contact
dermatitis; P200) identify a type of severe combined
immunodeficiency that may be missed by T cell
receptor excision circles newborn screening (TREC
NBS); P201) describe the symptoms and presentation
of patients with secretory IgA deficiency;
P202) recognize the potential for repeated severe
reactions to contrast media despite pretreatment with
steroids and discuss the role played by T-cell mediated
reactions; P203) identify potential chronic idiopathic
urticaria patients who may benefit from omalizumab
treatment; P204) recognize the presentation of
eosinophilic fasciitis (EF) and discuss possible causes
of EF; P205) recognize the occurence of a rare
malignancy in patient's with CVID and discuss the
possibility of follicular dendritic cell sarcoma in
patients with CVID; and P206) discuss the role of
steroid treatment for bronchiolitis obliterans in a
patient with common variable immunodeficiency
(CVID).
Clinical Immunology, Immunodeficiency
P
P
P
P
A Mother-Daughter Case of NK Cell Deficiency
Suggesting Autosomal Dominant Inheritance
S.C. Reznick*, R. Hostoffer, L. Chernin, D. Swender,
H. Tcheurekdjian, Cleveland, OH.
A “Good” History Gives the Diagnosis
C.S. Bauer*, R.N. Rao, J.M. Routes, Milwaukee, WI.
Identification of the TLR LF Variant in a
Patient With Chronic Mucocutaneous Candidiasis
S. Gendelman*, Y. Han, C. Isada, F.H. Hsieh,
Cleveland, OH.
Good’s Syndrome Associated With Lichen Planus
and Selective IgM Deficiency
R.R. Vatti* 1 , B.T. Ryhal 2 , 1. Granite Bay, CA; 2. Roseville,
CA.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
Tolerability and Safety of Recombinant Human
Hyaluronidase-Facilitated Subcutaneous Infusion
of Human Immune Globulin G, %, in Patients
With Primary Immunodeficiencies: A Study From
North America
R. Kobayashi* 1 , M.R. Stein 2 , A. Darter 3 , K. Paris 4 ,
S. Gupta 5 , A. Testori 6 , W. Engl 7 , H. Leibl 7 , K. Filhauer 7 ,
R.I. Schiff 8 , 1. Los Angeles, CA; 2. North Palm Beach, FL;
3. Oklahoma City, OK; 4. New Orleans, LA; 5. Irvine, CA;
6. Thornton, CO; 7. Vienna, Austria; 8. Westlake
Village, CA.
Efficacy of C-Inhibitor Concentrate (Berinert®) for
the Treatment of Peripheral Attacks of Acute
Hereditary Angioedema Compared to Untreated
Historical Controls
K. Bork* 1 , P. Staubach 1 , H. Feuersenger 2 , T. Machnig 2 ,
T.J. Craig 3 , 1. Mainz, Germany; 2. Marburg, Germany;
3. Hershey, PA.
Long-Term Safety and Pharmacokinetics of
Facilitated-Subcutaneous Infusion of Human
Immune Globulin G, %, and Recombinant
Human Hyaluronidase: Phase Extension Study in
Patients With Primary Immunodeficiencies
I. Melamed* 1 , R. Wasserman 2 , M.R. Stein 3 ,
A. Rubinstein 4 , J. Puck 5 , S. Gupta 6 , W. Engl 7 , H. Leibl 7 ,
D.M. Gelmont 8 , R.I. Schiff 8 , 1. Centennial, CO; 2. Dallas,
TX; 3. North Palm Beach, FL; 4. Bronx, NY; 5. San
Francisco, CA; 6. Irvine, CA; 7. Vienna, Austria;
8. Westlake, CA.
Pancytopenia, Splenomegaly and
Hypergammaglobulinemia in an -Year Old Male
C.T. Quezada-Chalita*, D.R. Pietropaolo Cienfuegos,
B.E. Del Río Navarro, L. Berrón, Mexico City, DF,
Mexico.
Lymphoid Neogenesis in Common Variable
Immunodeficiency Chronic Lung Disease
P.J. Maglione*, M. Ko, J.A. Strauchen, M.B. Beasley,
C. Cunningham-Rundles, New York, NY.
Efficacy and Safety of C Esterase Inhibitor
Concentrate (Berinert®) for the Treatment of Acute
Hereditary Angioedema in Obese Versus Non-
Obese Patients
J.A. Bernstein* 1 , T.J. Craig 2 , H. Keinecke 3 , T. Machnig 3 ,
1. Cincinnati, OH; 2. Hershey, PA; 3. Marburg, Germany.
A Fatal Good’s Syndrome With Pure Red Cell
Aplasia
U. Musabak, O. Kartal, F. Demirel*, M. Gulec, M. Safali,
B. Battal, O. Nevruz, A. Baysan, S. Yesillik, M. Karaman,
O. Sener, Ankara, Turkey.
P
P
P
P
P
P
P
P
P
P
P
Case Report: Intravenous Immunoglobulin Halts
Progression of Granulomatous Disease Associated
With Common Variable Immunodeficiency
K.J. Lim*, M. Riedl, Los Angeles, CA.
Atypical Case of Hypogammaglobulinemia
R. Patel*, M. Jawairia, M. Frieri, East Meadow, NY.
Mycosis Fungoides in an Adult Referred for
Chronic Urticaria
S. Min*, K. Zakarian, S. Thobani, M. Li, L. Scott, Los
Angeles, CA.
Experience With Subcutaneous Loading of
Vivaglobin® or Hizentra® in Primary
Immunodeficiency Patients Naive to
Immunoglobulin Replacement Therapy
A. Koterba*, K. Farnan, C. Sierra, D. Eufrasio,
M.R. Stein, North Palm Beach, FL.
Trisomy p and Monosomy q Associated With
Immunodeficiency
J.M. Welch*, H.J. Wedner, St. Louis, MO.
Atypical Presentation of X-Linked
Agammaglobulinemia and Its Inherent Difficulty
in Assessment of Response to IVIG
Y.W. Khan 1 , M. Hicar 2 , D.S. Hummell* 1 , 1. Nashville, TN;
2. Buffalo, NY.
Phellinus Tropicalis Abscess in a Patient With
Chronic Granulomatous Disease
M. Ramesh*, E. Resnik, V. La Bombardi, N. Bouvier,
Y. Hui, P.J. Maglione, H. Mehta, C. Cunningham-
Rundles, New York, NY.
A New Syndrome of Allergy, Recurrent Infection,
NK Deficiency and Adaptive Immune Dysfunction
J. Mendez* 1 , Y. Luna 1 , J.A. Bellanti 2 , 1. Mexico City, DF,
Mexico; 2. Washington, DC.
Disseminated Tuberculosis in Infant With Inborn
Defect in IFN-γ/Il-/Il- Axis
E. Sandoval-Ramirez*, B.E. Del Rio-Navarro,
D.R. Pietropaolo-Cienfuegos, L. Blancas-Galicia,
A. Zamora-Chávez, N. Ramírez Alejo, Mexico City, DF,
Mexico.
Biochemical Comparison of Commercially
Available C Esterase Inhibitor Concentrates for
Treatment of Hereditary Angioedema
A. Feussner* 1 , U. Kalina 1 , D. Schuermann 1 ,
T. Machnig 1 , W. Kreuz 2 , T.J. Craig 3 , 1. Marburg,
Germany; 2. Frankfurt, Germany; 3. Hershey, PA.
Diffuse Eczema and Staphylococcus Aureus in Two
Patients With X- Linked Agammaglobulinemia
(XLA)
S. Culverhouse*, C. Mesolella, G. Shear,
R. Damrongwatanasuk, J. Sleasman, R.F. Lockey,
Tampa, FL.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
Classical Natural Killer Deficiency: Description of a
Rare Case in a Year Old Female
A. Ghazi* 1 , R. Divekar 2 , R. Bonds 2 , 1. League City, TX;
2. Galveston, TX.
Immunodeficiency in Rett Syndrome
S.B. Sindher*, A. Djukic, J. Shliozberg, Bronx, NY.
Importance of the Histological Findings in the
Diagnosis of Chronic Granulomatous Disease:
Report of Cases With the Family Approach
L.O. Hernandez-Mondragon*, R.D. Pietropaolo-
Cienfuegos, A. Zamora, B.E. DelRio-Navarro,
L. Blancas-Galicia, Mexico City, DF, Mexico.
CMV Retinitis in Good Syndrome
K. Zakarian* 1 , S. Min 2 , S. Thobani 2 , L. Scott 2 , T. Kimia 2 ,
M. Li 2 , 1. Glendale, CA; 2. Los Angeles, CA.
Blood Dendritic Cell Immunophenotype in
Patients With Severe Multiple Drug Resistant
Pulmonary Tuberculosis
A.Y. Hancharou* 1 , L.P. Titov 1 , I.V. Ramanava 1 ,
V. Solodovnikova 1 , L.M. DuBuske 2 , 1. Minsk, Belarus;
2. Gardner, MA.
Brothers With X-Linked Agammaglobulinemia
(XLA): An Argument for Expanded Newborn
Screening
J.S. Tam*, M.K. Hintermeyer, T. Dasu, J.M. Routes,
J.W. Verbsky, Milwaukee, WI.
Level of Serum Th (Il-) and Th (Il-) Cytokines in
Patients With Oral Mucosal Lichen Planus
G.N. Drannik* 1 , A.I. Kurchenko 1 , R.A. Rehuretska 1 ,
L.M. DuBuske 2 , 1. Kiev, Ukraine; 2. Gardner, MA.
Hypocomplementemic Urticarial Vasculitis With
Eosinophilic Infiltrates
T.A. Kamdar*, K. McGrath, Chicago, IL.
Lupus-Like Syndrome in C Deficiency
P. Beerelli*, V. Dimitriades, New Orleans, LA.
Hyper-IgM Variant Due to a Thrmet Missense
Mutation
P. Patel* 1 , N. Mazer 1 , M. Eisenfeld 1 , T. Torgerson 2 ,
H. Ochs 2 , A. Rubinstein 1 , J. Shliozberg 1 , 1. Bronx, NY;
2. Seattle, WA.
Complement C Deficiency
T. Nguyen* 1 , L. Lim 2 , 1. Riverside, CA; 2. Hayward, CA.
Combined T and B Cell Defect Associated With
Jacobsen Syndrome
Y. Luo*, P. Ponda, Great Neck, NY.
A Case of Acquired C Esterase Inhibitor
Deficiency in a Female With IBD
K.J. Garg* 1 , R. Khanal 2 , S.R. Ayyappan 2 , T. Sher 2 ,
1. Cleveland Heights, OH; 2. Cleveland, OH.
P
P
P
P
P
P
P
P
P
P
Primary Immunedeficiency Diseases at Reference
and High Specialty Hospitals in Guanajuato State,
Mexico
E. Guaní-Guerra*, U.N. García-Ramírez, A.I. Jiménez-
Romero, J.M. Velázquez-Ávalos, F.J. Mendoza-
Espinoza, G. Gallardo-Martínez, León, GT, Mexico
Lps-Receptor Expression and Elevated C-Reactive
Protein Levels in Diabetes Mellitus Type Patients
May Induce Chronic Inflammation
V.A. Beloglazov* 1 , I.J. Dynaev 1 , A.I. Gordienko 1 ,
L.M. DuBuske 2 , 1. Simferopol, Ukraine; 2. Gardner, MA.
The Effect of Cyclosporine on Cytokine Levels in
Ocular Fluids of Patients With Uveitis
R. Khanferyan* 1 , S. Adgavi 1 , L.M. DuBuske 2 ,
1. Krasnodar, Russian Federation; 2. Gardner, MA.
The Inhibitory Effects of Fullerene C on the
Immunopathology of Experimental Adjuvant
Arthritis
I.P. Kaidashev* 1 , T.V. Mamontova 1 , L.E. Vesnina 1 ,
M.V. Mikityuk 1 , N.A. Bobrova 1 , L.A. Kutsenko 1 ,
I.L. Gordinskaya 1 , L.M. DuBuske 2 , 1. Poltava, Ukraine;
2. Gardner, MA.
IPEX “Immune Dysregulation, Polyendocrinopathy,
Enteropathy, X-Linked” Like Syndrome With
Reduced Foxp Expression in CD+T-Regulatory
Cells Without Foxp Mutation
S. Gierer*, M. Dasouki, O. Almadhoun, M. Le, Kansas
City, KS.
Gram Negative Sepsis in Children Leads to
Deficient Anti-Endotoxin Immunity
L.F. Pritulo 1 , Y.A. Bisyuk* 1 , L.M. DuBuske 2 ,
1. Simferopol, Ukraine; 2. Gardner, MA.
Dextrans As Ligands of Mannose Receptor and
DC-Sign Family Receptors: A Novel Means of
Modulating Th/Th Immune Responses
S.V. Pustylnikov*, T.I. Petrenko, Novosibirsk, Russian
Federation.
Acquired Cold Urticaria: A Case Report
K. Mejia*, S. Gonzalez, A. Arias, J. Buenfil, C. Gallego,
V. Yañez, L. Dominguez, M. Calva, L. Rangel,
H. Hernandez, Monterrey, Mexico.
Heterozygous Artemis Mutation Resulting in a
Combined Immunodeficiency
T. Dy*, P. Patel, A. Rubinstein, Bronx, NY.
Seasonality in Initial Presentation of Systemic
Lupus Erythematosus in a Pediatric Cohort
A. Mathew*, S. Panupattanapong, M. Kim,
J. Moallem, Brooklyn, NY.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
Hemophagocytic Lymphohistiocytosis Associated
With Epstein Barr Virus Infection in a Patient With
Common Variable Immune Deficiency
N. Kalra*, P. Bajaj, M. Bayerl, T. Craig, Hershey, PA.
Atypical Clinical Manifestations in Patients With
Agammaglobulinemia
K.L. Miro*, L. Geng, H. Jyonouchi, Newark, NJ.
Upper Respiratory Cytokine Production in
Children Infected With Novel Versus Seasonal
HN Influenza a Infection
H. Kobayaa* 1 , J. Domachowske 2 , E. Secord 1 ,
C. Bonville 2 , P. Lephart 1 , B. Asmar 1 , 1. Detroit, MI;
2. Syracuse, NY.
Recalcitrant Warts Secondary to Non-HIV Related
T- Cell Deficiency
S. Yee* 1 , C. Kirkpatrick 2 , 1. Denver, CO; 2. Aurora, CO.
Functional Natural Killer Cell Deficiency in An
Infant With Crohn’s: A Case Report
M. Relan*, Y. Khan, H. Lehman, Buffalo, NY.
Heterogeneous Pneumococcal Antibody Titers in
Patients With Antibody Deficiency Receiving
Subcutaneous Hizentra®
H. Niebur* 1 , D. Nguyen 2 , M. Dorsey 1 , T. Alberdi 1 ,
C. Duff 1 , S. Lukas 1 , J. Sleasman 1 , 1. St. Petersburg, FL;
2. Houston, TX.
Is It Really Crohn’s Disease
P. Lall*, L. Kobrynski, Atlanta, GA.
Atopic Disease Among Patients With Chromosome
q. Deletion Syndrome
M. Morsheimer* 1 , H. Hernandez-Trujillo 2 ,
D. McDonald-McGinn 1 , E. Zackai 1 , K. Sullivan 1 ,
T. Brown-Whitehorn 1 , 1. Philadelphia, PA; 2. West
Hartford, CT.
Severe T Cell Lymphopenia Identified Via TREC
Assay in a Patient With q Deletion Syndrome
(Jacobsen Syndrome)
H. Shah*, K. Paris, New Orleans, LA.
Upon completion of this session, participants should
be able to: P207) recognize that NK cell deficiency
likely has a genetic component with both recessive,
and now dominant, inheritance patterns reported;
P208) recognize the features commonly associated
with Good's syndrome; and state the importance of a
thorough history, including surgical history, when
evaluating a patient for immunodeficiency;
P209) identify mutations that are associated with
familial chronic mucocutaneous candidiasis other than
the AIRE mutation and identify different clinical
phenotypes associated with chronic mucocutaneous
candidiasis; P210) identify and manage immune
defects that are associated with thymomas;
P211) summarize safety and tolerability outcomes
from an interim analysis of a phase 2/3 study following
treatment with human hyaluronidase-facilitated
subcutaneous infusion of human immune globulin G
in patients with primary immunodeficencies;
P212) discuss the benefit of treatment of peripheral
attacks with C1-INH; P213) summarize safety and
pharmacokinetics outcomes following up to 3 years of
treatment with human hyaluronidase-facilitated
subcutaneous infusion of human immune globulin G
in patients with primary immunodeficencies;
P214) identify autoimmune lymphoproliferative
syndrome in patients with autoimmune phenomena,
splenomegaly and hypergammaglobulinemia;
P215) discuss the presence of lymphoid neogenesis in
CVID lung disease and its potential impact upon
disease pathogenesis; P216) discuss the benefit of
C1-INH in obese vs. non-obese patients; P217)
recognize that recurrent, atypical and drug-resistant
infections may be related to diseases of the immune
system and affect the appropriate selection of
antibiotic treatment, as well as, recognize that
autoimmune, allergic or malign diseases may be
associated with immune deficiency diseases and
examine patients with thymoma in terms of immune
deficiency diseases, as these can accompany their
clinical situation both before and after thymectomy;
P218) identify differences between sarcoidosis and
granulomatous disease in common variable
immunodeficiency and discuss possible management
options for granulomatous disease in common
variable immunodeficiency; P219) discuss selective
IgA deficiency and discuss progression to possible
common variable immunodeficiency (CVID); P220)
identify when to refer a patient to dermatology for
biopsy given atypical history of eczema or chronic
urticaria; P221) discuss the advantages/disadvantages
of subcutaneous vs intravenous immunoglobulin
replacement; P222) identify a novel genetic mutation
associated with an immunodeficiency; P223) describe
the utility of measurement of specific antibody titers
to serotypes of Streptococcus pneumonia as an
appropriate means of determining efficacy of IVIG
therapy in certain patients; P224) recognize Phellinus
tropicalis as a pathogen in chronic granulomatous
disease; P225) discuss the two major groups of
quantitative and functional types of NK deficiency and
the two major mechanisms of action of NK cell
function in direct cellular cytotoxicity and indirect
immunoglobulin-linked ADCC reactions and recognize
the association of NK cell dysfunction with
abnormalities of the adaptive immune system in
patients who present with recurrent infection and
allergic disease; P226) recognize defects in te IFNgamma-IL12-IL23
axis; P227) discuss the biochemical
differences between different C1-INH concentrates
regarding their impurity profile; P228) discuss
characteristics of X-linked agammaglobulinemia and
discuss the role of Staphylococcal aureus in eczema;
P229) discuss various differential diagnosis of
recurrent viral infections and maintain a high clinical
suspicion of Natural Killer (NK) cell deficiency disorder;
P230) identify that immunodeficiency may be a
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
concern in patients with Rett syndrome; P231) identify
typical histologic findings in a chronic granulomatous
disease (CGD); P232) identify characteristics of Good
syndrome and possible rare complications;
P233) discuss blood dendritic cell immunophenotype
in patients with severe multiple drug resistant
pulmonary tuberculosis; P234) discuss available
techniques not yet utilized for newborn screening
(NBS) for immunodeficiency and summarize the
advantages, disadvantages, and limitations of NBS;
P235) discuss level of serum Th1 (IL-2) and Th2 (IL-4)
cytokines in patients with oral mucosal lichen planus;
P236) recognize the presentation of urticarial vasculitis
and that histopathologic findings can include
eosinophils and describe the various treatment
options available for urticarial vasculitis;
P237) recognize the autoimmune manifestations of
complement deficiency; P238) discuss differences
between classical and rare phenotypes of hyper-IgM
syndromes; P239) recognize the role of complement
studies in evaluation of patients with possible
immunodeficiency; P240) identify humeral or cellular
immunodefiency associated with Jacobsen syndrome;
P241) identify the challenges associated with
diagnosis and treatment of patients with C1 esterase
inhibitor deficiency and IBD; P242) identify the
frequency and clinical spectrum of primary immune
deficiency (PID) and promptly diagnosis and treat PID;
P243) discuss LPS-receptor expression and elevated
C-reactive protein levels in diabetes mellitus type 1
patients that may induce chronic inflammation;
P244) describe the effect of cyclosporine on cytokine
levels in ocular fluids of patients with uveitis; P245)
describe the inhibitory effect of fullerene C60 on
immunopathology in experimental adjuvant arthritis;
P246) recognize that there may be variations in FOXP3
abnormalities; P247) recognize that gram negative
sepsis in children leads to deficient anti-endotoxin
immunity; P248) recognize that application of
dextrans may provide a new mechanism of treatment
of intracellular infections including tuberculosis, HIV,
viral hepatitis and influenza, as well as, in other future
uses in medicine as a means of immune modulation;
P249) discuss the diagnosis and treatment of acquired
cold urticaria; P250) summarize the clinical
manifestations of severe combined immunodeficiency
as well as identify mutations in ARTEMIS as a cause of
B- and T- lymphocyte radiosensitivity and discuss
subcutaneous gammaglobulin as a potential
treatment for patients with heterozygous ARTEMIS
mutations and resultant hypogammaglobulinemia;
P251) discuss environmental factors that have been
proposed to cause flares of systemic lupus
erythematosus (SLE) and discuss seasonality in the
initial presentation of SLE in this pediatric cohort;
P252) identify the clinical presentation of EBV
associated HLH syndrome and suspect and
appropriately manage this rare complication early in
adult CVID patients; P253) discuss the early diagnosis
and proper treatment of patients with
agammaglobulinemia, as late diagnosis can often lead
P
P
P
P
P
P
to atypical clinical manifestations and identify the
absence of tonsils on physical exam as an important
clinical tool in the early diagnosis of
agammaglobulinemia; P254) compare local upper
respiratory inflammatory pattern between novel and
seasonal H1N1 influenza A infection; P255) recognize
the presentation of a patient with immunodeficiency/
lymphocytopenia; P256) discuss functional Natural
Killer (NK) cell deficiencies and discuss how to
clinically approach a patient who presents with
abnormal NK cell function, including initial laboratory
testing; P257) recognize antibody titers required for
protection against pneumococcal disease in patients
with antibody deficiency and discuss the limitations of
inferring protection for pneumococcal disease from
steady state total IgG levels; P258) identify symptoms
and laboratory tests for chronic granulomatous
disease (CGD) and differentiate CGD from Crohn's
disease; P259) recognize that patients with
chromosome 22q11.2 deletion syndrome would
benefit from proactive screening for atopic disease;
and P260) recognize the newborn screening T-cell
receptor excision circle (TREC) assay's ability to identify
lymphopenia in clinical entities other than severe
combined immune deficiency (SCID).
Food Allergy
Food Protein-Induced Enterocolitis Syndrome
Triggered by Orange Juice
T. Federly*, P. Ryan, C. Dinakar, Kansas City, MO.
Performance of Skin Prick Testing and Serum
Specific IgE Testing in Pediatric Oral Food
Challenges to Cows Milk, Egg, and Peanut Allergy
M. Nanda*, P. Windom, J. Khoury, M. Lierl, A. Assa’ad,
Cincinnati, OH.
Late onset of Food Protein-Induced Enterocolitis
Syndrome After Food Challenge in a Boy With
Gastroschisis
C.T. Quezada-Chalita* 1 , R.T. Quezada Medrano 2 ,
1. Mexico City, DF, Mexico; 2. Tepic, NA, Mexico.
Epinephrine Auto-Injector and Medical Alert
Bracelet Preparedness in Pediatric Food Allergy
J. Shih*, K. Demuth, Atlanta, GA.
A Case of Concurrent Eosinophilic Esophagitis and
Eosinophilic Gastroenteritis Presenting With
Upper GI Bleed
D.R. Sun* 1 , J. Ko 2 , M.T. Nguyen 2 , 1. San Francisco, CA;
2. Oakland, CA.
Food Allergy and Anaphylaxis Educational
Curriculum in Urban Child Care Centers
B.J. Lanser*, J.A. Bird, A.T. Tang, Dallas, TX.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
P
P
P
P
P
Outgrowing IgE Food Allergy to Milk and
Developing Eosinophilic Esophagitis
S.M. Maggadottir*, J.M. Spergel, T.F. Brown-
Whitehorn, Philadelphia, PA.
Heiner Syndrome Masquerading as an Immune
Deficiency
J.A. Sigua* 1 , M. Zacharisen 2 , 1. Milwaukee, WI;
2. Bozeman, MT.
Food Protein-Induced Enterocolitis Triggered by
Pork: A Case Report
G. Ram*, J. Heimall, S.P. DaVeiga, Philadelphia, PA.
Engineered Osmotin Variant Demonstrates
Reduced Allergenic Potency With Hypersensitive
Patients’ Sera and Mice
P. Sharma*, S.N. Gaur, N. Arora, Delhi, India.
Food Hypersensitivity Presenting as Protein-
Losing Enteropathy Without Gastrointestinal
Symptoms
N. Farooqui*, R. Scherzer, D.W. Hauswirth,
Columbus, OH.
Current Food Allergy Diagnosis and Management
Practices of Pediatricians
R. Gupta* 1 , A. Dyer 1 , C.H. Lau 1 , M.W. Sohn 1 ,
B. Altshuler 2 , J.A. Brown 3 , J. Necheles 1 , 1. Chicago, IL;
2. Crystal Lake, IL; 3. Barrington, IL.
A Case of Delayed Anaphylaxis to Beef in Central
Florida
S.A. Aljubran*, R. Lockey, M. Glaum, Tampa, FL.
Eosinophilic Esophagitis in South Dakota
M.E. Bubak, L.R. Peterson*, Sioux Falls, SD.
Buckwheat Allergy- New Allergen to Watch in
the US
C. Radojicic, D. Mlinarik*, Independence, OH.
Safety of Multiple Allergen Oral Immunotherapy
With and Without Adjunct Omalizumab Therapy
A.K. Mehrotra*, T.L. Dominguez, L. Winterroth,
A. Sciancalepore, D. Pineda, A. Blakemore, M. Woch,
K. Sampson, K. Nadeau, Stanford, CA.
Pectin Anaphylaxis Associated With Cashew and
Pistachio Allergy
M. Rafeeq*, Oregon, OH.
Peanut Sensitization: A Circumstance of Affluence
in Children
S.K. Yip*, G.K. Yamane, T.S. Rans, J.M. Quinn,
J.L. Butler, San Antonio, TX.
Potential Unreliability of RAST Testing for
Diagnosis of Food Allergy
D.E. Riester*, Burlington, MA.
P
P
P
P
A Cohort Study of Peanut, Tree Nut Allergy:
Sensitization and Correlations With Clinical
Manifestations
L. Yang* 1 , R. Joks 2 , 1. Millburn, NJ; 2. Brooklyn, NY.
Serum Specific Immunoglobulin E (IgE) Levels of
Common Food Allergens in Children Presenting
With Food Allergy
M. Amin*, J.C. Khoury, A.H. Assa’ad, Cincinnati, OH.
Eosinophilic Esophagitis (EoE) to Unsuspected
Food Allergens
S.K. Mane*, P. Jordan, S.L. Bahna, Shreveport, LA.
Prevalence of Peanut Allergy in Children of Peanut
Farmers
A. Jagdis* 1 , G. Liss 1 , S. Maleki 2 , P. Vadas 1 , 1. Toronto,
ON, Canada; 2. New Orleans, LA.
Upon completion of this session, participants should
be able to: P261) discuss food protein-induced
enterocolitis syndrome (FPIES) induced by unusual
agents, such as oranges or other citrus fruits;
P262) identify the shortcomings of current skin prick
testing and serum specifiic IgE testing for clinically
relevant food allergy; P263) identify the possibility of a
late onset of food protein-induced enterocolitis
syndrome after a food challenge; P264) discuss the
reality of allergy preparedness in food allergic
pediatric patients; P265) differentiate between
different eosinophilic gastrointestinal diseases as well
as various diagnostic and treatment options;
P266) recognize the need for an educational
curriculum regarding food allergy and anaphylaxis
among child care center workers and discuss the
results of the pilot program, and goals of future
research; P267) discuss cases where apparent true IgE
mediated food allergy evolves or changes into
eosinophilic esophagitis and describe the plasticity of
food allergies.P268) identify common manifestations
of Heiner syndrome as well as discuss a differential
diagnosis of chronic pulmonary infiltrates and
summarize an appropriate diagnostic evaluation of
Heiner syndrome; P269) identify patients with FPIESmediated
food allergy and recognize mammalian
meats as a possible trigger for FPIES; P270) discuss the
reduction of allergenic potency with hypersensitive
patients’ sera and mice as demonstrated by an
engineered osmotin variant; P271) recognize
uncommon symptoms presenting as food
hypersensitivity; P272) summarize current trends in
management of food allergy among pediatricians and
compare current practices to the NIAID food allergy
management guidelines; P273) discuss delayed food
allergy and recognize allergy to alpha gal as possible
cause for delayed food allergy and anaphylaxis;
P274) discuss the current methods used for the
diagnosis and treatment of eosinophilic esophagitis by
allergists and gastroenterologists in the state of South
Dakota; P275) differentiate wheat allergy from
buckwheat wheat allergy and recognize potential
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
allergens in 'gluten-free food'; P276) discuss the
possible safety issues with multiple allergen oral
immunotherapy; P277) review presentation of pectin
allergy and anaphylaxis and discuss association of
pectin allergy with cashew and pistachio allergy;
P278) identify socioeconomic status as a potential risk
factor for peanut sensitization primarily in children
and not adults; P279) discuss the potential limits of
serological testing for food allergy; P280) discuss a
possible correlation between peanut and tree nut
sensitization and clinical allergic manifestations;
P281) interpret serum food specific IgE levels in
children for the common food allergens and recognize
that the rise of serum food specific IgE over time is an
expected finding; P282) obtain esophageal biopsy
even if the mucosa appears grossly normal and
conduct a detailed food allergy evaluation in spite of
lack of food suspicion by history; and P283) discuss
the prevalence of peanut allergy in children of peanut
farmers in comparison to the general population.
Immunotherapy, Immunizations
Evaluation of Systemic Reactions in Subcutaneous
Immunotherapy Patients
H. DelasAlas*, C. Stokes, J. Stokes, Omaha, NE.
Allergy Immunotherapy Quality of Life and
Perceived Efficacy Opinion Survey
P. Buddiga*, M. Baz, Fresno, CA.
Cost Benefit and Patient Satisfaction of Allergen
Immunotherapy
M.L. Vandewalker*, T. Vandewalker, Columbia, MO.
Cross-Reactivity Between Human Seminal Plasma
Fluid and Dog Dander: Possible Therapeutic
Implication
T.M. Nsouli* 1 , C.D. Schluckebier 2 , S.T. Nsouli 2 ,
C.M. Davis 2 , J.A. Bellanti 2 , 1. Burke, VA; 2. Washington,
DC.
Initiation of Specific Immunotherapy (SCIT & SLIT)
Among AR Patients in a US Allergy Practice
R. Anolik* 1 , F. Allen-Ramey 2 , A. Schwartz 1 ,
P. Lupinacci 3 , 1. Blue Bell, PA; 2. West Point, PA; 3. East
Norriton, PA.
Quality of Life (RQLQ(S)) During a Course of an
Ultra Short-Term Ragweed Immunotherapy
H.B. Kaiser* 1 , K.J. Fischer von Weikersthal-
Drachenberg 2 , L.M. DuBuske 3 , 1. Miinneapolis, MN;
2. Munich, Germany; 3. Gardner, MA.
Ragweed Allergen-Specific Immunoglobulin IgE
and IgG During a Course of Ultra Short-Term
Ragweed Immunotherapy
L.M. DuBuske* 1 , K.J. Fischer von Weikersthal-
Drachenberg 2 , H.B. Kaiser 3 , 1. Gardner, MA; 2. Munich,
Germany; 3. Minneapolis, MN.
P
P
P
P
P
P
P
P
P
P
P
Clinical Effects of Immunotherapy in Patients With
Allergic Disease in the National Institute of
Respiratory Diseases
G.G. Ma del Rosario*, M.H. Garcia Cruz, K. Ruiz
Cervantes, C. Najera Villatoro, F. Ramirez, Mexico City,
DF, Mexico.
The Safety and Efficacy of the United Allergy
Services Immunotherapy Protocol
L. Garner* 1 , L. Whelchel 1 , M. Ryals 1 , M. Ebeling 2 ,
T. Hulsey 2 , F.M. Schaffer 2 , 1. San Antonio, TX;
2. Charleston, SC.
The Safety of Home Immunotherapy Utilizing the
United Allergy Services Immunotherapy Protocol
F.M. Schaffer* 1 , L. Whelchel 2 , H. Soliz 3 , T. Crimmins 2 ,
M. Ebeling 1 , T. Hulsey 1 , L. Garner 2 , 1. Charleston, SC;
2. San Antonio, TX.
Th , Th and Th Cytokine Profiles in Pollen
Allergic Patients Before Treatment and After Two
Years of Sublingual Immunotherapy
L.P. Titov* 1 , L. Maslova 1 , A. Hancharou 1 ,
L.M. DuBuske 2 , 1. Minsk, Belarus; 2. Gardner, MA.
Rare Skin Manifestation Following Smallpox
Vaccination With ACAM
S. Dickson*, K.S. Johnson, Lackland AFB, TX.
Polymerization of Recombinant Allergens Modify
Allergenicity and IgE-Regulatory Cytokine Profile
R. Khanferyan* 1 , A. Aminian 2 , 1. Krasnodar, Russian
Federation; 2. Fresno, CA.
An Algorithm for Assessment of Pollen Allergen
Specific Immunotherapy
L.I. Romaniuk* 1 , O.P. Nazarenko 1 , L.M. DuBuske 2 ,
1. Kiev, Ukraine; 2. Gardner, MA.
Comparison of the Safety of Cluster Versus
Conventional Immunotherapy Schedules in a
Community Based Allergy Clinic
J. Jacobs, S. Somani*, R. Turner, Walnut Creek, CA.
Two-Day Ultra-Rush Insect Venom Immunotherapy
in Patients With Multiple Venom Allergies
T.J. Owens* 1 , T. Baker 2 , T. Rans 1 , 1. Lackland Air Force
Base, TX; 2. Joint Base Andrews, MD.
Seasonal Administration of Rush Immunotherapy
Is Not a Risk Factor for Systemic Reactions
M.E. Sunny*, M.L. Alvares, K. Hilton, T. Walton,
D.A. Khan, Dallas, TX.
Successful Immunotherapy in Skin Test Induced
Anaphylactic Reaction to Venom: Case Report
M. Ansstas*, M.B. Hammami, J. Temprano, St. Louis,
MO.
Upon completion of this session, participants should
be able to: P284) recognize the World Allergy

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
Association classificaiton of systemic reaction to
immunotherapy and identify potential risk factors for
developing these reactions and recognize
management options for these reactions as well as the
benefit/risk implicated by each; P285) discuss the
efficacy of subcutaneous allergen immunotherapy
from a patient perpspective; P286) use the Rhinitis
Outcomes Questionnaire to assess patient
improvement from immunotherapy and discuss
patient satisfaction and cost-benefit ratio of
immunotherapy in allergic rhinitis; P287) discuss the
possible beneficial role of dog dander immunotherapy
in patients suffering from human seminal plasma
allergy due to cross-reactivity between dog dander
and human prostatic specific antigen; P288) identify
factors that may influence a patient’s decision to
initiate immunotherapy, overall and for specific
modalities of SCIT and SLIT; P289) discuss quality of life
[RQLQ(S)] during a course of an ultra short-term
ragweed immunotherapy; P290) discuss ragweed
allergen-specific immunoglobulin IgE and IgG during a
course of an ultra short-term ragweed
immunotherapy; P291) identify the clinical effects of
immunotherapy in patients with allergic diseases;
P292) discuss differences in immunotherapy protocols
and their effects on the frequency of adverse systemic
reactions; P293) discuss and summarize issues
pertaining to safety, efficacy, and advantages/
disadvantages of home-based immunotherapy;
P294) describe Th2, Th1 and Th17 cytokine profiles in
pollen allergic patients before treatment and after two
years of sublingual immunotherapy; P295) identify the
various cutaneous rashes that can occur following
smallpox vaccine, in particular, generalized, selflimited
rashes; P296) discuss the possibility of
modifying recombinant allergens as a tool for possible
future specific immunotherapy; P297) utilize an
algorithm for assessment of pollen allergen specific
immunotherapy; P298) compare risks between
conventional and cluster immunotherapy schedules;
P299) describe an alternative ultra-rush venom
protocol with multiple flying hymenoptera extracts;
P300) identify the relationship between the seasonal
administration of pollens and the incidence of
systemic reactions during immunotherapy; and
P301) discuss the safe administration of
immunotherapy, even if anaphylactic shock occurs
secondary to skin testing.
Other
Stable IgA Nephropathy Post-Renal Transplant on
Immune Suppressive Therapy
S. Akkina*, M. Frieri, East Meadow, NY.
Clinical Trial Experience of Pediatric Patients
Treated With Ecallantide for Acute Attacks of
Hereditary Angioedema
A.J. MacGinnitie* 1 , M. Davis-Lorton 2 , L.E. Stolz 3 ,
R. Tachdjian 4 , 1. Boston, MA; 2. Mineola, NY;
3. Burlington, MA; 4. Los Angeles, CA.
P
P
P
P
P
P
P
Treatment Preferences in Patients With Moderate-
Severe Seasonal Allergic Rhinitis: Findings of a
Discrete Choice Experiment
S. Acaster* 1 , W. Carr 2 , P. Lieberman 3 , C. Bachert 4 ,
D. Price 5 , 1. Somerset, NJ; 2. Mission Viejo, CA;
3. Memphis, TN; 4. Ghent, Belgium; 5. Aberdeen, United
Kingdom.
Treatment of Abdominal Attacks of Hereditary
Angioedema With Ecallantide
A.L. Sheffer 1 , A.J. Lembo 1 , L.E. Stolz 2 , C. Stevens* 1 ,
1. Boston, MA; 2. Burlington, MA.
Management of Hereditary Angioedema in
Children: Clinical Symptoms and Treatment
Response
I. Martinez-Saguer*, E. Rusicke, E. Aygören-Pürsün,
T. Klingebiel, W. Kreuz, Frankfurt, Germany.
Formal and Computable Representations of
Allergic Diseases in the Electronic Health Record:
An Approach Based on the Ontology of General
Medical Science
A. Yu*, S. Schwartz, Buffalo, NY.
Mobile Technology and Social Media in the Care of
Adolescents With Asthma
A. Varadhi*, A. Nickels, R. Wolf, V. Dimov, Chicago, IL.
Rapid Growth of Twitter Use by Allergists and
Immunologists for Professional Purposes
N. Fenny*, R. Wolf, V. Dimov, Chicago, IL.
Exploring Physician-Patient Relationships With
Leader-Member Exchange Theory
S.K. Saini* 1 , K. Allgaier 1 , H. Huynh 2 , K. Sweeny 2 ,
1. Upland, CA; 2. Riverside, CA.
Upon completion of this session, participants should
be able to: P302) discuss IgA nephropathy, a common
form of idiopathic glomerulonephritis which can lead
to chronic kidney disease and summarize genetic
factors that can promote the overproduction of an
aberrant form of IgA pathogenesis and describe the
advantages of treatments for these patients;
P303) discuss use of ecallantide and its outcomes in
pediatric patients with HAE; P304) discuss an approach
to cost/effectiveness of therapeutic agents using a
discrete choice model that is widely accepted;
P305) describe the natural history of abdominal
hereditary angioedema (HAE) attacks and discuss
outcomes following ecallantide treatment for
abdominal HAE attacks; P306) discuss the importance
of early screening of pediatric patients with a known
family history of HAE; P307) discuss the use of defined
terms in electronic medical record systems as well as
the relevance to reusing encoded data in allergy/
immunology and describe techniques used in
representing medical knowledge in computer-based
systems; P308) review available modes of technology
that can be used for managing the health of
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
adolescents with asthma and discuss the advantages,
disadvantages, and possible future studies of using
mobile technology and social media in the care of
adolescents; P309) discuss the rapid increase of Twitter
use by allergists and immunologists and its potential
for use in professional development and patient
education and identify best practices of Twitter use for
patient and physician education; P310) relate the
correlation between patients’ ratings of relationship
quality with their physician and adherence behavior in
an asthma/allergy clinic; and P311) discuss the
similarities and differences between manifestation and
management of HAE in adult and pediatric patients
and summarize the benefits of self-administration of
C1-INH.
Pharmacology and Pharmacotherapeutics
P
P
P
P
P
P
P
P
Manifestation and Management of Hereditary
Angioedema in Children and Adults
I. Martinez-Saguer*, E. Rusicke, E. Aygören-Pürsün,
T. Klingebiel, W. Kreuz, Frankfurt, Germany.
Soluble Guanylyl Cyclase Activation Inhibits
Human Eosinophil Chemotaxis and Reduces
Murine Allergic Inflammation
L. Baldissera-Jr*, D.M. Squebola, M.C. Calixto, G. De
Nucci, E. Antunes, Campinas, SP, Brazil.
The Prescribing Patterns of Prednisone in the US
T. Lee*, G. Lee, M. Smith, Louisville, KY.
Device and Integrated Dose Counter Performance
of Beclomethasone Dipropionate Nasal Aerosol
During Daily Use
E.O. Meltzer* 1 , P.E. Korenblat 2 , B.Q. Lanier 3 , L. Kelley 4 ,
S.A. Dunbar 4 , S.K. Tantry 4 , 1. San Diego, CA; 2. St. Louis,
MO; 3. Fort Worth, TX; 4. Frazer, PA.
Allergy and Ménière’s Disease: Is There a
Relationship
T.M. Nsouli* 1 , S.T. Nsouli 2 , C.D. Schluckebier 2 ,
J.A. Bellanti 2 , 1. Burke, VA; 2. Washington, DC.
Adverse Outcomes Associated With Reported
Penicillin Allergy in Patients With Pneumonia and
Bacteremia
V. Reddy*, N. Baman, F.T. Ishmael, Hershey, PA.
Self Intravenous (IV) Administration of C-INH
Concentrate for Hereditary Angioedema: A
Retrospective Analysis of Patient Outcomes
R. Shapiro*, Plymouth, MN.
Sustained Duration of Action of Icatibant for the
Treatment of Acute Hereditary Angioedema
Attacks: Findings From a Predictive Clinical Model
Applied to the FAST- , - and - Phase III Clinical
Trials
K. Leach* 1 , C. Olivier 2 , T.G. McCauley 1 , 1. Lexington,
MA; 2. Eysins, Switzerland.
P
P
P
P
Use of a % Subcutaneous Immunoglobulin
Solution (Hizentra®) Allows for Lower Total Dosing
Volumes and Fewer Treatment Days Per Week
Compared to a % Subcutaneous Solution
R. Shapiro*, Plymouth, MN.
Upon completion of this session, participants should
be able to: P312) discuss the available
pharmacological theraphies used in allergic asthma
and compare with the experimental pharmacological
approach presented in this study, summarizing the
new contributions to asthma treatment strategies;
P313) discuss the prescribing patterns of prednisone
from 2000 to 2009 and the possible impact on current
and future practices; P314) critically evaluate the
performance of the BDP nasal aerosol device with
integrated dose counter and discuss how use of this
BDP device may impact disease control in patients
with perennial allergic rhinitis; P315) describe the
possible role of atopy in patients with Ménière’s
disease and discuss how treatment of allergic rhinitis
may have a potentially beneficial effect in patients
suffering from this clinically perplexing condition;
P316) identify possible adverse outcomes that can
result from documented penicillin allergies in patients
hospitalized for infections and discuss whether
penicillin allergy skin testing should be routinely done
in these patients prior to initiation of alternative
antibiotics; P317) discuss the concept of training
patients with HAE to self-administer C1-INH therapy at
home and evaluate data on the feasibility of this
management strategy; P318) describe data showing
bradykinin challenge data and the clinical duration of
action of icatibant; and P319) discuss the increased
dosing efficiency afforded with the use of 20% SCIG
versus 16% SCIG, as evidenced by lower weekly
product volume and fewer days per week
administration.
Rhinitis, Other Upper Airway and
Ocular Disorders
Comparison of Tolerability Between Two Allergy
Drops
M.M. Hom*, Azusa, CA.
An Alternative Aspirin Desensitization Protocol for
AERD Patients That Failed Standard Aspirin
Desensitization Protocol
D. Patel, J. Riar, S. Sekhsaria*, Baltimore, MD.
An Open-Label, Randomized, Pharmacokinetic
Comparison of Triamcinolone Acetonide HFA and
CFC Nasal Inhalers
K. Newman* 1 , B. Hafkin 2 , 1. Marlborough, MA;
2. Austin, TX.

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
A Randomized, Placebo Controlled, Double-Blind,
Parallel Group Therapeutic Equivalence
Comparison of Triamcinolone Acetonide HFA and
CFC Nasal Inhalers in Patients With Seasonal
Allergic Rhinitis
K. Newman 1 , E. Schenkel* 2 , 1. Marlborough, MA;
2. Bethlehem, PA.
Human Nasal Deposition of Mometasone Furoate
Aqueous Nasal Spray
S. Shah* 1 , R. Berger 1 , P. Gupta 1 , D. Monteith 1 ,
J. McDermott 2 , A. Connor 2 , W. Li 2 , 1. Whitehouse
Station, NJ; 2. Ruddington, United Kingdom.
Nasal Deposition of Beclomethasone Dipropionate
Nasal Aerosol Versus Fluticasone Propionate and
Mometasone Furoate Aqueous Nasal Sprays
C. Leach*, P. Kuehl, R. Chand, J. McDonald,
Albuquerque, NM.
Long-Term Safety and Efficacy of MP- (Novel
Intranasal Formulation of Azelastine
Hydrochloride and Fluticasone Propionate) in
Patients With Chronic Rhinitis
W. Berger* 1 , S. Shah 2 , D. Price 3 , J. Hadley 4 , L. Gever 1 ,
S. Bhatia 5 , 1. Somerset, NJ; 2. Collegeville, NJ;
3. Aberdeen, United Kingdom; 4. Naples, FL; 5. Mumbai,
India.
MP- Compared to Commercially Available
Azelastine Hydrochloride and Fluticasone
Propionate for the Treatment of Nasal and Ocular
Symptoms of Seasonal Allergic Rhinitis (SAR)
P. Ratner* 1 , F.C. Hampel 2 , W. Howland 3 , D. Ginsberg 1 ,
P. Lieberman 4 , 1. Somerset, NJ; 2. New Braunfels, TX;
3. Albuquerque, NM; 4. Memphis, TN.
Efficacy of Mp- (Intranasal Azelastine/
Fluticasone Propionate) Compared to Commercial
and Non-Commercial Formulations of Azelastine
Hydrochloride and Fluticasone Propionate for the
Treatment of Seasonal Allergic Rhinitis (Sar)
W. Carr* 1 , C. LaForce 2 , J. Hadley 3 , L. Gever 1 ,
E.O. Meltzer 4 , 1. Somerset, NJ; 2. Raleigh, NC; 3. Naples,
FL; 4. San Diego, CA.
Nasal Symptom Improvement Following once-
Daily Treatment With Beclomethasone
Dipropionate Nasal Aerosol ( ug or ug) in
Children With Seasonal Allergic Rhinitis
W.W. Storms* 1 , N.A. Nayak 2 , L. Kelley 3 , Y. Ding 3 ,
S.K. Tantry 3 , 1. Colorado Springs, CO; 2. Normal, IL;
3. Frazer, PA.
P
P
P
P
P
P
P
P
Efficacy, Safety, and Optimal Dose Selection of
Beclomethasone Dipropionate Nasal Aerosol for
the Treatment of Seasonal Allergic Rhinitis
W.E. Berger* 1 , G. Raphael 2 , D.S. Pearlman 3 , L. Kelley 4 ,
S.A. Dunbar 4 , S.K. Tantry 4 , 1. Mission Viejo, CA;
2. Bethesda, MD; 3. Denver, CO; 4. Frazer, PA.
Evaluation of Ocular Safety Following Long-Term
Treatment With Beclomethasone Dipropionate
Nasal Aerosol in Subjects With Perennial Allergic
Rhinitis
S.F. Weinstein* 1 , E.J. Schenkel 2 , J.A. Bardelas 3 ,
L.T. Chylack 4 , A. Tankelevich 5 , Y. Ding 5 , S.K. Tantry 5 ,
1. Huntington Beach, CA; 2. Bethlehem, PA; 3. High
Point, NC; 4. Duxbury, MA; 5. Frazer, PA.
Lower Symptom Severity Scores in Cetirizine-
Treated Patients With Moderate-Severe Perennial
Allergic Rhinitis
M.K. Patel* 1 , E.R. Urdaneta 1 , K.B. Franklin 2 , P. Du 3 ,
M. Wu 4 , 1. Fort Washington, PA; 2. Phoenixville, PA;
3. Shanghai, China; 4. Morris Plains, NJ.
Dentomaxillofacial Disorders in Children With
Allergic Rhinitis
C.I. Gallego* 1 , S.N. Gonzalez 1 , M. Hernandez 1 ,
A. Arias 1 , D. Garcia 2 , K.Y. Mejia 1 , M. Calva 1 ,
L.A. Dominguez, R. Carrillo, H.H. Torre, A. Venegas,
Monterrey, NL, Mexico.
Lower Symptom Severity Scores in Cetirizine-
Treated Patients With Moderate-Severe Seasonal
Allergic Rhinitis
E.R. Urdaneta* 1 , M.K. Patel 1 , K.B. Franklin 2 , P. Du 3 ,
M. Wu 1 , 1. Fort Washington, PA; 2. Phoenixville, PA;
3. Shanghai, China
Analysis of Improvement in Nasal and Ocular
Symptoms in the Morning Following Once-Daily
(Morning) Treatment With Ciclesonide Nasal
Aerosol in Patients With Seasonal Allergic Rhinitis
P.H. Ratner 1 , R. Jacobs 1 , D. Mohar* 2 , H. Huang 3 ,
S.Y. Desai 3 , 1. San Antonio, TX; 2. Kerrville, TX;
3. Marlborough, MA.
An Evaluation of the Effect of Ciclesonide
Hydrofluoroalkane Nasal Aerosol on Hypothalamic
Pituitary Adrenal Axis in Pediatric Patients With
Perennial Allergic Rhinitis
G. Berman* 1 , F. Hampel 2 , B. Wang 3 , M.R. Edwards 3 ,
1. Minneapolis, MN; 2. New Braunfels, TX;
3. Marlborough, MA.
Allergic Rhinitis-Induced Postnasal Drip and
Chronic Nausea: Is There a Relationship
T.M. Nsouli* 1 , C.D. Schluckebier 2 , S.T. Nsouli 2 ,
J.A. Bellanti 2 , 1. Burke, VA; 2. Washington, DC.
Posters

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
P
P
P
P
P
P
P
P
Investigation of the Laryngopharyngeal Mucosal
Distribution of Hydroxypropylmethyl Cellulose
(HPMC) Powder After Transnasal Aerosol
Application in Vivo
A. Seifalian 1 , M. Birchall 1 , L. Bielory* 2 , 1. London,
United Kingdom; 2. Springfield, NJ.
A Scintigraphy Study Evaluating the Nasal and
Pulmonary Deposition of a Radiolabeled Solution
of Ciclesonide Hydrofluoroalkane Nasal Aerosol
and a Radiolabeled Suspension of Ciclesonide
Aqueous Nasal Spray in Healthy Subjects
E.O. Meltzer* 1 , J. Karafilidis 2 , 1. San Diego, CA;
2. Marlborough, MA.
Objective Responses to External Nasal Dilators in
Normal Children
E.O. Meltzer* 1 , W. Becker 2 , G. Shanga 2 , 1. San Diego,
CA; 2. Parsippany, NJ.
Subjective Responses to External Nasal Dilators in
Normal Children
E.O. Meltzer* 1 , W. Becker 2 , G. Shanga 2 , 1. San Diego,
CA; 2. Parsippany, NJ.
Clinical Efficacy of Surfactants in the Treatment of
Chronic Rinosinusitis in Adult Patients
A.L. Burbano-Cerón*, A.A. Velasco-Medina,
A. González-Carsolio, G. Velázquez-Sámano, Mexico
City, DF, Mexico.
Dose Ranging of Sublingual Tablets of House Dust
Mite Allergen Extract: Results of an Environmental
Exposure Chamber Rhinitis Study
W.H. Yang* 1 , G.L. Sussman 2 , M. Roux 3 , A. Viatte 3 ,
V. Cadic 3 , R.K. Zeldin 3 , 1. Ottawa, ON, Canada;
2. Toronto, ON, Canada; 3. Antony, France.
Reduced Likelihood of Multiple Asthma-Related
Hospitalizations in Patients Newly Diagnosed With
Allergic Rhinitis Who Receive Intranasal
Corticosteroids
C.S. Hankin 1 , L. Cox 2 , A. Bronstone 1 , Z. Wang 1 ,
P.O. Buck* 3 , M.S. Lepore 3 , 1. Moss Beach, CA; 2. Fort
Lauderdale, FL; 3. Horsham, PA.
Efficacy of Timothy Grass Allergy Immunotherapy
Tablet in European and North American Patients
With Allergic Rhinoconjunctivitis
M. Blaiss* 1 , H. Nelson 2 , A. Bufe 3 , R. Dahl 4 , K. Murphy 5 ,
J. Maloney 6 , A. Kaur 7 , H. Nolte 7 , 1. Memphis, TN;
2. Denver, CO; 3. Bochum, Germany; 4. Aarhus,
Denmark; 5. Boys Town, NE; 6. Whitehouse Station, NY;
7. Whitehouse Station, NJ.
P
P
Assessing the Efficacy of Allergy Immunotherapy
Tablet Treatment: Are Local Application-Site
Reactions Unblinding the Trials and Confounding
Efficacy Measurements
K. Murphy* 1 , D. Bernstein 2 , G. Berman 3 , P. Creticos 4 ,
S. Gawchik 5 , J. Maloney 6 , A. Kaur 6 , N. Liu 6 , H. Nolte 6 ,
1. Boys Town, NE; 2. Cincinnati, OH; 3. Minneapolis,
MN; 4. Baltimore, MD; 5. Upland, PA; 6. Whitehouse
Station, NJ.
Efficacy of Ragweed Allergy Immunotherapy
Tablet on Ocular Symptoms Caused by Ragweed
Pollen-Induced Allergic Rhinoconjunctivitis
J. Maloney 1 , G. Berman 2 , P. Creticos 3 , S. Gawchik 4 ,
D. Bernstein 5 , K. Murphy 6 , A. Kaur 1 , N. Liu 1 , H. Nolte* 1 ,
1. Whitehouse Station, NJ; 2. Minneapolis, MN;
3. Baltimore, MD; 4. Upton, PA; 5. Cincinnati, OH;
6. Boys Town, NE.
Upon completion of this session, participants should
be able to: P320) describe the differences in
tolerability between two allergy drops; P321) discuss
the prevalence, diagnosis and management of aspirin
exacerbated respiratory disease (AERD) with a focus on
aspirin desensitization; P322) summarize the
pharmacokinetics of a new nasal steroid formulation;
P323) describe the efficacy and the dose response
curve for an aerosol formulation of a nasal steroid;
P324) discuss the deposition and nasal clearance of
mometasone furoate; P325) describe the difference in
deposition of BDP nasal aerosol (QNASLTM) compared
with fluticasone propionate aqueous nasal spray and
mometasone furoate aqueous nasal spray in patients
with allergic rhinitis; P326) evaluate the long-term
safety and efficacy of azelastine 137 mcg / fluticasone
propionate 50 mcg per spray; P327) discuss the results
of treating ocular as well as nasal symptoms with a
nasal spray combination of azelastine and fluticasone;
P328) discuss the difference in efficacy between
commercial vs. non-commercially available azelastine
and fluticasone propionate as well as the impact of
this difference; P329) discuss the favorable efficacy
profile of beclomethasone dipropionate nasal aerosol
for the treatment of nasal symptoms in children with
seasonal allergic rhinitis; P330) critically evaluate 3
doses of BDP nasal aerosol to determine the optimally
safe and effective dose for adolescents and adults
(12 years or older) with seasonal allergic rhinitis;
P331) discuss the ocular safety profile of
beclomethasone dipropionate nasal aerosol in
subjects with perennial allergic rhinitis; P332) evaluate
the efficacy of OTC cetirizine therapy for the treatment
of ARIA-consistent moderate-severe perennial allergic
rhinitis symptoms; P333) recognize the most frequent
dentomaxillofacial alterations in children with mouth
breathing and allergic rhinitis; P334) evaluate the
efficacy of OTC cetirizine therapy for the treatment of
ARIA-consistent moderate-severe seasonal allergic
rhinitis symptoms; P335) describe the effect of
ciclesonide nasal aerosol on improvement of the

Poster Session
12:30 – 1:30 pm, Saturday and Noon – 1:00 pm, Sunday
Hall C (1st Floor) • Anaheim Convention Center
morning nasal and ocular symptoms of seasonal
allergic rhinitis; P336) discuss the systemic safety of
the ciclesonide hydrofluoroalkane nasal aerosol 74
mcg once daily dose in pediatric patients 6-11 years
old with perennial allergic rhinitis; P337) discuss the
improvement of chronic nausea in patients presenting
with allergic-induced postnasal drip after treatment of
allergic rhinitis; P338) discuss the impact of a barrier
based therapeutic agent on mucosal surface of the
lung; P339) discuss the nasal and lung deposition of a
radiolabeled solution of the ciclesonide nasal aerosol
and a radiolabeled suspension of the ciclesonide
aqueous nasal spray; P340) explore the effect of 2
different mechanical external nasal dilators on nasal
patency as measured by peak nasal inspiratory flow in
normal children ages 6-12 years, in both the seated
and supine positions; P341) explore the effect of 2
different mechanical external nasal dilators on
perceived reduction of obstruction in normal children
ages 6-12 years, in both the seated and supine
position; P342) evaluate different treatments for
chronic rhinosinusitis and discuss bacterial biofilms as
a pathogenic mechanism for the persistence of this
condition; P343) discuss the latest data on efficacy and
safety of sublingual immunotherapy for house dust
mite-associated allergic rhinitis; P344) describe the link
between control of allergic rhinitis and asthma
morbidity and discuss the potential benefits of
intranasal corticosteroids in preventing severe asthma
exacerbations in patients with newly diagnosed
allergic rhinitis; P345) describe the consistency of
treatment effect of grass allergy immunotherapy
tablet between European and North American studies;
P346) explain the relevance of local application-site
reactions in the assessment of treatment effect of
ragweed allergy immunotherapy tablet; and
P347) describe the effect of ragweed allergy
immunotherapy tablet on ocular symptoms of allergic
rhinoconjunctivitis.
P
P
P
P
Type III Hereditary Angioedema: Clinical
Characteristics and Treatment Response With
Berinert* in a French Cohort
L. Bouillet* 1 , I. Boccon-Gibod 1 , D. Launay 2 , J. Laurent 3 ,
B. Floccard 4 , L. Martin 5 , F.A. Allaert 6 , H. Catovic 3 ,
O. Fain 7 , A. Gompel 3 , 1. Grenoble, France; 2. Lille,
France; 3. Paris, France; 4. Lyon, France; 5. Angers,
France; 6. Dijon, France; 7. Bondy, France.
Metoprolol-Induced Pustular Psoriasis
A. Keswani*, A.T. Peters, Chicago, IL.
Systemic Contact Dermatitis After Patch Test With
Hair Dye Containing Paraphenylenediamine
J. Kuryan*, A.M. Jongco, P. Ponda, S. Farzan, Great
Neck, NY.
Chronic Dyshydrotic Eczema Ultimately Diagnosed
as Contact Dermatitis Caused by the Resin in the
Stems of Alstomeria Species Flowering Plants
R.M. Harris*, Beverly Hills, CA.
Upon completion of this session, participants should
be able to: P348) discuss the clinical phenotype of
subjects with chronic urticaria and identify an
association of vitamin D and chronic urticaria;
P349) discuss type III hereditary angioedema and
describe the experience of a French centre where
patients are currently successfully treated with a
human plasma-derived C1-Inhibitor [C1 esterase
inhibitor (C1-INH), Human]; P350) discuss the
differential of a diffuse pustular skin eruption;
P351) recognize the potency of
paraphenylenediamine (PPD) as a contact allergen and
use caution in applying hair dye samples as a patch
test; and P352) identify the rate of response of chronic
urticaria patients to antihistamines and name several
immunomodulatory therapies for antihistamine
resistant chronic urticaria.
Posters
P
Skin Disorders
Role of Vitamin D in Chronic Urticaria and
Angioedema Treatment Study: Enrollment
Characteristics
W. Goldner, E. Lyden, J.A. Poole*, Omaha, NE.

Plenary & Symposia Faculty
Seema S. Aceves, MD, PhD
Associate Professor, Pediatrics and
Medicine, University of California, San
Diego, Rady Children's Hospital,
San Diego, CA
Amal H. Assa'ad, MD, FACAAI
Professor of Pediatrics, Cincinnati
Children's Hospital Medical Center,
Cincinnati, OH
Sami L. Bahna, MD, DrPH, FACAAI
Professor of Pediatrics & Medicine; Chief
of Allergy & Immunology Section;
Louisiana State University Health
Sciences Center, Shreveport, LA
Mark Ballow, MD, FACAAI
SUNY Buffalo, Division of Allergy &
Immunology, Buffalo, NY
Aleena Banerji, MD
Assistant Professor of Medicine,
Harvard University, Boston, MA
Donald V. Belsito, MD
Leonard C. Harber Professor of Clinical
Dermatology, Columbia University
Medical Center, New York, NY
William E. Berger, MD, MBA, FACAAI
Clinical Professor, Department of
Pediatrics, Division of Allergy and
Immunology, University of California,
Irvine, CA
David I. Bernstein, MD, FACAAI
Division of Immunology, Allergy and
Rheumatology University of Cincinnati
College of Medicine, Cincinnati, OH
Leonard Bielory, MD
Director, STARx Allergy and Asthma
Center, LLC; Attending, Robert Wood
Johnson University Hospital; Professor,
Rutgers University, Center for Environmental
Prediction, Springfield, NJ
Michael S. Blaiss, MD, FACAAI
Clinical Professor of Pediatrics and
Medicine, University of Tennessee
Health Science Center, Memphis, TN
Vincent R. Bonagura, MD
Associate Chair, Department of
Pediatrics; Chief, Division of Allergy and
Immunology; Jack Hausman Professor
of Pediatrics; Professor of Molecular
Medicine; Feinstein Institute for Medical
Research; Hofstra-NS-LIJ School of
Medicine, Manhasset, NY
Larry Borish, MD, FACAAI
Professor of Medicine, University
of Virginia Health System,
Charlottesville, VA
Kevin Brown, MD
Professor and Vice Chair, Department of
Medicine, National Jewish Health,
Denver, CO
A. Wesley Burks, MD, FACAAI
Curnen Distinguished Professor and
Chair, Department of Pediatrics, The
University of North Carolina, Chapel
Hill, NC
Warner W. Carr, MD, FACAAI
Allergy & Asthma Associates of
Southern California, Mission Viejo, CA
Mark L. Corbett, MD, FACAAI
Private Practice-Allergy Care,
Louisville, KY
William W. Crawford, MD
Assistant Clinical Professor of Medicine,
David Geffen School of Medicine at
UCLA, Los Angeles, CA
Richard D. deShazo, MD, FACAAI
Professor of Medicine and Pediatrics,
University of Mississippi Medical Center,
Jackson, MS
William K. Dolen, MD, FACAAI
Professor, Pediatrics and Medicine,
Georgia Health Sciences University,
Augusta, GA
Lawrence M. DuBuske, MD, FACAAI
Clinical Professor of Medicine, George
Washington University School of
Medicine, Washington, DC
Mark S. Dykewicz, MD, FACAAI
Professor of Internal Medicine; Director,
Allergy and Immunology; Allergy and
Immunology Fellowship Program
Director; Wake Forest University School
of Medicine, Winston-Salem, NC
Mary Beth Fasano, MD, FACAAI
Professor Clinical Medicine & Pediatrics,
University of Iowa, Iowa City, IA
Stanley M. Fineman, MD, MBA, FACAAI
Adjunct Associate Professor,
Department of Pediatrics, Emory Univ
School of Medicine, Atlanta, GA
Alessandro Fiocchi, MD, FACAAI (SC)
Director of Pediatrics, Melloni Hospital,
Milan, Italy
Michael B. Foggs, MD, FACAAI
Chief of Allergy, Asthma & Immunology,
Advocate Medical Group, Advocate
Health Care, Chicago, IL
Luz S. Fonacier, MD, FACAAI
Professor of Clinical Medicine, State
University of New York at Stony Brook,
Head of Allergy and Training Program
Director, Winthrop University Hospital,
Mineola, NY
Marianne Frieri, MD, PhD, FACAAI
Chief, Allergy Immunology,Nassau Univ.
Medical Center, Dept of Medicine,
Professor of Medicine & Pathology,
State Univ. of N.Y. at Stony Brook, Stony
Brook, NY
Sandra M. Gawchik, DO, FACAAI
Co-Director, Division of Allergy and
Immunology, Crozer Chester Medical
Center, Chester PA; Clinical Associate
Professor, Pediatrics Thomas Jefferson
Medical School, Upland, PA
Richard G. Gower, MD, FACAAI
Clinical Associate Professor of Medicine,
University of Washington, Spokane, WA
Mitchell H. Grayson, MD, FACAAI
Associate Professor of Pediatrics,
Medicine, Microbiology and Molecular
Genetics, The Medical College of
Wisconsin, Milwaukee, WI
Vivian Hernandez-Trujillo, MD, FACAAI
Director, Division of Allergy and Clinical
Immunology, Miami Children’s Hospital,
Miami, FL; Clinical Assistant Professor,
Herbert Wertheim School of Medicine,
Florida International University,
Miami, FL
Milton Hom, OD
Private Practice, Azusa, CA
Neal Jain, MD, FACAAI
Department of Pediatrics, Maricopa
Medical Center, Phoenix, AZ
Rohit K. Katial, MD, FACAAI
Professor of Medicine and Program
Director, University of Colorado,
National Jewish Health, Division of
Allergy/Immunology, Denver, CO
John M. Kelso, MD, FACAAI
Division of Allergy, Asthma and
Immunology, Scripps Clinic, San
Diego, CA
Stephen F. Kemp, MD, FACAAI
The University of Mississippi Medical
Center, Jackson, MS

Plenary & Symposia Faculty
David A. Khan, MD, FACAAI
Professor of Medicine, University of
Texas Southwestern Medical Center,
Dallas, TX
Hirohito Kita, MD
Professor of Immunology, Mayo Clinic,
Rochester, MN
David M. Lang, MD, FACAAI
Head, Allergy/Immunology Section,
Department of Pulmonary, Allergy, and
Critical Care Medicine, Division of
Medicine, Cleveland Clinic Foundation,
Cleveland, OH
Bobby Q. Lanier, MD, FACAAI
Clinical Professor Pediatrics/
Immunology North Texas University
Health Science Center, Fort Worth, TX
Teofilo Lee-Chiong, MD
National Jewish Health, University of
Colorado Denver School of Medicine,
Denver, CO
Kristin M. Leiferman, MD
Professor of Dermatology, Univ of Utah,
Health Sci Ctr, Dept Dermatology,
Immunoderm Lab, Salt Lake City, UT
James T. Li, MD, FACAAI
Professor of Medicine and Chair,
Division of Allergy and Immunology,
Mayo Clinic, Rochester, MN
Phillip L. Lieberman, MD, FACAAI
Clinical Professor Pediatrics and
Medicine, University of Tennessee
College of Medicine, Memphis, TN
Michael Littner, MD
Emeritus Professor of Medicine, David
Geffen School of Medicine at UCLA, Los
Angeles, CA
William R. Lumry, MD, FACAAI
Clinical Professor of Internal
Medicine/Allergy Division, University of
Texas Southwestern Medical School,
Dallas, TX
Todd A. Mahr, MD, FACAAI
Clinical Professor of Pediatrics,
University of Wisconsin School of
Medicine Public Health, Madison, WI
Gailen D. Marshall, MD, PhD, FACAAI
The R Faser Triplett Sr MD Chair of
Allergy and Immunology, Professor of
Medicine and Pediatrics, Director,
Division fo Clinical Immunology and
Allergy, University of Mississippi
Medical Center, Jackson, MS
Anthony Montanaro, MD, FACAAI
Professor and Chair, Division of Allergy
and Immunology; Vice Chair Department
of Medicine, Oregon Health and
Science University, Portland, OR
Maria Antonella Muraro, MD
Head of the Veneto Region Food Allergy
Diagnosis and Treatment Centre,
Pavlova, Italy
Richard A. Nicklas, MD, FACAAI
Clinical Professor of Medicine, The
George Washington University School
of Medicine, Washington, DC
Mark T. O'Hollaren, MD, FACAAI
Professor of Medicine and Vice-
President, Oregon Health and Science
University, Portland, OR
Jordan S. Orange, MD, PhD, FACAAI
Chief, Immunology Allergy and
Rheumatology, Texas Children’s
Hospital, Houston, TX
Lanny J. Rosenwasser, MD, FACAAI
Dee Lyons/Missouri Endowed Chair in
Pediatric Immunology Research;
Professor of Pediatrics, Allergy-
Immunology Division, Children's
Mercy Hospital, Kansas City, MO and
Professor of Pediatrics, Medicine, and
Basic Science, University of Missouri-
Kansas City School of Medicine,
Kansas City, MO
Marc E. Rothenberg, MD, PhD, FACAAI
Director, Division of Allergy and
Immunology, Director, Cincinnati
Center for Eosinophilic Disorders;
Professor of Pediatrics, Cincinnati
Children's Hospital Medical Center,
University of Cincinnati College of
Medicine, Cincinnati OH
Charles J. Siegel, MD, FACAAI
Assoc Clinical Prof, Univ. of Missouri @
Kansas City, School of Medicine, Dept of
Peds, Kansas City, MO
William S. Silvers, MD, FACAAI
Clinical Professor of Medicine, Division
of Allergy Clinical Immunology,
University of Colorado School of
Medicine
F. Estelle Simons, MD, FACAAI, FRCPC
Professor, Department of Pediatrics &
Child Health Sciences Centre, Professor,
Department of Immunology, The
University of Manitoba, Winnipeg,
MB, Canada
Joshua Solomon, MD
Assistant Professor of Medicine,
National Jewish Health, Denver, CO
Jonathan M. Spergel, MD, PhD, FACAAI
Chief, Allergy Section, The Children's
Hospital of Philadelphia, Perelman
School of Medicine, Philadelphia, PA
James L. Sublett, MD, FACAAI
Managing Partner, Family Allergy &
Asthma, Louisville, KY; Clinical Professor
& Chief, Section of Pediatric Allergy,
University of Louisville, Louisville, KY
James Verbsky, MD, PhD
Medical College of Wisconsin,
Madison, WI
Gerald W. Volcheck, MD, FACAAI
Associate Professor of Medicine,
Program Director Allergy and
Immunology Fellowship, Division of
Allergy and Immunology, Mayo Clinic,
Rochester, MN
Dana V. Wallace, MD, FACAAI
Associate Clinical Professor, Nova
Southeastern University, Davie, FL
Julie Wang, MD
Mount Sinai School of Medicine, New
York, NY
Richard W. Weber, MD, FACAAI
Professor of Medicine, National Jewish
Health, Denver, CO
Sally E. Wenzel, MD, FACAAI
University of Pittsburgh, Pittsburgh, PA
Myron J. Zitt, MD, FACAAI
Associate Professor of Clinical Medicine,
State University of New York, Stony
Brook, NY
Faculty

Faculty Index
Aaronson, Donald W. . . . . . . . .27, 29, 30
Abramson, Stuart L. . . . . . . . . . . . . . . . .32
Aceves, Seema S. . . . . . . . .29, 33, 71, 72
Aquino, Marcella R. . . . . . . . . .26, 27, 31
Arnold, Jeannette L. . . . . . . . . . . . . . . . .72
Assa'ad, Amal H. . . . . . . . . . . . .33, 51, 54
Bahna, Sami L. . . . . . . . . . . . . . . . . . .30, 33
Ballow, Mark . . . . . . . . . . . . . . . .32, 47, 60
Banerji, Aleena . . . . . . . . . . . . . .26, 54, 70
Belsito, Donald . . . . . . . . . . . . . . . . . . . . .52
Berger, William E. . . . . . . . . . . . . . . .39, 50
Bernstein, Cheryl K. . . . . . . . . . . . . . . . .73
Bernstein, David I. . . . . . . . . . . . . . . .38, 60
Bernstein, Jonathan A. . . . . . . . . . . . . . .30
Bhatt, Anand . . . . . . . . . . . . . . . . . . . . . .31
Bielory, Leonard . . . . . . . . . . . . . . . .50, 74
Blackwell, Cheryl A. . . . . . . . . . . . . . . . .73
Blaiss, Michael S. . . . . . . . . . . . .38, 51, 59
Boggs, Peter B. . . . . . . . . . . . . . . . . . . . . .27
Boguniewicz, Mark . . . . . . . . . . . . . . . . .31
Bonagura, Vincent R. . . . . . . . . . . .47, 60
Borish, Larry . . . . . . . . . . . . . . . .30, 46, 51
Bossard, Mary Kay . . . . . . . . . . . . . .71, 73
Brown, Kevin . . . . . . . . . . . . . . . . . . . . . . .45
Bukstein, Don A. . . . . . . . . . . . . . . . . . . .60
Burks, A. Wesley . . . . . . . . . . . . .29, 33, 51
Carlton, Gwen . . . . . . . . . . . . . . . . . .70, 73
Carr, Warner W. . . . . . . . . . . . . . . . . .39, 67
Chipps, Bradley E. . . . . . . . . . . . . . .31, 60
Cho, Seong . . . . . . . . . . . . . . . . . . . . . . . .28
Chojnacki, K. . . . . . . . . . . . . . . . . . . . . . . .70
Clay, K. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73
Conrad, Steven . . . . . . . . . . . . . . . . . . . . .30
Corbett, Mark L. . . . . . . . . . . . . . . . . . . . .62
Crawford, William W. . . . . . . . . . . . . . . . .38
Creticos, Peter S. . . . . . . . . . . . . . . .30, 51
Dalan, Dan A. . . . . . . . . . . . . . . . . . . . . . .31
Davis, R. . . . . . . . . . . . . . . . . . . . . . . . . . . . .70
DeMuth, Karen A. . . . . . . . . . . . . . . . . . .60
deShazo, Richard D. . . . . . . . . . . . . . . . .53
Dinakar, Chitra K. . . . . . . . . . . . . . . .27, 60
Dolen, William K. . . . . . . . . . . . . . . . . . . .59
Drake, Karen . . . . . . . . . . . . . . . . . . . . . . .74
DuBuske, Lawrence M. . . . . . . . . . .29, 43
Dykewicz, Mark S. . . . . . . . . . . . . . . . . . .38
El Sanadi, Nabil . . . . . . . . . . . . . . . . . . . . .29
Fasano, Mary Beth . . . . . . . . . . . . . . . . .62
Finegold, Ira . . . . . . . . . . . . . . . . . . . . . . . .31
Fineman, Stanley M. . . . . . . . . . . . . . . . .44
Fiocchi, Alessandro . . . . . . . . . . . . . . . . .33
Fleisher, Thomas A. . . . . . . . . . . . . . . . .116
Foggs, Michael B. . . . . . . . . . . . . . . .44, 59
Fonacier, Luz S. . . . . . . . . . . . . .27, 33, 52
Freeman, Theodore M. . . . . . . . . . . . . .26
Frieri, Marianne . . . . . . . . . . . . . . . . . . . .43
Gawchik, Sandra M. . . . . . . . . . . . . . . . .61
George, Maureen . . . . . . . . . . .71, 72, 73
Gleich, Gerald . . . . . . . . . . . . . . . . . . . . . .60
Goldsobel, Alan B. . . . . . . . . . . . . . .26, 51
Gower, Richard G. . . . . . . . . . . . . . . .32, 54
Graft, David F. . . . . . . . . . . . . . . . . . . . . . .26
Grayson, Mitchell H. . . . . . . . . . . . .46, 51
Gregory, Karen L. . . . . . . . . . . . . . . . . . .73
Gross, Gary N. . . . . . . . . . . . . . . . . . .27, 30
Hanson, I. Celine . . . . . . . . . . . . . . . . . . .51
Hayden, Mary Lou . . . . . . . . . .71, 72, 73
Hernandez-Trujillo, Vivian . . . . . . . . . . .38
Hom, Milton . . . . . . . . . . . . . . . . . . .31, 50
Honsinger, Richard W. . . . . . . . . . . . . . .29
Hopper, G. David . . . . . . . . . . . . . . .27, 28
Jain, Neal . . . . . . . . . . . . . . . . . . .27, 60, 67
Katial, Rohit K. . . . . . . . . . . . . . . . . . .44, 51
Kelkar, Pramod S. . . . . . . . . . . . . . . .26, 51
Kelso, John M. . . . . . . . . . . . . . . . . . .28, 38
Kemp, Stephen F. . . . . . . . . . . . . . . . . . . .46
Kennedy, Kevin . . . . . . . . . . . . . . . . . . . .32
Khan, David A. . . . . . . . . . . .38, 61, 72, 74
Kita, Hirohito . . . . . . . . . . . . . . . . . . . . . .54
Koepke, Jerald W. . . . . . . . . . . . . . . . . . .28
Lang, David M. . . . . . . . . . . . . . . . . . . . . .54
Lanier, Bobby Q. . . . . . . . . . . . . . . . .59, 61
Lape, Brooks . . . . . . . . . . . . . . . . . . . . . . .29
Le, Tao T. . . . . . . . . . . . . . . . . . . . . . . . . . . .31
Ledford, Dennis K. . . . . . . . . . . . . . . . . . .60
Lee-Chiong, Teofilo . . . . . . . . . . . . . . . . .53
Leiferman, Kristin M. . . . . . . . .28, 52, 60
Levetin, Estelle . . . . . . . . . . . . . . . . . . . . .26
Li, James T. . . . . . . . . . . . . . . . . . . . . . . . .38
Lieberman, Phillip L. . . . . . . . .28, 39, 46
Littner, Michael . . . . . . . . . . . . . . . . . . . .53
Long, Aidan A. . . . . . . . . . . . . . . . . . . . . .51
Lumry, William R. . . . . . . . . . . .32, 54, 60
Mahr, Todd A. . . . . . . . . . . . . . . .27, 37, 43
Marshall, Gailen D. . . . . . . . . . . . . . . . . .69
Martin, Bryan L. . . . . . . . . . . . .28, 31, 116
McKnight, A. Sean . . . . . . . . . . . . . .28, 31

Faculty Index
Meadows, J. Allen . . . . . . . . . . . . . .27, 29
Meltzer, Eli O. . . . . . . . . . . . . . . . . . . . . . . .30
Montanaro, Anthony . . . . . . . . . . . . . . .38
Muraro, Maria Antonella . . . . . . . . . . . .33
Murphy, Kevin . . . . . . . . . . . . . . . . . . . . . .28
Nelson, Michael R. . . . . . . . . . . . . . . . . .31
Nicklas, Richard A. . . . . . . . . . . . . . . . . . .38
Nsouli, Talal M. . . . . . . . . . . . . . . . . . . . . .51
O'Hollaren, Mark T. . . . . . . . . . . . . . . . . .38
Olson, Grant C. . . . . . . . . . . . . . . . . . . . .28
Oppenheimer, John J. . . . . . . .28, 31, 60
Orange, Jordan S. . . . . . . . . . . . . . . . . . .33
Phipatanakul, Wanda . . . . . . . . . . . . . . .60
Portnoy, Jay M. . . . . . . . . . . . . . .30, 32, 60
Pulver, Donald W. . . . . . . . . . . . . . . . . . . .28
Rosenwasser, Lanny J. . . . . . . . . . . .31, 54
Rothenberg, Marc E. . . . . . . . . . . . . . . .33
Sanders, Deidra . . . . . . . . . . . . . . . . . . . .73
Segall, Nathan . . . . . . . . . . . . . . . . . . . . .28
Sheikh, Javed . . . . . . . . . . . . . . . . . . . . . .28
Shroba, J. . . . . . . . . . . . . . . . . . . . . . . . . . .70
Shulan, David J. . . . . . . . . . . . . . . . .29, 31
Siegel, Charles J. . . . . . . . . . . . . . . . .30, 62
Silvers, William S. . . . . . . . . . . . . . . . . . .69
Simons, F. Estelle . . . . . . . . . . . . . . . . . . .37
Solensky, Roland . . . . . . . . . . . . . . . . . . .51
Solomon, Joshua . . . . . . . . . . . . . . . . . . .45
Spector, Sheldon L. . . . . . . . . .51, 60, 72
Spergel, Jonathan M. . . . . . . . .29, 33, 51
Sublett, James L. . . . . . . . . . . . . . . . . . . .69
Sullivan, Timothy J. . . . . . . . . . . . . . . . . .51
Tanner, David D. . . . . . . . . . . . . . . . . . . .27
Tilles, Stephen A. . . . . . . . . . . . .26, 60, 74
Tolomeo, Concettina . . . . . . . . . . . .71, 73
Tracy, James M. . . . . . . . . . . . . . . . . . . . .29
Verbsky, James . . . . . . . . . . . . . . . . .47, 51
Volcheck, Gerald W. . . . . . . . . . . . . . . . .38
Wagner, C. . . . . . . . . . . . . . . . . . . . . . . . . .74
Wallace, Dana V. . . . . . . . . . . . .29, 31, 37
Wang, Julie . . . . . . . . . . . . . . . . . . . . . . . . .69
Wasserman, Richard L. . . . . . . . . . .27, 31
Weber, Richard W. . . . . . . . . . . . . . .26, 45
Weldon, David R. . . . . . . . . . . . . . . .26, 70
Wenzel, Sally E. . . . . . . . . . . . . . . . . . . . . .44
Westley, C. Ross . . . . . . . . . . . . . . . . . . . .28
Williams, P. Brock . . . . . . . . . . . . . . . . . .30
Williams, P. . . . . . . . . . . . . . . . . . . . . . . . . .70
Windom, Hugh H. . . . . . . . . . . . . . . . . . .31
Zacharisen, Michael . . . . . . . . . . . . . . . .30
Zitt, Myron J. . . . . . . . . . . . . . . . . . . . .27, 67
Noga Askenazi, MD, FACAAI
Amal H. Assa’ad, MD, FACAAI
Don A. Bukstein, MD, FACAAI
Leonard Bielory, MD, FACAAI
Adrian M. Casillas, MD, FACAAI
Christina G. Ciaccio, MD, FACAAI
Linda Susan Cox, MD, FACAAI
Chair: Tao T. Le, MD, MHS, FACAAI
CME/CPD Committee
Vice Chair: Charles J. Siegel, MD, FACAAI
Vesselin Dimov, MD, FACAAI
Pinkus Goldberg, MD, FACAAI
Bret R. Haymore, MD, FACAAI
Curtis L. Hedberg, MD, FACAAI
Vivian Hernandez-Trujillo, MD, FACAAI
Charles J. Lane, MD
Gerald B. Lee, MD
Advisor: Kathleen R. May, MD
Please see Disclosures section for additional information.
Todd A. Mahr, MD, FACAAI
Lyndon E. Mansfield, MD, FACAAI
Bryan L. Martin, DO, FACAAI
Michael R. Nelson, MD, FACAAI
Myngoc T. Nguyen, MD, FACAAI
Joram S. Seggev, MD, FACAAI
David R. Weldon, MD, FACAAI
Faculty

Disclosures
ACAAI 2012 Annual Scientific Meeting
November 8-13, 2012, Anaheim, California
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American
College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors,
reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial
relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must
be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient
care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with
no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also
be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or
included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is
incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating
recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified conflicts of interest have been resolved.
Seema S. Aceves, MD, PhD
Stocks: Meritage Pharma
§Marcella R. Aquino, MD, FACAAI
Research Grant: Baxter, Dyax, Genentech,
Novartis, Roche, ViroPharma
Noga Askenazi, MD, FACAAI
Employee (spouse): Johnson and Johnson
§Sami L. Bahna, MD, DrPH, FACAAI
Consultant/Advisory Board: Abbott, Pharming
§Mark Ballow, MD, FACAAI
Consultant/Advisory Board: Baxter, CSL Behring,
Grifols; Speaker: Baxter, CSL Behring;
Honorarium: Baxter, CSL Behring, Data & Safety
Monitoring Board: Green Cross
Aleena Banerji, MD
Consultant/Advisory Board: CSL Behring, Dyax,
Shire; Research Grant: Shire
§William E. Berger, MD, MBA, FACAAI
Consultant/Advisory Board: Alcon, AstraZeneca,
GlaxoSmithKline, Meda, Novartis, Sunovion,
Teva; Speaker: Alcon, AstraZeneca,
GlaxoSmithKline, Meda, Novartis, Sunovion,
Teva; Honorarium: Alcon, AstraZeneca,
GlaxoSmithKline, Meda, Novartis, Sunovion,
Teva; Research Grant: Alcon, AstraZeneca,
GlaxoSmithKline, Meda, Novartis, Sunovion,
Teva
Cheryl K. Bernstein, RN, BSN, CCRC
Consultant/Advisory Board: Gerson-Lehrman,
Guidepoint Global, Merck, Sanofi; Research
Grant: Amgen, GlaxoSmithKline, Greer, Merck,
Novartis, Pfizer, Stallergenes, Teva
§David I. Bernstein, MD, FACAAI
Consultant/Advisory Board: Gerson-Lehrman,
Guidepoint Global, Merck, Sanofi; Research
Grant: Amgen, GlaxoSmithKline, Greer, Merck,
Novartis, Pfizer, Stallergenes, Teva
Jonathan A. Bernstein, MD, FACAAI
Medical Director: Flint Hills Resources
§Leonard Bielory, MD, FACAAI
Consultant/Advisory Board: Allergan, Bausch &
Lomb, Genentech, GlaxoSmithKline, ISTA, Meda,
Merck, Novartis, Ocusense, Otsuka, Pfizer,
Sanofi, Shire; Speaker: Meda, Merck, Sanofi;
Honorarium: Allergan, Meda, Merck; Research
Grant: Allergan, Genentech, Merck, Novartis,
Otsuka
Michael S. Blaiss, MD, FACAAI
Consultant/Advisory Board: Alcon, Allergan,
ISTA, JDP Therapeutics, Merck, Pfizer, Proctor &
Gamble, Sanofi, Sunovion; Speaker: Alcon,
Allergan, AstraZeneca, Genentech,
GlaxoSmithKline, ISTA, Merck, Sunovion, Takeda,
Teva; Honorarium: Alcon, Allergan, AstraZeneca,
Genentech, GlaxoSmithKline, ISTA, Merck, Pfizer,
Sanofi, Sunovion, Takeda, Teva; Stocks: JDP
Therapeutics, Pfizer
Peter B. Boggs, MD, FACAAI
Consultant/Advisory Board: Aerocrine; Speaker:
Aerocrine; Honorarium: Aerocrine; Research
Grant: Aerocrine
§Mark Boguniewicz, MD, FACAAI
Consultant/Advisory Board: Unilever, Valeant;
Data & Safety Monitoring Board: ApoPharma
Vincent R. Bonagura, MD
Consultant/Advisory Board: Baxter, CSL Behring;
Speaker: Baxter, CSL Behring: Honorarium:
Baxter, CSL Behring; Research Grant: CSL
Behring
Rana Bonds, MD, FACAAI
Stocks: General Electric
Larry Borish, MD, FACAAI
Consultant/Advisory Board: Sanofi; Honorarium:
Merck; Research Grant: National Institutes of
Health
Mary Kay Bossard, BS, RRT, AE-C
Speaker: Pharmaxis; Honorarium: Pharmaxis
Don A. Bukstein, MD, FACAAI
Consultant/Advisory Board: Teva; Speaker:
Alcon, AstraZeneca, Genentech, Merck, Meda,
Novartis, Teva; Research Grant: Genentech
A. Wesley Burks, MD, FACAAI
Consultant/Advisory Board: Dannon Probiotics,
Exploramed Development; Intelliject; McNeil
Nutritionals, Merck, Novartis, Pfizer, Portola;
Research Grant: Food Allergy Initiative, National
Peanut Board, National Institutes of Health,
Wallace Research Foundation; Stocks: Allertein,
Mast Cell
§Betty Gwen Carlton, DNP, AE-C
Consultant/Advisory Board: Speaker: Asthma &
Allergy Foundation of America, Genentech,
GlaxoSmithKline, Pharmaxis; Honorarium:
Asthma & Allergy Foundation of America,
Genentech, GlaxoSmithKline, Pharmaxis
Warner W. Carr, MD, FACAAI
Consultant/Advisory Board: Alcon, Meda,
Sunovion; Speaker: Alcon, GlaxoSmithKline,
Meda, Merck; Honorarium: Alcon, Meda;
Research Grant: Alcon, Meda
§Adrian M. Casillas, MD, FACAAI
Consultant/Advisory Board: CSL Behring, Merck;
Speaker: Merck; Research Grant: CSL Behring
§Helen H. Chan, MD, FACAAI
CEO: Vita Green Health
§Bradley E. Chipps, MD, FACAAI
Consultant/Advisory Board: AstraZeneca,
Genentech, GlaxoSmithKline, ISTA, Merck,
Mylan Specialty, Novartis, SRxA, Sunovion;
Speaker: AstraZeneca, Genentech,
GlaxoSmithKline, ISTA, Merck, Novartis,
Sunovion; Honorarium: AstraZeneca,
Genentech, GlaxoSmithKline, ISTA, Merck,
Mylan Specialty, Novartis, SRxA, Sunovion
Mark L. Corbett, MD, FACAAI
Consultant/Advisory Board: ISTA; Speaker:
AstraZeneca, ISTA, Teva
= Planner
§ = Moderator

Disclosures
Linda Cox, MD, FACAAI
Consultant/Advisory Board: Genentech,
Stallergenes; Speaker: Baxter, Thermo Fisher
Scientific
Peter S. Creticos, MD
Consultant/Advisory Board: Circassia, Greer,
Merck; Honorarium: Circassia, Greer, Merck;
Research Grant: Agency for Healthcare Research
and Quality (AHRQ), Circassia, Greer, Merck
Karla Davis, MD, FACAAI
Stocks: Pfizer
Ray S. Davis, MD, FACAAI
Consultant/Advisory Board: Alcon, Meda,
Sunovion; Speaker: Alcon, Meda, Merck, Mylan
Specialty; Honorarium: Alcon, Meda, Merck,
Mylan Specialty
§Chitra Dinakar, MD, FACCAI
Consultant/Advisory Board: AstraZeneca;
Speaker: Aerocrine, AstraZeneca, Honorarium:
Aerocrine, AstraZeneca
Lawrence M. DuBuske, MD, FACAAI
Consultant/Advisory Board: Allergy
Therapeutics, GlaxoSmithKline, Lypanosys,
Novartis, Sunovion; Speaker: GlaxoSmithKline,
Merck, Novartis, Sunovion: Honorarium: Allergy
Therapeutics, GlaxoSmithKline, Merck, Novartis,
Sunovion; Research Grant: Boehringer
Ingelheim, Genentech, Merck, Novartis, Rigel,
Sunovion
§Mark S. Dykewicz, MD, FACAAI
Consultant/Advisory Board: Merck; Honorarium:
Merck
Anne Ellis, MD
Consultant/Advisory Board: Paladin Labs;
Speaker: Pfizer; Research Grant: Circassia
Mary Beth Fasano, MD, MSPH, FACAAI
Research Grant: Genentech, Green Cross Corp,
Grifols
§Stanley M. Fineman, MD, MBA, FACAAI
Speaker: AstraZeneca; Research Grant:
Genentech, Sunovion
§Michael B. Foggs, MD, MBA, FACAAI
Consultant/Advisory Board: AstraZeneca,
GlaxoSmithKline, Hycor, Merck; Speaker:
AstraZeneca, GlaxoSmithKline, Hycor, Merck;
Honorarium: AstraZeneca, GlaxoSmithKline,
Merck
§Luz S. Fonacier, MD, FACAAI
Speaker: Baxter; Research Grant: Baxter, Dyax,
Genentech, Mylan Specialty
Theodore M. Freeman, MD, FACAAI
Consultant/Advisory Board: McKesson
§Marianne Frieri, MD, PhD, FACAAI
Speaker: Nutricia, Thermo Fisher Scientific;
Honorarium: Nutricia, Thermo Fisher Scientific;
Research Grant: Merck
Sandra M. Gawchik, DO, FACAAI
Consultant/Advisory Board: Merck; Speaker:
Johnson & Johnson, Merck; Honorarium:
AstraZeneca, Johnson & Johnson, Merck;
Research Grant: Amphastar, AstraZeneca,
Boehringer Ingelheim, Genentech,
MedImmune, Merck, Novartis, Sanofi, Sunovion,
Takeda, Teva; Stocks: AstraZeneca, Merck, Mylan
Specialty, Teva
§Maureen George, PhD, RN, AE-C
Consultant/Advisory Board: Novartis, Teva;
Speaker: Merck, Pharmaxis, Sunovion
Gerald Gleich, MD
Consultant/Advisory Board: Beiersdorf (spouse),
GlaxoSmithKline, MBL International (spouse);
Honorarium: Dyax; Research Grant: Dyax:
Stocks: Immune Design; Founder Patents:
ImmViz; Royalty: Mayo Foundation, Teva
Pinkus Goldberg, MD, FACAAI
Consultant/Advisory Board: Genentech, Meda;
Speaker: Baxter, Genentech, Merck, Mylan
Specialty; Honorarium: Baxter, Genentech,
Mylan Specialty, Merck; Research Grant: Array,
Genentech, GlaxoSmithKline, Merck
Rebecca Goldberg, RN
Speaker, Genentech, Merck, Mylan Specialty;
Honorarium: Genentech, Merck, Mylan
Specialty; Research Grant: Array, Genentech,
GlaxoSmithKline, Merck, Novartis
Alan B. Goldsobel, MD, FACAAI
Speaker: Merck, Teva; Research Grant:
AstraZeneca, Amphastar, Forest, Genentech,
Merck, Mylan Specialty, Novartis, Sanofi, Teva
Richard G. Gower, MD, FACAAI
Consultant/Advisory Board: CSL Behring,
Genentech, ISTA, Mylan Specialty, Novartis,
Roche, Shire, Teva, ViroPharma; Speaker: CSL
Behring, Genentech, ISTA, Mylan Specialty,
Novartis, Roche, Shire, Teva, ViroPharma;
Honorarium: CSL Behring, Genentech, ISTA,
Mylan Specialty, Novartis, Roche, Shire, Teva,
Viropharma; Research Grant: Boehringer
Ingelheim, CSL Behring, Genentech,
GlaxoSmithKline, ISTA, Novartis, Pharming,
Roche, Shire, Teva, ViroPharma; Stocks: Merck
David F. Graft, MD, FACAAI
Speaker: Mylan Specialty, Teva
Mitchell Grayson, MD, FACAAI
Research Grant: Merck
Linda D. Green, MD, FACAAI
Stocks: Merck, Pfizer
Matthew Greenhawt, MD, MBA, MSc
Consultant/Advisory Board: Thermo Fisher
Scientific; Speaker: Nurticia, Sunovion, Thermo
Fisher Scientific; Honorarium: Thermo Fisher
Scientific
Karen L. Gregory, DNP, APRN, CNS, RRT,
AE-C, FAARC
Speaker: Genentech, GlaxoSmithKline,
Monaghan, Novartis; Honorarium: Genentech,
GlaxoSmithKline, Monaghan, Novartis
Gary N. Gross, MD, FACAAI
Consultant/Advisory Board: Sunovion, Teva;
Speaker: Merck, Novartis, Teva; Research Grant:
Amgen, AstraZeneca, Forest, Merck, Novartis,
Sunovion, Teva
§Mary Lou Hayden, RN, MS, APRN, FNP-BC, AE-C
Consultant/Advisory Board: Genentech, Teva;
Speaker: Genentech, Mylan Specialty, Teva;
Honorarium: Genentech, Mylan Specialty, Teva
Curtis L. Hedberg, MD, FACAAI
Consultant/Advisory Board: US Healthrecord
§Vivian Hernandez-Trujillo, MD, FACAAI
Consultant/Advisory Board: Baxter; Speaker:
Baxter, CSL Behring, Merck
Jeff Hester, PhD
Research: ViraCor- IBT Laboratories
Douglas Hogarth, MD, FCCP
Consultant/Advisory Board: CSL Behring;
Speaker: Baxter, CSL Behring, Grifols
Milton M. Hom, OD, FAAO, FACAAI (SC)
Consultant/Advisory Board: Allergan, Bausch &
Lomb, ISTA; Speaker: Allergan, Bausch & Lomb,
ISTA; Honorarium: Allergan, Bausch & Lomb,
ISTA; Research Grant: Allergan, Bausch & Lomb,
ISTA
Neal Jain, MD, FACAAI
Consultant/Advisory Board: Aerocrine; Speaker:
Aerocrine, GlaxoSmithKline; Honorarium:
Aerocrine, GlaxoSmithKline
Rohit K. Katial, MD, FACAAI
Consultant/Advisory Board: Teva; Honorarium:
Teva; Research Grant: Teva
Kevin Kennedy, CIEC
Speaker: Healthy Housing Solutions;
Honorarium: Healthy Housing Solutions
David A. Khan, MD, FACAAI
Speaker: Genentech, Merck; Honorarium:
Genentech, Merck
Hirohito Kita, MD
Speaker: GlaxoSmithKline, MSD
Pharmaceuticals; Honorarium: GlaxoSmithKline,
MSD Pharmaceuticals, Novartis
Charles J. Lane, MD
Speaker: GlaxoSmithKline, Mylan Specialty;
Honorarium: ISC Communications
David M. Lang, MD, FACAAI
Consultant/Advisory Board: Hycor, Merck;
Speaker: Genentech, GlaxoSmithKline, Merck,
Novartis, Teva; Honorarium: Genentech,
GlaxoSmithKline, Merck, Novartis, Teva;
Research Grant: Genentech, Novartis
Disclosures
= Planner
§ = Moderator

Disclosures
Bob Lanier, MD, FACAAI
Research Grant: Genentech, Merck, Novartis
Brooks Lape
Employee: Reingold
Dennis K. Ledford, MD, FACAAI
Consultant/Advisory Board: Genentech;
Speaker: Genentech, Teva; Honorarium:
Genentech; Research Grant: Forest, Genentech,
Merck, Teva, ViroPharma
Teofilo Lee-Chiong, MD
Consultant/Advisory Board: CareCore National,
Elsevier, Philips Respironics; Research Grant:
Philips Respironics; Stocks: Philips Respironics
Kristin M. Leiferman, MD
Consultant/Advisory Board: Beiersdorf,
GlaxoSmithKline, MBL International; Research
Grants: Novartis; Stocks: Immune Design, Teva
Mitchell R. Lester, MD, FACAAI
Partner: New England Food Allergy Treatment
Center
§James T. Li, MD, FACAAI
Stocks: Abbott, Novartis
§Phillip L. Lieberman, MD, FACAAI
Consultant/Advisory Board: Baxter, Genentech,
Meda, Mylan Specialty, Sanofi; Speaker: Baxter,
Meda, Mylan, Sanofi
William R. Lumry, MD, FACAAI
Consultant/Advisory Board: CSL Behring, Dyax,
Shire HGT, ViroPharma; Speaker: CSL Behring,
Dyax, Shire HGT, ViroPharma; Honorarium: CSL
Behring, Dyax, Shire HGT, ViroPharma; Research
Grant: CSL Behring, Dyax, Pharming, Shire HGT,
ViroPharma
§Todd A. Mahr, MD, FACAAI
Consultant/Advisory Board: ISTA; Speaker:
Aerocrine, Genentech, GlaxoSmithKline, ISTA,
Merck, SRxA; Honorarium: Aerocrine,
Genentech, GlaxoSmithKline, ISTA, Merck, SRxA
§Lyndon Mansfield, MD, FACAAI
Consultant/Advisory Board: Aerocrine, ISTA,
Thermo Fisher Scientific; Speaker: Aerocrine,
Alcon, ISTA, Thermo Fisher Scientific; Research
Grant: GlaxoSmithKline
§Gailen D. Marshall, Jr., MD, PhD, FACAAI
Research Grant: National Institutes of Health,
Health Resources and Services Administration
A. Sean McKnight, MD, FACAAI
Speaker: GlaxoSmithKline, Mylan Specialty
§J. Allen Meadows, MD, FACAAI
Consultant/Advisory Board: Alcon, ISTA;
Speaker: Alcon, GlaxoSmithKline, ISTA,
Sunovion
Issac Melamed, MD
Speaker: Baxter BioScience, CSL Behring
Eli O. Meltzer, MD, FACAAI
Consultant/Advisory: Alcon, Alexza,
AstraZeneca, Bausch & Lomb, Boehringer
Ingelheim, Frost, ISTA, Johnson & Johnson,
Kalypsys, Meda, Merck, Mylan Specialty, ONO,
OptiNose, Proctor & Gamble, Rigel, Sanofi,
Stallergenes, Sunovion, Teva; Speaker: Alcon,
Allergies for Israel, American College of Allergy,
Asthma & Immunology, Florida Allergy Asthma
& Immunology Society, ISTA, Merck, Mylan
Specialty, Sunovion, Teva; Research Grant:
Alcon, Amgen, Apotex, AstraZeneca,
Boehringer Ingelheim, GlaxoSmithKline, HRA,
MedImmune, Merck, Novartis, Proctor &
Gamble, Sunovion, Teva
§Travis A. Miller, MD, FACAAI
Consultant/Advisory Board: ISTA, Meda,
Sunovion; Speaker: Alcon, AstraZeneca,
GlaxoSmithKline, ISTA, Merck, Novartis,
Sunovion; Honorarium: Alcon, AstraZeneca,
GlaxoSmithKline, ISTA, Merck, Novartis,
Sunovion
B. Mitchell
Research Grant: Shaw Inc.
Anthony Montanaro, MD, FACAAI
Speaker: Baxter, Genentech, GlaxoSmithKline,
Merck
Kevin R. Murphy, MD
Consultant/Advisory Board: AstraZeneca,
Genentech, Merck, Mylan Specialty, Novartis;
Speaker: AstraZeneca, Genentech, ISTA, Merck,
Mylan Specialty, Novartis, Sunovion;
Honorarium: AstraZeneca, Genentech, ISTA,
Merck, Mylan Specialty, Novartis, Sunovion;
Research Grant: AstraZeneca, Merck
§Michael R. Nelson, MD, PhD, FACAAI
Stocks: Amgen
Michael J. Noonan, MD, FACAAI
Consultant/Advisory Board: AstraZeneca;
Speaker: AstraZeneca; Research Grant:
Amphastar, AstraZeneca, Merck, Novartis,
Sanofi, Teva
Talal M. Nsouli, MD, FACAAI
Consultant/Advisory Board: Sunovion, Teva,
Thermo Fisher Scientific; Speaker: Sunovion,
Teva, Thermo Fisher Scientific
§Maeve E. O’Connor, MD, FACAAI
Consultant/Advisory Board: Thermo Fisher
Scientific; Speaker: GlaxoSmithKline, Sunovion,
Teva, Thermo Fisher Scientific; Honorarium:
GlaxoSmithKline, Sunovion, Teva, Thermo Fisher
Scientific
§John J. Oppenheimer, MD, FACAAI
Speaker: GlaxoSmithKline, Merck; Research
Grant: AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, MedImmune, Novartis
Jordan S. Orange, MD, PhD, FACAAI
Consultant/Advisory Board: Baxter Healthcare,
CSL Behring, Cangene, Grifols, ViraCor-IBT:
Reviewer: Octapharma USA
Wanda Phipatanakul, MD, MS, FACAAI
Research Grant: National Institutes of Health
Thomas AE Platts-Mills, MD, PhD, FACAAI
Consultant/Advisory Board: ViraCor-IBT,
Speaker: Thermo Fisher Scientific; Honorarium:
Thermo Fisher Scientific; Research Grant:
Thermo Fisher Scientific, National Institutes of
Health/National Institute of Allergy and
Infectious Disease; Patent: University of Virginia
Patent Foundation
§Jay M. Portnoy, MD, FACAAI
Consultant/Advisory Board: Thermo Fisher
Scientific
Christopher C. Randolph, MD, FACAAI
Consultant/Advisory Board: AstraZeneca,
GlaxoSmithKline; Speaker: AstraZeneca,
GlaxoSmithKline, ISTA, Meda, Merck, Mylan
Specialty; Honorarium: AstraZeneca,
GlaxoSmithKline, ISTA, Meda, Merck; Mylan
Specialty; Research Grant: AstraZeneca,
GlaxoSmithKline, Merck
Lanny J. Rosenwasser, MD, FACAAI
Consultant/Advisory Board: AstraZeneca,
Genentech, Novartis, Regeneron, Sanofi;
Honorarium: AstraZeneca, Genentech, Novartis,
Regeneron, Sanofi; Research Grant: Novartis
Marc Rothenberg, MD, PhD, FACAAI
Consultant/Advisory Board: Immune
Pharmaceuticals; Stocks: Immune
Pharmaceuticals; Ownership Interest: Teva
§Deidra Sanders, MSN, FNP-BC
Consultant/Advisory Board: Sunovion; Speaker:
Genentech, Novartis; Honorarium: Genentech,
Novartis, Sunovion; Stocks: Allergy Zone
Nathan Segall, MD, FACAAI
Research Grant: Forest, GlaxoSmithKline, Merck,
Novartis, Sanofi, Sunovion
Joram S. Seggev, MD, FACAAI
Consultant/Advisory Board: ISTA
§James M. Seltzer, MD, FACAAI
Consultant/Advisory Board: Indoor Hygienic
Technologies Corp; Speaker: GlaxoSmithKline;
Honorarium: GlaxoSmithKline; Research Grant:
Merck; Stocks: Indoor Hygienic Technologies
Corp
Russell Settipane, MD, FACAAI
Consultant/Advisory Board: Sunovion, Teva;
Speaker: Alcon, ISTA, Merck, Novartis, Sunovion,
Teva; Research Grant: Genentech, Merck,
Sunovion, Teva; Stocks: Oceanside Publications
= Planner
§ = Moderator

Disclosures
Javed Sheikh, MD
Consultant/Advisory Board: CSL Behring
Ketan Sheth, MD, MBA
Consultant/Advisory Board: GlaxoSmithKline,
ISTA, Teva; Speaker: GlaxoSmithKline, ISTA;
Honorarium: GlaxoSmithKline, ISTA; Stocks:
Merck
David J. Shulan, MD, FACAAI
Stocks: Apple, Cisco, General Electric, Google,
Hewlett Packard, IBM, Microsoft
Charles J. Siegel, MD, FACAAI
Consultant/Advisory Board: Meda, Teva;
Speaker: Alcon, Meda, Teva; Honorarium: Alcon,
Meda, Teva
William S. Silvers, MD, FACAAI
Speaker: Teva Respiratory
F. Estelle Simons, MD, FACAAI
Medical Advisory Board: ALK-Abello, Mylan
Specialty, Sanofi
Roland Solensky, MD
Research Grant: Merck
§Sheldon L. Spector, MD, FACAAI
Speaker: Novartis, Honorarium: Novartis;
Research Grant: Amgen, Array, Boehringer
Ingelheim, Genentech, GlaxoSmithKline, Merck,
Mylan Specialty, Novartis, Sanofi, Teva; Stocks:
GlaxoSmithKline, Merck
Jonathan M. Spergel, MD, PhD, FACAAI
Consultant/Advisory Board: DBV Technologies,
Dannone; Speaker; Nutricia; Research Grant:
Nutricia; Teva; Stocks: DBV Technologies
§James L. Sublett, MD, FACAAI
Consultant/Advisory Board: GlaxoSmithKline,
Teva; Speaker: GlaxoSmithKline, Merck,
Sunovion, Teva; Honorarium: GlaxoSmithKline,
Merck, Sunovion, Teva; Research Grant:
GlaxoSmithKline, Merck; Stocks: AllergyZone
LLC
§Timothy J. Sullivan, MD, FACAAI
Speaker: Baxter, Genentech, Novartis;
Honorarium: Baxter, Genentech, Novartis
James Thompson, MD
Speaker: Thermo Fisher Scientific
Stephen A. Tilles, MD FACAAI
Consultant/Advisory Board: Hycol, ISTA,
Strategic Pharmaceutical Advisors; Research
Grant: Amphastar, Astellas, Aventis, Bohringer
Ingelheim, Forest, Genentech, MedImmune,
Merck, National Institutes of Health, Novartis,
Nutricia, Sunovion, Teva
§Janna M. Tuck, MD, FACAAI
Stocks: Cel-Sci Corporation
§Mark L. Vandewalker, MD, FACAAI
Consultant/Advisory Board: Boehringer
Ingelheim; Speaker: Alcon, AstraZeneca, Boston
Scientific, GlaxoSmithKline, Merck; Research
Grant: Alcon, AstraZeneca, Boehringer
Ingelheim, GlaxoSmithKline, Greer, Merck,
Stallergenes, Teva
James Verbsky, MD, PhD
Speaker: Baxter
Christine Wagner, MSN, CPNP, FNP-BC, AE-C
Consultant/Advisory Board: Sunovion, Teva;
Speaker: Mylan Specialty, Teva; Honorarium:
Mylan Specialty, Sunovion, Teva
Dana V. Wallace, MD, FACAAI
Consultant/Advisory Board: Mylan Specialty;
Speaker: Mylan Specialty; Honorarium: Mylan
Specialty
Richard L. Wasserman, MD, PhD, FACAAI
Consultant/Advisory Board: Meditab
§Richard W. Weber, MD, FACAAI
Speaker: AstraZeneca, Genentech; Research
Grant: Genentech, GlaxoSmithKline, Merck,
Novartis
Andrew Weinstein, MD, FACAAI
Consultant/Advisory Board: Merck; Speaker:
Merck, Honorarium: Merck, Research Grant: NIH;
Stocks: Asthma Management Systems
§David R. Weldon, MD, FACAAI
Consultant/Advisory Board: Scott & White
Healthcare
Sally E. Wenzel, MD, FACAAI
Consultant/Advisory Board: Actelion, Gilead,
Merck, Novartis; Research Grant: Amgen, Array,
Genentech, GlaxoSmithKline, MedImmune,
Merck, Sanofi
Hugh H. Windom, MD
Research Grant: Forest, Genentech, Novartis,
Teva
Michael C. Zacharisen, MD, FACAAI
Speaker: Merck, Teva
Myron J. Zitt, MD, FACAAI
Consultant/Advisory Board: Aerocrine, ISTA,
Merck, Sunovion; Speaker: Integrity, ISTA,
Merck, Sunovion; Honorarium: Aerocrine,
Integrity, ISTA, Merck, Sunovion
The following have no relevant financial relationships to disclose:
Donald W. Aaronson, MD, JD, MPH, FACAAI
§Joseph A. Bellanti, MD, FACAAI
Asriani Chiu, MD, FACAAI
§Stuart L. Abramson, MD, PhD
Donald V. Belsito, MD
Seong H. Cho, MD
Charles Andrew, MD
Neeti Bhardwaj, MD, MS
Kathy Chojnacki, RN, MSN, CPNP-AC
Kristyn Anthony, MD
Anand Bhatt, MD
Eugene Choo, MD
Jeanette L. Arnold, CFNP
Cheryl A. Blackwell, RN
Akhilesh Chouksey, MD
Rajiv Arora, MD, FACAAI
Amy Boyd, MD
Christina Ciaccio, MD, FACAAI
Noga Askenasi, MD, FACAAI
§Amal H. Assa’ad, MD, FACAAI
Susan R. Bailey, MD, FACAAI
Puneet Bajaj, MD
Kevin K. Brown, MD
Mariana Castells, MD, PhD, FACAAI
Rabia Chaudhry, MD
Katherine Chiong-Manaysay, MD
§Kimberly G. Clay, NP
Christopher D. Codispoti, MD
Steven A. Conrad, MD, PhD
William W. Crawford, MD
Disclosures
= Planner
§ = Moderator

Disclosures
Dan A. Dalan, MD, FACAAI
§Karen A. DeMuth, MD, FACAAI
Richard D. deShazo, MD, FACAAI
A. DeZure, MD, MBA, MSc
Vesselin Dimov, MD
§William K. Dolen, MD, FACAAI
Paul J. Dowling, MD, FACAAI
Karen Drake, MA, SLP
Nabil El Sanadi, MD
Robyn Epstein, MD
Tolly Epstein, MD, MS
§Ira Finegold, MD, FACAAI
§Alessandro Fiocchi, MD
Thomas A. Fleisher, MD, FACAAI
Irene Fung, MD
Jackie Garrett, MD
Radoslaw Gawlik, PhD
Bob Geng, MD
Gisoo Ghaffari, MD
§J. Andrew Grant, MD
Dave Gupta, MD
Ruchi Gupta, MD, MPH
Maria Gutierrez, MD
Imelda C. Hanson, MD
Jill Hanson
Bret R. Haymore, MD, FACAAI
Mary Beth Hogan, MD
§Richard Honsinger, MD, MACP, FACAAI
G. David Hopper, MD
Joseph Inglefield, MD
§Charlotte Jacobsen, RN, MSN
§Mansi Kanuga, MD
Eric Karlin, MD
Jacob Kattan, MD
§Paul B. Keiser, MD
§Pramod S. Kelkar, MD
John M. Kelso, MD, FACAAI
Stephen F. Kemp, MD, FACAAI
Josh Kennedy, MD
Barzin Khalili, MD, FACAAI
Bilal Khan, MD
§Jerald W. Koepke, MD, FACAAI
Karoline Krause, MD
James Kuhlen, MD
Radoslaw Kumar, PhD
Raj Kumar, MD
§Tao T. Le, MD, MHS, FACAAI
Gerald B. Lee, MD
Donald N. Leibner, MD, FACAAI
Estelle Levetin, PhD
Michael Littner, MD
Bradley Locke, DO
Aidan Long, MD
Jun Lu, MD
Alnoor A. Malick, MD, FACAAI
§Bryan L. Martin, DO, FACAAI
Kathleen May, MD, FACAAI
Jennifer Mbuthia, MD
§Kevin P. McGrath, MD, FACAAI
Archana Mehta, MD
Irene Mikhail, MD
Cecilia Mikita, MD, MPH, FACAAI
R. Joseph Mittel, MD
Tania Mucci, MD
M Antonella Muraro, MD
Jack Mutnick, MD
Maya Nanda, MD
Anjuli S. Nayak, MD, FACAAI
Richard A. Nicklas, MD, FACAAI
Myngoc T. Nguyen, MD, FACAAI
§Mark T. O’Hollaren, MD, FACAAI
Grant C. Olson, MD, FACAAI
Ryon Parker, MD
§Ruby U. Pawankar, MD, PhD
Donald W. Pulver, MD, FACAAI
Daniel Ramirez, MD
David Rose, MD
John M. Routes, MD, FACAAI
Stuart Rusnak, MD, FACAAI
Geetika Sabharwal, MD
Shubhayu Saha, PhD
Rushani Saltzman, MD
§John R. Seyerle, MD
§Meagan Shepherd, MD
Jodi Shroba, RN, MSN, CPNP
Jerome Sigua, MD
Joshua Solomon, MD
Christine Song, MD
Alice Sottile
Jenny Stitt, MD
Nithya Swamy, MD
Jessica Tan, MD
David D. Tanner, MD, FACAAI
Michael S. Tankersley, MD, FACAAI
John W. Tole, DO, FACAA
Concettina Tolomeo DNP, AE-C
James M. Tracy, DO, FACAAI
Anubha Tripathi, MD
Timothy Trojan, MD
Gerald W. Volcheck, MD, FACAAI
Julie Wang, MD
C. Ross Westley, MD FACAAI
P. Brock Williams, PhD
Paul V. Williams, MD, FACAAI
§Brian G. Wilson, MD, FACAAI
Hugh Windom, MD
Robert Wood, MD
Yesim Yilmaz Demirdag, MD
Education Staff/Committee have no relevant financial relationships to disclose, except as may be listed above.
= Planner
§ = Moderator

Disclosures
Recommendations for the Management of Patients With Anaphylaxis: A Consensus Update
November 9, 2012 • Anaheim, California
Jointly Sponsored by the American College of Allergy, Asthma & Immunology and the
American Association of Certified Allergists (AACA)
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American
College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors,
reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial
relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must
be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient
care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with
no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also
be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or
included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is
incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating
recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified conflicts of interest have been resolved.
Lawrence M. DuBuske, MD, FACAAI
Consultant/Advisory Board: Allergy
Therapeutics, GlaxoSmithKline, Lypanosys,
Novartis, Sunovion; Speaker: GlaxoSmithKline,
Merck, Novartis, Sunovion: Honorarium: Allergy
Therapeutics, GlaxoSmithKline, Merck, Novartis,
Sunovion; Research Grant: Boehringer
Ingelheim, Genentech, Merck, Novartis, Rigel,
Sunovion
Marianne Frieri, MD, PhD, FACAAI
Speaker: Nutricia, Thermo Fisher Scientific;
Honorarium: Nutricia, Thermo Fisher Scientific;
Research Grant: Merck
Phillip L. Lieberman, MD, FACAAI
Consultant/Advisory Board: Genentech, Meda,
Merck, Mylan, Sanofi, Stallergenes; Speaker:
Meda, Mylan
§Sheldon L. Spector, MD, FACAAI
Consultant/Advisory Board: Johnson & Johnson,
Merck, Novartis, Sanofi, Takeda, Teva, Vectura;
Speaker: Merck; Research Grant: Array,
AstraZeneca, Boehringer Ingelheim, Genentech,
GlaxoSmithKline, Johnson & Johnson, Merck,
Mylan, Novartis, Sanofi, Sunovion, Takeda, Teva,
Vectura
Education Staff/Committee have no relevant financial relationships to disclose, except as may be listed above.
Disclosures
= Planner
§ = Moderator

Special Events
21st Annual FIT Bowl Competition
: – : pm, Saturday
Grand Ballroom EF • Anaheim Marriott Hotel
Complimentary
NOT FOR
CREDIT
All physicians, young and old, are invited to participate in this fun-filled learning
experience. It’s the 21st Annual FIT Bowl Competition. This entertaining program –
patterned after the old “College Bowl”TV quiz show – will pit various allergy training
program teams against each other as they answer serious and not-so-serious questions
about their specialty. Refreshments and snack will be served.
Supported by Sanofi U.S.
Alliance International Reception
: – : pm, Saturday
Platinum Ballroom 1-2 • Anaheim Marriott Hotel
International attendees are cordially invited to attend the International Reception hosted
by the ACAAI Alliance on Saturday.
President’s Welcome Reception & Awards
Ceremony
: – : pm, Saturday
Marquis Ballroom • Anaheim Marriott Hotel
This event begins at 7:30 pm with drinks and light appetizers, and will be followed by a
short program where we will honor our new Fellows for their accomplishments and
recognize the recipients of the Distinguished Fellow, International Distinguished
Fellow, Distinguished Service, Woman in Allergy, Young Faculty Support and the Clemens
von Pirquet Awards.
Finally, we will introduce this year’s winner of the prestigious Gold Headed Cane Award,
Rufus E. Lee, Jr., MD, FACAAI, and invite him on stage to accept the award and address
the audience.
Plan to join us for this fun-filled event.
Supported in part by Merck
Women in Medicine Luncheon
Noon – : pm, Monday
Grand Ballroom E • Anaheim Marriott Hotel
Pre-registration Required
Complimentary
This year’s luncheon will pay tribute to Kathleen R. May, MD, FACAAI, who will be
recognized for her place in the forefront of women in the specialty and for her
contributions to the national organization. All women allergists are invited.
Supported by Sunovion Pharmaceuticals Inc.

2012 Named Lectures
Each year, the American College of Allergy, Asthma and Immunology presents several named lectures during its annual
scientific meeting. The “Bela Schick” and “John P. McGovern” lectures are presented annually. The “Daniel J. Goodman” and
“Lester Mittelstaedt” lectures are presented on alternate years. This is the first year for the Anjuli S. Nayak Lecture.
The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom
the lectures are named. The College is proud to present the following named lectures at its 2012 Annual Meeting.
General Information
Luisa Businco
Memorial Lecture
Thursday, November 8, 1:15 pm
Ballroom A (3rd Floor)
Anaheim Convention Center
Predicting the Natural History of
Food Allergy
Amal H. Assa’ad, MD, FACAAI
Cincinnati, OH
The Businco Lecture is named in honor
of Professor Luisa Businco of Rome,
Italy. Her hard work in providing
excellent patient care, effective
teaching and quality research, led to
significant advances in understanding
several aspects of pediatric food
allergy. Her clinical and laboratory
research was focused on the
development, prediction and
prevention of allergy in children.
Dr. Businco worked with dedication in
promoting the specialty of pediatric
allergy and is widely survived in the
careers of the many physicians and
scientists taught and trained by her.
This lecture is presented during the
International Food Allergy Conference.
Daniel Goodman Lecture
Saturday, November 10, 8:15 am
Ballroom B-E (3rd Floor)
Anaheim Convention Center
Asthma Heterogeneity: Phenotypes
and Endotypes
Sally E. Wenzel, MD, FACAAI
Pittsburgh, PA
The biennial Goodman Lecture is
supported by a grant from Dr. Daniel
Goodman. His purpose in establishing
this lectureship was to leave a legacy to
honor individuals who have
demonstrated outstanding scholarship
and clinical abilities in the field of
allergy/immunology.
John P. McGovern
Lecture
Sunday, November 11, 8:35 am
Ballroom B-E (3rd Floor)
Anaheim Convention Center
Definining Contact Dermatitis:
More Than Just a Rash
Luz S. Fonacier, MD, FACAAI
Great Neck, NY
This annual lectureship is supported by
a grant from the John P. McGovern
Foundation. The Foundation sought to
establish a lectureship that would
recognize eminent physicians and
scientists, both clinicians and
researchers, who have contributed
meritoriously to the advancement of
knowledge in the specialty of allergyimmunology.
Lecturers receive the
prized John P. McGovern medallion,
created especially for the lectureship.
Dr. McGovern was a past president of
the College and a strong leader in the
field of patient care.
Bernard Berman
Memorial Lecture
Monday, November 12, 9:00 am
Ballroom B-E (3rd Floor)
Anaheim Convention Center
Evaluation and Management of
Pruritus Without Rash
Bobby Q. Lanier, MD, FACAAI
Fort Worth, TX
The Annual Bernard Berman Memorial
Lecture recognizes a kind, caring
clinician allergist with interests in the
various aspects of clinical allergy and a
passion for teaching. The Memorial
Lecture is a testament to Dr. Berman’s
caring nature, unique skills as a gifted
teacher and unselfish compassion for
his patients. He was a past president of
the College and one of the founders of
the American Board of Allergy and
Immunology.
Bela Schick Lecture
Tuesday, November 13, 9:00 am
Ballroom B-E (3rd Floor)
Anaheim Convention Center
The Future of Allergy:
What Would Bela Do
James L. Sublett, MD, FACAAI
Louisville, KY
The annual Bela Schick lecture is named
in honor of one of medicine’s most
respected scientists. Bela Schick was
born in Hungary and attended medical
school in Austria. After serving as
Extraordinary Professor of Children’s
Diseases at the University of Vienna, he
immigrated to the United States in 1923.
He was a pediatrician at Mt. Sinai in New
York for many years, loved by his
patients, and respected by his fellows.
Dr. Schick is best known for his work with
Clemens von Pirquet on anaphylaxis and
for the test he developed to assess
immunity to diphtheria.
Anjuli S. Nayak Lecture
Tuesday, November 13, 10:25 am
Ballroom B-E (3rd Floor)
Anaheim Convention Center
Use of Traditional Chinese Medicine in
Food Allergy
Julie Wang, MD
New York, NY
The Anjuli S. Nayak Lecture is
supported by a grant from the Nayak
Foundation and was established to
honor outstanding allergists focusing
on advances in allergy/immunology
research. Dr. Nayak is in private practice
and continues her dedication to
research in the specialty.

Tribute to Our Past Presidents
Past Presidents
• Bernard J. Efron, MD 1942–43 ACA
• French K. Hansel, MD 1943–45 ACA
• Harry L. Rogers, MD 1945–46 ACA
• Leon Unger, MD 1946–47 ACA
• Hal M. Davison, MD 1947–48 ACA
• George E. Rockwell, MD 1948–49 ACA
• Johnathan Forman, MD 1949–50 ACA
• John H. Mitchell, MD 1950–51 ACA
• Harold A. Abramson, MD 1951–52 ACA
• J. Warrick Thomas, MD 1952–53 ACA
• M. Murray Peshkin, MD 1953–54 ACA
• Homer E. Prince, MD 1954–55 ACA
• Lawrence J. Halpin, MD 1955–56 ACA
• Ethan Allan Brown, M.R.C.S. 1956–57 ACA
• Orval R. Withers, MD 1957–58 ACA
• Merle W. Moore, MD 1958–59 ACA
• Cecil M. Kohn, MD 1959–60 ACA
• Giles M. Koelsche, MD 1960–61 ACA
• Philip M. Gottlieb, MD 1961–62 ACA
• Mayer A. Green, MD 1962–63 ACA
• Morris A. Kaplan, MD 1963–64 ACA
• Boen Swinny, Sr., MD 1964–65 ACA
• Stanislaus H. Jaros, MD 1964–67 AACIA
• M. Coleman Harris, MD 1965–66 ACA
Lowell L. Henderson, MD 1966–67 ACA
• Howard G. Rapaport, MD 1967–68 ACA
• James E. Stroh, MD 1967–68 AACIA
• John P. McGovern, MD 1968–69 ACA
• Johnny A. Blue, MD 1968–69 AACIA
• Paul F. deGara, MD 1969–70 ACA
• Mason I. Lowance, MD 1969–70 AACIA
• G. Frederick Hieber, MD 1970–71 ACA
• Alex S. Friedlaender, MD 1970–71 AACIA
• Ralph Hale, MD 1971–72 ACA
Boen Swinny, Jr., MD 1971–72 AACIA
• Lamar B. Peacock, MD 1972–73 ACA
• Richard H. Jackson, MD 1972–73 AACIA
• Wm. Sawyer Eisenstadt, MD 1973–74 ACA
• Robert J. Brennan, MD 1973–74 AACIA
• Bernard A. Berman, MD 1974–75 ACA
• John L. Dewey, MD 1974–75 AACIA
• Ben C. Eisenberg, MD 1975–76 ACA
• Lester W. Mittelstaedt, MD 1975–76 AACIA
• Nathan Ernest Silbert, MD 1976–77 ACA
• Alexander McCausland, MD 1976–77 AACIA
• Orville C. Thomas, MD 1977–78 ACA
Gustav J. Beck, MD 1977–78 AACIA
Albert E. Hensel, Jr., MD 1978–79 ACA
Stanley L. Goldman, MD 1978–79 AACIA
• T. Reed Maxson, MD 1979–80 ACA
William H. Wilson, MD 1979–80 AACIA
• Solomon D. Klotz, MD 1980–81 ACA
• Walter R. MacLaren, MD 1980–81 AACIA
Robert J. Dockhorn, MD 1981–82 ACA
• Warren J. Raymer, MD 1981–82 AACIA
Gilbert D. Barkin, MD 1982–83 ACA
• Sidney Friedlaender, MD 1982–83 AACIA
Rufus E. Lee, Jr., MD 1983–84 ACA
Burton M. Rudolph, MD 1983–84 AACIA
• John G. Leonardy, MD 1984–85 ACA
• Albert G. Corrado, MD 1984–85 AACIA
Charles H. Banov, MD 1985–86 ACA
Donald L. Unger, MD 1985–86 AACIA
Peter B. Boggs, MD 1986–87 ACA
Donald C. McLean, MD 1986–87 AACIA
• Robert J. Becker, MD 1987 ACA
• R. Faser Triplett, MD 1987–88 ACAI
Donald W. Aaronson, MD, JD, MPH 1988–89 ACAI
Dale B. Sparks, MD 1989–90 ACAI
Edward J. O’Connell, MD 1990–91 ACAI
Joseph A. Bellanti, MD 1991–92 ACAI
• John C. Selner, MD 1992–93 ACAI
• Robert T. Scanlon, MD 1993–94 ACAI
Diane E. Schuller, MD 1994–95 ACAAI
Ira Finegold, MD 1995–96 ACAAI
Betty B. Wray, MD 1996–97 ACAAI
• Jean A. Chapman, MD 1997–98 ACAAI
Robert M. Miles, MD 1998-99 ACAAI
Don Q. Mitchell, MD 1999-00 ACAAI
Emil J. Bardana, Jr., MD 2000-01 ACAAI
Bobby Q. Lanier, MD 2001-02 ACAAI
William E. Berger, MD, MBA 2002-03 ACAAI
Michael S. Blaiss, MD 2003-04 ACAAI
Myron J. Zitt, MD 2004-05 ACAAI
William K. Dolen, MD 2005-06 ACAAI
Daniel Ein, MD 2006-07 ACAAI
Jay M. Portnoy, MD 2007-08 ACAAI
Richard G. Gower, MD 2008-09 ACAAI
Sami L. Bahna, MD, DrPH 2009-10 ACAAI
Dana V. Wallace, MD 2010-11 ACAAI
• Deceased

2012 Distinguished Fellows
ACAAI will award its “Distinguished Fellow” title to Myron J. Zitt, MD, FACAAI, and “International Distinguished Fellow” title
to Bee Wah Lee, MD and Revaz Sepiashvili, MD, FACAAI, during the President’s Welcome Reception and Awards Ceremony,
7:30 pm, Saturday, in the Marquis Ballroom at the Anaheim Marriott Hotel.
John P. McGovern, MD
M. Coleman Harris, MD
Howard Rapaport, MD
J. Warrick Thomas, MD
William Browning, MD
Jerome Glaser, MD
French K. Hansel, MD
Merle W. Moore, MD
M. Murray Peshkin, MD
Leon Unger, MD
Orval R. Withers, MD
Eloi Bauers, JD
Paul F. deGara, MD
John D. Gillaspie, MD
Giles A. Koelsche, MD
Stephen D. Lockey, MD
Homer E. Prince, MD
Harold Abramson, MD
Bernard A. Berman, MD
Ethan Allan Brown, MD
Ben C. Eisenberg, MD
Sawyer Eisenstadt, MD
Philip M. Gottlieb, MD
Mayer A. Green, MD
Ralph Hale, MD
Lowell Henderson, MD
G. Frederick Hieber, MD
Lamar B. Peacock, MD
George E. Rockwell, MD
Distinguished Fellow Recipients
Nathan E. Silbert, MD
Boen Swinny, Sr., MD
Susan C. Dees, MD
William C. Grater, MD
Frank Perlman, MD
Frederick Speer, MD
Cecil Collins–Williams, MD
Meyer B. Marks, MD
Orville C. Thomas, MD
Albert E. Hensel, Jr., MD
Melvin Newman, MD
Joseph A. Bellanti, MD
T. Reed Maxson, MD
Robert J. Becker, MD
G. Everett Gaillard, MD
Solomon D. Klotz, MD
Robert J. Dockhorn, MD
William T. Kniker, MD
Gilbert D. Barkin, MD
James C. Breneman, MD
Joseph E. Ghory, MD
Rufus E. Lee, Jr., MD
Roland B. Scott, MD
Robert Hamburger, MD
John G. Leonardy, MD
Harold S. Nelson, MD
Charles H. Banov, MD
Peter B. Boggs, MD
Robert J. Brennan, MD
Lloyd V. Crawford, MD
Joel D. Teigland, MD
Gerald Vanderpool, MD
Donald C. McLean, MD
Robert Moore, MD
Warren Richards, MD
Jean A. Chapman, MD
Bernard T. Fein, MD
R. Faser Triplett, MD
Donald Aaronson, MD
Martin J. Kaplan, MD
Betty B. Wray, MD
Burton M. Rudolph, MD
Sheldon L. Spector, MD
Dale B. Sparks, MD
Emil J. Bardana, Jr., MD
Allan T. Luskin, MD
Edward O’Connell, MD
Warren Raymer, MD
Herbert Mansmann, Jr., MD
Eli O. Meltzer, MD
R. Michael Sly, MD
Arnold A. Gutman, MD
John C. Selner, MD
Hyman Chai, MD
Bob Q. Lanier, MD
Robert M. Miles, MD
Stuart L. Rusnak, MD
Robert T. Scanlon, MD
Michael S. Blaiss, MD
Douglas S. Heiner, MD
Don Q. Mitchell, MD
Diane E. Schuller, MD
Ira Finegold, MD
John M. O’Loughlin, MD
Susan Rudd Bailey, MD
William E. Berger, MD
Alexander McCausland, MD
William W. Storms, MD
Linda B. Ford, MD
Bettina C. Hilman, MD
Richard Nicklas, MD
Stanley M. Fineman, MD
Lawrence S. Mihalas, MD
William K. Dolen, MD
Jay Portnoy, MD
Nathan Segall, MD
Phillip Lieberman, MD
Anthony Montanaro, MD
Suellyn S. Rossman, MD
Charles J. Siegel, MD
Richard W. Weber, MD
Sami L. Bahna, MD, DrPH
Lawrence DuBuske, MD
Jorge A. Quel, MD
John Andrew Grant, MD
Mark T. O’Hollaren, MD
Richard D. de Shazo, MD
Marianne Frieri, MD, PhD
Ernest Charlesworth, MD
John E. Moffitt, MD
Michael B. Foggs, MD
Gailen D. Marshall, Jr., MD, PhD
Kathleen R. May, MD
James L. Sublett, MD
Bryan L. Martin, DO
Myron J. Zitt, MD
General Information
Jose Luis Cortes, MD
Angel Marchand, MD
Felicidad Cua–Lim, MD
Jose Huerta Lopez, MD
Israel Glazer, MD
Samuel Malka, MD
Sami Bahna, MD, DrPH
Attilio Boner, MD
Luisa Businco, MD
Antero Palma–Carlos, MD
Sten Dreborg, MD
International Distinguished Fellow Recipients
Julio Croce, MD
Moises Zebede, MD
Charles K. Naspitz, MD
Mario La Rosa, MD
Hugo E. Neffen, MD
Giuliana Baldini, MD
Natalio Salmun, MD
Giovanni Cavagni, MD
Cassim Motala, MD
Sebastiano Guarnaccia, MD
João Ferreira Mello, MD
Sergio Bonini, MD
Anthony Frew, MD
Maurizio Miraglia
Del Giudice, MD
Marek Kowalski, MD
Alessandro Fiocchi, MD
Constance Katerlaris, MD
Helen Hei-ling Chan, MD
Pakit Vichyanond, MD
Daniel Aguilar, MD
Kamal M. Hanna, MD
S.G.O. Johansson, MD, PhD
Carlos Baena-Cagnani, MD
Todo A. Popov, MD
Paul van Cauwenberge, MD
Ruby U. Pawankar, MD
Daphne Tsitoura, MD, PhD
Ignacio Ansotegui, MD
Desiree L. Larenas-
Linnemann, MD
Noel Rodriguez Perez, MD
Alejandro Escobar-Gutierrez, MD
G. Walter Canonica, MD
Yehia M. El-Gamal, MD, PhD
Yin Jia, MD
Sang-Il Lee, MD, PhD
Giovanni Pajno, MD
Fares Zatoun, MD
Bee Wah Lee, MD
Revaz Sepiashvili, MD

ACAAI Foundation
ACAAI Foundation “10K Club”
The following donors have met or exceeded their pledge of $10,000 to the ACAAI Foundation:
Sami L Bahna, MD, DrPH
Emil J Bardana, Jr., MD, MACP
Joseph A Bellanti, MD
Bradley E Chipps, MD
Lawrence M DuBuske, MD
David B Engler, MD
Stanley M Fineman, MD, MBA
Linda B Ford, MD, AE-C
Richard G Gower, MD
J. Andrew Grant, MD
Bobby Q Lanier, MD
Phillip L Lieberman, MD
Alnoor A Malick, MD
Kathleen R May, MD
Edward J O'Connell, MD
Nathan Segall, MD
James L Sublett, MD
Dana V Wallace, MD
Richard W Weber, MD
Betty B Wray, MD
ACAAI
Alliance of the ACAAI
New England Society of Allergy
Texas Allergy, Asthma &
Immunology Society
ACAAI Foundation “5K Club”
The following donors have met or exceeded their pledge of $5,000 to the ACAAI Foundation:
Suresh C Anand, MD
Suresh Anne, MD
Eric S Applebaum, MD
Robert J Becker, MD
William E Berger, MD, MBA
Michael S Blaiss, MD
Larry Borish, MD
David A Brown, MD
Jean A Chapman, MD
Ernest N Charlesworth, MD
Susan H Chua-Apolinario, MD
James R Claflin, MD
Joanne F Domson, MD
Daniel Ein, MD
Andrew C Engler, MD
John E Erffmeyer, MD
Jafar Farnam, MD
Ira Finegold, MD
Luz S Fonacier, MD
Mary B Hudelson, MD
Bobby Z Joseph, MD
Martin J Kaplan, MD
Roger M Katz, MD
Kenneth T Kim, MD
Jerald W Koepke, MD
Phillip E Korenblat, MD
Chao I Lin, MD
William R Lumry, MD
Lyndon E Mansfield, MD
Gailen D Marshall, MD,PhD
Bryan L Martin, DO
Kevin P McGrath, MD
J Allen Meadows, MD
Lawrence S Mihalas, MD
Robert M Miles, MD
Mark W Minor, MD
Don Q Mitchell, MD
John E Moffitt, MD
Anthony Montanaro, MD
David L Morris, MD
Robert A Nathan, MD
Harold S Nelson, MD
David S Pearlman, MD
Hobert L Pence, MD
Jay M Portnoy, MD
Bruce M Prenner
Gullapalli K Rao, MD
Russell R Roby, MD
Anthony R Rooklin, MD
Diane E Schuller, MD
John C Selner, MD
Dennis L Spangler, MD
Dale B Sparks, MD
Sheldon L Spector, MD
Dexter W Walcott, MD
Myron J Zitt, MD
IEINE
Whitehall-Robins

Alliance Program
The Hospitality Suite at the Anaheim Marriott Hotel is open for
registered spouses and guests only during the following hours:
Friday – Monday
8:00 – 10:30 am
The following presentations will take place in the Hospitality Suite and
are complimentary to registered spouses/guests and families:
Friday
Sunday
Alliance Program
The History of Anaheim
8:30 – 9:30 am Orange County Ballroom
A historian from the Anaheim Historical Society will present
an account of Anaheim’s past, its people and highlight things
to do during your visit to the city.
Saturday
Artistic Anaheim
8:30 – 9:30 am Orange County Ballroom
A world-renowned Disney artist will talk about past, present
and future public art exhibited in and around Anaheim.
ACAAI KIDS: Learn to Draw
9:30 – 10:30 am Orange County Ballroom
A local sketch artist will teach the kids how fun and easy
drawing can be. This interactive session will enable the
children to follow along and practice as they learn. Supplies
will be provided.
Making a Difference, One Bowl of Pasta at a Time
8:30 – 9:30 am Orange County Ballroom
Head chef and owner at the Anaheim White House
restaurant, Bruno Serato is a local sensation – he’ll tell his
story of how he became one of CNN’s Top 10 Heroes in 2011!
ACAAI KIDS: Anaheim History for Kids
9:30 – 10:30 am Orange County Ballroom
Costumed storytellers will show the kids what life was like in
Victorian Anaheim and bring a hands-on activity for them to
take home as a memento of their trip.
Active Members of the Alliance
are invited to attend the Annual
Business Meeting and Luncheon
Sunday
12:30 – 3:00 pm
Tiffany Terrace & Patio, Sheraton Park Hotel
Fee $15 • Registration Required
Limit 75

Fellows-in-Training
All Fellows-in-Training are encouraged to participate in the following special activities designed to meet their unique needs
and interests. Friday’s Business Meeting includes the nomination and election of a Fellow-in-Training representative to the
Board of Regents and distribution of Travel Grant checks.
Friday
FIT Program – NEW
3:30 – 5:30 pm Room 304CD • Anaheim Convention Center
Join us for two special lectures:
Immunodeficiency: Review of Current Data
Thomas A. Fleisher, MD, FACAAI
What Will the Future Practice of Allergy
Look Like
Bryan L. Martin, DO, FACAAI
Upon completion of this session, participants should be able to:
1) define primary immunodeficiency disorders associated with
increased IgE levels, including those wih atopy; 2) define the
underlying genetic bases of human susceptibility to non-tuberculous
mycobacterial infections; 3) define the role of TLR function in normal
host; 4) recognize the changing role of the physician and the factors
that are driving change in American medicine; and 5) recognize the
impact of national changes in health care that may affect the practice
of allergy and immunology.
NOT FOR
CREDIT
FIT Business Meeting (Agenda below)
5:30 – 6:30 pm Room 304CD • Anaheim Convention Center
Supported by Sunovion Pharmaceuticals Inc.
FIT Bowl Competition
5:00 – 7:00 pm Grand Ballroom EF • Anaheim Marriott Hotel
Supported by Sanofi U.S.
President’s Welcome Reception and
Awards Ceremony
7:30 – 9:00 pm Marquis Ballroom • Anaheim Marriott Hotel
Doctors’ Job Fair
Noon – 3:00 pm
Saturday
Supported in part by Merck
Sunday
NOT FOR
CREDIT
NOT FOR
CREDIT
NOT FOR
CREDIT
Hall C (1st Floor)
Anaheim Convention Center
FIT Welcome Reception
6:30 – 7:30 pm Orange County Ballroom
Anaheim Marriott Hotel
Supported by GREER
5:30 pm Introduction and Welcome
Meagan W. Shepherd, MD
Chair, Fellow-in-Training Committee
5:35 pm ACAAI Update
Stanley M. Fineman, MD, MBA, FACAAI
President
Membership in the ACAAI
Curtis L. Hedberg, MD and
Kevin P. McGrath, MD, FACAAI
Co-Chairs, Membership Recruitment
Committee
ACAAI Alliance
Rebecca A. Goldberg, RN
Alliance President
NOT FOR
CREDIT
Fellows-in-Training Business Meeting Agenda
5:30 – 6:30 pm, Friday • Room 304CD • Anaheim Convention Center
Supported by Sunovion Pharmaceuticals Inc.
5:50 pm Faculty Development
Bryan L. Martin, DO, FACAAI
ACGME/RRC and FITs
David B. Peden, MD, FACAAI
JCAAI – Why It’s Important to Join
Richard A. Honsinger, MD, MACP, FACAAI
JCAAI President
ABAI Certification
Mary Beth Fasano, MD, FACAAI
Chair, The American Board of Allergy
and Immunology
6:15 pm FIT Section Update
Meagan W. Shepherd, MD
Senior FIT Representative
Candidate Speeches and Election of Junior
FIT Representative

Fellows-in-Training Awards
Clemens von Pirquet Awards
The ACAAI Alliance will present Clemens von Pirquet Awards to three Fellows-in-Training for their outstanding abstracts. The
presentations will be made at the President’s Welcome Reception & Awards Ceremony, 7:30 pm, Saturday. The recipients of
the Awards are:
Recipients include:
Irene Fung, MD
The Alliance Memorial Award recipient
is Dr. Irene Fung, Children’s Hospital of
Philadelphia, Philadelphia, PA, who will
receive a $2,500 first place award for
her abstract, “Microarray Component
Testing in Association with IgE
Mediated Food Allergy: A Retrospective
Analysis Assessing Performance of
Multiple Versus Individual
Components.”
Bob Geng, MD
The second place award of $1,500 will
be presented to Dr. Bob Geng, for his
abstract, “Nasal Lavage Cytokine Levels
after Rhinoscopy Directed Allergen
Challenge.” Dr. Geng is currently a
Fellow-in-Training at UCLA and he
performed the work on this abstract
during his residency at Washington
University School of Medicine,
St. Louis, Missouri.
Young Faculty Support Awards
Joshua L. Kennedy, MD
Dr. Joshua Kennedy, University of
Virginia Medical Center, Charlottesville,
VA, will receive a $1,000 third place
award for his abstract, “Sino-nasal
Outcome Test (SNOT-22): A Predictor of
Post-surgical Improvement in Patients
with Chronic Sinusitis.”
The Foundation of ACAAI will present two $50,000 Young Faculty Support Awards at the President’s Welcome Reception &
Awards Ceremony, 7:30 pm, Saturday. Recipients include:
Fellows-In-Training
J. Andrew Bird, MD, UT Southwestern
Medical Center, Dallas, Texas, will
conduct research on “Sublingual
Immunotherapy as an Early Interventional
Treatment for Peanut Allergy.”
Kelly M. Maples, MD, Children’s
Hospital of The King’s Daughters,
Eastern Virginia Medical School,
Norfolk, VA, will conduct research on
“A Non-Invasive Approach to Evaluate
Disease Activity in Eosinophilic
Esophagitis.”

Travel Grant Recipients
Thanks to the generosity of those who provided funding for travel grants, the College awarded travel grants to
212 Fellows-in-Training to attend the 2012 Annual Meeting. Following are the travel grant recipients and their sponsors:
J. Thad Abbott, MD
Kansas City, KS
Family Allergy & Asthma
Manar Abdalgani, MD
Richmond, VA
Travis A. Miller, MD, FACAAI
Stephanie Albin, MD
New York, NY
Safa Nsouli, MD
Salman Aljubran, MD
Tampa, FL
Allergy and Asthma Proceedings
Neil Amar, MD
Galveston, TX
Allergy and Asthma Proceedings
William C. Anderson, III, MD
Denver, CO
Colorado Asthma & Allergy Centers
Doerthe Adriana Andreae, MD
New York, NY
Mylan Specialty L.P.
Michael Ansstas, MD
St. Louis, MO
Mylan Specialty L.P.
Sara Anvari, MD
Kansas City, MO
Merck
Sunena Argo, MD
Kansas City, MO
Merck
Tania Aung, MD
Iowa City, IA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Puneet Bajaj, MD
Hershey, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sindhura Bandi, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Selene Bantz, MD
New Haven, CT
Mylan Specialty L.P.
Cindy Bauer, MD
Milwaukee, WI
ALK, Inc.
Pavana Beerelli, MD
New Orleans, LA
The Scanlon Family Fund
Matthew Bell, MD
Madison, WI
McNeil Consumer Healthcare
Monica Bhagat, MD
Philadelphia, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Neeti Bhardwaj, MD
Hershey, PA
Sanofi U.S.
Geeta Bhargave, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Amy Boyd, MD
Gainesville, GA
Dr. and Mrs. Stanley Fineman
Kanwaljit K. Brar, MD
Brooklyn, NY
Mylan Specialty L.P.
Jean Brown, MD
St. Petersburg, FL
Mylan Specialty L.P.
Becky Buelow, MD
Milwaukee, WI
Mylan Specialty L.P.
Trever Burnett, MD
Denver, CO
Colorado Asthma & Allergy Centers
Ahmed Butt, MD
Tampa, FL
HollisterStier Allergy
Jennifer Camacho, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
S. Nicole Chadha, MD
Nashville, TN
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Wan-Yin Chan, MD
Yorba Linda, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sanny Chan, MD
Houston, TX
Merck
John Chase, MD
Los Angeles, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Rabia Q. Chaudhry, MD
Newark, NJ
Sanofi U.S.
Soo Hyun Choi, MD
Los Angeles, CA
Mylan Specialty L.P.
Preeti Chopra, MD
Los Angeles, CA
Mylan Specialty L.P.
Chris Cleveland, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
ACAAI Thanks its Travel Grant Sponsors
The Fellows-in-Training Section of ACAAI expresses its appreciation to the following institutions and physicians who
sponsored Fellows-in-Training Travel Grants this year:
Drs. David Engler and Alnoor Malick
Dr. and Mrs. Stanley Fineman
Travis A. Miller, MD
Safa Nsouli, MD
Jeffrey B. Raub, MD
Allergy and Asthma Proceedings
Colorado Asthma & Allergy Centers
Family Allergy & Asthma
The Scanlon Family
ALK, Inc.
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
HollisterStier Allergy
McNeil Consumer Healthcare
Merck
Mylan Specialty L.P.
Sanofi U.S.

Travel Grant Recipients
Thanks to the generosity of those who provided funding for travel grants, the College awarded travel grants to
212 Fellows-in-Training to attend the 2012 Annual Meeting. Following are the travel grant recipients and their sponsors:
Susan Culverhouse, MD
Tampa, FL
Merck
Nora Daher, MD
Germantown, TN
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Harold DelasAlas, MD
Omaha, NE
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Marine Demirjian, MD
Los Angeles, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Rohit Divekar, MD
Galveston, TX
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sandy Durrani, MD
Madison, WI
McNeil Consumer Healthcare
Tiffany Dy, MD
Bronx, NY
Merck
Brandi Dyer, MD
New Orleans, LA
Mylan Specialty L.P.
Sahar Faghih, MD
Peabody, MA
HollisterStier Allergy
Kevin Farnam, MD
Davis, CA
ALK, Inc.
Nabeel Farooqui, MD
Columbus, OH
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Tara Federly, MD
Kansas City, MO
Merck
Timothy J. Franxman, MD
Ann Arbor, MI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
James Friedlander, MD
Boston, MA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Irene Fung, MD
Philadelphia, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Claudia Gallego, MD
Monterrey, Mexico
Mylan Specialty L.P.
Nikki Garg, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Jackie Garrett, MD
Philadelphia, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Michael Gates, MD
Birmingham, AL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Tatyana Gavrilova, MD
Newark, NJ
Mylan Specialty L.P.
Samantha Gendelman, MD
Cleveland, OH
ALK, Inc.
Bob Geng, MD
Los Angeles, CA
Sanofi U.S.
Matthew Germinaro, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Aasia Ghazi, MD
Galveston, TX
Sanofi U.S.
Justin Greiwe, MD
Cleveland, OH
Mylan Specialty L.P.
Alekh Gupta, MD
Buffalo, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Dave S. Gupta, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Ravi C. Gutta, MD
Irvine, CA
McNeil Consumer Healthcare
Maria J. Gutierrez, MD
Hershey, PA
Mylan Specialty L.P.
Autumn Chandler Guyer, MD
Boston, MA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Joud Hajjar, MD
Richmond, VA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sherwin R. Hariri, MD
Los Angeles, CA
Merck
Darren Hirsch, MD
Great Neck, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sandra Ho, MD
Galveston, TX
Mylan Specialty L.P.
Caroline Hobbs, MD
Chapel Hill, NC
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Jillian Hochfelder, MD
Great Neck, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Margaret Hollister, MD
Shreveport, LA
Merck
Roland Honeine, MD
Buffalo, NY
Merck
Julie Hong, MD
St. Louis, MO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Brett W. Hronek, MD
St. Louis, MO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Joy Hsu, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
David J.T. Huang, MD
Toronto, ON
Merck
Yiqun Hui, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Travel Grants

Travel Grant Recipients
Thanks to the generosity of those who provided funding for travel grants, the College awarded travel grants to
212 Fellows-in-Training to attend the 2012 Annual Meeting. Following are the travel grant recipients and their sponsors:
Tracy Hwangpo, MD
Birmingham, AL
Mylan Specialty L.P.
Marc Ikeda, MD
Pittsburgh, PA
Mylan Specialty L.P.
Amanda Jagdis, MD
Toronto, ON
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Sangeeta Jain, MD
New Orleans, LA
Mylan Specialty L.P.
Artemio Jongco, MD, PhD
Great Neck, NY
HollisterStier Allergy
Nealu Kalra, MD
Hershey, PA
Mylan Specialty L.P.
Thatchai Kampitak, MD
Toronto, ON
ALK, Inc.
Lukena Karkhanis, MD
St. Louis, MO
Merck
Eric Karlin, MD
Nashville, TN
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Anilkumar Katta, MD
St. Louis, MO
Mylan Specialty L.P.
Jacob Kattan, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Joshua Kennedy, MD
Charlottesville, VA
Merck
Anjeni Keswani, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Bilal Khan, MD
Jackson, MS
Drs. David Engler and Alnoor Malick
Fatima Khan, MD
Seattle, WA
Merck
Javaid Khan, DO
Miami, FL
McNeil Consumer Healthcare
Yasmeen Khan, MD
Buffalo, NY
Merck
Maleewan Kitcharoensakkul, MD
St. Louis, MO
Merck
Edward Kleiman, MD
Brooklyn, NY
Mylan Specialty L.P.
Hazar Kobayaa, MD
Detroit, MI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Anna Kochin, MD
Bronx, NY
Merck
Yelena Kopyltsova, MD
Great Neck, NY
Sanofi U.S.
Caroline Kuo, MD
Los Angeles, CA
Merck
John Kuryan, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Nina Lakhani, MD
Toronto, ON
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Priyanka Lall, MD
Atlanta, GA
Merck
Emily W. Langley, MD
Nashville, TN
Merck
Timothy Lax, MD
Boston, MA
Merck
Lin Li, MD
Ann Arbor, MI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Newton Li, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Kellie Lim, MD
Los Angeles, CA
Merck
Henry Lin, MD
Los Angeles, CA
Merck
Bradley Locke, MD
Milwaukee, WI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Ankmalika Louis, MD
Irvine, CA
Merck
Solrun M. Maggadottir, MD
Philadelphia, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Paul J. Maglione, MD
New York, NY
Sanofi U.S.
Shikha Mane, MD
Shreveport, LA
Merck
Krikor Manoukian, MD
Irvine, CA
McNeil Consumer Healthcare
Ashlei Mathew, MD
Brooklyn, NY
Mylan Specialty L.P.
Archana Mehta, MD
Philadelphia, PA
McNeil Consumer Healthcare
Harshna Mehta, MD
New York, NY
Merck
Reena Mehta, MD
Galveston, TX
Merck
Karla Yanneth Mejia Salas, MD
Monterrey, Mexico
Mylan Specialty L.P.
Natalie Miller, MD
St. Louis, MO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Stuart Min, MD
Los Angeles, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Katie Miro, MD
Newark, NJ
Mylan Specialty L.P.
Farheen Mirza, MD
Iowa City, IA
Merck

Travel Grant Recipients
Thanks to the generosity of those who provided funding for travel grants, the College awarded travel grants to
212 Fellows-in-Training to attend the 2012 Annual Meeting. Following are the travel grant recipients and their sponsors:
Ronald J. Mittel, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Brian Modena, MD
Pittsburgh, PA
Merck
Maaz Mohiuddin, MD
Denver, CO
Merck
Joanne Moreau, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
David W. Morris, MD
Cincinnati, OH
Jeffrey B. Raub, MD, FACAAI
Megan Morsheimer, MD
Philadelphia, PA
Mylan Specialty L.P.
Susan Mozzicato, MD, MHS
Charlottesville, VA
Sanofi U.S.
Tania Mucci, MD
Mineola, NY
Mylan Specialty L.P.
Maya Nanda, MD
Cincinnati, OH
Merck
Hassan Nasir, DO
Miami, FL
McNeil Consumer Healthcare
Florina Neagu, MD
Chicago, IL
Sanofi U.S.
Lisanne Newton, MD
Cleveland, OH
Mylan Specialty L.P.
Hana Niebur, MD
St. Petersburg, FL
Mylan Specialty L.P.
Andrea Pappalardo, MD
Chicago, IL
Merck
Purvi Parikh, MD
Bronx, NY
Mylan Specialty L.P.
Jennifer Patel, MD
Memphis, TN
Mylan Specialty L.P.
Payal Patel, MD
Bronx, NY
Merck
Reenal Patel, MD
East Meadow, NY
Jeffrey B. Raub, MD
Sujan Patel, MD
Rochester, MN
McNeil Consumer Healthcare
Kathryn Payne, MD
Bethesda, MD
Merck
Mayra Alondra Lievano Perez, MD
Mexico City, Mexico
Mylan Specialty L.P.
Sarah Peterson, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Jenna Podjasek, MD
Rochester, MN
Mylan Specialty L.P.
Benjamin T. Prince, MD
Chicago, IL
Mylan Specialty L.P.
Nashmia Qamar, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Carlos Tiberio Quezada, MD
Mexico City, Mexico
McNeil Consumer Healthcare
Vahid Rahimian, MD
New York, NY
Mylan Specialty L.P.
Jessica Rajan, MD
San Diego, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Nikita Raje, MD
Kansas City, MO
Sanofi U.S.
Gita Ram, MD
Philadelphia, PA
Mylan Specialty L.P.
Manish Ramesh, MD
New York, NY
McNeil Consumer Healthcare
Anupama Ravi, MD
Rochester, MN
Mylan Specialty L.P.
Ashwini Reddy, MD
Galveston, TX
Sanofi U.S.
Manisha Relan, MD
Buffalo, NY
Merck
Jennifer A. Rumpel, MD
Detroit, MI
Sanofi U.S.
Angela Sabry, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Monika Saeedian, MD
Los Angeles, CA
Sanofi U.S.
Nauman Salim, MD
Tampa, FL
Mylan Specialty L.P.
Shefali Samant, MD
Rochester, MN
Mylan Specialty L.P.
Yana Samarasena, MD
Los Angeles, CA
Sanofi U.S.
Eunice Sandoval-Ramirez
Mexico City, Mexico
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Edan Sarid, MD
Brooklyn, NY
Mylan Specialty L.P.
Sarena Sawlani, MD
St. Louis, MO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Nikhila Schroeder, MD
Charlottesville, VA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
David R. Scott, MD
San Diego, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Neha Seth, MD
Houston, TX
Sanofi U.S.
Heena Shah, MD
New Orleans, LA
Mylan Specialty L.P.
Alireza Shakouri, MD
Shreveport, LA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Travel Grants

Travel Grant Recipients
Thanks to the generosity of those who provided funding for travel grants, the College awarded travel grants to
212 Fellows-in-Training to attend the 2012 Annual Meeting. Following are the travel grant recipients and their sponsors:
Saira Zafer Sheikh, MD
Chapel Hill, NC
Mylan Specialty L.P.
Meagan Shepherd, MD
Columbus, OH
Mylan Specialty L.P.
Janelle Sher, MD
Stanford, CA
Mylan Specialty L.P.
Jennifer Shih, MD
Atlanta, GA
HollisterStier Allergy
Jerome Sigua, MD
Milwaukee, WI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Maria A. Slack, MD
Columbus, OH
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Kristin Sokol, MD
Galveston, TX
Merck
Christine Song, MD
Toronto, ON
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Collette Spalding, MD
New York, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Robert Sporter, MD
Great Neck, NY
Mylan Specialty L.P.
Srividya Sridhara, MD
Rochester, MN
Merck
Whitney Stevens, MD
Chicago, IL
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Patricia Stewart, MD
Jackson, MS
Mylan Specialty L.P.
Jenny Stitt, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Ahila Subramanian, MD
Cleveland, OH
Mylan Specialty L.P.
Diane R. Sun, MD
Richmond, VA
Merck
Merin Sunny, MD
Dallas, TX
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Nithya Swamy, MD
Dallas, TX
Mylan Specialty L.P.
Neetu Talreja, MD
Tampa, FL
Merck
Jonathan Tam, MD
Milwaukee, WI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Jessica Tan, MD
Cincinnati, OH
Mylan Specialty L.P.
Millard L. Tierce, IV, DO
Detroit, MI
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Anita Trikha, MD
League City, TX
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Anubha Tripathi, MD
Charlottesville, VA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Timothy D. Trojan, MD
Dallas, TX
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Gina Tsai, MD
London, ON
Mylan Specialty L.P.
Kevin Tse, MD
La Jolla, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Maria-Anna Vastardi, MD
Brooklyn, NY
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Natalia Vernon, MD
Hershey, PA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Kelley Von Elten, MD
Bethesda, MD
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Hannah Walford, MD
San Diego, CA
Mylan Specialty L.P.
Luke Wall, MD
New Orleans, LA
Mylan Specialty L.P.
Emily Weis, MD
Rochester, NY
Mylan Specialty L.P.
Jennifer Welch, MD
St. Louis, MO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Aerik Williams, MD
Clemmens, NC
Mylan Specialty L.P.
Shruti Priyanka Wilson, MD
Stanford, CA
Mylan Specialty L.P.
Ya Xu, MD
Burlington, ON
Mylan Specialty L.P.
Lihua Yang, MD
Brooklyn, NY
Merck
Michelle Yasharpour, MD
Beverly Hills, CA
Mylan Specialty L.P.
Sharon Yee, MD
Denver, CO
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Alexander Yu, MD
Buffalo, NY
Merck
Karine Zakarian, MD
Los Angeles, CA
Genentech, Inc. and Novartis
Pharmaceuticals Corporation
Yuriy Zgherea, MD
Kansas City, KS
Merck
Lan Zhou, MD
Jackson, MS
Mylan Specialty L.P.
Ningxi Zhu, MD
Omaha, NE
Genentech, Inc. and Novartis
Pharmaceuticals Corporation

Saturday Product Theaters
These are commercial presentations conducted by exhibitors in specially constructed theaters on the exhibit floor.
This year we will have two Product Theaters located in Hall C where a limited number of 25-minute and 55-minute
sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums
organized by industry and designed to enhance your learning experience.
NOT FOR
CREDIT
Product Theater
10:35 – 11:00 am • Product Theater #1
Supported by Teva Respiratory, LLC
Advances in Exercise-Induced Bronchospasm:
Therapeutic Considerations
Presented by:
William W. Storms, MD
The presentation, sponsored by Teva Respiratory, will review
considerations in asthma therapy and discuss the impacts of different
aerosol inhaler design on patient treatment. The presentation will also
cover the under-recognition and potential under-treatment of
exercise-induced bronchospasm in America.
Also, visit Teva Respiratory, LLC at Booth #
Product Theater
10:35 – 11:00 am • Product Theater #2
Supported by CSL Behring
On-Demand: The How and Why of
Evolving HAE Management
Presented by:
Ralph Shapiro, MD
Director of the Midwest Immunology Clinic
Clinical Assistant Professor at the University of Minnesota
A discussion on the evolving role of acute therapy for effective
treatment of frequent hereditary angioedema (HAE) attacks. Hear
from an HAE patient who self-administers C1-INH on-demand at the
first sign of an attack, and a HAE thought-leader experienced in the
real world management of HAE patients.
Also, visit CSL Behring at Booth #
12:35 – 1:30 pm • Product Theater #1
Supported by Teva Respiratory, LLC
Allergic Rhinitis: Addressing the Unmet Needs
Presented by:
Ketan K. Sheth, MD, MBA
Allergic Rhinitis: Addressing the Unmet Needs, highlights the complex
pathophysiology of allergic rhinitis (AR) and a new treatment option
for nasal allergy symptoms.
Also, visit Teva Respiratory, LLC at Booth #
-
12:35 – 1:30 pm • Product Theater #2
Supported by MEDA PHARMACEUTICALS®
Presenting New DYMISTA
(azelastine hydrochloride and fluticasone propionate)
Nasal Spray, mcg/ mcg per Spray
Presented by:
Warner W. Carr, MD, FACAAI and
William E. Berger, MD, MBA, FACAAI
Meda Pharmaceuticals is excited to sponsor a Product Theater during
the 2012 ACAAI Annual Meeting featuring a presentation on New
DYMISTA (azelastine hydrochloride and fluticasone propionate)
Nasal Spray, 137 mcg/50 mcg per Spray.
Visit www.Dymista.com for more information about DYMISTA.
Also, visit MEDA PHARMACEUTICALS® at Booth #
3:05 – 3:30 pm • Product Theater #2
Supported by AstraZeneca
Novel Approaches to Assessing Lung Function:
Implications for Clinical Practice
Presented by:
William E. Berger, MD, MBA, FACAAI
Clinical Professor, Department of Pediatrics
Division of Allergy and Immunology
University of California, Irvine
Asthma is characterized by chronic large and small airway
inflammation. As such, it is important to consider a range of lung
function measures when assessing control and initiating and/or
adjusting therapy. This presentation will explore lung function
assessments and their usefulness in the clinical setting. These will be
reviewed by William E. Berger, MD.
Also, visit AstraZeneca at Booth # 2021600
Product Theater

Sunday Product Theaters
These are commercial presentations conducted by exhibitors in specially constructed theaters on the exhibit floor.
This year we will have two Product Theaters located in Hall C where a limited number of 25-minute and 55-minute
sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums
organized by industry and designed to enhance your learning experience.
NOT FOR
CREDIT
Product Theater
10:05 – 10:30 am • Product Theater #1
Supported by Teva Respiratory, LLC
The Value of Targeting the Small Airways in Asthma
Presented by:
Phil Lieberman, MD
The Value of Targeting the Small Airways in Asthma presentation,
sponsored by Teva Respiratory, LLC, will review important evidence
showing how small airway dysfunction correlates with poor asthma
control. In addition, the presentation will cover advances in asthma
treatment options and how they affect lung function.
Also, visit Teva Respiratory, LLC at Booth #
Product Theater
10:05 – 10:30 am • Product Theater #2
Supported by AstraZeneca
Novel Approaches to Assessing Lung Function:
Implications for Clinical Practice
Presented by:
William E. Berger, MD, MBA, FACAAI
Clinical Professor, Department of Pediatrics
Division of Allergy and Immunology
University of California, Irvine
Asthma is characterized by chronic large and small airway
inflammation. As such, it is important to consider a range of lung
function measures when assessing control and initiating and/or
adjusting therapy. This presentation will explore lung function
assessments and their usefulness in the clinical setting. These will be
reviewed by William E. Berger, MD.
Also, visit AstraZeneca at Booth # 2021600
12:05 – 1:00 pm • Product Theater #1
Supported by Mylan Specialty L.P.
Anaphylaxis Action Plans: Are You Engaging and
Empowering Your Patients
Presented by:
Eli Meltzer, MD
Allergy & Asthma Medical Group and Research Center
San Diego, CA
This Product Theater will detail strategies that may help you engage
your patients in dynamic Anaphylaxis Action Planning.
Join Dr. Meltzer for this interactive, peer-to-peer Product Theater.
Also, visit Mylan Specialty L.P. at Booth #
12:05 – 1:00 pm • Product Theater #2
Supported by Genentech, Inc. and
Novartis Pharmaceuticals Corporation
The Evolving Science of Asthma
Presented by
Dr. Bradley Chipps, MD
Medical Director, Capital Allergy and Respiratory Center
Sacramento, CA
This interactive presentation will detail the cells and molecular
mediators of the respiratory immune system, how those components
drive the pathology of asthma and how different therapeutic classes
affect these interactions.
3:05 – 3:30 pm • Product Theater #1
Supported by Boston Scientific Corporation
Bronchial Thermoplasty – Improved Asthma-Related
Quality of Life for Patients
Presented by:
Reynold A. Panettieri, Jr., MD
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA
Bronchial Thermoplasty (BT) is a revolutionary long-lasting procedure
proven to safely relieve the progressive burden of asthma. Hear from
Dr. Panettieri on his clinical experience and patient selection for this
novel treatment option for adults 18 years and older whose asthma is
not well controlled with ICS and LABA.
Also, visit Boston Scientific Corporation at Booth #
3:05 – 3:30 pm • Product Theater #2
Supported by Thermo Fisher Scientific
uKnow® Peanut Molecular Allergy Testing:
Practical Applications in Clinical Practice
Presented by
Inderpal Randhawa, MD and Robert Reinhardt, MD
Gain new clarity about peanut allergy. The uKnow® Peanut Molecular
Allergy Test is changing the way peanut allergy is diagnosed. The test
utilizes the first and only FDA-cleared peanut components, and
assesses peanut allergy at the molecular level, providing a level of
detail previously unattainable to help diagnose peanut allergy.
Also, visit Thermo Fisher Scientific at Booth #

Monday Product Theater
These are commercial presentations conducted by exhibitors in specially constructed theaters on the exhibit floor.
This year we will have two Product Theaters located in Hall C where a limited number of 25-minute and 55-minute
sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums
organized by industry and designed to enhance your learning experience.
NOT FOR
CREDIT
Product Theater
10:05 – 10:30 am • Product Theater #2 in Hall C
Supported by Thermo Fisher Scientific
uKnow® Peanut Molecular Allergy Testing:
Practical Applications in Clinical Practice
Presented by
Inderpal Randhawa, MD and Robert Reinhardt, MD
Gain new clarity about peanut allergy. The uKnow® Peanut Molecular
Allergy Test is changing the way peanut allergy is diagnosed. The test
utilizes the first and only FDA-cleared peanut components, and
assesses peanut allergy at the molecular level, providing a level of
detail previously unattainable to help diagnose peanut allergy.
Also, visit Thermo Fisher Scientific at Booth #
Product Theater

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Exhibit Hours
9:45 am – 4:00 pm, Saturday
9:45 am – 4:00 pm, Sunday
9:45 am – 1:30 pm, Monday
Actient Pharmaceuticals LLC
Booth
150 S Saunders Rd, Ste 120
Lake Forest, IL 60045
Phone: (847) 607-8890
Fax: (847) 607-9019
Website: www.actientpharma.com
Actient Pharmaceuticals, a Lake Forest, IL-based specialty
therapeutics company, is focused on delivering innovative
solutions to those treating urologic and respiratory
conditions. We offer both pharmaceutical and medical device
technologies for urology, and we are pleased to offer Theo-24
and Semprex-D to our respiratory care prescribers and
patients throughout the US. Moreover, we are actively
pursuing additional respiratory care products to add to our
current portfolio. We look forward to seeing you at Booth
#2202 in Anaheim!
Aerocrine
SILVER PARTNER
Booth
5151 McCrimmon Pkwy, Ste 260
Morrisville, NC 27560
Phone: (866) ASK-NIOX
Website: www.aerocrine.com
Aerocrine is a breakthrough Medical Technology Company
focused on improved management and care of patients
with inflammatory airway diseases. NIOX MINO® enables
fast, reliable measurements of airway inflammation and
may therefore play a critical role in more effective
diagnosis, treatment and follow-up of patients.
Alcon Laboratories
Booth
6201 South Freeway
Fort Worth, TX 76134-2099
Phone: (800) TO-ALCON
Website: www.alcon.com
Alcon, the global leader in eye care, provides innovative
products that enhance quality of life by helping people see
better. The three Alcon businesses – Surgical, Pharmaceutical
and Vision Care – offer the widest spectrum of products
addressing the world’s most pressing eye care needs. For
more information, visit www.alcon.com.
ALK, Inc.
Booth
1700 Royston Ln
Round Rock, TX 70664
Phone: (800) 325-7354
Fax: (888) 329-2551
Website: www.alk.net/us
ALK is a research driven, global pharmaceutical company
focusing on allergy treatment, prevention and diagnosis. As
the world leader in allergy immunotherapy, a treatment
given to increase immunity to substances causing allergic
symptoms, ALK is devoted to improving the quality of life for
people with allergies by creating products that treat the
cause of allergies. ALK is also committed to supporting the
business of allergy by providing diagnostic tools, automation
software and customized business, technical and clinical
consulting services.
SILVER PARTNER
Airware Labs
28399 E Indian School Rd, Suite 202
Scottsdale, AZ 85251
Phone: (480) 588-8612
Fax: (480) 588-8613
Website: www.airwarelabs.com
Booth
Allergan, Inc.
Booth
2525 Dupont Dr
Irvine, CA 92612
Phone: (714) 246-4500
Fax: (714) 246-4971
Website: www.allergan.com
Recently celebrating its 60th anniversary, Allergan is a
global leader in discovering and developing therapeutic
agents to advance patient care. Allergan is also one of the
fastest-growing eye care companies worldwide. Eye care
professionals and patients rely on Allergan products to
treat a variety of eye conditions. Visit www.allergan.com for
more information.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Allergy & Asthma Network,
Mothers of Asthmatics (AANMA)
Booth
8201 Greensboro Dr, Ste 300
McLean, VA 22102
Phone: (703) 641-9595
Fax: (703) 288-5271
Website: www.aanma.org
Allergy & Asthma Network, Mothers of Asthmatics (AANMA)
is a non-profit organization whose mission is to eliminate
needless asthma and allergy deaths and suffering through
education, advocacy and community outreach. AANMA
offers multiple resources for consumer education and
information-sharing including magazines, newsletters and
brochures along with medical materials such as AANMA’s
unique series of respiratory and inhaler posters that help
healthcare professionals connect with, educate and bridge
potential language barriers with patients. AANMA helps lead
a range of outreach efforts in communities across the nation
to deliver practical, common-sense information and solutions
for people with allergies and asthma.
Allergy & Asthma Proceedings
Booth
95 Pitman St
Providence, RI 02906
Phone: (401) 331-2510
Fax: (401) 331-0223
Website: www.oceansidepubl.com
The primary focus of Allergy & Asthma Proceedings is the
publication of articles with the highest degree of clinical
relevance for the practicing allergist/immunologist.
Additionally, the Proceedings is committed to medical
education, having recently published the teaching tool
Northwestern University A-I Syllabus for Medical Students &
Residents. Academically, the Proceedings has established a
33 year reputation as a National Library of Medicine/PubMed
indexed journal with circulation at 5000 and a respectable
impact factor (2.17). The Proceedings, together with the
American Journal of Rhinology & Allergy and Allergy &
Rhinology (open access) are published by OceanSide
Publications in Providence, RI.
www.allergyandasthmaproceedings.com.
Allergy Control Products
Booth
22 Shelter Rock Ln
Danbury, CT 06810
Phone: (203) 438-9580
Fax: (203) 431-8963
Website: www.allergycontrol.com
For almost 30 years Allergy Control Products has been a
trusted source for helpful allergen avoidance information
and effective allergy relief products. We value our
relationship with ACAAI physicians and look forward to
seeing many of you who have supported us since the first
introduction of Allergy Control® brand encasings years ago.
We also look forward to meeting with physicians who wish to
know more about environmental controls and how we can
partner with them for better patient outcomes. Please visit us
at Booth #2627.
Allergy Guardian
Booth
7422 Carmel Executive Park, Ste 310B
Charlotte, NC 28226
Phone: (704) 910-8075
Fax: (704) 544-5596
Website: www.allergyguardian.com
Welcome to Allergy Guardian! Please stop by booth #2822 to
learn about our company, our staff and the services we offer.
Our “Ready, Set, Guard!” program will assist your patients in
“Taking Action Against Allergens” and help identify the best
allergen avoidance program for their condition. In addition to
our Allergy Guardian encasings, we offer a range of effective
products for relief from allergies, asthma, sinusitis, dermatitis
and more. Our team has many years of experience in the
allergy industry and we have carefully selected the effective
products found on our website, www.allergyguardian.com
for a healthier home and a healthier lifestyle.
Allergy Laboratories, Inc.
Booth
PO Box 348
Oklahoma City, OK 73109
Phone: (800) 654-3971
Fax: (800) 811-3389
Website: www.allergylabs.com
Allergy Laboratories, Inc. is proud to be the oldest American
owned allergenic extract manufacturer. We produce a full
range of diagnostic and therapeutic allergens, as well as
sterile empty vials and pre-filled vials of allergenic extract
diluting solutions. We invite your inquires.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Allergy Therapeutics PLC
Booth
Dominion Way
Worthing
West Sussex, BN14 8SA
United Kingdom
Phone: 44(0)1903 844 700
Fax: 44(0)1903 844 744
Website: www.allergytherapeutics.com
Allergy Therapeutics is a European-based specialty
pharmaceutical company focused upon the treatment and
prevention of allergy. Our mission is to ‘transform allergy
treatment’.
Allergy Therapeutics has a long-term commitment to
research and in particular, the development of innovative
therapies for both treatment and prevention of allergyrelated
conditions.
Allermed Laboratories, Inc.
Booth
7203 Convoy Ct
San Diego, CA 92111
Phone: (800) 221-2748
Fax: (858) 292-7834
Website: www.allermed.com
Allermed Laboratories, Inc. is a federally licensed manufacturer
of allergenic extracts. The company has manufactured a
reliable source of quality allergenic products for both
diagnostic and therapeutic purposes since 1974, including a
full product line of inhalant allergen extracts and custom
extract mixtures. Allermed manufactures standardized
allergenic extracts including mite, cat and grass pollens. In
addition to providing bulk allergenic extracts, Allermed offers
compounding services for patient prescriptions. We also
provide related supplies and services such as sterile empty
vials, diluent, vial trays, skin testing devices and mold
identification plates for the practitioner’s convenience.
In addition to providing quality products, the company’s goal
is to provide excellent service to the physician by offering
competitive prices and timely delivery.
American Board of Allergy
& Immunology (ABAI)
Booth
111 S Independence Mall E, Ste 701
Philadelphia, PA 19106-2515
Phone: (215) 592-9466
Fax: (215) 592-9411
Website: www.abai.org
The ABAI was established in 1971 as a Conjoint Board of the
ABIM and ABP. The internal medicine subspecialty existed
from 1936-1971 and the pediatric subspecialty existed from
1944-1971. The ABAI is committed to working closely with its
parent boards to maintain the highest educational and
clinical standards in the specialty of allergy/immunology. The
ABAI currently has 5,946 Diplomates who are board-certified
in Allergy and Immunology.
American Express OPEN
Booth
200 Vesey St
New York, NY 10285
Phone: (212) 640-2000
Fax: (646) 638-5408
Website: www.open.com
We’d like to introduce you to the business cards that say
you’re a business owner. As an American Express OPEN SM Card
member you’ll have access to a wide selection of products,
tools and services that can help run your business. Track and
manage spending online, earn valuable rewards on business
purchases, get answers to your questions 24/7, and tap into
exclusive resources and information. American Express
OPEN SM can help take your business where you want to go.
American Latex Allergy Association
Booth
PO Box 198
Slinger, WI 53086
Phone: (888) 97ALERT
Website: www.latexallergyresources.org
A national, non-profit, 501(c)3, educational and support
organization, founded in 1993, the American Latex Allergy
Association’s mission is to create awareness of latex allergy
through education, and to provide support to allergists and
their patients who have developed latex allergy. We
emphasize the reinforcement of the doctor-patient
relationship through the provision of our educational
materials. Our website, www.latexallergyresources.org,
provides alternative product lists, educational support, news
updates and links. Our Online Locate an Allergist Registry is
helping individuals seeking diagnosis and treatment for latex
allergy. If you have expertise in latex allergy, you can register
for our Online Locate an Allergist, join our professional
membership and receive our quarterly newsletter, brochures,
and other resources for your office and patients. Stop by our
booth to see samples of the resource materials available.
American Outcomes Management
Booth
490 Rte 304
New City, NY 10956
Phone: (800) 746-9089
Fax: (800) 528-9860
Website: www.americanoutcomes.com
American Outcomes Management (AOM) is a physician
owned and operated, nationwide, leading provider of home
infusion services specializing in the care of patients with
chronic and acute disease conditions. Our goal is to work
with patients, families, physicians, case managers and other
healthcare providers to develop improved and more costeffective
ways of delivering care.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
AstraZeneca
1800 Concord Pike, A3B-304
Wilmington, DE 19803
Phone: (302) 885-5418
Fax: (302) 885-8881
Website: www.astrazeneca.com
Baltimore CVB
SILVER PARTNER
Booth
Booth
100 Light St, 12th Flr
Baltimore, MD 21202
Phone: (410) 659-7303
Fax: (443) 817-0462
Website: www.baltimore.org
Baltimore’s easy to get to and easy to get around. And nearly
everything is “just two feet away” from the spacious
Baltimore Convention Center and the famed Inner Harbor.
Great restaurants, world-class attractions and museums,
outstanding sports venues and 8,500 hotel rooms are part of
the city’s compact, convenient “convention community.”
Neighborhoods — from the cultural hub of Mount Vernon to
historic Federal Hill and Fell’s Point to kitschy Hampden —
are great places for your attendees to discover Baltimore. For
more information on bringing your next meeting to
Baltimore, contact Visit Baltimore at 800.343.3468 or click on
www.baltimore.org.
Baxter – Global Medical Affairs
Booth
One Baxter Pkwy
Deerfield, IL 60015
Phone: (800) 422-9837
Fax: (800) 568-5020
Website: www.baxter.com
The BioTherapeutics Medical Affairs booth will be staffed by
Baxter Medical Affairs representatives who are able to answer
medical and scientific questions about Baxter’s
immunoglobulin products. For more information on
BioTherapeutics, please visit www.baxter.com.
Baxter Healthcare Corporation
Booth
One Baxter Pkwy
Deerfield, IL 60015
Phone: (800) 422-9837
Fax: (800) 568-5020
Website: www.baxter.com
Baxter provides purified plasma treatments containing
antibodies called immunoglobulins that help Primary
Immune Deficiency patients fight off infection.
Immunoglobulins are also indicated to treat a number of
conditions including Kawasaki Syndrome, Chronic
Lymphocytic Leukemia (CLL) and Idiopathic
Thrombocytopenic Purpura (ITP).
BioRx
GOLD PARTNER
Booth
10828 Kenwood Rd
Cincinnati, OH 45242
Phone: (513) 338-8418
Website: www.biorx.net
BioRx is a specialized provider of pharmacy and infusion
services targeted at rare, chronic, costly diseases, including
hemophilia, immune deficiencies, autoimmune disorders,
nutrition and digestive disorders, alpha-1 antitrypsin
deficiency and hereditary angioedema. An ACHC-accredited
provider, BioRx delivers savings by providing increased
patient monitoring and clinical assistance. Learn more at
www.biorx.net.
Boston Scientific Corporation
Booth
888 Ross Dr, Ste 100
Sunnyvale, CA
Phone: (888) 272-1001
Fax: (508) 683-5071
Website: www.btforasthma.com
Boston Scientific has developed a bronchoscopic procedure
for the treatment of severe persistent asthma in adults not
well controlled on ICS and LABA alone. The Alair® Bronchial
Thermoplasty System reduces the amount of excessive
airway smooth muscle, decreasing the ability of the airway
walls to contract and narrow during an asthma attack,
providing long-lasting and improved asthma control for
adult severe asthma patients. For more information, please
visit www.BTforAsthma.com.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
BreatheAmerica, Inc.
Booth
One Burton Hills Blvd, Ste 375
Nashville, TN 37215
Phone: (615) 665-7103
Fax: (615) 665-8776
Website: www.breatheamerica.com
BreatheAmerica, Inc. is a company dedicated to improving
how healthcare services are delivered to patients who suffer
from chronic airway diseases – allergy, sinusitis, asthma and
other related allergic and inflammatory diseases – with the
goal of improving outcomes, reducing overall healthcare
expenditures, and delivering an exceptional and
differentiated patient experience. As an operator of
outpatient medical centers, we believe that chronic airway
disease is best managed in a single, comprehensive “homebase”
setting and through medical services that are
evidence-based and led by an allergist. Based in Nashville,
TN, BreatheAmerica has a national scope and currently
operates in seven states across the US.
Carestream Health
Booth
1765 The Exchange
Atlanta, GA 30339
Phone: (770) 226-3290
Website: www.carestream.com/ent-allergy
For over a century, Carestream Health has provided state-ofthe-art
diagnostic imaging products and support to
healthcare professionals across the globe. Today, we continue
our tradition of innovation with the CS 9300, an affordable
point-of-care CT system that is designed to meet the imaging
needs of allergists. Compact and easy-to-use, the CS 9300 fits
into virtually any office, and delivers an attractive return on
investment – even at low scan volumes. And, as always, the
system comes with the expert CT accreditation support,
training and technical support that customers have come to
expect from Carestream.
CE Symmetry
Booth
1488 Briargrove Way
Oldsmar, FL 34677
Phone: (888) 488-4452
Fax: (888) 384-1904
Website: www.cesym.com
Changing Management of Acute HAE Events
Visit the CE Symmetry Therapeutic Tour® exhibit at booth
2327 during the 2012 ACAAI Annual Meeting and Exhibition.
Participate in an audio tour that provides an overview of the
CE program, the faculty, and the objectives. While at the
Therapeutic Tour® exhibit, you will be able to register for the
program or request a reminder e-mail with a link to this
valuable new CE offering.
Centers For Disease Control
and Prevention
Booth
1600 Clifton Rd NE, MS A-19
Atlanta, GA 30329
Phone: (404) 639-8091
Website: www.cdc.gov
The Centers for Disease Control and Prevention’s
Immunization Program provides information on vaccines and
vaccine-preventable diseases for children, adolescents and
adults. The program provides resources and training for
health care providers and information for patients. The
exhibit emphasizes the importance of the influenza vaccine
for high-risk populations.
COPD Foundation
2937 SW 27th Ave, Ste 302
Miami, FL 33133
Phone: (866) 731-COPD
Fax: (305) 567-1317
Website: www.copdfoundation.org
Corpus Christi Allergy & Asthma Center
Booth
Booth
2502 Morgan Ave
Corpus Christi, TX 78405
Phone: (361) 888-6782
Website: www.asthmaandallergy.com
Currently seeking a Physician to join the practice: The Corpus
Christi Allergy-Asthma-Dermatology Center is offering an
outstanding opportunity for a BC/BE allergist to join one of
the largest and most prestigious solo Allergy-Asthma-
Immunology practices in the country that has been directed
by James A. Caplin, MD for the past 33 years. Hospitals are
dangerous places for asthmatics. The Corpus Christi Allergy-
Asthma-Dermatology Center is committed to keeping
asthmatics, of all ages, well and out of the hospital. It is our
belief that, “The Best Allergist Uses the Fewest Medicines,”
and thus avoids their dangerous side effects.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
CSL Behring
Booth
1020 First Ave
King of Prussia, PA 19406
Phone: (610) 878-4000
Fax: (610) 290-9058
Website: www.cslbehring-us.com
CSL Behring is a global leader in the plasma protein
therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
safe and effective plasma-derived and recombinant therapies
worldwide. These therapies are used to treat coagulation
disorders including hemophilia and von Willebrand disease,
primary immune deficiencies, hereditary angioedema and
inherited respiratory disease. Additional therapies are used in
cardiac surgery, organ transplantation, burn treatment and to
prevent hemolytic diseases in the newborn.
CSL Behring operates one of the world’s largest plasma
collection networks, CSL Plasma. CSL Behring is a subsidiary
of CSL Limited, a biopharmaceutical company with
headquarters in Melbourne, Australia. For more information,
visit www.cslbehring-us.com.
Demandforce
Booth
22 Fourth St, 12th Flr
San Francisco, CA 94103
Phone: (800) 246-9853
Fax: (415) 532-2800
Website: www.demandforce.com
Demandforce is a leader in online marketing and
communications and is the easiest and most effective way for
service businesses to communicate with their customer base.
Demandforce automatically syncs with your practice
management system to automate appointment scheduling,
confirmations and reminders, and helps practices enhance
their online reputation with promotions, newsletters and
more. Demandforce certified reviews reach a total of 200
million monthly unique visitors across the Web, helping local
consumers find you when searching online. Best of all,
Demandforce automatically tracks results and revenue to
provide real-time visibility into the success of your practice.
Dyax Corp.
Booth
55 Network Dr
Burlington, MA 01803
Phone: (617) 225-2500
Fax: (617) 225-2501
Website: www.dyax.com
Dyax’s mission is to discover, develop and commercialize
innovative biopharmaceuticals for unmet medical needs
while delivering outstanding value to patients and
stockholders. At the core of our success is our powerful and
proprietary drug discovery technology, phage display. This
technology provides us a unique advantage of being able to
identify and develop our own clinical leads to fuel our
internal pipeline. We also leverage phage display into
licenses and collaborations with companies and researchers
interested in furthering their own pipelines.
ELSEVIER, INC.
Booth
1600 JFK Blvd, Ste 1800
Philadelphia, PA 19103-2899
Phone: (215) 239-3490
Fax: (215) 239-3494
Website: www.us.elsevierhealth.com
ELSEVIER is a leading publisher of health science
publications, advancing medicine by delivering superior
reference information and decision support tools to doctors,
nurses, health practitioners and students. With an extensive
media spectrum – print, online and handheld, we are able to
supply the information you need in the most convenient
format.
Forest Pharmaceuticals, Inc.
Booth
13600 Shoreline Dr
St Louis, MO 63045
Phone: (800) 678-1605
Fax: (314) 493-7450
Website: www.forestpharm.com
Forest Pharmaceuticals, Inc. is a wholly-owned subsidiary of
New York City-based Forest Laboratories, Inc. Forest’s
longstanding global partnerships and track record
developing and marketing pharmaceutical products in the
United States have yielded its well-established central
nervous system and cardiovascular franchises and an
emerging portfolio in anti-infective and respiratory medicine.
The Company’s pipeline, the most robust in its history,
includes product candidates in all stages of development
across a wide range of therapeutic areas.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Georgetown Immunology Center
Medical Dental Bldg Rm 308 NW
3900 Reservoir Rd NW
Washington, DC 20057
Phone: (202) 687-8227
Fax: (202) 784-3597
Website: www.immunologycenter.org
Booth
Bellanti’s long-awaited Immunology IV: Clinical Applications
in Health and Diseases is a completely rewritten 2012 edition
of his classic textbook. The book brings the science of
immunology to clinical practice. Each chapter is written by a
noted authority who contributes state-of-the-art knowledge
on each particular topic in a 1000+ page volume containing
25 chapters, over 800 vivid colored figures accompanied by
an online multilevel teaching format with animations/
hyperlinks, clinical case studies with interactive Q & A and
continual clinically relevant updates. Come visit us in the
Exhibit Hall, Booth 2325, for a book signing.
GREER – Commercial
Booth
PO Box 800
Lenoir, NC 28645-0800
Phone: (828) 754-5327
Fax: (828) 754-5320
Website: www.greerlabs.com
GREER® is devoted to furthering the specialty of allergy
immunotherapy. We provide allergy professionals with
allergenic extracts, sterile empty vials, sterile diluting fluids,
skin testing devices, and a full line of ancillary products
needed to successfully test and treat allergic patients.
GREER – Medical Affairs
Booth
PO Box 800
Lenoir, NC 28645
Phone: (828) 754-5327
Fax: (828) 754-5320
Website: www.greerlabs.com
GREER® is devoted to furthering the specialty of allergy
immunotherapy. We provide allergy professionals with
allergenic extracts, sterile empty vials, sterile diluting fluids,
skin testing devices, and a full line of ancillary products
needed to successfully test and treat allergic patients.
HAE: Learn About It, Talk About It
Booth
730 Stockton Dr
Exton, PA 19341
Phone: (610) 458-7300
Website: www.LetsTalkHAE.com
HAE: Learn About It, Talk About It is a growing collaboration
among the American College of Allergy, Asthma and
Immunology (ACAAI), the American Gastroenterological
Association (AGA) Institute, the World Allergy Organization
(WAO), the American College of Emergency Physicians
(ACEP), the American Academy of Nurse Practitioners (AANP),
the Society of Emergency Medicine Physician Assistants
(SEMPA) and the European Academy of Allergy and Clinical
Immunology (EAACI). The program is supported by
ViroPharma Incorporated.
HollisterStier Allergy
Booth
3525 N Regal
Spokane, WA 99207
Phone: (800) 992-1120
Fax: (800) 752-6258
Website: www.hsallergy.com
HollisterStier Allergy is dedicated to being your partner in
allergy management. Our complete line of high quality
products and testing supplies allow allergy professionals to
provide patients with the best possible care. Stop by booth
#2511 to hear about the new products available from
HollisterStier Allergy!
International Association for Food
Protein Enterocolitis (IAFFPE)
Booth
2372 Rte 9S
Howell, NJ 07731
Phone: (908) 910-4419
Fax: (732) 751-4568
Website: www.iaffpe.org
The International Association for Food Protein Enterocolitis
(IAFFPE) provides research, education, support and advocacy
for patients and families affected by Food Protein-Induced
Enterocolitis Syndrome (FPIES). We strive to bridge the gap
between patient, family and physician while also bringing
non-IgE allergies to the forefront of medical interest on par
with IgE allergies.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
ISTA Pharmaceuticals
50 Technology
Irvine, CA 92618
Phone: (949) 788-6000
Fax: (949) 789-3139
Website: www.istavision.com
Jones Medical Instrument Co.
Booth
Booth
200 Windsor Dr
Oak Brook, IL 60523
Phone: (630) 571-1980
Fax: (630) 571-2023
Website: www.jonesmedical.com
SPIROMETRY – While on the exhibit floor, stop by the Jones
Medical booth for the latest advances in spirometry for the
Allergy practice. On display will be the NEW Satellite/Base
Station 3 System, today’s most popular office spirometer
featuring the least expensive disposable sensor available,
EMR compatibility, fully cordless operation and the fastest
print time. The Satellite/Base Station 3 combination provides
the most efficient and convenient means of spirometry
testing for the Allergist’s office. Choosing the right
spirometer company is as important as choosing the right
spirometer…Jones now has over 90 years of spirometer
design and manufacturing experience. Stop by today to take
advantage of our special convention offer!
Mayo Clinic
Booth
200 First St SW
Rochester, MN 55905
Phone: (507) 284-4873
Website: www.mayoclinic.org
Mayo Clinic is a world-class academic medical center that is
consistently recognized by U.S. News and World Report as
one of America’s “Best Hospitals.”The multi-disciplinary group
practice consists of 3,800 physicians/scientists working in a
collaborative environment that brings together the best in
patient care, groundbreaking research and innovative
medical education.
GOLD PARTNER
MEDA PHARMACEUTICALS®
Booth
265 Davidson Ave
Somerset, NJ 07726
Phone: (732) 564-2200
Fax: (732) 564-2224
Website: www.meda.us
MEDA PHARMACEUTICALS® is a global specialty
pharmaceutical company that develops, markets and
promotes branded prescription products in the respiratory,
pain, women’s health and men’s health therapeutic areas.
Kaz USA Inc. Honeywell
Booth
250 Turnpike Rd
Southboro, MA 01772
Phone: (508) 490-7214
Fax: (508) 480-0502
Website: www.kaz.com
Honeywell is the market leader in portable air purification
products, offering True Hepa permanent filtration and
providing your patients with superior air cleaning products
for over 25 years!
Lincoln Diagnostics, Inc.
Booth
P.O. Box 1128
Decatur, IL 62525
Phone: (800) 537-1336
Fax: (217) 877-5645
Website: www.lincolndiagnostics.com
Lincoln Diagnostics is displaying state-of-the-art, safetyengineered,
allergy skin testing devices that meet all
current OSHA requirements – the “new” Multi-Test® PC
(pain control), Multi-Test® II, Multi-Test®, Duotip-Test® II and
Duotip-Test®. Please visit our exhibit to learn about the
economic value of using Lincoln devices and why they are
the most widely used and most extensively published on
devices available.
Meditab Software, Inc.
Booth
333 Hegenberger Rd, Ste 800
Oakland, CA 94621
Phone: (510) 632-8021
Fax: (510) 686-8409
Website: www.meditab.com
Established in 1998, Meditab Software Inc., developers of IMS
(Intelligent Medical Software), offers clinical automation
systems that maximize productivity, advance patient care,
manage utilization and reduce costs. Meditab develops and
supports a multi-award-winning, multi-certified Electronic
Health Records (EHR) system that combines clinical charting,
e-prescribing, population management, decision support,
analytics and reporting, document imaging and much more,
all on a single database platform. The company takes
tremendous pride in providing comprehensive, user-friendly,
and affordable solutions for each practice’s unique needs.
Time tested and proven, IMS generates tangible returns for
medical practices of all sizes.
Headquartered in Oakland, California, with offices across the
United States, Meditab supports tens-of-thousands of clients
nationwide. For more information, please visit
www.meditab.com or call 866-99-Go-EMR.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Merck
Booth
One Merck Dr
PO Box 100
Whitehouse Station, NJ 08889
Phone: (908) 423-1000
Website: www.merck.com
Today’s Merck is a global healthcare leader working to help
the world be well. Merck is known as MSD outside the
United States and Canada. Through our prescription
medicines, vaccines, biologic therapies, and consumer care
and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative
health solutions. We also demonstrate our commitment to
increasing access to healthcare through far-reaching
policies, programs and partnerships that donate and
deliver our products to the people who need them. For
more information, visit www.merck.com.
Micro Direct, Inc.
GOLD PARTNER
Booth
803 Webster St
Lewiston, ME 04240
Phone: (207) 786-7808
Fax: (207) 786-7280
Website: www.micro-direct.com
Micro Direct is pleased to offer Total Spirometry Solutions
with five models priced from $1,595 to $2,395, all designed
to meet your needs and each with your choice of inexpensive
cardboard mouthpieces, one-way mouthpieces or full
protection pulmonary filters. Micro Direct also offers an
inexpensive peak flow meter and a finger pulse oximeter.
Stop by our booth to see the complete Micro Direct product
line and ask about our show specials!
Mission Pharmacal Company
Booth
PO Box 786099
San Antonio, TX 78278-6099
Phone: (210) 696-8400
Fax: (210) 581-8719
Mission Pharmacal Company is a privately held
Pharmaceutical company based in San Antonio, Texas. For
sixty-five years, the company has been dedicated to
identifying unmet health needs in the marketplace and
developing innovative prescription and over-the-counter
products to meet them.
Mission: Allergy, Inc.
Booth
28 Hawleyville Rd
Hawleyville, CT 06440
Phone: 1-877-NoAllergy
Fax: (203) 426-5607
Website: www.missionallergy.com
Mission: Allergy manufactures products for allergenavoidance,
including the highest quality allergen-proof
microfiber pillow and mattress encasings. Our Allergy Self-
Help Guide for patients contains scientifically accurate
allergen-avoidance advice for patients. Please stop by our
booth to request your free supply – and to view an unusual
display of live High-Definition Dust Mites!
ModuleMD, LLC
Booth
8359 Office Park Dr
Grand Blanc, MI 48439
Phone: (248) 434-0444
Fax: (269) 441-1920
Website: www.modulemd.com
ModuleMD is the leader in Allergy EMR and Practice
Management, Billing and Revenue Management for Allergy
practices and physician groups. With its fully integrated skin
testing module, immunotherapy, vaccine preparation, lab
ordering and reporting, eRx, scheduling, charge entry, claims
submission, revenue collection and reporting modules,
ModuleMD is fulfilling the needs of Meaningful Use in the
most integrated manner for Allergy practices.
Mylan Specialty L.P.
DIAMOND PARTNER
Booth
110 Allen Rd, 4th Flr
Basking Ridge, NJ 07920
Phone: (908) 542-1999
Fax: (908) 542-2522
Website: www.mylan.com
Mylan Specialty L.P. is a specialty pharmaceutical company
focused on the development, manufacturing and
marketing of prescription drug products for the treatment
of respiratory diseases, life-threatening allergic reactions
and psychiatric disorders. It is a subsidiary of Mylan Inc.,
one of the world’s leading generics and specialty
pharmaceutical companies.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
National Allergy Supply, Inc.
Booth
1620 Satellite Blvd, Ste D
Duluth, GA 30097
Phone: (800) 522-1448
Fax: (800) 395-9303
Website: www.nationalallergy.com
Just like you, National Allergy believes that avoiding airborne
allergens can help improve patient outcomes. We are firmly
established as the leader in the allergen avoidance products
market having sold to hundreds of thousands of customers
through the referrals of thousands of doctors since our start
in 1988. Our colorful patient flyers are super easy to use as
compared to bulky catalogs and offer your patients Free
Shipping on their first order with us. Our BedCare barrier
encasings are Made in the USA and set the standard for
comfort, quality, and affordable allergen protection. See for
yourself by visiting our booth and we’ll be happy to give you
a FREE Standard Size Pillow Encasing.
NeilMed Pharmaceuticals, Inc.
Booth
601 Aviation Blvd
Santa Rosa, CA 95403
Phone: (707) 525-3784
Fax: (707) 525-3785
Website: www.neilmed.com
The mission of the company is to create and maintain safe,
affordable and effective products to sustain long-term
growth and create drug free and effective nasal/sinus care
devices for millions of consumers worldwide. Please visit the
website www.neilmed.com for more details. NeilMed
supports medical research in several countries and believes
in excellent 24 hour live customer service. NeilMed supports
local communities, donates for natural disasters and supports
education.
Novartis Pharmaceuticals Corporation
Booth
1 Health Plaza
East Hanover, NJ 07936
Phone: (862) 778-1899
Novartis Pharmaceuticals is dedicated to discovering,
developing, manufacturing and marketing prescription
drugs that help meet our customers’ medical needs and
improve their quality of life. Please visit the Novartis exhibit
where our sales representatives will be available to discuss
our products.
nSpire Health, Inc.
Booth
1830 Lefthand Circle
Longmont, CO 80501
Phone: (800) 574-7374
Fax: (303) 666-5588
Website: www.nspirehealth.com
nSpire Health is a leading provider of respiratory diagnostic
products and core lab services. Our featured products
include the KoKo® Spirometry systems and PiKo® home lung
health monitoring devices. Revolutionary in design, the PiKo®
is a miniature home lung health monitor that exceeds all
published accuracy standards. Our KoKo® Legend portable
research-grade Spirometer exceeds ATS/ERS 2005 standards.
We also continue to develop and provide the Wright
Respirometers and Pocket Asthma Management products.
Please stop by our booth to receive more information and
see a demonstration of these products.
Panatrex, Inc.
Booth
1648 Sierra Madre Circle
Placentia, CA 92870-6626
Phone: (714) 630-5582
Fax: (714) 630-5572
Website: www.panatrex.com
Panatrex, Inc. manufactures the Quanti-Test skin test system
in California. The Quanti-Test System provides depth control
and will ensure the most accurate and reproducible results.
Quanti-Well wipes out excessive allergens to keep costs low.
Perrigo Company
Booth
515 Eastern Ave
Allegan, MI 49101
Phone: (269) 686-1040
Fax: (269) 620-5963
Website: www.perrigo.com
PERRIGO is the world’s largest manufacturer of “store-brand”
OTC medicines for the nation’s leading retailers, club stores
and pharmacy chains. Store-brand products offer consumers
significant savings over national brands and contain the
same FDA-approved active ingredients. In addition to
Fexofenadine (Allegra®), Perrigo’s portfolio of allergy
products includes all the big name brand equivalents from
“B to Z” (Benadryl® to Zyrtec®), and other popular storebrands
in between. Visit us at booth #2826 today to learn
more about quality, affordable prescription and OTC
healthcare from Perrigo.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Pharmaceutical Specialties, Inc.
Booth
PO Box 6298
Rochester, MN 55903-6298
Phone: (800) 325-8232
Fax: (507) 288-7603
Website: www.psico.com
PSI develops, manufactures and distributes skin care
products for people with sensitive skin. All products are free
of fragrance, masking fragrance, dyes, parabens, lanolin and
formaldehyde. Products include the Vanicream and Free
Clear Sensitive Skin and Hair Products, along with new
Vaniply Ointment.
PME Communications
6701 Baum Dr, Ste 140
Knoxville, TN 37919
Phone: (865) 584-5727
Fax: (865) 450-9904
Website: www.pmecomm.com
Rosch Visionary Systems, Inc.
Booth
Booth
501 Howard Ave, Ste A204
Altoona, PA 16601
Phone: (800) 307-3320
Fax: (814) 941-1115
Website: www.roschvisionary.com
At Rosch Visionary Systems, we’re your allergy technology
specialists. Our Rosch Immunotherapy software, the most
widely used allergy extract and injection management
program, is an efficient, cost effective analysis and
management tool. Rosch Immunotherapy identifies, verifies,
and tracks patient allergy vials (extracts/aeroallergens and
venoms) as well as other biologics such as Xolair and
vaccines.
Rosch Immunotherapy is specifically designed to address the
issues of allergen extract administration errors by verifying
patients with photo, birth date and, most importantly, vial
barcode verification.
Interface with your EHR or use as stand-alone software;
client-server, hosted, or Citrix options available.
Sanofi U.S.
GOLD PARTNER
Booth
55 Corporate Dr
Bridgewater, NJ 08807-0977
Phone: (800) 981-2491
Website: www.sanofi.us
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on
patients’ needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases,
consumer healthcare, emerging markets and animal
health. Sanofi is listed in Paris (EURONEXT: SAN) and in New
York (NYSE:SNY).Sanofi is the holding company of a
consolidated group of subsidiaries and operates in the
United States as Sanofi U.S., also referred to as Sanofiaventis
U.S. LLC. For more information on Sanofi U.S., please
visit http://www.sanofi.us or call 1-800-981-2491.
Shire Global Medical Affairs
Learning Lab
Booth
300 Shire Way
Lexington, MA 02421
Phone: (617) 349-0200
Website: www.shire.com
As one of the world’s leading specialty biopharmaceutical
companies, Shire has emerged as a company fully focused on
a single purpose: to enable people with life-altering
conditions to lead better lives. Through our Human Genetic
Therapies business, we pursue opportunities to develop
therapies on behalf of patients and families living with
orphan diseases.
Shire Human Genetic Therapies
Booth
300 Shire Way
Lexington, MA 02421
Phone: (617) 349-0200
Website: www.shire.com
As one of the world’s leading specialty biopharmaceutical
companies, Shire has emerged as a company fully focused on
a single purpose: to enable people with life-altering
conditions to lead better lives. Through our Human Genetic
Therapies business, we pursue opportunities to develop
therapies on behalf of patients and families living with
orphan diseases.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Simply Saline – Church & Dwight
Booth
469 N Harrison St
Princeton, NJ 08540
Phone: (609) 683-5900
Website: www.simplysaline.com
Simply Saline® is a naturally derived nasal solution for relief of
congestion, allergies and colds. It provides instant relief for
babies, children and adults.
Solutionreach
Booth
3098 Executive Pkwy, Ste 300
Lehi, UT 84043
Phone: (866) 605-6867
Fax: (801) 772-2034
Website: www.solutionreach.com
Solutionreach is a patient engagement software service
designed to maintain and retain existing patients while
identifying and acquiring new patients. Utilizing the latest
automated text/email messaging technologies and social
media tools, Solutionreach helps you to increase productivity
and grow your practice, while you focus on your patients.
SunButter
Booth
Red River Commodities, Inc.
PO Box 3022
Fargo, ND 58108
Phone: (877) 873-4501
Fax: (701) 282-5325
Website: www.sunbutter.com
SunButter® is a delicious and healthy alternative to peanut
butter that is made from specially roasted sunflower seed
and completely peanut, tree nut and gluten free. Please stop
by booth #2821 to receive a free sample kit!
DIAMOND PARTNER
Sunovion Pharmaceuticals Inc.
Booth
84 Waterford Dr
Marlborough, MA 01752
Phone: (508) 481-6700
Website: www.sunovion.com
Sunovion is a leading pharmaceutical company dedicated
to discovering, developing and commercializing products
that advance the science of medicine in the CNS and
respiratory disease areas to improve the lives of patients
and their families. Sunovion is a subsidiary of Dainippon
Sumitomo Pharma Co., Ltd. To learn more visit
www.sunovion.com.
TeleVox
Booth
1110 Montlimar Dr, Ste 700
Mobile, AL 36609
Phone: (800) 644-4266
Fax: (251) 633-2420
Website: www.televox.com
TeleVox communication solutions enable you to engage with
patients throughout the patient lifecycle. With greater impact
and for less expense than mailed or manual staff efforts, you
can connect for appointment reminders, recalls, patient
balance notifications, test result communications, wellness
initiatives and more!
Teva Respiratory, LLC
DIAMOND PARTNER
Booth
425 Privet Rd
Frazer, PA 19355
Phone: (888) 482-9522
Website: www.tevarespiratory.com
Stop by our booth to learn more about Qvar®
(beclomethasone dipropionate HFA) and ProAir HFA
(albuterol sulfate). Information, education materials,
resources and giveaways to benefit your practice will be
available.
The Mastocytosis Society
Booth
PO Box 129
Hastings, NE 68902-0129
Phone: (952) 905-6778
Website: www.tmsforacure.org
The Mastocytosis Society, Inc. is a 501(c)3 non-profit
dedicated to supporting and educating doctors, nurses and
their patients affected by Mastocytosis/Mast Cell Activation
Disorders, as well as families, and caregivers, through
education, research, advocacy and support. At our booth we
offer an informational DVD with the latest research articles as
well as Mastocytosis Chronicles for Medical Professionals,
Emergency Room Guide and TMS-AAAAI DVD on Mast Cell
Activation Symptomatology. Stop by for your copy.
Exhibits

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
Thermo Fisher Scientific
Booth
4169 Commercial Ave
Portage, MI 49002
Phone: (800) 346-4364
Fax: (888) 243-5214
Website: www.thermoscientific.com/phadia
As the immunodiagnostic experts within Thermo Fisher
Scientific, we work to dramatically improve the management
of allergy, asthma and autoimmune diseases. We do this by
providing healthcare professionals with superior diagnostic
technologies and clinical expertise. This results in better
healthcare and quality of life for millions of patients and their
families.
The uKnow® Peanut Molecular Allergy Test is changing the
way peanut allergy is diagnosed. The test utilizes the first and
only FDA-cleared peanut components, and assess peanut
allergy at the molecular level, providing a level of detail
previously unattainable to help diagnose peanut allergy.
Thomson Reuters
5901 Priestly Dr, Ste 200
Carlsbad, CA 92008
Phone: (760) 230-0161
Booth
US Hereditary Angioedema Association Booth
Seven Waterfront Plaza
500 Ala Moana Blvd
Honolulu, HI 96813
Phone: (866) 798-5598
Fax: (508) 437-0303
Website: www.haea.org
The US Hereditary Angioedema Association is a non-profit
patient advocacy organization that provides a wide range of
patient services and pioneers new clinical research for this
rare genetic disease, also called C1 Inhibitor Deficiency, as
well as all types of angioedema.
Viracor-IBT Laboratories, Inc.
Booth
1001 NW Technology Dr
Lee’s Summit, MO 64086
Phone: (816) 554-5171
Fax: (816) 347-0143
Website: www.viracoribt.com
Viracor-IBT Laboratories is redefining patient care through
innovative molecular and immune-diagnostics. With a menu
of more than 2,000 tests and dedication to excellence in
science and client service, the company offers an
unparalleled array of immunology, infectious disease and
allergy testing with the fastest turnaround in the industry.
Viracor-IBT serves physicians, hospitals, commercial
laboratories and biopharmaceutical companies throughout
the United States. To learn more about our menu and testing
services, visit us at www.ViracorIBT.com.
ViroPharma Incorporated
Booth
730 Stockton Dr
Exton, PA 19341
Phone: (888) 651-0201
Fax: (610) 458-7380
Website: www.viropharma.com
ViroPharma Incorporated is an international
biopharmaceutical company committed to developing and
commercializing innovative products that address unmet
medical needs. CINRYZE® (C1 esterase inhibitor [human]) is
an FDA-approved therapy for patients with hereditary
angioedema (HAE, also known as C1 esterase inhibitor
deficiency). CINRYZE® is a C1 esterase inhibitor that is used
to prevent attacks and swelling in teenagers and adults
with HAE.
Vitalograph, Inc.
Booth
13310 W 99th St
Lenexa, KS 66215
Phone: (913) 888-4221
Fax: (913) 888-4259
Website: www.vitalograph.com
If you are a CRO, clinician or anyone involved in clinical trials,
you must come to our booth to see our latest ePRO diary
with or without integrated spirometer. The In2itive e-diary is
validated and certified for the EXACT PRO COPD, Juniper
ACQ, AQLQ, ACD quality of life and Quality Metrics ACT
asthma questionnaires. We can program in your
questionnaire, please come and talk to us.
Vitalograph=spirometry. Come and see our exciting new
range of PC, desktop and hand held spirometers and
respiratory monitors with applications from telemedicine to
global centralized data to simple stand-alone devices.
Vitamix Corporation
GOLD PARTNER
Booth
8615 Usher Rd
Cleveland, OH 44138
Phone: (800) 848-2649
Website: www.vitamix.com
The Vitamix Machine enables you to create healthy, greattasting
meals in minutes – juices, hot soups, ice creams, dips
and more! Vita-Mix Corporation believes in helping our
customers live a healthier lifestyle and has been
manufacturing high performance durable kitchen
equipment in the USA for over 85 years.

Exhibits
Hall C (1st Floor) • Anaheim Convention Center
World Allergy Organization (WAO)
Booth
555 E Wells St, Ste 1100
Milwaukee, WI 53202
Phone: (414) 276-1791
Fax: (414) 276-3349
Website: www.worldallergy.org
The World Allergy Organization (WAO) is an international
umbrella organization whose members consist of 89 regional
and national allergology and clinical immunology societies
from around the world. By collaborating with member
societies, WAO is a global resource and advocate in the field
of allergy, advancing excellence in clinical care through
education, research and training as a worldwide alliance of
allergy and clinical immunology societies in nearly 100
countries around the globe. Visit our booth to learn more
about WISC 2012 from 6-9 December in Hyderabad, India
and WAAC 2013 22-26 June in Milan, Italy.
Xoran Technologies, Inc.
Booth
5210 South State Rd
Ann Arbor, MI 48108-7936
Phone: (734) 418-5168
Fax: (734) 418-5001
Website: www.xorantech.com
Xoran Technologies is the innovator and market leader in
compact, specialized medical CT scanners. Xoran is a
customer-focused medical imaging company that is
passionate about bringing fresh, common sense solutions to
patient care. The Xoran MiniCAT generates immediate,
digitally versatile images of exceptional quality, allowing
physicians to accelerate patient diagnosis and treatment.
MiniCAT is a compact, upright in-office CT scanner
designed for high-resolution, low radiation dose bone
window imaging of the sinuses, temporal bones and skull
base. MiniCAT provides immediate access to images at the
patient’s point-of-care resulting in a faster diagnosis
and treatment.
Yodle
Booth
50 W 23 St, Ste 401
New York, NY 10010
Phone: (877) 276-5104
Fax: (212) 542-5422
Website: www.yodle.com
Yodle, a leader in local online marketing, offers a full-service
and cost-effective solution to small businesses. The
deliverables are tangible and simple: small businesses receive
quality calls and emails from local consumers who intend to
purchase their services. To generate those leads for each of
its 30,000+ customers, Yodle establishes a comprehensive
desktop and mobile web presence, implements unique SEO
techniques that support a “first-page guarantee,” and deploys
proprietary paid search technology that dynamically
optimizes online media buys across multiple desktop and
mobile outlets. Yodle’s solution also includes display
advertising, review/offer management and a simple
performance dashboard.
Exhibits

Index of Exhibits
Exhibits – Listed by Category
Allergy Extracts
ALK, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2410
Allergy Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2620
Allermed Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2200
GREER - Medical Affairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2725
HollisterStier Allergy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2511
Sanofi U.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2603
Allergy-Friendly Product
SunButter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2821
Bronchial Thermoplasty
Boston Scientific Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . 2431
Care Provider
BreatheAmerica, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2315
Clinical Research Organization
Vitalograph, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2624
Computer Hardware/Software
Meditab Software, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2525
ModuleMD, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2723
NSpire Health, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2918
Rosch Visionary Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . 2311
Solutionreach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2626
Diagnostic Equipment
Xoran Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2804
Diagnostic Testing
Aerocrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2705
Carestream Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2819
GREER - Commercial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2724
Lincoln Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2711
Thermo Fisher Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2816
Viracor-IBT Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . 2800
Environmental Products
Allergy Control Products. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2627
Kaz USA Inc./Honeywell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2326
Mission: Allergy, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2701
Equipment/Supplies
Allergy Guardian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2822
Forest Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2806
Panatrex, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2204
Financial Services
American Express OPEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2422
Health & Wellness
Vitamix Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2630
Health/Body Care
Perrigo Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2826
Home Infusion
American Outcomes Management. . . . . . . . . . . . . . . . . . . . . 2520
Immunotherapy
Allergy Therapeutics PLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2428
Baxter - Global Medical Affairs . . . . . . . . . . . . . . . . . . . . . . . . . 2926
Baxter Healthcare Corporation. . . . . . . . . . . . . . . . . . . . . . . . . 2831
BioRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2726
CSL Behring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2810
Information Solutions
Thomson Reuters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2823
Lit, Ed Videos
Shire Global Medical Affairs Learning Lab . . . . . . . . . . . . . . 2206
Shire Human Genetic Therapies. . . . . . . . . . . . . . . . . . . . . . . . 2207
Marketing Patient Comm
Demandforce . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2631
Nasal Spray
Simply Saline - Church & Dwight . . . . . . . . . . . . . . . . . . . . . . . 2210

Index of Exhibits
Exhibits – Listed by Category
Other
Airware Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2432
Baltimore CVB. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2225
National Allergy Supply, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2625
Pharmaceutical Specialties, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 2416
Patient/Public Education
Allergy & Asthma Network,
Mothers of Asthmatics (AANMA) . . . . . . . . . . . . . . . . . . . 2531
American Latex Allergy Association . . . . . . . . . . . . . . . . . . . . 2218
COPD Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2227
International Association for
Food Protein Enterocolitis (IAFFPE) . . . . . . . . . . . . . . . . . 2212
PME Communications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2426
TeleVox . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2729
The Mastocytosis Society . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2222
US Hereditary Angioedema Association . . . . . . . . . . . . . . . . 2214
Pharmaceuticals
Actient Pharmaceuticals LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . 2202
Alcon Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2801
Allergan, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2219
AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2824
Centers For Disease Control And Prevention. . . . . . . . . . . . 2230
Dyax Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2517
ISTA Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2425
MEDA PHARMACEUTICALS® . . . . . . . . . . . . . . . . . . . . . . . . . . . 2609
Merck. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2403
Mission Pharmacal Company . . . . . . . . . . . . . . . . . . . . . . . . . . 2421
Mylan Specialty L.P.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2813
NeilMed Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 2621
Novartis Pharmaceuticals Corporation . . . . . . . . . . . . . . . . . 2215
Sunovion Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 2417
Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2201
ViroPharma Incorporated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2411
Physician Education
American Board of Allergy & Immunology (ABAI) . . . . . . . 2228
CE Symmetry. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2327
Georgetown Immunology Center . . . . . . . . . . . . . . . . . . . . . . 2325
HAE: Learn About It, Talk About It . . . . . . . . . . . . . . . . . . . . . . 2730
World Allergy Organization (WAO) . . . . . . . . . . . . . . . . . . . . . 2216
Physician Recruitment
Corpus Christi Allergy & Asthma Center . . . . . . . . . . . . . . . . 2533
Mayo Clinic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2521
Publications
Allergy & Asthma Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . 2323
ELSEVIER, INC.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2226
Spirometry
Jones Medical Instrument Co.. . . . . . . . . . . . . . . . . . . . . . . . . . 2317
Micro Direct, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2324
Websites
Yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2727
Exhibits

Index of Exhibitors
Exhibitors – Listed by Booth
Booth 2200 . . . . . . . . . . . . . . . . . . . . . . Allermed Laboratories, Inc.
Booth 2201 . . . . . . . . . . . . . . . . . . . . . . . . . . . Teva Respiratory, LLC
Booth 2202 . . . . . . . . . . . . . . . . . . . . Actient Pharmaceuticals LLC
Booth 2204 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Panatrex, Inc.
Booth 2206. . . . . . . . Shire Global Medical Affairs Learning Lab
Booth 2207 . . . . . . . . . . . . . . . . . Shire Human Genetic Therapies
Booth 2210 . . . . . . . . . . . . . . . . Simply Saline - Church & Dwight
Booth 2212 . . . . . . . . . . . . . . . . . . . . . . . International Association
for Food Protein Enterocolitis (IAFFPE)
Booth 2214 . . . . . . . . . US Hereditary Angioedema Association
Booth 2215. . . . . . . . . . . Novartis Pharmaceuticals Corporation
Booth 2216 . . . . . . . . . . . . . . World Allergy Organization (WAO)
Booth 2218 . . . . . . . . . . . . . American Latex Allergy Association
Booth 2219 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergan, Inc.
Booth 2222 . . . . . . . . . . . . . . . . . . . . . . . The Mastocytosis Society
Booth 2225 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Baltimore CVB
Booth 2226 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ELSEVIER, INC.
Booth 2227 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . COPD Foundation
Booth 2228 . . . . . . . . . . . . . . . . . . . . American Board of Allergy &
Immunology (ABAI)
Booth 2230 . . . . . Centers For Disease Control And Prevention
Booth 2311. . . . . . . . . . . . . . . . . . . . Rosch Visionary Systems, Inc.
Booth 2315 . . . . . . . . . . . . . . . . . . . . . . . . . . . . BreatheAmerica, Inc.
Booth 2317 . . . . . . . . . . . . . . . . . . . Jones Medical Instrument Co.
Booth 2323 . . . . . . . . . . . . . . . . . . Allergy & Asthma Proceedings
Booth 2324. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Micro Direct, Inc.
Booth 2325 . . . . . . . . . . . . . . . Georgetown Immunology Center
Booth 2326. . . . . . . . . . . . . . . . . . . . . . . . . Kaz USA Inc./Honeywell
Booth 2327 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CE Symmetry
Booth 2403 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Merck
Booth 2410 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ALK, Inc.
Booth 2411 . . . . . . . . . . . . . . . . . . . . . . . ViroPharma Incorporated
Booth 2416 . . . . . . . . . . . . . . . . . Pharmaceutical Specialties, Inc.
Booth 2417. . . . . . . . . . . . . . . . . . Sunovion Pharmaceuticals, Inc.
Booth 2421. . . . . . . . . . . . . . . . . . . . Mission Pharmacal Company
Booth 2422. . . . . . . . . . . . . . . . . . . . . . . . . American Express OPEN
Booth 2425 . . . . . . . . . . . . . . . . . . . . . . . . . . . ISTA Pharmaceuticals
Booth 2426 . . . . . . . . . . . . . . . . . . . . . . . . . . PME Communications
Booth 2428 . . . . . . . . . . . . . . . . . . . . . . . . Allergy Therapeutics PLC
Booth 2431 . . . . . . . . . . . . . . . . . . . Boston Scientific Corporation
Booth 2432 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Airware Labs
Booth 2511 . . . . . . . . . . . . . . . . . . . . . . . . . . . . HollisterStier Allergy
Booth 2517 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dyax Corp.
Booth 2520 . . . . . . . . . . . . . . American Outcomes Management
Booth 2521 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mayo Clinic
Booth 2525 . . . . . . . . . . . . . . . . . . . . . . . . . . Meditab Software, Inc.
Booth 2531. . . . . . . . . . . . . . . . . . . . . . Allergy & Asthma Network,
Mothers of Asthmatics (AANMA)
Booth 2533. . . . . . . . . . Corpus Christi Allergy & Asthma Center
Booth 2603 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sanofi U.S.
Booth 2609. . . . . . . . . . . . . . . . . . . . . MEDA PHARMACEUTICALS®
Booth 2620 . . . . . . . . . . . . . . . . . . . . . . . . Allergy Laboratories, Inc.
Booth 2621. . . . . . . . . . . . . . . . . . . NeilMed Pharmaceuticals, Inc.
Booth 2624 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vitalograph, Inc.
Booth 2625. . . . . . . . . . . . . . . . . . . . . National Allergy Supply, Inc.
Booth 2626 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Solutionreach
Booth 2627 . . . . . . . . . . . . . . . . . . . . . . . . Allergy Control Products
Booth 2630 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vitamix Corporation
Booth 2631. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Demandforce
Booth 2701 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mission: Allergy, Inc.
Booth 2705. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aerocrine
Booth 2711 . . . . . . . . . . . . . . . . . . . . . . . . Lincoln Diagnostics, Inc.
Booth 2723. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ModuleMD, LLC
Booth 2724 . . . . . . . . . . . . . . . . . . . . . . . . . . . . GREER - Commercial
Booth 2725 . . . . . . . . . . . . . . . . . . . . . . . . . GREER - Medical Affairs
Booth 2726. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . BioRx
Booth 2727. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yodle
Booth 2729. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . TeleVox
Booth 2730 . . . . . . . . . . . . . . . HAE: Learn About It, Talk About It
Booth 2800 . . . . . . . . . . . . . . . . . . . . Viracor-IBT Laboratories, Inc.
Booth 2801. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alcon Laboratories
Booth 2804 . . . . . . . . . . . . . . . . . . . . . . . . Xoran Technologies, Inc.
Booth 2806 . . . . . . . . . . . . . . . . . . . . . Forest Pharmaceuticals, Inc.
Booth 2810 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CSL Behring
Booth 2813 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mylan Specialty L.P.
Booth 2816. . . . . . . . . . . . . . . . . . . . . . . . . Thermo Fisher Scientific
Booth 2819 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Carestream Health
Booth 2821 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SunButter
Booth 2822. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergy Guardian
Booth 2823 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Thomson Reuters
Booth 2824 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AstraZeneca
Booth 2826 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Perrigo Company
Booth 2831 . . . . . . . . . . . . . . . . . . Baxter Healthcare Corporation
Booth 2918 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . nSpire Health, Inc.
Booth 2926. . . . . . . . . . . . . . . . . . . Baxter - Global Medical Affairs

Index of Exhibitors
Exhibitors – Listed Alphabetically
Actient Pharmaceuticals LLC . . . . . . . . . . . . . . . . . . . . Booth 2202
Aerocrine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2705
Airware Labs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2432
Alcon Laboratories. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2801
ALK, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2410
Allergan, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2219
Allergy & Asthma Network,
Mothers of Asthmatics (AANMA) . . . . . . . . . . . . . . Booth 2531
Allergy & Asthma Proceedings . . . . . . . . . . . . . . . . . . Booth 2323
Allergy Control Products . . . . . . . . . . . . . . . . . . . . . . . . Booth 2627
Allergy Guardian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2822
Allergy Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2620
Allergy Therapeutics PLC . . . . . . . . . . . . . . . . . . . . . . . . Booth 2428
Allermed Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . Booth 2200
American Board of Allergy &
Immunology (ABAI). . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2228
American Express OPEN. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2422
American Latex Allergy Association . . . . . . . . . . . . . Booth 2218
American Outcomes Management . . . . . . . . . . . . . . Booth 2520
AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2824
Baltimore CVB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2225
Baxter - Global Medical Affairs. . . . . . . . . . . . . . . . . . . Booth 2926
Baxter Healthcare Corporation . . . . . . . . . . . . . . . . . . Booth 2831
BioRx. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2726
Boston Scientific Corporation . . . . . . . . . . . . . . . . . . . Booth 2431
BreatheAmerica, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2315
Carestream Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2819
CE Symmetry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2327
Centers For Disease Control And Prevention . . . . . Booth 2230
COPD Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2227
Corpus Christi Allergy & Asthma Center. . . . . . . . . . Booth 2533
CSL Behring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2810
Demandforce. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2631
Dyax Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2517
ELSEVIER, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2226
Forest Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . Booth 2806
Georgetown Immunology Center . . . . . . . . . . . . . . . Booth 2325
GREER - Commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2724
GREER - Medical Affairs . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2725
HAE: Learn About It, Talk About It . . . . . . . . . . . . . . . Booth 2730
HollisterStier Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2511
International Association for
Food Protein Enterocolitis (IAFFPE) . . . . . . . . . . . . Booth 2212
ISTA Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2425
Jones Medical Instrument Co. . . . . . . . . . . . . . . . . . . . Booth 2317
Kaz USA Inc./Honeywell. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2326
Lincoln Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2711
Mayo Clinic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2521
MEDA PHARMACEUTICALS®. . . . . . . . . . . . . . . . . . . . . Booth 2609
Meditab Software, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2525
Merck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2403
Micro Direct, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2324
Mission Pharmacal Company. . . . . . . . . . . . . . . . . . . . Booth 2421
Mission: Allergy, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2701
ModuleMD, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2723
Mylan Specialty L.P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2813
National Allergy Supply, Inc.. . . . . . . . . . . . . . . . . . . . . Booth 2625
NeilMed Pharmaceuticals, Inc.. . . . . . . . . . . . . . . . . . . Booth 2621
Novartis Pharmaceuticals Corporation. . . . . . . . . . . Booth 2215
nSpire Health, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2918
Panatrex, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2204
Perrigo Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2826
Pharmaceutical Specialties, Inc. . . . . . . . . . . . . . . . . . Booth 2416
PME Communications . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2426
Rosch Visionary Systems, Inc.. . . . . . . . . . . . . . . . . . . . Booth 2311
Sanofi U.S. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2603
Shire Global Medical Affairs Learning Lab. . . . . . . . Booth 2206
Shire Human Genetic Therapies . . . . . . . . . . . . . . . . . Booth 2207
Simply Saline - Church & Dwight . . . . . . . . . . . . . . . . Booth 2210
Solutionreach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2626
SunButter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2821
Sunovion Pharmaceuticals, Inc.. . . . . . . . . . . . . . . . . . Booth 2417
TeleVox. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2729
Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2201
The Mastocytosis Society . . . . . . . . . . . . . . . . . . . . . . . Booth 2222
Thermo Fisher Scientific. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2816
Thomson Reuters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2823
US Hereditary Angioedema Association . . . . . . . . . Booth 2214
Viracor-IBT Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . Booth 2800
ViroPharma Incorporated . . . . . . . . . . . . . . . . . . . . . . . Booth 2411
Vitalograph, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2624
Vitamix Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2630
World Allergy Organization (WAO) . . . . . . . . . . . . . . Booth 2216
Xoran Technologies, Inc. . . . . . . . . . . . . . . . . . . . . . . . . Booth 2804
Yodle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 2727
Exhibits

Hall C (1st Floor) • Anaheim Convention Center
Exhibit Hall Map
F&B
F&B
ENTRANCE
Stage
F&B
F&B
ENTRANCE
Stage
2200
Allermed
Laboratories,
Inc
2201
Teva
Respiratory
2202
Actient
Pharmaceuticals,
LLC
2204
Panatrex,
Inc
2206
2207
Shire Human
Genetic
Therapies
2210
Simply
Saline
2212
IAFFPE
2214
USHAA
2215
Novartis
Pharmaceuticals
Corp 2216
WAO
2219
Allergan
2225
Baltimore
CVB
2227
COPD
Foundation
2229
2231
2233
2311
Rosch
Visionary
Systems,
Inc
2315
Breathe
America,
Inc
2317
Jones Medical
Instrument Co
2323
Allergy &
Asthma
Proceedings
2324
Micro
Direct,
Inc
2325
Georgetown
Immunology
Center
2326
Kaz
USA,
Inc
2327
2329
2330
2332
2333
2403
Merck
2410
ALK
2411
ViroPharma
Incorporated
2416
Pharmaceutical
Specialties, Inc
2417
Sunovion
Pharmaceuticals
Inc
2421
Mission
Pharmacal
Company
2422
American
Express
Open
2425
ISTA
Pharmaceuticals 2426
PME
Communications
2428
Allergy
Therapeutics
2431
Boston
Scientific
Corporation
2432
2511
HollisterStier
Allergy
2517
Dyax Corp.
2520
American
Outcomes
Management
2521
Mayo
Clinic
2525
Meditab
Software,
Inc
2531
AANMA
2533
Corpus
Christi
2537
Mylan Interactive
Timeline
2603
Sanofi
U.S.
2609
Meda
Pharmaceuticals
2620
Allergy
Laboratories,
Inc
2621
NeilMed
Pharmaceuticals, Inc
2624
Vitalograph,
Inc
2625
National
Allergy
Supply, Inc
2626
Solutionreach
2627
Allergy
Control
Products
2630
Vitamix
Corporation
2631
Demandforce
2632
2633
2701
Mission:
Allergy,
Inc
2705
Aerocrine
2711
Lincoln
Diagnostics,
Inc
2723
ModuleMD,
LLC
2724
GREER
Laboratories
(Commercial)
2725
GREER-
Medical
Affairs
2726
BioRx
2727
Yodle
2729
TeleVox
2730
HAE
2732
2800
Viracor-IBT
Laboratories,
Inc
2801
Alcon
Laboratories,
Inc
2804
Xoran
Technologies,
Inc
2806
Forest
Pharmaceuticals,
Inc
2810
CSL
Behring
2813
Mylan, Inc.
2816
Thermo
Fisher
Scientific
2819
Carestream
2821
SunButter
2822
Allergy
Guardian
2823
Thomson
Reuters
2824
AstraZeneca
2825
2826
Perrigo
Company
2827
2829
2831
Baxter
Healthcare
Corporation
2918
Nspire
Health, Inc
2920
2922
2924
2926
Baxter-Global
Medical
Affairs
2928
2930
2932
Service
Desk
2222
The
Mastocytosis
2218
ALAA
2230
CDC
2228
ABAI
2226
Elsevier,
Inc
CE
Symmetry
Airware
Labs
F&B
Shire
GMALL
ENTRANCE
Doctors’ Job Fair
Posters
Product
Theater
Product
Theater

Anaheim Convention Center
LEVEL
Maps
Exhibits
&
Posters
*ACAAI Registration*
LEVEL
Internet Café
LEVEL
General Session

Anaheim Marriott Hotel
GARDEN ROOM
EAST WING
GARDEN
ROOMS
SOUTH WING
GARDEN ROOMS
PALMS TOWER
LOBBY
PALMS
TOWER
Lobby Shop
SHUTTLE TO
DISNEYLAND RESORT
OASIS
TOWER
ENTRANCE
ORANGE COUNTY
BALLROOM
ROLL-UP DOOR
ELEVATOR
GRAND
BALLROOM
SOUTH
REGISTRATION
COUNTER
MARQUIS
BALLROOM
NORTH
REGISTRATION
COUNTER
GOLD KEY
PLATINUM
REGISTRATION
BALLROOM FOYER
E L I T E
1 2 3
GOLD
KEY
III
OASIS
TOWER
FITNESS
CENTER
MEN
WOMEN
BALLROOM
FOYER
8
PLATINUM BALLROOM
9
BALLROOM
ENTRANCE
SELF PARKING
ANAHEIM
CONVENTION
CENTER
PLATINUM PATIO
CAFÉ
DEL SOL
CENTER
REGISTRATION
COUNTER
4
5 6
7
3
2
1
10
ROLL-UP
DOOR
ATM
VALET
STARBUCKS
PATIO
BALLROOM
FOYER
GARAGE
ENTRANCE
HOTEL ENTRANCE

Future Meetings
November -,
Baltimore, Maryland
November -,
Atlanta, Georgia
November -,
San Antonio, Texas
November -,
San Francisco, California
October -,
Boston, Massachusetts
West Algonquin Road, Suite • Arlington Heights, IL
Phone: () - • Fax: () - • www.acaai.org

Notes

Improved asthma-related
quality of life for your patients
Days a year
Visit Boston Scientific at Booth #2431.
Product Theater #1, Hall C — Bronchial Thermoplasty —
Improved Asthma-Related Quality of Life For Patients
Sunday, November 11th at 3:05pm
The Product Theater content and views expressed therein are those of the sponsor and not of the American
College of Allergy, Asthma & Immunology.
Now you can offer a treatment option that provides long-term asthma
control. Bronchial Thermoplasty is a novel treatment for adults with
severe asthma that reduces the risk of asthma exacerbations, ER visits,
hospitalizations and missed daily activities due to asthma. Discover how BT
can help your patients. Learn more at: www.BTforAsthma.com/ACAAI.
Brief Statement of Relevant Indications for Use, Contraindications, Warnings, and Adverse Events: The Alair Bronchial
Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose
asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. The Alair System is not for use in
patients with an active implantable electronic device or known sensitivity to medications used in bronchoscopy. Previously
treated airways of the lung should not be retreated with the Alair system. Patients should be stable and suitable to undergo
bronchoscopy. The most common side effect of bronchial thermoplasty is an expected transient increase in the frequency and
worsening of respiratory-related symptoms. Results from case studies are not predictive of results in other cases. Results in
other cases may vary.
© 2012 by Boston Scientific Corporation or its affiliates. Alair and are registered trademarks of Boston Scientific
Corporation or its affiliates. Alair Bronchial Thermoplasty is complementary to, and not a replacement for, conventional drug
therapy. Bronchial Thermoplasty is an add-on therapy to current asthma medications.
CAUTION: Law restricts this device to sale by or on the order of a physician. Indications, contraindications, precautions and
warnings can be found with product labeling.
ENDO-79415-AA April 2012

Now Available
Visit us at booth #26O9
©2012 Meda Pharmaceuticals Inc. Dymista is a trademark of Meda Pharmaceuticals Inc. 9/12 DYM-12-0130